<SEC-DOCUMENT>0000320017-22-000057.txt : 20220804
<SEC-HEADER>0000320017-22-000057.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804164428
ACCESSION NUMBER:		0000320017-22-000057
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CALADRIUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		221137363

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>clbs-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba,d:3286f9fcb6234a6dac2ebc53f9a97a6e--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:clbs="http://www.caladrius.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>clbs-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV8zLTEtMS0xLTIwMzYw_7b1d448e-6651-4b43-9e7e-595745c12935">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV80LTEtMS0xLTIwMzYw_a874b216-2224-49bf-934c-e29e49690e19">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV81LTEtMS0xLTIwMzYw_641607ea-32b6-4378-b25e-377247df660d">2022</ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV82LTEtMS0xLTIwMzYw_d4d29c33-0693-490d-a022-5fd6bf92723b">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV83LTEtMS0xLTIwMzYw_5633f277-0eda-4678-91af-819832e6e536">false</ix:nonNumeric><ix:nonNumeric contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i12ea05efc6ab4cc59782212d5667a800_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3Mw_d6c91bb1-b895-4964-8aed-4a7cfaa67b1d">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="clbs-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3a997d407f4fc9ab8117094e2692af_I20220804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i36939ec815f849cd909b1f34151f6a3b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6a4a7a34fc2249628d10e950713caaf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826be2afc3e749308a9751d74830964a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144cc71857f7429bb51d544f0b8f9310_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7256a903af4b431abebe6883b6c15999_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5008ebb64ec147a187a521f9673cad8e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b06dfb1afa472fb9d01295762e7c9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939cc2c2c6074c0c982765101de3e1fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210747314c0e49419773d046301904e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ed3ac0e8cc48fd808c48dea00e34fe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31306c1aab0247159feb2af89726ee3f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a0e8a04a5dd47a2955a1779dfb31298_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1123d58c65b6489e899c1698307885f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acaa30e875044229e6d0b25653dfa68_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2302b303b3d24af1bcafe4350909d9ee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a24b47dd254dc19e95b10e49ccbed7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bed893df04e44c1ad362c17a93cfdaf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18265c74af504470b75337fdb7546118_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3285245ca04f458aa72087031b59e41b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84bb799d59f441f8d0036b10575869f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c77282d142f4fb59c41c5f204dbfe92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b047433f88e46ecbc8f6948247e2441_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c105eba1be9452dbca6993cb4fae77b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa027f593cfd45789ab829afc443cd85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b9cf1c6314423d88f7c7d52b11e494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifade1f65a2fc44a9a294052965852540_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1246f6d72c59416bb70643adff3c35cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3384336a7944494b8cb1446514d3f7e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd00509623ed44ddb8f0004f1abf6120_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c32da30d114addbead3f239466b8e9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c2932e69ef4d54ac788754fdca2d18_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6af4cb66e154f95939adbff59e13392_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9599115241c54766a1a636684b8b060e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad465c32b5844118f00a809aaff3997_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b43e8ae838c493d815ea92bdae4b1fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603559893c614cd2912e389072705619_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65449c0457314898a5bd53ecab85713e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4c8cad9db9466db265fc7fc23b3c86_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b57810d948345c6bc01749f37102642_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff1dcadd5124a7ba11055ac74a67ee4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840c3e9cbefb43e9b146dfd41f33662f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id525428cb5044f9dad07f0198a966b18_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4aa152b86594c1daab508f7a3371e7e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief022a2aaa62471fba1ace6d10742f26_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11509a49300e4d2cad12d712bd9a7433_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c51dda04204b5ea7441d1f68c81706_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a95e7cdc8d4bc1ad9b84ffd5e3f68b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6aedcf6bdef487f875f1aafded60667_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1573c590f9ad4ed5bbed7597658b47ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a41562d90542fdbfbc872ae7d68b02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04d15ea5e1d45368d6e6e3fe784f7e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1920cbc31b314e8681271adf19a0cce4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052a9e1cdcbe4746bce1dc6273233d80_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:CendTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:AgreementAndPlanOfMergerAndReorganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7de6a11cd3474c6287cb381192ae5762_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:CLBS16TreatmentOfCMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0492a0dc655845a9b2daa971f3aa0ee6_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clbs:SeriesDPreferredStockCendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d7e60b43454d24bd9f8aab2bdd049a_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clbs:SeriesDPreferredStockCendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3345a69c3d4ae293e0976208942eda_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2adcb8be9d2546328e9ae61565dec3b3_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CendTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfdf542e13048bbbd63568d248c0ea6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clbs:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760113b860d24918972b88966a39461f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d7da78337e4f97b4635d629086a480_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f028c9834d4aa8851347d4e1ac46ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie67a57e844cf4196b7d6aaece131e76a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i472af80a2f724a30858b9461b417ed5e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c748eba28b4b64a8ec1143527c0ae4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie46e3b754c67413c88f24c3ddff1552f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c93d7a7931742669a283947008740ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5ab7d1d8304b70a0409715de916340_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5311053f8ab4baab4847164c5f36d3a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f725c87ad542dcb3ff3f4d00fc0e9d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6233584e5a4a50b728139e0d6c6159_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461576cc6a4e4084a8c496c3c34ed239_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib070372249f24e5daa9dce2156efdc26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4f1d501291470683152d8d06246393_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169c2b19485743c494294b605e1c9637_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0af1b219794ef094dabc670988af20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="office"><xbrli:measure>clbs:office</xbrli:measure></xbrli:unit><xbrli:context id="i881d1b5361494535a4dff620655e80cc_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d46abc623a4ea5a97d1bf45a62c876_I20210604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14632cb149ee4f8e824d0bc59caba108_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ea05efc6ab4cc59782212d5667a800_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68930bc1046341ffaf2ee9a38956674a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d7272724ce4f578cc742d1dc931327_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15f75b9306d45999b283daf73a43b48_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61b5af72af5c4772bf134572a931b93d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c459ae881647fd8f328d90c28330bf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f0d245d793c45a1ba1cb80e8b960908_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823661ad4a944545a75121b92daaf1a9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62c6b1a91ccc4441ba38426fe098aeb0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief352e26ae67416cafff90b9793d7ccd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a169106c4a54b75a790607dc184b040_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1213c6cc96c2467caca65a5f1102dc7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96074b249ba4cb3811d86696759685a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id96396af1f5f4e578519538caff67b2c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i069758af4d36436e817e90b87a8a130d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia572f9b4029b4d02bd17de8d331b2d60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce48fc27b9345c79034d9b1582abdf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8328428e264834bf3b4a202bab364f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17745a6d80b45f587961fd01e5ac1bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a9b55d334b140a0a9c8cf4c0b5ced19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148b071e62cb48e389a032a63261b95b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e7dbcff99b643cba5824b529d4831aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-22</xbrli:startDate><xbrli:endDate>2022-02-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI4_f70b5934-1300-4580-a695-0487f0aa8684">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6ODRiNjM1MzUyMmEzNGU5YmJmNzBiYmU0YzhiZTJhMTEvdGFibGVyYW5nZTo4NGI2MzUzNTIyYTM0ZTliYmY3MGJiZTRjOGJlMmExMV8wLTAtMS0xLTIwMzYw_0670e054-2f58-48a0-8401-d3bb0ab84728">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8xMjY_af4bcc92-0210-4376-8948-903660d98d80">June&#160;30, 2022</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6NGIxYjcxMDA2M2EwNDQ5Y2EzY2NkNWFiZjQ1MmMyYjMvdGFibGVyYW5nZTo0YjFiNzEwMDYzYTA0NDljYTNjY2Q1YWJmNDUyYzJiM18wLTAtMS0xLTIwMzYw_c4ccb3fd-2a18-41fb-90c7-4f3558c7c995">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI5_759e4136-b32e-4b6d-baeb-a12d7531daef">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDMw_807f02c7-93d7-4892-8abe-d9c805bb76d0">CALADRIUS BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8wLTAtMS0xLTIwMzYw_2b583f67-b5fd-4c58-b980-76a6e1800f47">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8wLTEtMS0xLTIwMzYw_453fba70-432b-440c-8757-9b73dac1ceaf">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfNA_7baf7899-ebad-4996-b490-d41e6e1d9600">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfOA_f1a52abc-f405-4a50-9d76-ea2b3b961676">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfMTI_a3781d64-4ae7-49de-b8b5-22f5ea6cf504">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTEtMS0xLTIwMzYw_d8534c45-3e74-458f-89d3-81ec7d2c9989">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDMz_fa869d76-7486-45c9-9905-ef2dcfe3e77d">908</ix:nonNumeric>-<ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDM0_f10bd18a-eecb-4b7d-86a0-2c49e08c068b">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:34.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTAtMS0xLTIwMzYw_d1f2f95a-2948-43e0-8217-4a01820fc06e">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTEtMS0xLTIwMzYw_b64e81c9-fda5-483f-9d6e-1a2087b0dd8c">CLBS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTItMS0xLTIwMzYwL3RleHRyZWdpb246MDBmNjE5YWFhMWRmNGEwYTk2ZWRiMDMxZTQzMzIxZDRfOA_9350cacc-baae-442d-a8c5-f67d7c815020">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI0_3d686061-207e-4677-a953-546835f488ba">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI2_f3add66f-fd31-4567-b4fc-2bc0e8574c46">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8xLTAtMS0xLTIwMzYw_30c76bdf-e80b-421a-bcf4-fa8e4264f2ce">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8xLTQtMS0xLTIwMzYw_e75f95e1-98a4-4159-8da3-b817358815b4">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8yLTQtMS0xLTIwMzYw_d7b7607c-99db-4515-9614-be5b8cd46cd4">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI3_64727023-e2f5-4143-ac57-25537dccf861">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of August 4, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d3a997d407f4fc9ab8117094e2692af_I20220804" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6NjY4N2E4MmM1YmEwNGYyZmI3YTNhOGNhOGE2MDhiOGIvdGFibGVyYW5nZTo2Njg3YTgyYzViYTA0ZjJmYjdhM2E4Y2E4YTYwOGI4Yl8xLTEtMS0xLTIwMzYw_da2c2fdd-3dc0-4ceb-ab03-c5874eb22607">60,583,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to complete the proposed merger with Cend Therapeutics, Inc. (&#8220;Cend&#8221;);<br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business;&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, including our proposed merger with Cend, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;<br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 pandemic may impact our business, including our clinical trials and financial condition; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 22, 2022 (our &#8220;2021 Form 10-K&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2021 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16">Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16">, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">months ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19"> June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">Consolidated Statements of Equity for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">a</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">nd six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">, 2022 and 2021 (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_28">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_31">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_76">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_88">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_91">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_97">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_100">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_103">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_106">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_109">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_112">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_115">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_118">36</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMi0xLTEtMS0yMDM2MA_4f8ffaf4-63c8-480f-83e9-912d55954a02">33,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMi0zLTEtMS0yMDM2MA_e6c34f06-7fe8-4cc1-a132-f035b60b87d2">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMy0xLTEtMS0yMDM2MA_8800017c-4e85-4188-bba6-33a0b27a4109">39,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMy0zLTEtMS0yMDM2MA_7b82aa10-2e3d-4fb5-852d-174c690a4d4c">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNC0xLTEtMS0yMDM2MA_0f6828c3-28e2-4b7d-9935-7b64c7680234">1,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNC0zLTEtMS0yMDM2MA_e370a2e0-964d-4652-a40b-63542407f1e6">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNS0xLTEtMS0yMDM2MA_6decff44-26b7-4b6f-937d-d72fb0e8232f">74,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNS0zLTEtMS0yMDM2MA_b2083575-b2f2-480d-9de6-3a001261fa9a">96,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNi0xLTEtMS0yMDM2MA_4bfac620-2e2b-4952-9fb3-20b99f835d0e">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNi0zLTEtMS0yMDM2MA_2f18792a-6e8f-46a8-bd8d-49320dda9dde">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Cend Therapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0xLTEtMS0yMTU2Ng_71646e90-f826-4b64-a887-cebacaeea4ae">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0zLTEtMS0yMTU2Ng_b4160191-372d-4a36-980f-716245a09a6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0xLTEtMS0yMDM2MA_66bcaed6-6dd0-45f7-be53-64389eff4242">648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0zLTEtMS0yMDM2MA_7f74760c-11e2-418a-8e0e-34085e41215f">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfOC0xLTEtMS0yMDM2MA_602e7ec7-b8f8-48ab-81ff-8a798f55f6c4">85,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfOC0zLTEtMS0yMDM2MA_a9c9222a-2a72-49d0-8739-49d7b271ff97">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTItMS0xLTEtMjAzNjA_8d0e34ea-ca2d-4563-8798-897e496a1859">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTItMy0xLTEtMjAzNjA_e4fab26a-3816-4935-b00e-077641897924">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTMtMS0xLTEtMjAzNjA_d0437f3b-17e1-4683-b4eb-dd3cf9ca52a0">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTMtMy0xLTEtMjAzNjA_a59522c2-3ce1-4c09-a868-2488a41c90f4">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTQtMS0xLTEtMjAzNjA_c794ccec-e768-4b80-bd04-f86619046d2b">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTQtMy0xLTEtMjAzNjA_b2327a68-7ddc-40e7-b38c-af615bc45574">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTUtMS0xLTEtMjAzNjA_75e631b2-c17b-4412-be79-73e34a5b1be6">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTUtMy0xLTEtMjAzNjA_7079a0f2-1377-4702-bbe8-7db119a43fa7">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTYtMS0xLTEtMjAzNjA_595c5e38-d7f8-423a-a39a-f818b224ea79">3,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTYtMy0xLTEtMjAzNjA_84e74549-722d-46b3-96ce-d975b157a965">5,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTctMS0xLTEtMjAzNjA_65ff7bab-cfb7-46a2-8bcc-d0f1c49b3282"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTctMy0xLTEtMjAzNjA_aa3f500f-5812-48c8-bf13-a9dd36634718"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, authorized, <ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8zNA_56986b53-2c9b-4fe8-b78a-bc575387b9ff"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8zNA_f3595206-15ac-41ee-90db-31603c09fcd0">20,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B convertible redeemable preferred stock liquidation value, <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMTE_54e439d3-652d-42d8-9554-f6242060e168"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMTE_735a50b8-7418-4bb8-ad99-c70e23a7ba25">0.001</ix:nonFraction></ix:nonFraction> share of common stock,</span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMzc_010a9481-ff8f-44b3-8981-60dda3a2bc39"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMzc_d521978d-445e-4255-af66-0e7fa871156d">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xNTE_470dbfa8-1703-43ab-96df-463cba5ffe51"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xNTE_dff22cb9-0d46-4bf3-afea-a88086766bc1">825,000</ix:nonFraction></ix:nonFraction> shares designated; issued and outstanding, <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_163f451f-6ee6-4786-b029-9958c5cfca0c"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_855fc3a1-7ef7-41ed-a7a2-61fdee7298c0"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_dfb1cdcf-f2be-4a1e-aa90-d780205c7974"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_f8e3fd0d-d6ed-4022-92df-e0add07e5eff">10,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares at </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMS0xLTEtMjAzNjA_e04d0d3d-836b-4e8d-8823-7f7c2c5e1b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMy0xLTEtMjAzNjA_4f804783-4e3f-4025-8b15-78be2fa658a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xOA_c240b118-6268-4e8a-8b81-7c6ef6d97644"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xOA_c6f3d7cc-ce9b-46b9-b2fc-cd920b45fe07">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV80Mw_161df537-c134-4629-84de-525c855bc156"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV80Mw_3ec9394d-3dfc-4ac7-ba5e-94cc9e9c53ee">500,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV82MQ_05ac8c12-0f5b-4a4d-96e0-0faaca73fcf3">60,594,329</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV82OA_a31286fa-d45f-4207-990f-5f722139b0d8">59,800,792</ix:nonFraction> shares at June 30, 2022 and December 31, 2021, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xNTE_e448d452-2aba-4292-95dd-4d297ec86e01">60,583,249</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xNTg_eecaac50-f235-49db-956c-2135216bffe2">59,789,712</ix:nonFraction> shares at June 30, 2022 and December 31, 2021, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMS0xLTEtMjAzNjA_2c799a8f-34ec-4ea9-beed-8b9adc9c4feb">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMy0xLTEtMjAzNjA_635cec90-56eb-4d0b-a44c-2ca7c9883282">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjItMS0xLTEtMjAzNjA_1c755929-d414-49de-8bc2-a9cfb176ebd1">546,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjItMy0xLTEtMjAzNjA_d943878a-81fc-4082-9cd1-582e2d163009">545,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjo4ZjNhMTk1NTMzNTI0NDg3YjRkYzg1MjFjZjQ1MjMwMV8yOQ_760eb86a-c56d-4985-9075-433cff4d84f6"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjo4ZjNhMTk1NTMzNTI0NDg3YjRkYzg1MjFjZjQ1MjMwMV8yOQ_ff21d8af-a2b3-40ce-b557-f3df797de1b9">11,080</ix:nonFraction></ix:nonFraction> shares at June 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMS0xLTEtMjAzNjA_2c600767-e764-40cf-965f-8889f982085d">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMy0xLTEtMjAzNjA_6dba7feb-a81d-46f9-aacd-d4a007cfdc33">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjQtMS0xLTEtMjAzNjA_2f0917c0-356b-46c0-ab55-5247c6684e4d">463,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjQtMy0xLTEtMjAzNjA_d57cb2d3-89fc-4519-95b4-28b1389ac6ed">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjUtMS0xLTEtMjAzNjA_5002b8cb-fbad-46f6-871e-0a17b7b8c87a">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjUtMy0xLTEtMjAzNjA_ffd6359a-7f02-4fce-b07d-38dddf74622b">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Caladrius Biosciences, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjYtMS0xLTEtMjAzNjA_bf6b785a-e34c-47cd-b314-01aa73e1788e">82,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjYtMy0xLTEtMjAzNjA_be4bd98a-08d4-423a-9fdd-39292d1ac254">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjctMS0xLTEtMjAzNjA_db0cf75d-c77a-43bf-95ce-cf1f169e7750">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjctMy0xLTEtMjAzNjA_810d0bbb-6048-4678-b18a-a76055526b26">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjgtMS0xLTEtMjAzNjA_b06ff435-82ec-4525-8be7-ea74d110cc6b">82,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjgtMy0xLTEtMjAzNjA_2f1f7f8c-4163-4a6a-b5b5-316a20896a9e">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests  and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjktMS0xLTEtMjAzNjA_e1a70ba7-eab9-406b-bd4b-63c6715cce86">85,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjktMy0xLTEtMjAzNjA_163e7789-4d40-4751-a7c4-50d58d2f5369">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:58.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy0xLTEtMS0yMDM2MA_02cc104e-672e-4f19-b521-00fae57ef0a4">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy0zLTEtMS0yMDM2MA_e6cb550e-1179-42f3-91a7-bc9573e93a19">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy01LTEtMS0yMDM2MA_b200d892-a2ec-4b0e-8987-da65160f9492">6,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy03LTEtMS0yMDM2MA_ba1b9c21-44ce-413d-80d9-89babfe44311">9,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC0xLTEtMS0yMDM2MA_657ac2f8-eab6-4a84-a92d-d3a9cc2b691b">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC0zLTEtMS0yMDM2MA_3f2ed090-da4d-4aa3-b1cf-dbdd33183004">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC01LTEtMS0yMDM2MA_6ca1f979-837f-452e-9eeb-44475fe6ba50">6,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC03LTEtMS0yMDM2MA_509b4e17-f479-4bfb-9f08-a82f054e6fa0">5,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS0xLTEtMS0yMDM2MA_1f9bfc1c-a421-426f-a294-a15ea3d14f06">6,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS0zLTEtMS0yMDM2MA_4b0099ca-7b60-49cd-94bb-faa5f68c4021">7,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS01LTEtMS0yMDM2MA_d490444c-b320-488f-bc49-d5f9636e96bb">13,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS03LTEtMS0yMDM2MA_bf162895-ac81-4e95-8bb9-3cfac9f3f55f">15,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy0xLTEtMS0yMDM2MA_1f12bd8d-a66d-4e54-b0ac-27019cc071c3">6,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy0zLTEtMS0yMDM2MA_e90952bd-cd04-46ac-8b0d-1e9d173828e0">7,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy01LTEtMS0yMDM2MA_c5fa1b80-2e1e-47bb-8da5-f44c2ddd8151">13,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy03LTEtMS0yMDM2MA_0ae0128c-1c8a-4ad5-9d96-52efab2053eb">15,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtMS0xLTEtMjAzNjA_e7f6cc33-ff16-4873-a35c-95241af04af8">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtMy0xLTEtMjAzNjA_42fcfa86-3152-400d-92a3-afb6cb2e022d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtNS0xLTEtMjAzNjA_e0e98cfd-444d-49aa-bfd1-43ea9e622bab">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtNy0xLTEtMjAzNjA_aba121a1-5802-409f-8726-8287433cf6c2">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtMS0xLTEtMjAzNjA_24677c41-63a1-4301-8528-7359bcc20639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtMy0xLTEtMjAzNjA_af06b5b3-1dce-475a-a560-2bbc37ce2eb4">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtNS0xLTEtMjAzNjA_443c45af-f498-40b0-bdb7-43320898239e">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtNy0xLTEtMjAzNjA_1e2da3e9-55fc-4f1f-a8c1-f4b28374c6f6">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItMS0xLTEtMjAzNjA_50b1a52e-6b34-4dad-b643-b59b8c9b9126">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItMy0xLTEtMjAzNjA_327445df-df04-41da-a4e3-c1d9f752f9d7">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItNS0xLTEtMjAzNjA_be0a891f-9036-4bbf-ac81-0deeee8ed5d3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItNy0xLTEtMjAzNjA_379b8bc3-73bb-4592-8d0b-3b443f2e18c1">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtMS0xLTEtMjAzNjA_7d67629f-f20c-4fe7-9b25-ec579f2455b3">6,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtMy0xLTEtMjAzNjA_5ce7a17b-b30f-4827-b13e-fcf6fe101e53">7,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtNS0xLTEtMjAzNjA_2657742e-2b98-4a5c-b777-cc56d74469c0">13,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtNy0xLTEtMjAzNjA_0f2c75eb-58ee-499a-992b-857f8245675b">15,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtMS0xLTEtMjAzNjA_f2ff4842-328a-4d20-8f24-a5c691eefc7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtMy0xLTEtMjAzNjA_d0c8a8ed-dc67-4da7-90dd-fed3fd4704d3">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtNS0xLTEtMjAzNjA_1445bce1-46fa-4185-b6ee-d80df273fb02">2,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtNy0xLTEtMjAzNjA_ba3f4f4c-9b92-44da-a3d3-e0ca27e9baf0">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtMS0xLTEtMjAzNjA_0c7fe10f-e276-45e5-85ed-f018562dd1bf">6,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtMy0xLTEtMjAzNjA_977662a6-25c4-4b2b-9892-6f1c7b83c44b">5,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtNS0xLTEtMjAzNjA_cdb6ac01-0dc9-40f2-98cc-a98fb9ef5c63">10,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtNy0xLTEtMjAzNjA_aa4f35b5-c80e-4008-b73b-ddf4cea2b90e">13,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caladrius Biosciences, Inc. common stockholders</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMS0xLTEtMjAzNjA_a0526032-8395-41e3-85ed-dc3b7fe0e4ba"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMS0xLTEtMjAzNjA_c7dd9f93-2319-4ef4-9b38-0eff2bac1fb9">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMy0xLTEtMjAzNjA_9c2fd36c-dc16-43d3-9a42-1e964e4e26e7"><ix:nonFraction unitRef="usdPerShare" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMy0xLTEtMjAzNjA_ffd14dcc-f4b6-44ff-99ea-4f3699a13653">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNS0xLTEtMjAzNjA_7684db9d-aa21-4f31-b5ad-962c966eddfe"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNS0xLTEtMjAzNjA_ac04932f-77b8-4c97-95bc-f8a40d988d48">0.18</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNy0xLTEtMjAzNjA_6f6eeecf-700b-4245-b0c4-eb0aa88b9ca0"><ix:nonFraction unitRef="usdPerShare" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNy0xLTEtMjAzNjA_725d7ac2-8533-44a0-9617-714f48e18a03">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMS0xLTEtMjAzNjA_69421ae0-18aa-4148-82d4-c784f6e9f7e3"><ix:nonFraction unitRef="shares" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMS0xLTEtMjAzNjA_bba99ab3-c157-41e8-9837-93afa3e7540f">60,533</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMy0xLTEtMjAzNjA_1a399f05-11a5-4c86-bc80-8e25658eca5d"><ix:nonFraction unitRef="shares" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMy0xLTEtMjAzNjA_447970ac-5fa2-405f-be1a-234b19196f01">59,510</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNS0xLTEtMjAzNjA_a45d68f7-a43a-4167-8465-0b4b6bbeb878"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNS0xLTEtMjAzNjA_da36d905-c40c-40ba-ba03-3f84e2ed2b06">60,546</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNy0xLTEtMjAzNjA_30ca7c2f-eb96-4b51-9ade-bb59a6bb9e62"><ix:nonFraction unitRef="shares" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNy0xLTEtMjAzNjA_daf15435-9961-42ab-aaa8-92e5297524a0">50,862</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:56.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi0xLTEtMS0yMDM2MA_d3bbf3b3-4ad8-496e-9366-d1027c6c1304">6,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi0zLTEtMS0yMDM2MA_ad3f4e11-7595-4da5-9055-874f4b471c3f">5,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi01LTEtMS0yMDM2MA_dc7e5961-88e1-4c12-a4eb-b6d98e4b8526">10,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi03LTEtMS0yMDM2MA_e08c004f-70d0-4303-9bba-968ba53a3b70">13,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS0xLTEtMS0yMDM2MA_cab84911-c12a-4925-8730-928732fafdf9">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS0zLTEtMS0yMDM2MA_64a66cbd-d3af-4555-9695-a28d66abde93">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS01LTEtMS0yMDM2MA_5a262f60-7fd0-47d6-bb54-56846e921fd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS03LTEtMS0yMDM2MA_ce780232-a3b2-496a-9d25-c2aa2e9eccdf">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi0xLTEtMS0yMDM2MA_b66bd60e-2bc8-4eaf-8d42-46c387ea05ad">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi0zLTEtMS0yMDM2MA_32a2158d-8d47-4200-8e91-ae9893fc0dc4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi01LTEtMS0yMDM2MA_c4c9b122-e48b-4d57-b564-ce418062b365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi03LTEtMS0yMDM2MA_ec6d7342-8606-4e0b-909d-902439c64411">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Caladrius Biosciences, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItMS0xLTEtMjAzNjA_c8f823a3-31a1-4ef1-9c90-d64384c1a188">6,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItMy0xLTEtMjAzNjA_7e47396f-bf4a-45b6-8a15-066d79c90f8e">5,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItNS0xLTEtMjAzNjA_dc2ea0f7-896b-4374-b668-c997533dd1f7">10,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItNy0xLTEtMjAzNjA_7f52c839-ef76-4163-abc9-6ec86582deb1">13,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:22.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.870%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Mar 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i826be2afc3e749308a9751d74830964a_I20220331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_1638f7bf-46d4-4adb-bf11-412392e12518"><ix:nonFraction unitRef="shares" contextRef="i826be2afc3e749308a9751d74830964a_I20220331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_ee6f9f92-711f-4634-82f4-142fbb104c88"><ix:nonFraction unitRef="shares" contextRef="i826be2afc3e749308a9751d74830964a_I20220331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_f85e2175-6756-4d58-b01e-f51a56beb57c">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i826be2afc3e749308a9751d74830964a_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0zLTEtMS0yMDM2MA_1c1b4a12-4baa-4e2d-8a64-b4cdd634f9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i144cc71857f7429bb51d544f0b8f9310_I20220331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi01LTEtMS0yMDM2MA_ab2b967a-9347-4491-8c5c-fa43da6ede5b">60,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144cc71857f7429bb51d544f0b8f9310_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi03LTEtMS0yMDM2MA_46515b87-42d3-4fbc-bc44-b902e6f39b3f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7256a903af4b431abebe6883b6c15999_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi05LTEtMS0yMDM2MA_6a0dfa4d-cccb-4234-aa3a-7d585f2ccd87">546,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5008ebb64ec147a187a521f9673cad8e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xMS0xLTEtMjAzNjA_06789f19-8e68-4a82-8d20-0a4eeaf7a55a">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7b06dfb1afa472fb9d01295762e7c9e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xMy0xLTEtMjAzNjA_11901f33-987d-4893-a464-4f58b5a0e668">457,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939cc2c2c6074c0c982765101de3e1fa_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xNS0xLTEtMjAzNjA_30a7980a-782d-456b-ad4f-403222754118">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210747314c0e49419773d046301904e1_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xNy0xLTEtMjAzNjA_b5052771-5fea-417d-97e6-a938eeb7c7bc">88,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ed3ac0e8cc48fd808c48dea00e34fe_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xOS0xLTEtMjAzNjA_78b786e3-61b4-4b91-ac95-e26d5d534bb1">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31306c1aab0247159feb2af89726ee3f_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0yMS0xLTEtMjAzNjA_3cc6231e-f18b-41e1-98f9-90d43cea1594">88,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a0e8a04a5dd47a2955a1779dfb31298_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0xMy0xLTEtMjAzNjA_edf167e7-283b-4c3e-8eeb-552195f9cf86">6,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0xNy0xLTEtMjAzNjA_f341a27a-68f6-4804-a359-872bd17aa3ad">6,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0yMS0xLTEtMjAzNjA_db5573e8-f179-4022-b727-a9a0bc4ffd0f">6,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1123d58c65b6489e899c1698307885f5_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0xMS0xLTEtMjAzNjA_81e22ae7-cf7a-4b32-93ad-823c5f679dd0">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0xNy0xLTEtMjAzNjA_444aed04-5289-45d7-b3c9-7e0dec7cba74">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0yMS0xLTEtMjAzNjA_3813266a-791a-4a62-aa8e-b3dfc0398a35">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS01LTEtMS0yMDM2MA_a938f9d6-9549-4491-871e-761a868ac1b9">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS05LTEtMS0yMDM2MA_eb79f6a1-c10d-447d-9302-5c2403b14923">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS0xNy0xLTEtMjAzNjA_33e1723c-f517-4702-8dca-29694939296a">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS0yMS0xLTEtMjAzNjA_2109c702-d09e-4423-8ab5-c2bf8722efae">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi01LTEtMS0yMDM2MA_6595dd45-c87d-4e34-a686-2b758ede1c68">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi05LTEtMS0yMDM2MA_410ff332-45a4-44cc-bcff-277a48018ccc">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi0xNy0xLTEtMjAzNjA_1a4bb583-0701-4e90-ba8e-549a67a92e18">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi0yMS0xLTEtMjAzNjA_95831b43-2adf-42a0-af7b-6e41631e646f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xLTEtMS0yMDM2MA_667ea17f-6ae7-40c9-9b79-931c34752add">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0zLTEtMS0yMDM2MA_85597fe9-6a06-4945-a082-fc1f5dfaeaf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS01LTEtMS0yMDM2MA_965cdc6a-4ea5-459b-9077-9bf8a213c294">60,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS03LTEtMS0yMDM2MA_06942d96-9dcf-491f-8c99-3cf2ebf03f57">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a24b47dd254dc19e95b10e49ccbed7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS05LTEtMS0yMDM2MA_d6e5d19b-757d-4324-9de3-77fba0e276be">546,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bed893df04e44c1ad362c17a93cfdaf_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xMS0xLTEtMjAzNjA_ef8d7109-16a8-42ca-abbf-d0306078654d">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18265c74af504470b75337fdb7546118_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xMy0xLTEtMjAzNjA_359644ff-1af8-4089-b1de-de3578999098">463,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3285245ca04f458aa72087031b59e41b_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xNS0xLTEtMjAzNjA_6807c491-4e35-45c0-a10d-5dc452101853">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xNy0xLTEtMjAzNjA_13da9c32-e7cd-4473-8bc8-3642df3178d9">82,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie84bb799d59f441f8d0036b10575869f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xOS0xLTEtMjAzNjA_92dc2b90-97b2-4ef8-857f-0e65210a234c">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0yMS0xLTEtMjAzNjA_e8a99f19-040e-43f1-9315-7f88efd9609d">82,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMS0xLTEtMjAzNjA_fdfa2ca1-ecd1-4156-b288-f685b41d3db7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMy0xLTEtMjAzNjA_c707f6eb-78a8-4bfc-b8df-99dee0c1f0c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtNS0xLTEtMjAzNjA_305dea48-9e66-49cd-8241-a81871c4bc54">59,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtNy0xLTEtMjAzNjA_f67639ec-0e35-4811-a581-f9418853733c">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c77282d142f4fb59c41c5f204dbfe92_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtOS0xLTEtMjAzNjA_a508ec91-e8a4-4590-9ad0-cbcda1e03ad0">545,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b047433f88e46ecbc8f6948247e2441_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTEtMS0xLTIwMzYw_0ee3606a-7c64-4939-a5ea-9b946d0d7386">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c105eba1be9452dbca6993cb4fae77b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTMtMS0xLTIwMzYw_76dc3113-0450-4ff8-855e-92aa6c9bac71">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa027f593cfd45789ab829afc443cd85_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTUtMS0xLTIwMzYw_9efaa2f0-ab17-41d7-8250-9013e9ac6e84">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b9cf1c6314423d88f7c7d52b11e494_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTctMS0xLTIwMzYw_f8852cd4-2f93-4c2f-8dac-4b1da1b20893">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifade1f65a2fc44a9a294052965852540_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTktMS0xLTIwMzYw_b93e0ed2-8e01-45ef-9781-92cce8af4a27">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMjEtMS0xLTIwMzYw_7fda6695-5925-4852-bfe6-ff5827050999">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1246f6d72c59416bb70643adff3c35cb_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMTMtMS0xLTIwMzYw_b347b50c-f843-4f2a-9dc8-27826e40b664">10,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMTctMS0xLTIwMzYw_cd18c3fe-158d-435d-a5d4-2cfaa053e7b8">10,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMjEtMS0xLTIwMzYw_10c4dcdd-a0fc-4a33-bb24-db24d24834b4">10,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctNS0xLTEtMjAzNjA_6584c6f2-8bd4-4213-a162-d26d1909d032">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctNy0xLTEtMjAzNjA_56ee592d-25fd-4a1a-af01-87e3a7f89d35">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctOS0xLTEtMjAzNjA_738e4919-ea8c-47f9-9261-fb66ea586e6f">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctMTctMS0xLTIwMzYw_014688ae-2d8b-4631-968e-9a368e03bf51">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctMjEtMS0xLTIwMzYw_99b0053b-dc81-4c4a-83cf-9b5d8e2e745b">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtNS0xLTEtMjAzNjA_a432c79f-24fd-4d19-8baa-7c66defa4fb0">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtNy0xLTEtMjAzNjA_ce060ff3-acae-4d0b-bafc-0f20f76b2b4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtOS0xLTEtMjAzNjA_c59f59c9-7d29-4cc7-807d-26a2205b0fac">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtMTctMS0xLTIwMzYw_73de6f1a-9025-40f0-a5f8-230acf35f99f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtMjEtMS0xLTIwMzYw_6e2ac21e-b1c1-461f-af89-87b19e0108ad">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMS0xLTEtMjAzNjA_9c011e9f-ffd7-4d56-adb0-3ed663203037">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMy0xLTEtMjAzNjA_e0fc36b1-e321-490b-9d5d-bd46df74031e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtNS0xLTEtMjAzNjA_48e66ded-127d-4ac8-9270-f7b03ae731d9">60,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtNy0xLTEtMjAzNjA_1e62d892-f136-4b01-a01c-30bd606583fc">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a24b47dd254dc19e95b10e49ccbed7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtOS0xLTEtMjAzNjA_62b480e9-4f10-42c2-a03d-8014d99284fa">546,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bed893df04e44c1ad362c17a93cfdaf_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTEtMS0xLTIwMzYw_7a31190a-15a8-4829-8348-6123f7b42a28">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18265c74af504470b75337fdb7546118_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTMtMS0xLTIwMzYw_582dc3f9-7e34-4005-a1ed-f2036fb53e7c">463,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3285245ca04f458aa72087031b59e41b_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTUtMS0xLTIwMzYw_46077275-6191-4ad4-b845-c3afefb29b03">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTctMS0xLTIwMzYw_f60e5d1c-e6bc-48f1-acca-a49bd619cfd4">82,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie84bb799d59f441f8d0036b10575869f_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTktMS0xLTIwMzYw_3712f806-a538-4c96-9fe3-ccdaca24ddc4">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMjEtMS0xLTIwMzYw_130cb90c-d8fb-40c1-8b22-48aa5f89cf79">82,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:22.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.870%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Mar 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3384336a7944494b8cb1446514d3f7e_I20210331" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xLTEtMS0yMDM2MA_f3af4651-b986-4d08-af54-4a9d045e8b02">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3384336a7944494b8cb1446514d3f7e_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0zLTEtMS0yMDM2MA_17ec84bc-aab2-424b-80a7-5f6fdda3395b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi01LTEtMS0yMDM2MA_e9be90a6-9d7e-47dd-aad5-1191a2cfd247">59,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi03LTEtMS0yMDM2MA_3c6d00ba-162b-4f66-ab22-ac75bdb18085">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd00509623ed44ddb8f0004f1abf6120_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi05LTEtMS0yMDM2MA_44f28e41-2eef-4064-b61f-f8638d5260bb">544,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88c32da30d114addbead3f239466b8e9_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xMS0xLTEtMjAzNjA_cd2d6592-d52f-4b68-8ee8-af766533a4a6">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78c2932e69ef4d54ac788754fdca2d18_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xMy0xLTEtMjAzNjA_f074ffd3-7c53-4487-9c84-8c6dec5eea89">433,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6af4cb66e154f95939adbff59e13392_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xNS0xLTEtMjAzNjA_c4ed690c-b841-43ad-8f36-d8589a7f3890">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9599115241c54766a1a636684b8b060e_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xNy0xLTEtMjAzNjA_64e147d9-99b9-44ce-8159-9069c6bb5bdf">110,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ad465c32b5844118f00a809aaff3997_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xOS0xLTEtMjAzNjA_e5f992a2-4c7f-476a-9e94-6144eceacf5e">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b43e8ae838c493d815ea92bdae4b1fc_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0yMS0xLTEtMjAzNjA_715d4f47-f56e-4238-a685-0fd1c3914be1">110,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i603559893c614cd2912e389072705619_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0xMy0xLTEtMjAzNjA_6e4014d9-855a-4c20-a655-6ff79d0b7a16">5,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0xNy0xLTEtMjAzNjA_d9915101-f81d-4be8-8d70-0f73a7b4bc68">5,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0yMS0xLTEtMjAzNjA_1b28a9c6-4c44-4627-b6c4-141ec5ff0192">5,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4c8cad9db9466db265fc7fc23b3c86_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0xMS0xLTEtMjAzNjA_a1353bc7-90c7-44c0-bec6-697c3e91981d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0xNy0xLTEtMjAzNjA_7de8edb3-0870-47ef-a932-3de26eea5569">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0yMS0xLTEtMjAzNjA_b2074ec5-cb14-412a-9ef7-d07f6c34e2eb">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b57810d948345c6bc01749f37102642_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS05LTEtMS0yMDM2MA_801f875e-04c1-46bc-b414-9439aadaa4ba">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS0xNy0xLTEtMjAzNjA_a438e982-7829-458c-bdfa-ae41abd2abe0">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS0yMS0xLTEtMjAzNjA_68527e79-f524-4bc3-8257-da1037089b01">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi01LTEtMS0yMDM2MA_c4fa84a5-ee1e-48f6-aea7-671a7cbfcdd5">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi03LTEtMS0yMDM2MA_c247b5b0-3ae6-4977-ad43-d5bf7ecd53e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b57810d948345c6bc01749f37102642_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi05LTEtMS0yMDM2MA_fccf4540-83e5-4f75-8ed6-6548182dbec6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi0xNy0xLTEtMjAzNjA_0deb88fc-40b0-4000-8868-26f7bc14ed5a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi0yMS0xLTEtMjAzNjA_b16883f4-cea3-412e-b7d6-8f2c4615e19e">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xLTEtMS0yMDM2MA_f747dc02-1dfb-462c-aed2-a27f47d2d495">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0zLTEtMS0yMDM2MA_499ec592-fed6-4d2f-b072-5147f6752051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS01LTEtMS0yMDM2MA_5e9251e2-592c-4d1f-83f6-8748567898cd">59,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS03LTEtMS0yMDM2MA_7df58f32-561c-4d20-8695-d11eb1ecc663">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525428cb5044f9dad07f0198a966b18_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS05LTEtMS0yMDM2MA_ef0d1e0c-b809-4681-aa84-19654b126267">544,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xMS0xLTEtMjAzNjA_31e6dc75-0c28-4a7e-abc1-7f9f21950a09">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xMy0xLTEtMjAzNjA_fc2be709-8296-4817-b82a-9df24e62e8a6">439,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNS0xLTEtMjAzNjA_128cb016-3c1d-499b-9a4c-4aabb9a54403"><ix:nonFraction unitRef="usd" contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNS0xLTEtMjAzNjA_821dc3db-2050-445b-af2c-1f89e54deb51">708</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNy0xLTEtMjAzNjA_b9350a0e-58d5-4ac9-8796-0d262ea47875">104,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4aa152b86594c1daab508f7a3371e7e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xOS0xLTEtMjAzNjA_24ad045c-fb6f-4cf0-b0f6-1233a3a4f57e">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0yMS0xLTEtMjAzNjA_9af7c39c-0a5c-43f3-b819-9a7a79a19f7d">104,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11509a49300e4d2cad12d712bd9a7433_I20201231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMS0xLTEtMjAzNjA_e4106993-e811-47a1-8d9d-1f63cbb958be">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11509a49300e4d2cad12d712bd9a7433_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMy0xLTEtMjAzNjA_323dea8c-de26-4661-bca2-b959a1c3ae5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtNS0xLTEtMjAzNjA_bb55cec7-27e8-4d3e-b995-df6468966612">19,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtNy0xLTEtMjAzNjA_4ef518c2-b122-4a93-a6ec-ba1040e759fd">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c51dda04204b5ea7441d1f68c81706_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtOS0xLTEtMjAzNjA_8c93266e-a287-478b-9e0f-3751e639aa76">458,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92a95e7cdc8d4bc1ad9b84ffd5e3f68b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTEtMS0xLTIwMzYw_874bc0bf-6e6a-4e33-9429-81ba092b6e4b">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6aedcf6bdef487f875f1aafded60667_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTMtMS0xLTIwMzYw_508e87f3-7216-4b99-9584-d4379810c10d">425,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1573c590f9ad4ed5bbed7597658b47ec_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTUtMS0xLTIwMzYw_4bf0b7cd-687e-4c5f-91dd-b05494c4eb3b">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a41562d90542fdbfbc872ae7d68b02_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTctMS0xLTIwMzYw_446f3176-16b0-4ea3-9cf7-09a060281976">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib04d15ea5e1d45368d6e6e3fe784f7e8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTktMS0xLTIwMzYw_070e771f-089a-400d-8bfb-89f876954574">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMjEtMS0xLTIwMzYw_6233b26a-2b62-4de8-9ecb-f45ee169c852">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1920cbc31b314e8681271adf19a0cce4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMTMtMS0xLTIwMzYw_784a98d7-a064-400c-8ce9-824d4b920571">13,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMTctMS0xLTIwMzYw_9893c7d1-def3-4129-bd57-3aaf8b9b9832">13,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMjEtMS0xLTIwMzYw_dbb98d6e-969b-4b71-8158-f0a14a25b1a6">13,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i052a9e1cdcbe4746bce1dc6273233d80_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMTEtMS0xLTIwMzYw_61ccffca-550e-475a-afb6-4b4f939e7714">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMTctMS0xLTIwMzYw_a5e8aa26-53f8-435f-85cf-c0366099fe06">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMjEtMS0xLTIwMzYw_905e36de-f2f1-4d27-895f-556ecdd841d1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctNS0xLTEtMjAzNjA_6ac46fc1-7a59-45b8-83ee-33db3daac138">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctOS0xLTEtMjAzNjA_948ebc70-0d69-4298-8b87-12eb9eda8581">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctMTctMS0xLTIwMzYw_f76069e0-67a7-4c0e-8f56-a744674186c1">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctMjEtMS0xLTIwMzYw_efb284a9-021c-4ef6-8fa7-1ebaf740b949">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtNS0xLTEtMjAzNjA_7005bfd5-bfc4-4d0d-b320-a30a2e2b57c7">39,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtNy0xLTEtMjAzNjA_9fdbfba4-834d-471d-86e1-414937fea460">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtOS0xLTEtMjAzNjA_a3a54fdd-9bd9-422b-b3a2-335c6175f81c">85,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtMTctMS0xLTIwMzYw_9983ef26-b8e1-42ba-864a-33f4300c2142">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtMjEtMS0xLTIwMzYw_dbccf54d-d1f6-45fd-91d0-c50950b1eef1">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktNS0xLTEtMjAzNjA_71ccf796-3605-4c7d-b56b-354aa9c75e2d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktOS0xLTEtMjAzNjA_e5ab5b5e-7575-4646-aa60-78e8e910085f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktMTctMS0xLTIwMzYw_a7d33ca4-cad4-42a9-bc6d-0fd5d24c483b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktMjEtMS0xLTIwMzYw_9e1af3e9-63ed-4ef2-b50f-47930694f7d0">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMS0xLTEtMjAzNjA_ebbcd55a-00ad-402d-b71b-5a435f02a337">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMy0xLTEtMjAzNjA_83c5d3db-e0f5-4ec3-9d94-4ab5f110e1e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtNS0xLTEtMjAzNjA_9497b17e-a406-4466-92d9-1893a00dc2fe">59,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtNy0xLTEtMjAzNjA_bfc7dd68-ab5b-4690-a467-e6d3c0a24534">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525428cb5044f9dad07f0198a966b18_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtOS0xLTEtMjAzNjA_2615bef3-d8eb-4b2e-84da-d1bc7c907edc">544,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTEtMS0xLTIwMzYw_4a3beff4-bf46-469d-86e0-0eb56e31c7f0">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTMtMS0xLTIwMzYw_0c24463e-f5a7-46d3-bfaa-de26afdf29e3">439,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTUtMS0xLTIwMzYw_d254625e-4df7-45c6-8f14-8c30e4ce0766">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTctMS0xLTIwMzYw_db8ebe49-d2b3-4f65-bc26-650bdee87f95">104,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4aa152b86594c1daab508f7a3371e7e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTktMS0xLTIwMzYw_fffb59e1-6f88-4613-b2e4-baa6bdf395e8">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMjEtMS0xLTIwMzYw_fd10a50d-0491-49e8-b3c5-226d2351e759">104,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMy0xLTEtMS0yMDM2MA_0d52e56e-dda2-423d-ab75-63ae34433aa9">10,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMy0zLTEtMS0yMDM2MA_b8946df4-6ebf-42ae-9b4f-02e086703cae">13,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNS0xLTEtMS0yMDM2MA_53a2daa5-d7ab-4939-8d4f-b2d4c5022d8f">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNS0zLTEtMS0yMDM2MA_af6c5881-6f76-41d2-a73f-743307321d21">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNi0xLTEtMS0yMDM2MA_93899255-4291-4d58-8d54-24656bd709f5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNi0zLTEtMS0yMDM2MA_b0bf4537-4753-48e6-b17d-0222e8fbc155">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfOS0xLTEtMS0yMDM2MA_e2246424-52c3-4565-9539-a482d2a4de7e">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfOS0zLTEtMS0yMDM2MA_c4f2aa91-824d-4c57-88b3-096cecfaaaf8">1,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTEtMS0xLTEtMjAzNjA_de5f9b81-7511-4c29-90a9-a31f1b4afd3d">744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTEtMy0xLTEtMjAzNjA_3ee88200-0684-4de9-ac3f-833ac0137f35">1,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTItMS0xLTEtMjAzNjA_1f9cc056-39b7-4c6e-a49a-49a3eda6c248">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTItMy0xLTEtMjAzNjA_692f20e0-66c3-4350-b34e-31ed09736f6c">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTMtMS0xLTEtMjAzNjA_f55857f9-f5b0-4c3c-9046-03e39cb15f25">1,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTMtMy0xLTEtMjAzNjA_017c0ee6-d473-4553-b382-b066fdb03f07">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTQtMS0xLTEtMjAzNjA_b08d7043-7382-4c7a-a325-9c46805e466c">10,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTQtMy0xLTEtMjAzNjA_4d96deb6-032b-4a17-91fc-9f7498bfc173">12,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTYtMS0xLTEtMjAzNjA_e5674435-8626-49f4-8c53-969921b30120">30,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTYtMy0xLTEtMjAzNjA_82eeec67-da61-45a1-ba42-fa902dcfdbd8">105,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTctMS0xLTEtMjAzNjA_8759fcc4-7314-4c05-bb8e-41acdeb2a3d3">60,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTctMy0xLTEtMjAzNjA_75282651-a163-4459-b76a-3f2bdfa8a57f">29,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTgtMS0xLTEtMjAzNjA_e5ab22d8-64bc-40cf-99d2-6ac2eb3dcc9e">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTgtMy0xLTEtMjAzNjA_1fcb8772-62b2-4d88-ae44-37d37534350f">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Cend Therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMS0xLTEtMjE1NDQ_59ae514d-ed03-4031-b4f8-98afb4aa50d5">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMy0xLTEtMjE1NTE_5ccb8733-b27d-466b-ae4a-dc3feaf74873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMS0xLTEtMjAzNjA_00d87df8-00a6-4b73-bb43-f5ca07e4fcca">19,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMy0xLTEtMjAzNjA_efd01db6-55ea-4700-9fe7-b17ab86cb542">76,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjEtMS0xLTEtMjAzNjA_3f1b0e67-9412-4fc8-9244-3488bdc1b21f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjEtMy0xLTEtMjAzNjA_959019cd-ceef-4ea9-8331-81433da208b3">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjItMS0xLTEtMjAzNjA_699e2f88-430e-4995-9f1c-9ff6c4e9bd26">168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjItMy0xLTEtMjAzNjA_a205fab6-9125-4314-b781-8f66fc0f182a">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjMtMS0xLTEtMjAzNjA_1e35468d-6d17-48fd-b1fb-8387dac0bfab">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjMtMy0xLTEtMjAzNjA_4d43769a-eba0-4882-8e71-76e91eec3479">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjUtMS0xLTEtMjAzNjA_9ed4a323-0bb0-4666-9f8f-4fb3c90c4163">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjUtMy0xLTEtMjAzNjA_77a4b12e-cad6-4176-a865-35baa60901be">85,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjYtMS0xLTEtMjAzNjA_4a32edc4-0c65-44ae-9cb1-e173f9a48896">8,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjYtMy0xLTEtMjAzNjA_f2949196-8790-480a-a566-686281005409">3,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjctMS0xLTEtMjAzNjA_526dea1e-88d6-4584-82e1-6083fec9a1aa">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjctMy0xLTEtMjAzNjA_e92f504f-22f4-4b44-aaba-12bebc68eafa">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjgtMS0xLTEtMjAzNjA_6777f4a5-79de-4d09-9e3f-601e78386b2a">33,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjgtMy0xLTEtMjAzNjA_a41ff09e-80b5-42a5-8181-f016d86df5aa">12,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:BusinessTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ3OTg_b551a274-0a3b-4b31-a571-ff72e197a0e5" continuedAt="if9c5e6a0c04346978490a1fef46016d3" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="if9c5e6a0c04346978490a1fef46016d3" continuedAt="i01ee1cedc0234849ad29ab7ce1d5ea4b"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 26, 2022, the Company and Cend Therapeutics, Inc., a Delaware corporation (&#8220;Cend&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;), subject to the terms of the Merger Agreement and stockholder approval of the transaction. Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately <ix:nonFraction unitRef="number" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="2" name="clbs:MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjQ5MA_9c40cddc-44de-46e2-b939-bbc317934c2a">50</ix:nonFraction>% of the outstanding shares of Caladrius Common Stock and the Company&#8217;s stockholders as of immediately prior to the Merger are expected to own approximately <ix:nonFraction unitRef="number" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="2" name="clbs:MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjY0OA_72bd1fdb-04fe-43f3-a44c-e8d49f9a49d8">50</ix:nonFraction>% of the outstanding shares of Caladrius Common Stock.  The actual allocation will be subject to adjustment based on our net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $<ix:nonFraction unitRef="usd" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="-3" name="clbs:MergerAgreementTransactionExpensesThresholdForRatioAllocation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjg3NA_22dbf7d4-ed3a-4c7e-a9d6-556bec2fb96c">250</ix:nonFraction>&#160;thousand at the time of closing. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including but not limited to Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, with the assistance of a $<ix:nonFraction unitRef="usd" contextRef="i7de6a11cd3474c6287cb381192ae5762_I20171231" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfNDM5Nw_19c088d9-c3fc-4640-839d-8378885416f3">1.9</ix:nonFraction>&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept, open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i01ee1cedc0234849ad29ab7ce1d5ea4b" continuedAt="i448e6ae38fd64e73b5aca70cfbc9d752"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease and was expected to complete enrollment in approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">as well as with a contrast agent typically used in many catheter laboratories. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intends to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The interim analysis is expected to be completed in the third quarter of 2022, and the next steps in development of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> will subsequently be determined after appropriate regulatory and business review, expected to be announced prior to year-end 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment in the fourth quarter of 2021. Following study suspension, the Company completed all protocol-defined patient observations and is preparing the clinical study report. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is now in the pre-consultation phase of the registration process with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan.  Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan has been compiled and is expected to be reviewed by PMDA during the third quarter of 2022 after which the PMDA is expected to provide important perspective to be considered in preparation for the formal consultation meetings which precede the Japanese new drug application. The Company is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan. This may include the completion of enrollment of the four-remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's PMDA under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt of orphan designation from FDA in March 2021 in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue U.S. development in Buerger's disease at this time.<br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol includes six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study then permitted the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. The Company treated the first patient in the CLBS201 proof-of-concept study in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i448e6ae38fd64e73b5aca70cfbc9d752" continuedAt="ide22f1d2880047d79ea75cc1eb8736ef"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">end Merger Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, the Company and Cend entered into the Merger Agreement. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Cend and the Company&#8217;s satisfaction of a minimum net cash threshold at closing, expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="-5" name="clbs:MergerAgreementMinimumNetCashThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTAyNA_43407bfc-1a29-47d0-bd96-65023c98da08">64.9</ix:nonFraction>&#160;million assuming a closing at the end of the third quarter of 2022, and as described further in the Merger Agreement. The Merger Agreement contains certain termination rights for both the Company and Cend, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Cend a termination fee of $<ix:nonFraction unitRef="usd" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="-5" name="clbs:MergerAgreementPotentialTerminationFeePayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTAzOQ_f05dcf7f-a6b4-4c0c-b1aa-96fbbc218e6a">1.0</ix:nonFraction>&#160;million, Cend may be required to pay the Company a termination fee of $<ix:nonFraction unitRef="usd" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="-5" name="clbs:MergerAgreementPotentialTerminationFeeReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA1Mw_d61324ab-67fc-4cd9-939c-131b2e1fea75">4.0</ix:nonFraction>&#160;million, or in some circumstances reimburse the other party&#8217;s expenses up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426" decimals="-5" name="clbs:MergerAgreementPotentialExpenseReimbursement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA2Nw_12927c8a-7b9c-4aee-9603-fa24c01fd9d4">1.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the effective time of the Merger, the Company&#8217;s Board of Directors is expected to consist of nine members, four of whom will be designated by the Company, four of whom will be designated by Cend and one member who will be mutually agreed between the Company and Cend.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide Cend with capital for its development programs prior to the closing of the Merger, the Company and Cend entered into a Series D Preferred Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company purchased from Cend <ix:nonFraction unitRef="shares" contextRef="i0492a0dc655845a9b2daa971f3aa0ee6_D20220426-20220426" decimals="INF" name="clbs:PurchaseOfPreferredStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA5MQ_8dcfa27a-c899-42a5-a6e7-6ac104c7d353">1,135,628</ix:nonFraction> shares of Series D Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib7d7e60b43454d24bd9f8aab2bdd049a_I20220426" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA4MQ_2e52e780-90ed-4606-8a35-38eaa8ecb819">0.00001</ix:nonFraction> par value per share (the &#8220;Series D Preferred Stock&#8221;), of Cend at a purchase price per share equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426" decimals="4" name="clbs:PurchaseOfPreferredStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTE0Mg_f991113e-356f-4513-9f34-95fb83034635">8.8057</ix:nonFraction> per share (the &#8220;Series D Original Issue Price&#8221;), or approximately $<ix:nonFraction unitRef="usd" contextRef="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426" decimals="-6" name="clbs:PurchaseOfPreferredStockAggregatePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTEwMg_9b8aa6f3-427c-4aab-b91d-ee61dcb5fef3">10</ix:nonFraction>&#160;million in the aggregate. The Series D Preferred Stock ranks senior to Cend&#8217;s common stock and the other series of preferred stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of Cend. The Series D Preferred Stock has a liquidation preference equal to the Series D Original Issue Price plus an amount equal to any accrued and unpaid dividends to the date of payment and will participate with Cend&#8217;s common stockholders and other preferred stockholders thereafter on an as-converted basis. The Series D Preferred Stock shall vote with the common stock on an as-converted basis on any matters presented to the stockholders of Cend.  Each share of Series D Preferred Stock is convertible, at the option of the holder thereof, into such number of shares of Cend common stock as is determined by dividing the Original Issue Price by the conversion price in effect at the time of conversion, which conversion price shall be the Original Issue Price as appropriately adjusted for stock splits, stock dividends, combinations, and subdivisions of Cend common stock, and as adjusted pursuant to a weighted-average antidilution adjustment. The Series D Preferred Stock will automatically convert into shares of Cend common stock upon the closing of a firm-commitment underwritten initial public offering implying a pre-equity offering value of at least $<ix:nonFraction unitRef="usd" contextRef="i1b3345a69c3d4ae293e0976208942eda_I20220426" decimals="-6" name="clbs:PreEquityOfferingValueAfterConversion" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTExNQ_8e0b51b6-b7cb-4057-afdb-d1e28e23776c">250</ix:nonFraction>&#160;million, resulting in at least $<ix:nonFraction unitRef="usd" contextRef="i2adcb8be9d2546328e9ae61565dec3b3_D20220426-20220426" decimals="-6" name="clbs:GrossProceedsOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTEyOQ_b4d1f75f-41a4-496c-a59d-ca9830b3c3b7">50</ix:nonFraction>&#160;million of gross proceeds to Cend. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with such Purchase Agreement, Cend entered into a Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;), pursuant to which the Company agreed to collaborate with Cend on certain developmental and clinical activities prior to the closing of the Merger. Pursuant to the Collaboration Agreement, the Company and Cend have formed a joint steering committee (the &#8220;Committee&#8221;) comprised of individuals from both entities. The Committee meets regularly and is responsible for monitoring ongoing studies and making recommendations for development activity and trial planning. Cend has agreed to pay each member of the Committee from the Company an hourly consulting fee for such service.  As of June 30, 2022 the cumulative services provided under the agreement totaled $<ix:nonFraction unitRef="usd" contextRef="i4bfdf542e13048bbbd63568d248c0ea6_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTE1MQ_4fc8d1c1-c74a-49c9-bdd1-8aa207091841">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as well as with a contrast </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="ide22f1d2880047d79ea75cc1eb8736ef"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ4MDk_ba206e7b-debb-4d3a-ad56-3e07fe6b1450" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ3OTM_145d6f5f-7d74-4b85-b0e4-436ea404802b" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ4MDU_10e7d46f-3f1f-4886-9f54-ac5bcbb5b8aa" continuedAt="iabd60c150f8f443083e250b4e6c73b36" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iabd60c150f8f443083e250b4e6c73b36">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.<br/></span></div></ix:continuation><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE1MA_30c08881-5dca-468e-a70f-3030ab9f8f20" continuedAt="i65fd34c5083d4bae93b5776c1072875b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i65fd34c5083d4bae93b5776c1072875b" continuedAt="ib5cd1e1ee4d240a8bf4f6758bd4aa385"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2021 Form 10-K. There were no changes to these policies during the three and six months ended June&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE2NQ_1d071ebc-eccb-44b9-a61b-8343dcae0c34" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE1Mw_eb02d4c5-dc5f-4980-8267-9bf906fd7914" continuedAt="id1ae489fef1f4ed794e7439f47daba63" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="ib5cd1e1ee4d240a8bf4f6758bd4aa385"><ix:continuation id="id1ae489fef1f4ed794e7439f47daba63"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Cend Therapeutics</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in which the Company has no significant influence (generally less than a 20% ownership interest) or does not have the ability to exercise significant influence are accounted for under the measurement alternative method pursuant to ASC 321, Investments&#8201;&#8212;&#8201;Equity Securities (&#8220;ASC 321&#8221;) as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as investments on the consolidated balance sheets and any impairment recognized related to these investments are presented in other income (expense), on the consolidated statements of operations (see Note 5, &#8220;Fair Value Measurements&#8221;).</span></div></ix:continuation></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_40"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjI1_48f4a56d-20cc-4494-8e45-d1b2e7e92eb9" continuedAt="ic24fac9596174080a02d1549893febdf" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="ic24fac9596174080a02d1549893febdf"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjMy_2b003a50-ba34-4b9b-a721-d6c18ba5b6d3" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xLTEtMS0yMDM2MA_87a6c368-4e87-4edc-880f-5bc580b233aa">26,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0zLTEtMS0yMDM2MA_a2a83651-1b1d-4699-a4b2-11186fdebc1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy01LTEtMS0yMDM2MA_6f13a452-a08b-44ec-bc15-6c99d664913d">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy03LTEtMS0yMDM2MA_879ff263-28ba-49e0-9b8d-b904a8a94059">26,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760113b860d24918972b88966a39461f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy05LTEtMS0yMDM2MA_cb551253-bdd5-4706-9387-1a36226f074a">53,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760113b860d24918972b88966a39461f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xMS0xLTEtMjAzNjA_e26b78c9-69f9-4325-b029-8c7d2cd16008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i760113b860d24918972b88966a39461f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xMy0xLTEtMjAzNjA_75f3c899-8948-4938-b677-9cf9bb3237ee">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760113b860d24918972b88966a39461f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xNS0xLTEtMjAzNjA_f3b964d3-b90b-42b1-ab7a-4c8379069632">53,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7da78337e4f97b4635d629086a480_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xLTEtMS0yMTYwMw_65edb7d1-875f-4257-acf5-a04c7384483a">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7da78337e4f97b4635d629086a480_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0zLTEtMS0yMTYwMw_a5249772-451a-4e58-8bfc-ce643b35482b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7da78337e4f97b4635d629086a480_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC01LTEtMS0yMTYwMw_ae0ca589-e7dc-46e4-8411-cad45f9a712b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d7da78337e4f97b4635d629086a480_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC03LTEtMS0yMTYwMw_9beb4dc4-978c-4ff1-8366-c9a15167081c">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC05LTEtMS0yMTYxMg_c5608a0d-182b-42dc-b6aa-804a5412fcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMS0xLTEtMjE2MTI_9769d7eb-075b-409d-b954-869066ab9e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMy0xLTEtMjE2MTI_64606d78-72e7-4f56-8b47-b697ee007924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xNS0xLTEtMjE2MTI_6094f52b-fc00-4156-98f3-10cfce1acbdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xLTEtMS0yMDM2MA_e7c6c9ce-38ec-4e67-9c9a-8783ec696e2e">22,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0zLTEtMS0yMDM2MA_9ffb08cf-b230-4d86-ae4f-000ddc243576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC01LTEtMS0yMDM2MA_a772f4d5-9e7f-4c54-8f31-9990a711e117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC03LTEtMS0yMDM2MA_49d82579-ab7d-4001-ac2c-08a03f9cc74d">22,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC05LTEtMS0yMDM2MA_73db7af9-68dc-444d-8d76-039e2b935933">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMS0xLTEtMjAzNjA_2c0debed-b097-49c9-8add-2f5037e49dbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMy0xLTEtMjAzNjA_c74541cc-cd02-461c-b0b9-4997022a681a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xNS0xLTEtMjAzNjA_5903f9ab-0b89-401d-9e04-abbf12a25fb7">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xLTEtMS0yMDM2MA_8c5aaa19-5a09-4fce-9d8e-125d1463f2d2">17,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0zLTEtMS0yMDM2MA_088a8480-0757-46c5-abb4-08433e65b7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS01LTEtMS0yMDM2MA_94ca56db-4939-4ecd-b971-6935e3b78326">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS03LTEtMS0yMDM2MA_5a8e4c37-53ee-42a8-bfa3-d3cd1869bd29">17,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS05LTEtMS0yMDM2MA_b11cb87a-65d2-494c-87a9-af10686acfef">20,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xMS0xLTEtMjAzNjA_42c1c03e-e4e7-423e-9eb2-e6df7c733daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xMy0xLTEtMjAzNjA_de075489-fdc7-4ada-8d89-fcf5aef28193">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xNS0xLTEtMjAzNjA_86b2da08-1f5c-42e9-ad0d-7c9367f1ec39">20,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xLTEtMS0yMDM2MA_0ef32d82-a840-4838-afe4-02de7eee7603">69,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0zLTEtMS0yMDM2MA_bb0babeb-24eb-449b-b02d-ff6e1da65265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy01LTEtMS0yMDM2MA_5bbfa505-aef5-47cf-8da1-7083073ac5b3">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy03LTEtMS0yMDM2MA_4f554193-84c6-4710-827a-d9b9f396645a">69,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy05LTEtMS0yMDM2MA_8a043697-4c9c-4234-b5eb-deed64e4bf01">91,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xMS0xLTEtMjAzNjA_4fb2293b-a06c-4e50-807f-92288c276f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xMy0xLTEtMjAzNjA_6240405b-5a9f-44b6-ac39-c8cb2a184324">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xNS0xLTEtMjAzNjA_4078118e-1173-43e8-a1b5-c952c95add07">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjM2_84de7add-e433-4853-a448-9ce0bb23f188" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMS0xLTEtMS0yMDM2MA_ba466893-1194-430d-a85f-72d606e418f5">30,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMS0zLTEtMS0yMDM2MA_f0a71969-a319-4ffe-a7f5-a3785a3c8dce">21,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMi0xLTEtMS0yMDM2MA_ee31ff35-cfbf-460d-8364-44e40eeae84a">39,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMi0zLTEtMS0yMDM2MA_46bac5fd-7fc8-4385-897a-b1034eb3e82a">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMy0xLTEtMS0yMDM2MA_edaf0f87-0c15-45af-b45c-c160024eed09">69,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMy0zLTEtMS0yMDM2MA_7d4b6f46-700c-470f-8762-dae11deb5567">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjE5_ac11ad65-564b-4956-8f12-1a3a81e2bd98" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMi0xLTEtMS0yMDM2MA_e96dc9d1-9e4c-40a5-a024-7accffdc7919">69,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMi0zLTEtMS0yMDM2MA_e845e779-c265-45e2-b419-1430432818c4">69,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMy0xLTEtMS0yMDM2MA_4922db38-246e-4df3-8969-ca5ff24845e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMy0zLTEtMS0yMDM2MA_3238389f-5de7-496a-b13a-ee9978acbfd6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfNC0xLTEtMS0yMDM2MA_da2ad5bf-b7ab-49ff-904a-e361fed33661">69,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfNC0zLTEtMS0yMDM2MA_e42658d8-9e18-4b1e-966a-e86a00425b41">69,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_46"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RleHRyZWdpb246YTMzZGE4MDg3OGY2NDI5Nzg3OThjMWI3MDk3ZWExZDJfMzIx_eb3a4bef-ab82-47e5-ad67-8ffabaa4660e" continuedAt="ia8e6edb551b1459f82792620aa5b443a" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8e6edb551b1459f82792620aa5b443a" continuedAt="ie483a3344c8e4777b7723b0c3c021323">For the six months ended June&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RleHRyZWdpb246YTMzZGE4MDg3OGY2NDI5Nzg3OThjMWI3MDk3ZWExZDJfMzMw_93fe93e8-e106-42be-90a4-e6608edbf746" continuedAt="i555c2a90af234036bee42856691ecf68" escape="true">At June&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-top:5pt"><ix:continuation id="ie483a3344c8e4777b7723b0c3c021323"><ix:continuation id="i555c2a90af234036bee42856691ecf68"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMi0xLTEtMS0yMDM2MA_60119a0d-d1a2-4b90-a50f-753db078be31">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie46e3b754c67413c88f24c3ddff1552f_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMi0zLTEtMS0yMDM2MA_f6d4b0f1-1ed5-4533-96f1-4516b0166336">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c93d7a7931742669a283947008740ed_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMy0xLTEtMS0yMDM2MA_2286d22d-0d04-4aa5-bd4c-5765f9f51094">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d5ab7d1d8304b70a0409715de916340_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMy0zLTEtMS0yMDM2MA_faa7b193-b935-4af6-8715-6957e1fc1484">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5311053f8ab4baab4847164c5f36d3a_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfNS0xLTEtMS0yMDM2MA_1edbcfe7-5501-4997-8bd9-c8032597b7ab">1,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94f725c87ad542dcb3ff3f4d00fc0e9d_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfNS0zLTEtMS0yMDM2MA_539c3d59-602c-40ba-bfbc-139210cf98a7">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_49"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RleHRyZWdpb246OWMxNmVhMTI1YjQ5NDI5YWFkNTMyMWI5YTIxMTA3ODBfMTQ2Ng_9022c1c4-69d6-4fed-8abe-c1ad4cd1a403" continuedAt="i5658362b011a4b34a3093a041dcf6b84" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i5658362b011a4b34a3093a041dcf6b84"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RleHRyZWdpb246OWMxNmVhMTI1YjQ5NDI5YWFkNTMyMWI5YTIxMTA3ODBfMTQ3Mw_3ec1aa52-8c3f-4edd-b65f-0548261e762b" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6233584e5a4a50b728139e0d6c6159_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0yLTEtMS0yMDM2MA_99d52455-5aa4-4c94-a575-6d34f80a2ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461576cc6a4e4084a8c496c3c34ed239_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy00LTEtMS0yMDM2MA_45243f7b-0dbf-447b-a705-de0f26bd39a8">39,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy02LTEtMS0yMDM2MA_23e496ac-25bc-40ec-90e8-f7ccbda60518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy04LTEtMS0yMDM2MA_ca790a49-3aae-40ea-bd7f-c1ea764bdd71">39,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xMC0xLTEtMjAzNjA_21290d85-cd84-4911-8f62-007427a9658b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4f1d501291470683152d8d06246393_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xMi0xLTEtMjAzNjA_081cc60a-4bd5-40bb-b14c-0104eda0d8dc">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169c2b19485743c494294b605e1c9637_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xNC0xLTEtMjAzNjA_8f037b27-bd6e-4fbc-ab9d-80533856259c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0af1b219794ef094dabc670988af20_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xNi0xLTEtMjAzNjA_5457aed6-a27b-41e9-a081-8074834258da">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Cend Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC02LTEtMS0yMjM1OA_6d69934b-22a9-48bf-83cf-4a0fc34189be">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC04LTEtMS0yMjM1OA_aafb351d-e201-4d2d-a679-efae6599cbc6">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6233584e5a4a50b728139e0d6c6159_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0yLTEtMS0yMDM2MA_e09c9ad2-aed0-440c-97f1-f3101de0cc18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461576cc6a4e4084a8c496c3c34ed239_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC00LTEtMS0yMDM2MA_39939a70-8776-4a04-baca-1cf37b67a838">39,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC02LTEtMS0yMDM2MA_09c90a15-4cc1-4dcf-9951-43f907c8d141">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC04LTEtMS0yMDM2MA_7ed1a111-08ad-49a4-b66f-58ce7d45cac8">49,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xMC0xLTEtMjAzNjA_fe108514-d8fb-474c-86ff-09cf8cd2349b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4f1d501291470683152d8d06246393_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xMi0xLTEtMjAzNjA_3b4d7bed-cc7a-45fd-b2b5-ad1ab2d6789b">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169c2b19485743c494294b605e1c9637_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xNC0xLTEtMjAzNjA_15308ece-77fb-4a16-acf7-2e1890657da4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0af1b219794ef094dabc670988af20_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xNi0xLTEtMjAzNjA_05ef0f97-a6f7-4b09-9ad1-881135df1693">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6&#160;&#8211;&#160;<ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RleHRyZWdpb246MDFiZmZkMDk5MjMyNDg1OWJmMTFmYjQ3OTBhYzkyMDRfMTEx_bf9edcfe-6baf-49b7-91ac-317995802644" continuedAt="if2563017379d49faaff3b3cf72ef12bb" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="if2563017379d49faaff3b3cf72ef12bb"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RleHRyZWdpb246MDFiZmZkMDk5MjMyNDg1OWJmMTFmYjQ3OTBhYzkyMDRfMTA1_b7fe9dc6-55c1-431a-ab53-a764eb1db588" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMS0xLTEtMS0yMDM2MA_219319ea-1bfc-4dd3-a003-a286dfc8a721">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMS0zLTEtMS0yMDM2MA_f6def31c-5b03-45ce-8401-d354ad9473c3">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMi0xLTEtMS0yMDM2MA_bcb5b5a4-c853-4c60-9b65-9f442595d710">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMi0zLTEtMS0yMDM2MA_5323a087-f664-46a3-ba66-efa363e4108f">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNC0xLTEtMS0yMDM2MA_f6f42f50-553a-4a96-bafc-efbc3631a5f5">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNC0zLTEtMS0yMDM2MA_a2391194-62ff-468a-ac2b-1775ddc62e26">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNS0xLTEtMS0yMDM2MA_1f14510d-7591-411a-a913-9855d466d392">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNS0zLTEtMS0yMDM2MA_321c3301-b869-4407-bb35-3486364abfa3">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE3Mg_f4a48ce6-74d2-4bf1-998f-17ab07fae016" continuedAt="ie5ce0206cc784d8d963732a0dc8ae448" escape="true">Operating Leases</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5ce0206cc784d8d963732a0dc8ae448" continuedAt="i128b55fc0b98471892901d616ec6d779">The Company has operating leases for <ix:nonFraction unitRef="office" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:NumberOfOfficesUnderOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfNjg_d445bfaf-25b2-4d4c-aeb7-04c70b8a7e61">two</ix:nonFraction> offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i128b55fc0b98471892901d616ec6d779"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE2Nw_d2728b85-7632-4afe-af64-8917c8c7d585" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0xLTEtMS0yMDM2MA_992f2392-43e0-4a9b-9f95-49c076077f95">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0zLTEtMS0yMDM2MA_9c5922ae-316f-4bc5-a971-7facf44c1f8a">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMy0xLTEtMS0yMDM2MA_04b93eee-984a-4379-b03c-518b1998b231">608</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMy0zLTEtMS0yMDM2MA_6eb1d5c1-c981-4e05-bda6-1d8491cf5976">724</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0xLTEtMS0yMDM2MA_5bd24eaa-5457-46c0-9a3b-e41906247f58">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0zLTEtMS0yMDM2MA_6a742051-317f-4298-a0e6-ef51b38fe8d0">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0xLTEtMS0yMDM2MA_ffcb3ed0-6753-471c-8012-77d8954c0059">383</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0zLTEtMS0yMDM2MA_fae04fb0-9807-40ee-8b95-2224459ce8d9">485</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfOC0xLTEtMS0yMDM2MA_d6d96300-6077-4ba7-b9fd-18666d534a18">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfOC0zLTEtMS0yMDM2MA_d4b22cb7-9b80-4842-a15d-8402e53e311a">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfOTky_5dad1846-b3f4-4604-97b6-5550ce107b12">2.0</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTA2NA_99b1f0c2-14ec-443b-9c12-1bdbc26a088d">9.625</ix:nonFraction>%. <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE3NQ_29e29cf2-016f-4245-a87c-34ca36c771f3" continuedAt="i62d0c2249c624e25a712171ac9055e29" escape="true">Future minimum lease payments under the lease agreements as of June&#160;30, 2022 were as follows (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i62d0c2249c624e25a712171ac9055e29"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfMy0xLTEtMS0yMDM2MA_07b15fe0-21e8-4702-b9ee-129f8d1235ad">103</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNC0xLTEtMS0yMDM2MA_b6702b9c-cbe7-47fe-9562-b46544cce97a">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNS0xLTEtMS0yMDM2MA_52134554-e247-4e0a-bad9-34696a660c8c">190</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNi0xLTEtMS0yMDM2MA_50419458-fe84-46f0-a05c-e3752d0ddb78">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNy0xLTEtMS0yMDM2MA_d515bc0b-8a10-460f-a34e-07744450b834">653</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfOC0xLTEtMS0yMDM2MA_b0e918b9-f35e-4648-8ee9-63d567168bfc">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfOS0xLTEtMS0yMDM2MA_7c69977f-187e-4210-ae97-d7a646445064">561</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_58"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ1NA_9078072a-fbcc-4251-944b-67e4075c3fad" continuedAt="i20d71e0a5cfb4637a3b08e772024bbab" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i20d71e0a5cfb4637a3b08e772024bbab" continuedAt="ia40fe0ca5cb04046b14c059971881063"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDI2_4d0555dc-10d6-495b-9d81-efe4bee5a3fe">26.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional <ix:nonFraction unitRef="shares" contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331" decimals="INF" name="clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNjM4_ac5b2834-0e57-4110-a8f5-ebfecbb35fd7">181,510</ix:nonFraction> shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased <ix:nonFraction unitRef="shares" contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNzQ1_f008399a-4572-4ff7-8e84-bcf6b2908488">250,000</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNzg2_3fb06001-7c7b-4299-8a33-77268da32e56">4.00</ix:nonFraction> per share, for a total gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfODM2_98214274-0cb5-4dad-9474-2b6980fa645b">1.0</ix:nonFraction> million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the <ix:nonNumeric contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTAxNA_8bd746ea-96d3-4ac8-b349-98feb3694d71">36</ix:nonNumeric>-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to <ix:nonFraction unitRef="shares" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="INF" name="clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTE5OQ_2baac941-2ade-4a91-a32f-ab3fe9d87da1">100,000</ix:nonFraction> shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $<ix:nonFraction unitRef="usd" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="-5" name="clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTM5Mw_34176516-b168-4375-a622-3cccd63ffc6b">2.5</ix:nonFraction> million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTkzOA_083597c1-81d1-4ad8-802f-3719bb0c4141">300</ix:nonFraction>% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMjAyNw_1bcaf354-3a6f-41d9-bfea-08d080686830">30</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="ia40fe0ca5cb04046b14c059971881063" continuedAt="i9130b252aba142deaef5740fa4ce200e"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="number" contextRef="i881d1b5361494535a4dff620655e80cc_I20190630" decimals="4" name="clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMjkyNw_e301408c-f778-421e-844a-278bfecc3c4e">9.99</ix:nonFraction>% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the <ix:nonNumeric contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMzMzNA_8bd746ea-96d3-4ac8-b349-98feb3694d71">36</ix:nonNumeric> months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with HCW, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ib0d46abc623a4ea5a97d1bf45a62c876_I20210604" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDAwNg_7c18e3b2-8222-45bf-88ce-9cbff69dcebd">50.0</ix:nonFraction>&#160;million.  During the six months ended June&#160;30, 2022 and since inception the Company had <ix:nonFraction unitRef="shares" contextRef="i14632cb149ee4f8e824d0bc59caba108_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDA2NA_5a1d09fc-b0ed-4df4-ae8e-f0a34368b4a5">no</ix:nonFraction>t issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#8217;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i9130b252aba142deaef5740fa4ce200e" continuedAt="i4b010ff8c29c4f5abcf8479d99c5af6e"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ0OQ_60462343-52bf-4074-8af8-7feb70bdb42a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the six months ended June&#160;30, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0yLTEtMS0yMDM2MA_fb8eed84-92e8-4df8-acc1-6ff4e567833d">2,131,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi00LTEtMS0yMDM2MA_49111974-b778-47f6-a291-ef79838baa4e">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi02LTEtMS0yMDM2MA_177c83c2-fe01-4d9f-a313-52acc2e20877">7.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi04LTEtMS0yMDM2MA_9da29be0-522f-43fa-afc3-1e7be20359c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xMC0xLTEtMjAzNjA_af2a468e-bddf-4bce-b85b-5462216885c1">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xMi0xLTEtMjAzNjA_a0793e1c-2ddf-4f3c-be4c-1d12631b23ee">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xNC0xLTEtMjAzNjA_a7b44f37-3f8e-4662-9767-d37ff539f4fd">4.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xNi0xLTEtMjAzNjA_a31c4f9f-684c-4637-89c4-72c5293cc7a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0yLTEtMS0yMDM2MA_7ee66662-b97f-4dc9-bbe9-ca6fde8abd80">547,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS00LTEtMS0yMDM2MA_64801435-a666-413d-89d6-7e3d25f4e001">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="clbs:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0xMC0xLTEtMjAzNjA_61b73a04-47e7-4bf3-880a-d21ca8ee7a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0xMi0xLTEtMjAzNjA_d24c4d14-1fbf-4ff3-bf07-b3ad1dc2483d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0yLTEtMS0yMDM2MA_77a7d8a6-afac-4085-a49b-05a903314b20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi00LTEtMS0yMDM2MA_74954e2b-e208-412c-9161-41b758337dee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="clbs:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0xMC0xLTEtMjAzNjA_06193ea1-931f-4f2b-a82e-faad5cbe5704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0xMi0xLTEtMjAzNjA_007f9b12-832e-4481-b6c7-37c3adf4a15b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0yLTEtMS0yMDM2MA_f5c0e9e0-fbc4-4404-8183-5678d9d1b620">17,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy00LTEtMS0yMDM2MA_53a3fd51-19c8-48d8-969d-8ab9287f92d5">1.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="clbs:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0xMC0xLTEtMjAzNjA_d73bbe88-2f55-4165-bb65-e332272f34aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0xMi0xLTEtMjAzNjA_036c847b-319a-4ad8-89a6-a6bd5c49268e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0yLTEtMS0yMDM2MA_c1f1aef4-3a18-4ba4-9121-cbb378eb952f">49,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC00LTEtMS0yMDM2MA_8275c343-7f4e-461d-8fbb-29d9893896f3">27.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="INF" name="clbs:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0xMC0xLTEtMjAzNjA_60350fc5-ee99-4ff9-9810-7c2307f9c633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0xMi0xLTEtMjAzNjA_2fd8ac21-30e5-4bac-ab48-6580e9646686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0yLTEtMS0yMDM2MA_c2bb9eb8-d209-40ef-97f6-c31ec10f4513">2,612,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS00LTEtMS0yMDM2MA_4d8d6b71-28bd-4f6a-a1b5-1a4a3e666bc4">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS02LTEtMS0yMDM2MA_a23f7425-2df2-42ae-a79a-05698bfa794d">7.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS04LTEtMS0yMDM2MA_6955ea21-1058-4de5-aaa7-912a0778865e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xMC0xLTEtMjAzNjA_6404a0d3-b210-43d5-8172-ac245759d1c4">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xMi0xLTEtMjAzNjA_2e5374f7-b82e-418a-a0c0-e5b18105bbe1">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xNC0xLTEtMjAzNjA_7a0595b9-f98b-4294-a89a-cc8a4ee3da26">3.88</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xNi0xLTEtMjAzNjA_a3a70b44-8dee-4282-ba04-976d8008155c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMi0xLTEtMjAzNjA_7fafb4e0-90e6-42b1-980b-93e6b613c885">2,574,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtNC0xLTEtMjAzNjA_49837db1-6484-4294-aa48-88a3d5e06a53">4.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtNi0xLTEtMjAzNjA_9019aedc-e80e-4506-ad27-b353ba35c204">7.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtOC0xLTEtMjAzNjA_ab384704-9ace-48f9-bd1b-b7b57ecd2277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTAtMS0xLTIwMzYw_035c85ad-5114-4e66-b692-c6ef37ad4da0">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTItMS0xLTIwMzYw_85ff6790-e46a-44b5-bc1b-1a9498550063">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTQtMS0xLTIwMzYw_8722b8ce-a670-4dc9-85ab-26b4b17f702b">3.88</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTYtMS0xLTIwMzYw_a5f16089-e0e7-462c-8421-5ab06d890637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMi0xLTEtMjAzNjA_2730cb7d-68af-4103-9127-288bb160ae38">1,388,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtNC0xLTEtMjAzNjA_67fa33b1-5b75-4c38-a5ea-5f75610728ed">6.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:OptionsVestedweightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtNi0xLTEtMjAzNjA_4b337edb-980d-4725-9446-7a123bd947ae">6.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtOC0xLTEtMjAzNjA_c7cbe95f-6165-44e4-81ec-4f0beb9a27e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="INF" name="clbs:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTAtMS0xLTIwMzYw_0ba5cb29-6346-411a-9178-a31ed84ebc81">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTItMS0xLTIwMzYw_e46930b6-b3b3-44d6-b063-1fbce4a46f72">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="clbs:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTQtMS0xLTIwMzYw_af16ebc5-487a-454a-811d-5b5388aac219">3.88</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTYtMS0xLTIwMzYw_d43a7779-323b-4dc3-b2fd-ae459a23d587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ1Mw_34be6c0b-6a5e-4459-b90c-5825c2a1ab72" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMi0yLTEtMS0yMDM2MA_e29bd974-041a-46b1-834c-8553db384e3e">1,061,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMi00LTEtMS0yMDM2MA_f41dd045-0a6a-4a6c-b495-2fc559eeac38">300,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMy0yLTEtMS0yMDM2MA_98347c5a-277d-4e77-9f08-4b53c8171853">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMy00LTEtMS0yMDM2MA_ee67d256-7fc7-43ff-b904-cd8d9443893d">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3Mw_d6c91bb1-b895-4964-8aed-4a7cfaa67b1d">one</span> to <ix:nonNumeric contextRef="i68930bc1046341ffaf2ee9a38956674a_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3OQ_f88b315d-4c7c-4694-9fcf-9fafc97f71c8">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQzNQ_8002941e-2766-4e37-b8f9-7cce8bd03d14" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMi0xLTEtMS0yMDM2MA_16432650-559c-48e3-a2a5-deaa707ff245">1,379,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMi0zLTEtMS0yMDM2MA_414f6fdb-c3cd-4c8a-ad9c-246813fc0972">458,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMy0xLTEtMS0yMDM2MA_39ad31f1-f36e-4d65-ae37-b63fc2285a3f">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMy0zLTEtMS0yMDM2MA_3f90ab96-b24a-4823-babf-50f26349f248">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b010ff8c29c4f5abcf8479d99c5af6e">The weighted average estimated fair value of restricted stock issued for services in the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTE0Mw_ae9acfcf-ff0d-4196-ba1e-0a5e6b68fb90">0.92</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTE1MA_c8714a2f-6692-4971-b550-50de1734364c">1.59</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTM3MA_9784bf97-f168-406c-bd30-619d6488f1bb">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_64"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTEzNw_3bde1e0a-5bcc-4d3f-a7f8-3e82814dfe0a" continuedAt="i39cce22b8f974e8ca0430e86c60d78bb" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i39cce22b8f974e8ca0430e86c60d78bb" continuedAt="i03df22fab8c447ae937292f519fa54b6"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTExOA_97bc88bf-3174-4664-833a-57b23c69fb14" continuedAt="i9c51c58d85c24a8ea15cea69f29c53f8" escape="true">The following table summarizes the components of share-based compensation expense for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i03df22fab8c447ae937292f519fa54b6"><div style="text-align:center;text-indent:18pt"><ix:continuation id="i9c51c58d85c24a8ea15cea69f29c53f8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49d7272724ce4f578cc742d1dc931327_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi0xLTEtMS0yMDM2MA_af5e813a-3e0a-4476-8fd5-8d622213ce7e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15f75b9306d45999b283daf73a43b48_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi0zLTEtMS0yMDM2MA_5047badb-8e4a-40ec-bcfa-49457460fba3">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b5af72af5c4772bf134572a931b93d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi01LTEtMS0yMDM2MA_fd50db6d-9b71-4095-9d8a-b4a727278fe3">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c459ae881647fd8f328d90c28330bf_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi03LTEtMS0yMDM2MA_990006d2-3ddc-444c-b907-fe1767341801">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0d245d793c45a1ba1cb80e8b960908_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy0xLTEtMS0yMDM2MA_338f7531-6b8d-4269-b0f9-36a845c32a83">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823661ad4a944545a75121b92daaf1a9_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy0zLTEtMS0yMDM2MA_f63d8c13-ba1d-42dd-8fe7-a46bd90e94aa">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62c6b1a91ccc4441ba38426fe098aeb0_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy01LTEtMS0yMDM2MA_056986e4-a6c4-4d2b-ac03-840e7e949ef4">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief352e26ae67416cafff90b9793d7ccd_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy03LTEtMS0yMDM2MA_bc6870da-2f5b-497b-b9ae-bc0dc6524b71">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC0xLTEtMS0yMDM2MA_92de5f52-b7e1-485c-883a-72e656743fee">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC0zLTEtMS0yMDM2MA_f3a4f4ba-4a47-4fe3-9f45-a42e01c15c25">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC01LTEtMS0yMDM2MA_c353e828-5a12-43f1-aa34-a2ed9317355b">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC03LTEtMS0yMDM2MA_b8d44c72-70c0-4a03-bf20-e8a752c6581f">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTExOQ_aa89684d-7f44-4c37-9135-ae9cd51872b8" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a169106c4a54b75a790607dc184b040_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS0xLTEtMS0yMDM2MA_18a7b5ea-5100-4fd7-a810-cbed24c024a3">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1213c6cc96c2467caca65a5f1102dc7b_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS0zLTEtMS0yMDM2MA_f7e218b5-3599-4e69-bf65-d0d669d2071f">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96074b249ba4cb3811d86696759685a_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS01LTEtMS0yMDM2MA_b4fbfc86-bcd1-4cf7-aad4-456f107900b6">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi0xLTEtMS0yMDM2MA_0f04182a-26e7-4394-ad81-b7f62573f474">1.56</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi0zLTEtMS0yMDM2MA_3db41851-da1b-4bd2-93c0-3205645fb903">0.74</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi01LTEtMS0yMDM2MA_caa4b558-7ed3-46aa-8a1d-ab6403874a3c">2.04</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTEyNA_5be9b866-345e-4cb3-9162-d025be09be11" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfMy0xLTEtMS0yMDM2MA_e5274880-3bb2-4205-864c-14b8f3ed8cc9">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfMy0zLTEtMS0yMDM2MA_98ce1e6e-4460-4db2-9798-cf00d5b58ec9">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfNC0xLTEtMS0yMDM2MA_58f17911-b21d-4da5-ab82-ecc8b4a209fc">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfNC0zLTEtMS0yMDM2MA_a4434cf4-6d0b-49cc-8dbd-c4f92822e529">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_67"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDI2Nw_d10c359f-b215-400a-ad1e-4e86ede6e107" continuedAt="ife74f159e2c543ccacdf1c20fedf6012" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ife74f159e2c543ccacdf1c20fedf6012" continuedAt="i9e3a2a6df4a248b19f9ac0ab1be7e192"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#8220;NOLs&#8221;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i069758af4d36436e817e90b87a8a130d_I20211231" decimals="-3" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNTQw_29d5a3c2-26d2-4dd0-99fa-8ed7f6280db4">281</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia572f9b4029b4d02bd17de8d331b2d60_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNTQ3_1b73cdf1-aad8-4e3c-81db-647c7382dd82">264</ix:nonFraction>&#160;million, respectively of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $<ix:nonFraction unitRef="usd" contextRef="i069758af4d36436e817e90b87a8a130d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsSetToExpireWrittenDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfODIy_edc18b95-2881-41a6-bcb3-35b0d99b09cd">169</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i069758af4d36436e817e90b87a8a130d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfODMy_ccd701c7-f0ec-44b3-b65e-6312aad97f2d">281</ix:nonFraction>&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="i069758af4d36436e817e90b87a8a130d_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTAwMA_5cd9e9ef-3a0e-4043-b9d9-d10678344db3">112</ix:nonFraction>&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231" decimals="-5" name="clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTQ4NA_4bf52eea-1b77-4a99-8ffc-a4145ba0cd2f">1.1</ix:nonFraction>&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020 the Company had state NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="i2ce48fc27b9345c79034d9b1582abdf0_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTY5NQ_1c029349-9ffa-4bd4-bc18-ca86c8656264">97</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibc8328428e264834bf3b4a202bab364f_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTcwMg_6e03f66c-e469-4c03-b4a8-ae6cef60226a">99</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="ib17745a6d80b45f587961fd01e5ac1bd_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTczNA_03f34e69-d93c-4fe6-87a1-285af0838716">70</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9a9b55d334b140a0a9c8cf4c0b5ced19_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc0MQ_12aa2b1c-b311-463e-bfb5-13d87b960651">70</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="i148b071e62cb48e389a032a63261b95b_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc4MA_d0150d39-517e-4f51-a650-f74ecae7c133">13</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0e7dbcff99b643cba5824b529d4831aa_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc4Nw_65c17bac-8830-4b8b-b983-0ccc45d8359b">13</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><ix:continuation id="i9e3a2a6df4a248b19f9ac0ab1be7e192"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $<ix:nonFraction unitRef="usd" contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMzg5OQ_913afdf3-e8f3-4900-920d-ef257082d3b6">2.5</ix:nonFraction>&#160;million of its NJ NOLs related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDA3MA_d2363882-46cd-4a7a-8ea5-c56aa0701cf0">2.3</ix:nonFraction>&#160;million. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDA5Ng_1ee36a08-6883-4a1e-b01e-026eac210668">2.5</ix:nonFraction>&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $<ix:nonFraction unitRef="usd" contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222" decimals="-5" name="clbs:LossOnSaleOfNetOperatingLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDE4NA_1ec64946-ea26-4591-b153-e79e04b8af35">0.1</ix:nonFraction>&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_70"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV83MC9mcmFnOjFhNmUyOGZkYWU1NTRkMmU4NmU2NmEzMzNkNDUwNGE2L3RleHRyZWdpb246MWE2ZTI4ZmRhZTU1NGQyZTg2ZTY2YTMzM2Q0NTA0YTZfNDMz_ed8005ad-9524-4584-9fb5-09ef42cc900f" continuedAt="ia44c88ac522d4fda9bf00679e7d5b8ab" escape="true">Contingencies</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ia44c88ac522d4fda9bf00679e7d5b8ab" continuedAt="ie52729a358cd4b7c8731d9b9cead7d40">Contingencies</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie52729a358cd4b7c8731d9b9cead7d40">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2021 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. We are developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories, including cardiovascular and oncology. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include:<br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. CLBS12 was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;). </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cend Merger</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we, CS Cedar Merger Sub, Inc., a Delaware corporation and our wholly owned subsidiary (&#8220;Merger Sub&#8221;), and Cend Therapeutics, Inc., a Delaware corporation (&#8220;Cend&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Cend, with Cend continuing as our wholly owned subsidiary and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, (a) each outstanding share of Cend common stock and Cend preferred stock will be converted into the right to receive a number of shares of our common stock (&#8220;Caladrius Common Stock&#8221;) equal to an exchange ratio calculated pursuant to the terms of the Merger Agreement; and (b) each outstanding Cend stock option that has not previously been exercised prior to the closing of the Merger will be assumed by us.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock  and our stockholders as of immediately prior to the Merger are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock.  The actual allocation will be subject to adjustment based on our net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $250 thousand at the time of closing. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of Caladrius and Cend, and Caladrius&#8217; satisfaction of a minimum net cash threshold at closing, expected to be approximately $64.9 million assuming a closing at the end of the third quarter of 2022, and as described further in the Merger Agreement. In accordance with the terms of the Merger Agreement, (i) certain executive officers, directors and stockholders of Cend (solely in their respective capacities as Cend stockholders) holding approximately 77.5% of the outstanding Cend capital stock have entered into support agreements with Caladrius to vote all of their shares of Cend capital stock in favor of adoption of the Merger Agreement (the &#8220;Cend Support Agreements&#8221;) and (ii) certain executive officers and directors of Caladrius (solely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in their respective capacities as Caladrius stockholders) holding approximately 1.8% of the outstanding Caladrius common stock have entered into support agreements with Cend to vote all of their shares of Caladrius common stock in favor of approval of the Merger Agreement (the &#8220;Caladrius Support Agreements,&#8221; together with the Cend Support Agreements, the &#8220;Support Agreements&#8221;). The Support Agreements include covenants with respect to the voting of such shares in favor of approving the transactions contemplated by the Merger Agreement and against any competing acquisition proposals and place certain restrictions on the transfer of the shares of Caladrius and Cend held by the respective signatories thereto.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, certain officers and directors of Caladrius holding approximately 1.8% of the outstanding Caladrius common stock and certain officers, directors and stockholders of Cend holding approximately 77.5% of the Cend capital stock have entered into lock-up agreements (the &#8220;Lock-Up Agreements&#8221;) pursuant to which they accepted certain restrictions on transfers of shares of Caladrius Common Stock for the 120-day period following the closing of the Merger. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement contains certain termination rights for both us and Cend, and further provides that, upon termination of the Merger Agreement under specified circumstances, we may be required to pay Cend a termination fee of $1.0 million, Cend may be required to pay us a termination fee of $4.0 million, or in some circumstances reimburse the other party&#8217;s expenses up to a maximum of $1.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the Merger, our Board of Directors is expected to consist of nine members, four of whom will be designated by us, four of whom will be designated by Cend and one member who will be mutually agreed between us and Cend.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cend Investment and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide Cend with capital for its development programs prior to the closing of the Merger, we and Cend entered into a Series D Preferred Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which we purchased from Cend 1,135,628 shares of Series D Preferred Stock, $0.00001 par value per share (the &#8220;Series D Preferred Stock&#8221;), of Cend at a purchase price per share equal to $8.8057 per share (the &#8220;Series D Original Issue Price&#8221;), or approximately $10 million in the aggregate. The Purchase Agreement contains customary representations, warranties and agreements by us and Cend and customary conditions to closing. The Series D Preferred Stock ranks senior to Cend&#8217;s common stock and the other series of preferred stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of Cend. The Series D Preferred Stock has a liquidation preference equal to the Series D Original Issue Price plus an amount equal to any accrued and unpaid dividends to the date of payment and will participate with Cend&#8217;s common stockholders and other preferred stockholders thereafter on an as-converted basis. The Series D Preferred Stock shall vote with the common stock on an as-converted basis on any matters presented to the stockholders of Cend.  Each share of Series D Preferred Stock is convertible, at the option of the holder thereof, into such number of shares of Cend common stock as is determined by dividing the Original Issue Price by the conversion price in effect at the time of conversion, which conversion price shall be the Original Issue Price as appropriately adjusted for stock splits, stock dividends, combinations, and subdivisions of Cend common stock, and as adjusted pursuant to a weighted-average antidilution adjustment. The Series D Preferred Stock will automatically convert into shares of Cend common stock upon the closing of a firm-commitment underwritten initial public offering implying a pre-equity offering value of at least $250 million, resulting in at least $50 million of gross proceeds to Cend.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Purchase Agreement, we and Cend entered into a Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;), pursuant to which we agreed to collaborate with Cend on certain developmental and clinical activities prior to the closing of the Merger. Pursuant to the Collaboration Agreement, we and Cend have formed a joint steering committee (the &#8220;Committee&#8221;) comprised of individuals from both entities. The Committee meets regularly and is responsible for monitoring ongoing studies and making recommendations for development activity and trial planning. Cend has agreed to pay each member of the Committee from Caladrius an hourly consulting fee for such service.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;padding-left:1.44pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), we initiated our program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept, open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, we commenced enrollment in our Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease and was expected to complete enrollment in approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as well as with a contrast agent typically used in many catheter laboratories. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment. In May 2022, we announced that enrollment in the FREEDOM Trial had been suspended and that we intend to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.  The interim analysis is expected to be completed in the third quarter of 2022 and the next steps in development of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> will subsequently be determined after appropriate regulatory and business review, expected to be announced prior to year-end 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:0.72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspended further enrollment in the fourth quarter of 2021. Following study suspension, we completed all protocol-defined patient observations and are preparing the clinical study report. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is now in the pre-consultation phase of the registration process with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan.  Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan has been compiled and is expected to be reviewed by PMDA during the third quarter of 2022 after which the PMDA is expected to provide important perspective to be considered in preparation for the formal consultation meetings which precede the Japanese new drug application. We are focusing our efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan.  This may include the completion of enrollment of the four-remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of submitting the existing data to Japan's PMDA under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt of orphan designation from FDA in March 2021 in the United States for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration, we have decided not to pursue U.S. development in Buerger's disease at this time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, we have elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol includes six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by an independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study then permitted the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be our ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. The Company treated the first patient in the CLBS201 proof-of-concept study in April 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present substantial public health and economic challenges around the world, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of our employees and families, we implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With our expectation that COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, we elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient data already accrued. In addition, our phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States has also experienced delays in enrolling patients as a result of COVID-19, as described above. In May 2022, we announced that enrollment in the FREEDOM Trial had been suspended and that we intend to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.<br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond its impact on our development pipeline described above, the extent to which COVID-19 ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain COVID-19 or treat its impact, including vaccination campaigns, among others. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. It is possible that our clinical development timelines could continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition and results of operations. See &#8220;Risk Factors&#8221; in our 2021 Form 10-K for additional discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition and results of operations.</span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_79"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2022 Compared to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended  June&#160;30, 2022 and June&#160;30, 2021:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:56.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $6.6 million for the three months ended June&#160;30, 2022, compared to $5.7 million for the three months ended June&#160;30, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022, operating expenses totaled $6.7 million compared to $7.1 million for the three months ended June&#160;30, 2021, representing a decrease of 6%.  Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $3.2 million for the three months ended June&#160;30, 2022, compared to $4.3 million for the three months ended June&#160;30, 2021, representing a decrease of $1.1 million or 25%. This decrease was primarily due to a decrease in expenses associated with HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan, revenue received from the Collaboration Agreement and one off recruiting expenses in the prior year. Research and development in both periods focused on the advancement of our ischemic repair platform and related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.25pt">expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial) which commenced in the fourth quarter of 2020 with the first patient in the study treated in January 2021; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing registration-eligible study expenses for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in critical limb ischemia in Japan which focused on patient enrollment completion. The study's enrollment has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency that have persisted there for most of 2020, 2021 and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the complete unpredictability of the timing of site enrollment re-initiation, we will focus our efforts on consummating a partnership with a Japanese company in order to complete the study enrollment as well as to explore the possibility of submitting the existing data to PMDA under the SAKIGAKE designation;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation of our filing of an IND and study start-up expenses for the clinical study of CLBS201 for treatment of diabetic kidney disease. A Phase 1b, open-label, proof-of-concept trial which includes six subjects in total.  The trial commenced in the first quarter of 2022 with the first patient in the study treated in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023. <br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.5 million for the three months ended June&#160;30, 2022, compared to $2.8 million for the three months ended June&#160;30, 2021, representing an increase of 24%. This increase was primarily due to an increase in fees associated with the proposed merger with Cend Therapeutics, Inc. Our general and administrative expenses focus on general corporate-related activities.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised of investment income on cash, cash equivalents and marketable securities and a loss on sale related to the sale of our NJ NOLs.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compared to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended  June&#160;30, 2022 and June&#160;30, 2021:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:56.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,893)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,852)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,745)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $10.9 million for the six months ended June&#160;30, 2022, compared to $13.7 million for the six months ended June&#160;30, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022, operating expenses totaled $13.3 million compared to $15.2 million for the six months ended June&#160;30, 2021, representing a decrease of 12%.  Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $6.5 million for the six months ended June&#160;30, 2022, compared to $9.4 million for the six months ended June&#160;30, 2021, representing a decrease of $2.9&#160;million or 31%. This decrease was primarily due to a decrease in expenses associated with manufacturing start-up costs and process development expenses for our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial), a decrease in expenses associated with HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan, revenue received from the Collaboration Agreement and one off recruiting expenses in the prior year. Research and development in both periods focused on the advancement of our ischemic repair platform and related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.25pt">expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial) which commenced in the fourth quarter of 2020 with the first patient in the study treated in January 2021; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing registration-eligible study expenses for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in critical limb ischemia in Japan which focused on patient enrollment completion. The study's enrollment has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency that have persisted there for most of 2020, 2021 and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the complete unpredictability of the timing of site enrollment re-initiation, we will focus our efforts on consummating a partnership with a Japanese company in order to complete the study enrollment as well as to explore the possibility of submitting the existing data to PMDA under the SAKIGAKE designation; and</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation of our filing of an IND and study start-up expenses for the clinical study of CLBS201 for treatment of diabetic kidney disease. A Phase 1b, open-label, proof-of-concept trial which includes six subjects in total.  The trial commenced in the first quarter of 2022 with the first patient in the study treated in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023.  <br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $6.8 million for the six months ended June&#160;30, 2022, compared to $5.8 million for the six months ended June&#160;30, 2021, representing an increase of 17%. This increase was primarily due to an increase in fees associated with the review of potential strategic transactions and an increase in fees </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with the proposed merger with Cend Therapeutics, Inc. Our general and administrative expenses focus on general corporate-related activities.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised of investment income on cash, cash equivalents and marketable securities and a loss on sale related to the sale of our NJ NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The $2.5 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, we had cash, cash equivalents and marketable securities of approximately $73.0 million, working capital of approximately $71.6 million, and stockholders&#8217; equity of approximately $82.4 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,704)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the six months ended June&#160;30, 2022 was $10.7 million, which is comprised of (i) our net loss of $10.9 million, adjusted for non-cash expenses totaling $2.0 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities using approximately $1.9 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the six months ended June&#160;30, 2021 was $12.6 million, which is comprised of (i) our net loss of $13.7 million, adjusted for non-cash expenses totaling $2.0 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $0.9 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the six months ended June&#160;30, 2022 totaled $19.5 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the six months ended June&#160;30, 2021 totaled $76.3 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the six months ended June&#160;30, 2022 totaled $0.1 million, consisted primarily of  tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the six months ended June&#160;30, 2021 totaled $85.3 million, primarily consisted of (i) net proceeds of $23.1 million through the issuance of common shares and warrants in our January 2021 private placement, (ii) net proceeds of $1.8 million in connection with warrant exercises, (iii) net proceeds of $60.6 million through the issuance of common shares and warrants in both of our February 2021 registered direct offerings, which was partially offset by tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements, absent any impact from the Merger, if consummated. Our future capital requirements are difficult to forecast and will depend on many factors, including our ability to consummate the Merger; if the Merger is not completed, the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide Cend with capital for its development programs prior to the closing of the Merger, pursuant to the Purchase Agreement, we purchased 1,135,628 shares of Series D Preferred Stock of Cend for an aggregate purchase price of approximately $10.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell shares of our common stock, having an aggregate offering price of up to $50.0 million. On February 18, 2022, we received a deficiency notice from Nasdaq informing us that we are not in compliance with the Minimum Bid Price Requirement. As such, we will not be able to sell shares under the ATM Agreement until we regain compliance, if ever. As of June&#160;30, 2022, we had not issued any shares under the ATM Agreement. HCW is only obligated to make sales when we are in compliance with all Nasdaq listing standards. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we received preliminary approval from the NJEDA to participate in the NJ Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their NJ NOLs to unrelated profitable corporations. On February 22, 2022, we received final approval from NJEDA to sell $2.5 million of our NJ NOL Tax Benefits, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. <br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_85"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that our operations are seasonal in nature.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three and six months ended June&#160;30, 2022, compared to those reported in our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_91"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are the controls and other procedures we have designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we carried out an evaluation, with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_97"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no material changes to the disclosures previously reported in our 2021 Form 10-K.<br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_100"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as set forth below, there have been no material changes to the risk factors previously reported in our 2021 Form 10-K. See the risk factors set forth in our 2021 Annual Report on Form 10-K under the caption &#8220;Item 1 A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently do not meet the continued listing standards of the Nasdaq Capital Market, which require a minimum closing bid price of $1.00 per share. Our failure to meet Nasdaq&#8217;s continued listing standards could result in the delisting of our common stock, negatively impact the price of our common stock and negatively impact our ability to raise additional capital.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market. Nasdaq provides various continued listing requirements that a company must meet in order for its stock to continue trading on the Nasdaq Capital Market. Among these requirements is the requirement that the Company&#8217;s stock trades at a minimum closing bid price of $1.00 per share. Our stock has recently and consistently traded below $1.00 per share, including closing bid prices below $1.00 per share. On February 18, 2022, we received a deficiency letter from The Nasdaq Stock Market which provided us a grace period of 180 calendar days, or until August 17, 2022, to regain compliance with the minimum bid price requirement. We may achieve compliance during this 180-day period if the closing bid price of our common stock is at least $1.00 per share for a minimum of 10 consecutive business days before August 17, 2022. If we fail to regain compliance on or prior to August 17, 2022, we may be eligible for an additional 180 day compliance period. Additionally, if we fail to comply with any other continued listing standards of Nasdaq, our common stock will also be subject to delisting. If that were to occur, our common stock would be subject to rules that impose additional sales practice requirements on broker-dealers who sell our securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our common stock. This would significantly and negatively affect the ability of investors to trade our securities and would significantly and negatively affect the value and liquidity of our common stock. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our common stock. If we seek to implement a reverse stock split in order to remain listed on The Nasdaq Capital Market, the announcement and/or implementation of a reverse stock split could significantly negatively affect the price of our common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our merger with Cend may not be consummated or may not deliver the anticipated benefits we expect.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the Merger will be completed in a timely manner or at all. In addition, even if the Merger is completed, there can be no assurance that the Merger will enhance stockholder value. The Merger Agreement is subject to many closing conditions and termination rights, as set forth in the Merger Agreement. If we do not close the Merger, our board of directors may elect to attempt to complete another strategic transaction similar to the Merger. Attempting to complete another strategic transaction similar to the Merger would be costly and time consuming, and we cannot make any assurances that a future strategic transaction will occur on commercially reasonable terms or at all. We are devoting a significant amount of our time and resources to consummating this transaction, however, there can be no assurance that such activities will result in the consummation of this transaction or that such transaction will deliver the anticipated benefits or enhance stockholder value.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our net cash may be less than the required amount at the closing of the Merger, which would result in our stockholders owning a smaller percentage of the combined organization and could even result in the termination of the Merger Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement includes a net cash requirement as a condition precedent for closing of the Merger. For purposes of the Merger Agreement, net cash is subject to certain reductions, including, without limitation, accounts payable, accrued liabilities (except those related to the Merger), current liabilities payable in cash, unpaid expenses related to the Merger and certain other unpaid obligations, including declared but unpaid cash dividends. In the event the amount of our net cash is smaller or such reductions are greater than anticipated, our stockholders could hold a significantly smaller portion of the combined organization. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to complete the Merger may result in us paying a termination fee or expenses to Cend and could harm the price of our common stock and our future business and operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Merger is not completed, we are subject to the following risks: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">if the Merger Agreement is terminated under certain circumstances, we will be required to pay certain transaction expenses of Cend, up to a maximum of $1.0 million; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">if the Merger Agreement is terminated under certain circumstances, we will be required to pay Cend a termination fee of $4.0 million, or in some circumstances reimburse the other party&#8217;s expenses up to a maximum of $1.0 million; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the price of our common stock may decline and remain volatile; and </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">certain of the costs related to the Merger, such as legal and accounting fees, must be paid even if the Merger is not completed. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the Merger Agreement is terminated and our Board of Directors or the Cend Board of Directors determines to seek another business combination, there can be no assurance that we will be able to diversify and enhance our product candidate portfolio on terms equivalent or more attractive than the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Merger may be completed even though material adverse changes may result from the announcement of the Merger, industry-wide changes and other causes.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, either we or Cend can refuse to complete the Merger if there is a material adverse change affecting the other party between the date of the Merger Agreement, and the Closing. However, certain types of changes do not permit either party to refuse to complete the Merger, even if such change could be said to have a material adverse effect on us or Cend, including: </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any rejection or non-acceptance by a governmental body of a registration or filing relating to certain of our intellectual property rights; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the taking of any action, or the failure to take any action, by either us or Cend required to comply with the terms of the Merger Agreement; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any effect resulting from the announcement or pendency of the Merger or any related transactions; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any natural disaster or any act or threat of terrorism or war anywhere in the world, any armed hostilities or terrorist activities anywhere in the world, any threat or escalation or armed hostilities or terrorist activities anywhere in the world or any governmental or other response or reaction to any of the foregoing; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any change in accounting requirements or principles of any change in applicable laws, rules or regulations or the interpretation thereof; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any general economic or political conditions or conditions generally affecting the industries in which we and Cend operate; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any changes in research in development, clinical trials or other drug development activities conducted on our behalf;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">continued losses from our operations or decreases in our cash balance;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">any epidemics, pandemics, disease outbreaks, or other public health emergencies or the escalation or worsening thereof, including COVID-19;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">with respect to us, any change in the stock price or trading volume of our common stock excluding any underlying effect that may have caused such change; and </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">with respect to Cend, any change in the cash position of Cend that results from operations in the ordinary course of business. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adverse changes occur and we and Cend still complete the Merger, the price of our common stock may suffer. This in turn may reduce the value of the Merger to our stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock following the Merger may decline as a result of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may decline as a result of the Merger for a number of reasons if: </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">investors react negatively to the prospects of the combined organization&#8217;s business and prospects from the Merger; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the effect of the Merger on the combined organization&#8217;s business and prospects is not consistent with the expectations of financial or industry analysts; or </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">the combined organization does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the combined organization is unable to realize the full strategic and financial benefits currently anticipated from the Merger, our stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined organization is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stockholders will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined organization following the completion of the Merger as compared to their current ownership and voting interests.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the completion of the Merger, our current stockholders will own a smaller percentage of the combined organization than their ownership prior to the Merger. Immediately after the Merger, our stockholders, whose shares of common stock will remain outstanding after the Merger, will own approximately 50% of the fully-diluted common stock of the combined organization, excluding out-of-the-money securities. These estimates are based on the anticipated exchange ratio and are subject to adjustment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the pendency of the Merger, we may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect our respective businesses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Merger Agreement impede our ability to make acquisitions, subject to certain exceptions relating to fiduciary duties, or to complete other transactions that are not in the ordinary course of business pending completion of the Merger. As a result, if the Merger is not completed, we may be at a disadvantage to our competitors during such period. In addition, while the Merger Agreement is in effect, we are generally prohibited from soliciting, initiating, encouraging or entering into certain extraordinary transactions, such as merger, sale of assets or other business combination outside the ordinary course of business with any third party, subject to certain exceptions relating to fiduciary duties. Any such transactions could be favorable to our stockholders.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Merger Agreement prohibit us from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances when our board of directors determines in good faith that an unsolicited alternative takeover proposal is or is reasonably likely to be inconsistent with the board&#8217;s fiduciary duties. Moreover, even if we receive what our board of directors determines is a superior proposal, the Merger Agreement does not permit us to terminate the Merger Agreement to enter into a superior proposal.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the conditions of the Merger are not met, the Merger will not occur.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Merger is approved by our stockholders and Cend Stockholders, specified conditions must be satisfied or waived to complete the Merger. These conditions are set forth in the Merger Agreement, which is attached to this Quarterly Report as Exhibit 2.1. We cannot assure you that all of the conditions will be satisfied or waived. If the conditions are not satisfied or waived, the Merger will not occur or will be delayed, and we may lose some or all of the intended benefits of the Merger.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_103"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_112"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_115"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CALADRIUS BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   President and Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </span></div></div></div><div id="i3286f9fcb6234a6dac2ebc53f9a97a6e_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3286f9fcb6234a6dac2ebc53f9a97a6e_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:461.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/ex21-mergeragreement10pf.htm">2.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger and Reorganization, dated April 26, 2022, among Caladrius Biosciences, Inc., CS Cedar Merger Sub, Inc., and Cend Therapeutics, Inc. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit22-supportagreeme.htm">2.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Support Agreement, by and between Caladrius Biosciences, Inc. and certain securityholders of Cend Therapeutics, Inc. (filed as Exhibit 2.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit23-supportagreeme.htm">2.3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Support Agreement, by and between Cend Therapeutics, Inc. and certain securityholders of Caladrius Biosciences, Inc. (filed as Exhibit 2.3 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit24-lockxupagreeme.htm">2.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Lock-Up Agreement, by and between Caladrius Biosciences, Inc. and certain securityholders of Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 2.4 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit101-stockpurchase.htm">10.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series D Preferred Stock Purchase Agreement, dated April 26, 2022, among Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit102-collaboration.htm">10.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration Agreement, dated April 26, 2022, between Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex311_20220630xq2.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex32_20220630q2.htm">32</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:502.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>clbs-ex311_20220630xq2.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i87f4c4af64a3429bb4be53be2c9e944b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;4, 2022 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>clbs-ex32_20220630q2.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2fdbfba1fcff467896c6c470619cbac3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Caladrius Biosciences, Inc. (the &#8220;Company&#8221;) for the quarter ended June&#160;30, 2022 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;August&#160;4, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clbs-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clbs="http://www.caladrius.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>2101101 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessDetails" roleURI="http://www.caladrius.com/role/TheBusinessDetails">
        <link:definition>2402401 - Disclosure - The Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>2105103 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>2306301 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>2110104 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>2311302 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>2412405 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>2113105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>2314303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>2415406 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>2116106 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>2317304 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>2418407 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>2119107 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>2320305 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>2421408 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>2124108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>2325306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>2129109 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>2330307 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>2134110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>2435417 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>2136111 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="clbs_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_PurchaseOfPreferredStockAggregatePrice" abstract="false" name="PurchaseOfPreferredStockAggregatePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" abstract="false" name="RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_NumberOfOfficesUnderOperatingLeases" abstract="false" name="NumberOfOfficesUnderOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_MergerAgreementMinimumNetCashThreshold" abstract="false" name="MergerAgreementMinimumNetCashThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_PreferredStockSharesDesignated" abstract="false" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_MergerAgreementPotentialTerminationFeePayable" abstract="false" name="MergerAgreementPotentialTerminationFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" abstract="false" name="MergerAgreementTransactionExpensesThresholdForRatioAllocation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_LincolnParkAgreementMember" abstract="true" name="LincolnParkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_PurchaseOfPreferredStockShares" abstract="false" name="PurchaseOfPreferredStockShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_PreEquityOfferingValueAfterConversion" abstract="false" name="PreEquityOfferingValueAfterConversion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MergerAgreementPotentialTerminationFeeReceivable" abstract="false" name="MergerAgreementPotentialTerminationFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_GrossProceedsOnTransaction" abstract="false" name="GrossProceedsOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" abstract="false" name="OperatingLossCarryforwardsSetToExpireWrittenDown" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" abstract="false" name="MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CLBS16TreatmentOfCMDMember" abstract="true" name="CLBS16TreatmentOfCMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_PreferredStockLiquidationPreferenceShare" abstract="false" name="PreferredStockLiquidationPreferenceShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CendTherapeuticsIncMember" abstract="true" name="CendTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_CendSeriesDPreferredStockPurchaseAgreementMember" abstract="true" name="CendSeriesDPreferredStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_LossOnSaleOfNetOperatingLosses" abstract="false" name="LossOnSaleOfNetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" abstract="false" name="MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_MergerAgreementPotentialExpenseReimbursement" abstract="false" name="MergerAgreementPotentialExpenseReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" abstract="false" name="OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" abstract="false" name="SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_PurchaseOfPreferredStockPricePerShare" abstract="false" name="PurchaseOfPreferredStockPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_AgreementAndPlanOfMergerAndReorganizationMember" abstract="true" name="AgreementAndPlanOfMergerAndReorganizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_SeriesDPreferredStockCendMember" abstract="true" name="SeriesDPreferredStockCendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedAsConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" abstract="false" name="SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>clbs-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f8fc4a78-0ddc-40d4-957c-0411460d6d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ef33bbc0-e662-440d-b223-b3b47473daa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8fc4a78-0ddc-40d4-957c-0411460d6d50" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ef33bbc0-e662-440d-b223-b3b47473daa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_74f90e59-5074-4141-adb7-7b61111bbd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8fc4a78-0ddc-40d4-957c-0411460d6d50" xlink:to="loc_us-gaap_OtherInvestments_74f90e59-5074-4141-adb7-7b61111bbd46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d0b0e15d-b0e8-4246-b06d-0bdc803d3486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8fc4a78-0ddc-40d4-957c-0411460d6d50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d0b0e15d-b0e8-4246-b06d-0bdc803d3486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_209e7c93-09bc-4359-9aac-1e83f8228f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f8fc4a78-0ddc-40d4-957c-0411460d6d50" xlink:to="loc_us-gaap_AssetsCurrent_209e7c93-09bc-4359-9aac-1e83f8228f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5256cd1-4da9-438d-af50-d5ab67234575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25a09e45-8bac-4d0e-9558-784b198ed597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5256cd1-4da9-438d-af50-d5ab67234575" xlink:to="loc_us-gaap_StockholdersEquity_25a09e45-8bac-4d0e-9558-784b198ed597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_08a8cb3a-d2b9-47ac-81fe-3c4358919cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5256cd1-4da9-438d-af50-d5ab67234575" xlink:to="loc_us-gaap_MinorityInterest_08a8cb3a-d2b9-47ac-81fe-3c4358919cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_332aea0d-41ab-4088-8464-b4de60a8aac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12e5c57c-42ed-44ef-9d8a-e5ed281f4f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_332aea0d-41ab-4088-8464-b4de60a8aac7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12e5c57c-42ed-44ef-9d8a-e5ed281f4f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_344e9054-0f72-4688-9d80-48318a85612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_332aea0d-41ab-4088-8464-b4de60a8aac7" xlink:to="loc_us-gaap_MarketableSecurities_344e9054-0f72-4688-9d80-48318a85612f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e9511ae-4415-40b6-871b-b80a380811ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_332aea0d-41ab-4088-8464-b4de60a8aac7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e9511ae-4415-40b6-871b-b80a380811ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_43eade3d-b7d5-4ef1-9eb3-59a5c8853431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06d44a51-c502-488c-af5c-f972272c0e29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_43eade3d-b7d5-4ef1-9eb3-59a5c8853431" xlink:to="loc_us-gaap_LiabilitiesCurrent_06d44a51-c502-488c-af5c-f972272c0e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_82c3bd6e-5ca0-4b6b-b5d4-87588d161326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_43eade3d-b7d5-4ef1-9eb3-59a5c8853431" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_82c3bd6e-5ca0-4b6b-b5d4-87588d161326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e2dcbc-9222-4ee7-a0d5-b614ca7f90f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_26006b92-9ecd-4637-86cb-92f5d8c97975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e2dcbc-9222-4ee7-a0d5-b614ca7f90f0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_26006b92-9ecd-4637-86cb-92f5d8c97975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0d428ea2-7aae-4151-a55b-d83e406b5f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e2dcbc-9222-4ee7-a0d5-b614ca7f90f0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0d428ea2-7aae-4151-a55b-d83e406b5f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6143b2a7-d2ad-4340-a6f0-ae77b8ccffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e2dcbc-9222-4ee7-a0d5-b614ca7f90f0" xlink:to="loc_us-gaap_Liabilities_6143b2a7-d2ad-4340-a6f0-ae77b8ccffe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9bce8ea9-cea7-4cf0-8cc3-3622bc885899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_281a61a2-d5d4-4c94-beda-1e804df5e7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bce8ea9-cea7-4cf0-8cc3-3622bc885899" xlink:to="loc_us-gaap_AccountsPayableCurrent_281a61a2-d5d4-4c94-beda-1e804df5e7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c2a821de-089b-474b-b2b4-18ddc2c19e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bce8ea9-cea7-4cf0-8cc3-3622bc885899" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c2a821de-089b-474b-b2b4-18ddc2c19e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ae13e83c-bbdf-48ff-a184-808c766bb8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_PreferredStockValue_ae13e83c-bbdf-48ff-a184-808c766bb8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6049e51f-3c21-4c65-ad7f-dab9646b5edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_CommonStockValue_6049e51f-3c21-4c65-ad7f-dab9646b5edc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c91d8f3f-bedd-408f-ab66-8e31d9d98053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c91d8f3f-bedd-408f-ab66-8e31d9d98053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_02cf2af7-439a-477e-841b-b52298bc356b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_TreasuryStockCommonValue_02cf2af7-439a-477e-841b-b52298bc356b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79fba288-9c01-44fb-b6b3-07d66b3ccfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79fba288-9c01-44fb-b6b3-07d66b3ccfdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_752cef00-8a88-4583-a042-91636cff9368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25349720-4663-4050-af3e-7e89008ea705" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_752cef00-8a88-4583-a042-91636cff9368" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_88d9fef5-9c62-4dd7-827d-3f3976018a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_eb86837b-5fac-48a7-a76d-d1b97c9bb78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_88d9fef5-9c62-4dd7-827d-3f3976018a87" xlink:to="loc_us-gaap_OperatingExpenses_eb86837b-5fac-48a7-a76d-d1b97c9bb78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0112f46b-39c1-4b6e-a965-dba3d8de6174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_12b142e5-afc6-450e-8f21-f339c2b57bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0112f46b-39c1-4b6e-a965-dba3d8de6174" xlink:to="loc_us-gaap_OperatingIncomeLoss_12b142e5-afc6-450e-8f21-f339c2b57bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_03f48a91-b884-488b-8f91-45e9a7704938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0112f46b-39c1-4b6e-a965-dba3d8de6174" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_03f48a91-b884-488b-8f91-45e9a7704938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5d55469d-832c-490e-a5df-714e34409521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_33f2cba3-e93a-403e-b08d-4dbe5cda81c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5d55469d-832c-490e-a5df-714e34409521" xlink:to="loc_us-gaap_InvestmentIncomeNet_33f2cba3-e93a-403e-b08d-4dbe5cda81c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3c68c648-3096-4d2c-9fde-085dd7a31b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5d55469d-832c-490e-a5df-714e34409521" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3c68c648-3096-4d2c-9fde-085dd7a31b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6c5300ec-8172-4f30-a336-385fd87ed3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6fd5df59-5fdb-46eb-b7ee-fe75256eb18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6c5300ec-8172-4f30-a336-385fd87ed3b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6fd5df59-5fdb-46eb-b7ee-fe75256eb18f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0ea5bd9e-0470-48dc-9427-b1a87b0fff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6c5300ec-8172-4f30-a336-385fd87ed3b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0ea5bd9e-0470-48dc-9427-b1a87b0fff6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9febda66-c656-4746-8879-ccc1191d2205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_28d7cf3f-e271-490d-8dc7-4c8d0a0b0ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9febda66-c656-4746-8879-ccc1191d2205" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_28d7cf3f-e271-490d-8dc7-4c8d0a0b0ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_98f3b47d-6ea6-48a7-9921-f02243100e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9febda66-c656-4746-8879-ccc1191d2205" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_98f3b47d-6ea6-48a7-9921-f02243100e12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_811c5c63-0c41-49db-b557-879585d75a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8bb62dac-0190-4686-8ce3-2fe87688a59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_811c5c63-0c41-49db-b557-879585d75a65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8bb62dac-0190-4686-8ce3-2fe87688a59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_86acdc29-0371-4036-bfec-1b9efdb92089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9460cb69-3717-45f2-9469-f4c7908a8203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_86acdc29-0371-4036-bfec-1b9efdb92089" xlink:to="loc_us-gaap_ProfitLoss_9460cb69-3717-45f2-9469-f4c7908a8203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d294adab-c39a-4876-8122-dedad76c0eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_86acdc29-0371-4036-bfec-1b9efdb92089" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d294adab-c39a-4876-8122-dedad76c0eba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_15a06819-9ebe-4686-83a5-98cf886232a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_ProfitLoss_15a06819-9ebe-4686-83a5-98cf886232a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ef47cb50-840f-40ba-ad9d-ce53a59e18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_ef47cb50-840f-40ba-ad9d-ce53a59e18fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_29feb689-12b8-44ae-8c2d-308ce0a2470b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_DepreciationAndAmortization_29feb689-12b8-44ae-8c2d-308ce0a2470b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e3a58a58-7cc8-425a-ae75-15cc57500f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e3a58a58-7cc8-425a-ae75-15cc57500f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8ef2a9b-6b41-48b3-a174-60e653fa9579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8ef2a9b-6b41-48b3-a174-60e653fa9579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ff9f4814-c831-4f47-a5fd-92ff3eff15ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ff9f4814-c831-4f47-a5fd-92ff3eff15ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_74ad26ad-1284-446d-abe0-0dbab59e014b" xlink:href="clbs-20220630.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57450aaf-eb77-4762-8b5c-61df05ebba93" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_74ad26ad-1284-446d-abe0-0dbab59e014b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2545fc2-ae86-4340-aa6b-b98816e3a536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_134023a4-5739-4b8a-aa54-717a7bc8095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2545fc2-ae86-4340-aa6b-b98816e3a536" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_134023a4-5739-4b8a-aa54-717a7bc8095d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f0218817-bc67-4025-907d-70b7cc82e358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2545fc2-ae86-4340-aa6b-b98816e3a536" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f0218817-bc67-4025-907d-70b7cc82e358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3eee7e28-95c2-449b-b2b8-296b23f0b775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2545fc2-ae86-4340-aa6b-b98816e3a536" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3eee7e28-95c2-449b-b2b8-296b23f0b775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed26fc49-aa3c-4a5b-9729-facc2b7d56cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2545fc2-ae86-4340-aa6b-b98816e3a536" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ed26fc49-aa3c-4a5b-9729-facc2b7d56cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16ff5c68-aa4a-494c-82c1-b1836673f293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_30e95ba7-de4f-481a-8dd4-5aaf26f50163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16ff5c68-aa4a-494c-82c1-b1836673f293" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_30e95ba7-de4f-481a-8dd4-5aaf26f50163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a49cb836-fa34-4bbf-a3a1-da69c5c34fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16ff5c68-aa4a-494c-82c1-b1836673f293" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a49cb836-fa34-4bbf-a3a1-da69c5c34fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9d3b425e-43eb-443b-be07-34b6222ac8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16ff5c68-aa4a-494c-82c1-b1836673f293" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9d3b425e-43eb-443b-be07-34b6222ac8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c18e968-c86a-47ff-9ac0-f6c93af548cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd9b6559-21ef-4f0c-800c-582958d8503d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c18e968-c86a-47ff-9ac0-f6c93af548cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd9b6559-21ef-4f0c-800c-582958d8503d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1f3a01a-5d13-40c1-ab01-280c3e75d87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c18e968-c86a-47ff-9ac0-f6c93af548cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1f3a01a-5d13-40c1-ab01-280c3e75d87b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28969460-1b99-43cf-9f23-22ce0bf20e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7c18e968-c86a-47ff-9ac0-f6c93af548cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28969460-1b99-43cf-9f23-22ce0bf20e7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5eab9e4-4174-40a1-8edb-67ccd9089274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0fb38eee-4026-4757-862f-0952e3c474f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5eab9e4-4174-40a1-8edb-67ccd9089274" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0fb38eee-4026-4757-862f-0952e3c474f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9cfc9c8f-5b68-4c9a-8a95-f3925e0302c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5eab9e4-4174-40a1-8edb-67ccd9089274" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9cfc9c8f-5b68-4c9a-8a95-f3925e0302c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d18b9e6b-5be0-402f-a372-a1360184aab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b5eab9e4-4174-40a1-8edb-67ccd9089274" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d18b9e6b-5be0-402f-a372-a1360184aab9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d1ba5635-2fbe-4ffe-a2c3-b968ba5270ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1d63bcf4-0b26-4795-a1ea-10bde716b1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d1ba5635-2fbe-4ffe-a2c3-b968ba5270ec" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_1d63bcf4-0b26-4795-a1ea-10bde716b1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_3eab974f-d140-4511-83fd-67771851e083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d1ba5635-2fbe-4ffe-a2c3-b968ba5270ec" xlink:to="loc_us-gaap_MarketableSecurities_3eab974f-d140-4511-83fd-67771851e083" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b612ca42-40b5-410f-b0f0-9849fd75372b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_91a4bea8-1652-4c95-8ac3-255d210ddfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b612ca42-40b5-410f-b0f0-9849fd75372b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_91a4bea8-1652-4c95-8ac3-255d210ddfa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_f9bdc774-8cc3-4c24-905a-de4e07cf3de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b612ca42-40b5-410f-b0f0-9849fd75372b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_f9bdc774-8cc3-4c24-905a-de4e07cf3de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30a621bf-6de0-4f60-a96b-da90617f5a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_8e48ee6d-ef8b-4c37-a650-6a53d20520d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30a621bf-6de0-4f60-a96b-da90617f5a86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_8e48ee6d-ef8b-4c37-a650-6a53d20520d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_d5ed756d-54ea-4867-ae0d-f2e5a054fcba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_30a621bf-6de0-4f60-a96b-da90617f5a86" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_d5ed756d-54ea-4867-ae0d-f2e5a054fcba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d66f7eb2-5ffe-47d8-956c-dfdb0872a7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b1c2a2d5-3a81-42d7-a5c3-5b82818199a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d66f7eb2-5ffe-47d8-956c-dfdb0872a7fc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b1c2a2d5-3a81-42d7-a5c3-5b82818199a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1b0fbefa-4083-4225-9c0e-87ab554ba04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82d45699-c16b-4221-9335-e283c6ca6bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1b0fbefa-4083-4225-9c0e-87ab554ba04f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_82d45699-c16b-4221-9335-e283c6ca6bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3a2caa0-722b-4777-befa-472a8f61b293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1b0fbefa-4083-4225-9c0e-87ab554ba04f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d3a2caa0-722b-4777-befa-472a8f61b293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5bae1749-0ab9-468f-8225-0361062d60e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_1b0fbefa-4083-4225-9c0e-87ab554ba04f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5bae1749-0ab9-468f-8225-0361062d60e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8c141ce1-eccf-4e54-8ffa-dede26a29582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b00f5cd2-d2b1-4fb6-840b-f6dacc3286a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8c141ce1-eccf-4e54-8ffa-dede26a29582" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b00f5cd2-d2b1-4fb6-840b-f6dacc3286a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e824679a-d432-4e8f-b089-fb3c6d4e28d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8c141ce1-eccf-4e54-8ffa-dede26a29582" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e824679a-d432-4e8f-b089-fb3c6d4e28d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c7bbb8c9-a89d-49a3-9c47-da34e3928322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_390868a1-4113-43e6-98b9-7d4bc8fdce73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c7bbb8c9-a89d-49a3-9c47-da34e3928322" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_390868a1-4113-43e6-98b9-7d4bc8fdce73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8dcf66ed-8ce6-4253-aac2-33bcf6e03f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c7bbb8c9-a89d-49a3-9c47-da34e3928322" xlink:to="loc_us-gaap_OperatingLeaseLiability_8dcf66ed-8ce6-4253-aac2-33bcf6e03f76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bf6913b-7255-41b4-bd90-36da06ddf600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd84d553-ed12-4ed3-96b2-5c273f32b39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bf6913b-7255-41b4-bd90-36da06ddf600" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd84d553-ed12-4ed3-96b2-5c273f32b39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a721bbef-dd22-4a02-9edf-2024a2a48006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bf6913b-7255-41b4-bd90-36da06ddf600" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a721bbef-dd22-4a02-9edf-2024a2a48006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_daed8dcd-8ad2-4808-8f62-fa1356846d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bf6913b-7255-41b4-bd90-36da06ddf600" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_daed8dcd-8ad2-4808-8f62-fa1356846d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6dde419-acbc-45ac-92fa-ba300bf49c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6bf6913b-7255-41b4-bd90-36da06ddf600" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6dde419-acbc-45ac-92fa-ba300bf49c0e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>clbs-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="ie0a4d8e2c4454058a9337b603537bff1_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_830cfda3-cd48-4ea9-8da3-8d82d0f1decf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_830cfda3-cd48-4ea9-8da3-8d82d0f1decf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26652d97-c22a-46dc-a846-aa9077c60972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26652d97-c22a-46dc-a846-aa9077c60972" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09fbf933-d30f-42a5-9e38-c737cbd23701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09fbf933-d30f-42a5-9e38-c737cbd23701" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f4ec236-8f59-4857-98ee-494274047a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_ProfitLoss_0f4ec236-8f59-4857-98ee-494274047a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7dc8cc60-15f7-4696-87a4-15145bcb91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7dc8cc60-15f7-4696-87a4-15145bcb91c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88333777-dea8-43c9-b815-42ac8cd18c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88333777-dea8-43c9-b815-42ac8cd18c55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4d848374-6de1-470f-a4c6-2e641fe11002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4d848374-6de1-470f-a4c6-2e641fe11002" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dff12b13-1f79-41a5-a95d-eed5fb3652fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dff12b13-1f79-41a5-a95d-eed5fb3652fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa7b7108-e219-4a89-9c42-28fb564449ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa7b7108-e219-4a89-9c42-28fb564449ba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acca60b7-1428-4b5b-989c-b504d717d255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acca60b7-1428-4b5b-989c-b504d717d255" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d2f620b-f823-4952-8760-d6b48d721f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d2f620b-f823-4952-8760-d6b48d721f8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0308265b-c6d3-46f7-a1b8-df16c4d25f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b545749d-1049-41df-9267-5661bb2417ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02bce24d-0ba0-4c32-8cad-208ad377b13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:to="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a807979f-c665-4d8b-b7b4-8e645454eb7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:to="loc_us-gaap_EquityComponentDomain_a807979f-c665-4d8b-b7b4-8e645454eb7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:to="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:to="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_068bc310-41cc-4190-b98f-f925be98d097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_PreferredStockMember_068bc310-41cc-4190-b98f-f925be98d097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86b31684-75e4-4216-8edc-f0baac07e6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_CommonStockMember_86b31684-75e4-4216-8edc-f0baac07e6c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53f96426-c3ca-4087-bdd2-b8fd14032ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53f96426-c3ca-4087-bdd2-b8fd14032ab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09cda4f7-ba65-4282-9859-36c22a1589c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09cda4f7-ba65-4282-9859-36c22a1589c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8cd77b2f-829e-40ee-a542-ac8f9683d914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_RetainedEarningsMember_8cd77b2f-829e-40ee-a542-ac8f9683d914" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_840832b5-b4fa-40d5-a48b-54bb257e5d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_TreasuryStockCommonMember_840832b5-b4fa-40d5-a48b-54bb257e5d8a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_95337893-4478-488f-b537-d12bf98e21d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_95337893-4478-488f-b537-d12bf98e21d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#TheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended" id="ie472dbfad8f94a819cf1841af3b1c4cd_TheBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_b99e6373-e121-4771-89ee-3c1ff74e5b11" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_b99e6373-e121-4771-89ee-3c1ff74e5b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_26561b2d-8ba3-4691-8318-26d0abca89bf" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_26561b2d-8ba3-4691-8318-26d0abca89bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_d5e200f4-edc8-4799-9585-99bef8406449" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_d5e200f4-edc8-4799-9585-99bef8406449" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_092c9611-87c3-4ca9-a784-0120d4154049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_GrantsReceivable_092c9611-87c3-4ca9-a784-0120d4154049" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementMinimumNetCashThreshold_796fb500-efdd-48db-9624-b41bb21aa943" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementMinimumNetCashThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementMinimumNetCashThreshold_796fb500-efdd-48db-9624-b41bb21aa943" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeePayable_61550e71-c33b-4ca5-9e47-c172f05a54cf" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialTerminationFeePayable_61550e71-c33b-4ca5-9e47-c172f05a54cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable_ffba5bd3-aed3-4e38-875d-669000274972" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable_ffba5bd3-aed3-4e38-875d-669000274972" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialExpenseReimbursement_1625e306-a020-44e0-8d8b-8d09d40e2139" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialExpenseReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialExpenseReimbursement_1625e306-a020-44e0-8d8b-8d09d40e2139" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockShares_bd00715d-2022-45f9-b34e-c0abf44aba60" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockShares_bd00715d-2022-45f9-b34e-c0abf44aba60" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0dbe4c71-6e45-44ad-9c53-5f501e79cb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0dbe4c71-6e45-44ad-9c53-5f501e79cb64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockPricePerShare_6022d1a0-9eb1-4dd6-8bd8-2719e2b60f16" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockPricePerShare_6022d1a0-9eb1-4dd6-8bd8-2719e2b60f16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockAggregatePrice_1af2e1dc-664e-4093-92e5-d8871062df5f" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockAggregatePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockAggregatePrice_1af2e1dc-664e-4093-92e5-d8871062df5f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreEquityOfferingValueAfterConversion_f63685a3-8323-4ea6-a25b-77f76bad879d" xlink:href="clbs-20220630.xsd#clbs_PreEquityOfferingValueAfterConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PreEquityOfferingValueAfterConversion_f63685a3-8323-4ea6-a25b-77f76bad879d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_GrossProceedsOnTransaction_436185c4-2833-4519-a54c-e3ccf809bc9a" xlink:href="clbs-20220630.xsd#clbs_GrossProceedsOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_GrossProceedsOnTransaction_436185c4-2833-4519-a54c-e3ccf809bc9a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_375806e2-95c2-4c27-b815-eac09c510d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_375806e2-95c2-4c27-b815-eac09c510d2b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_6a370e37-5626-4caa-89fa-77cf82556f6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:to="loc_us-gaap_ProjectMember_6a370e37-5626-4caa-89fa-77cf82556f6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:to="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember_006ad411-581e-4100-b9a7-97da2eebb0f5" xlink:href="clbs-20220630.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:to="loc_clbs_CLBS16TreatmentOfCMDMember_006ad411-581e-4100-b9a7-97da2eebb0f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember_a87f6ad9-2227-411c-ba15-cdaff0f423c9" xlink:href="clbs-20220630.xsd#clbs_AgreementAndPlanOfMergerAndReorganizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:to="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember_a87f6ad9-2227-411c-ba15-cdaff0f423c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b038c408-5cf8-493f-b1bc-234eb8e2bd22_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b038c408-5cf8-493f-b1bc-234eb8e2bd22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendTherapeuticsIncMember_1cab5f0d-d924-4fba-9049-9263a647d096" xlink:href="clbs-20220630.xsd#clbs_CendTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:to="loc_clbs_CendTherapeuticsIncMember_1cab5f0d-d924-4fba-9049-9263a647d096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cdf4a4e1-381a-42a3-bcae-bb1177f86d27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:to="loc_us-gaap_ClassOfStockDomain_cdf4a4e1-381a-42a3-bcae-bb1177f86d27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:to="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SeriesDPreferredStockCendMember_15a36716-9c69-4a0c-b216-02193f918c2a" xlink:href="clbs-20220630.xsd#clbs_SeriesDPreferredStockCendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:to="loc_clbs_SeriesDPreferredStockCendMember_15a36716-9c69-4a0c-b216-02193f918c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_3df04576-4a53-41cb-9618-e46630ae2a64" xlink:href="clbs-20220630.xsd#clbs_CendSeriesDPreferredStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:to="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_3df04576-4a53-41cb-9618-e46630ae2a64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_54306c44-03c0-4952-825b-f574e9de5498_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:to="loc_dei_EntityDomain_54306c44-03c0-4952-825b-f574e9de5498_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:to="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendTherapeuticsIncMember_5070be41-4742-48a5-b7e0-5922c9bdb2bd" xlink:href="clbs-20220630.xsd#clbs_CendTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:to="loc_clbs_CendTherapeuticsIncMember_5070be41-4742-48a5-b7e0-5922c9bdb2bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e22a025b-0b7b-426e-8ced-b54a0e74be1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e22a025b-0b7b-426e-8ced-b54a0e74be1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborationAgreementMember_298d8f98-38e9-41ee-8729-1b80a405967d" xlink:href="clbs-20220630.xsd#clbs_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:to="loc_clbs_CollaborationAgreementMember_298d8f98-38e9-41ee-8729-1b80a405967d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended" id="i9b4b9057546d47e284f966e23f436959_AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49eb0cf1-9434-4e2f-bb99-300cd5ae2aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49eb0cf1-9434-4e2f-bb99-300cd5ae2aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc70a987-1587-49fb-a602-206f4ca27d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc70a987-1587-49fb-a602-206f4ca27d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ea76f1d-29ca-4eed-87fe-a81f08ffcac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ea76f1d-29ca-4eed-87fe-a81f08ffcac9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb2295ca-8c8c-45a8-b217-ff72522b3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb2295ca-8c8c-45a8-b217-ff72522b3c19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac019230-3364-4493-9476-2cda72c7c835_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac019230-3364-4493-9476-2cda72c7c835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_27e3b89a-6f3c-4698-83cf-0192d5f9a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_27e3b89a-6f3c-4698-83cf-0192d5f9a879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aa3de1c8-669c-421b-ba1a-a35676c319a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_CommercialPaperMember_aa3de1c8-669c-421b-ba1a-a35676c319a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_22d30343-8faa-41d2-9920-3b408c9d66a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_22d30343-8faa-41d2-9920-3b408c9d66a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_afb4fd23-2f4f-4268-98ed-e7386e4b3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_afb4fd23-2f4f-4268-98ed-e7386e4b3ebf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended" id="i5090643d184042efbb605c7fa8dc1d89_IncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92f57a1f-7004-4a0f-8084-57b9f20b3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92f57a1f-7004-4a0f-8084-57b9f20b3e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7a098dfa-6b69-43c9-8613-de97b7e6f6e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7a098dfa-6b69-43c9-8613-de97b7e6f6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df989564-76c0-4fb7-86e7-afe40a189992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df989564-76c0-4fb7-86e7-afe40a189992" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ebeb9181-6d80-44ec-a035-93029ad0532d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_WarrantMember_ebeb9181-6d80-44ec-a035-93029ad0532d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0c104a8b-5427-4168-bc3f-6aa924ae70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0c104a8b-5427-4168-bc3f-6aa924ae70e8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i5898b049e0684200b2f40f10542d9932_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4b5408d2-324f-41ba-9aa1-9898908a38a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4b5408d2-324f-41ba-9aa1-9898908a38a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4c7bb5bc-5ba3-4fec-9a19-ff3649876876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4c7bb5bc-5ba3-4fec-9a19-ff3649876876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6308d963-9cee-4d61-b984-55cf67978163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6308d963-9cee-4d61-b984-55cf67978163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fae4e065-b83c-4112-9f29-2d1fe225ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fae4e065-b83c-4112-9f29-2d1fe225ba74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_08ab1f2a-28b7-44a3-a118-6afe52288ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_08ab1f2a-28b7-44a3-a118-6afe52288ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e87e4d74-7afc-4509-ba33-c377b1cd7f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e87e4d74-7afc-4509-ba33-c377b1cd7f34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_361f208a-8ecb-476b-8e05-faab304d8865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_361f208a-8ecb-476b-8e05-faab304d8865" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended" id="i5459ed69430848ff8df1a198ca99e3ee_StockholdersEquityEquityIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_3b8b8d5c-d2ed-497f-8917-bd477129214c" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_3b8b8d5c-d2ed-497f-8917-bd477129214c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_1b6d58ba-2d8b-431d-b1e2-1a5c5a91e10f" xlink:href="clbs-20220630.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_1b6d58ba-2d8b-431d-b1e2-1a5c5a91e10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76ca9d88-8bf6-446b-9c5a-0fb87ec29220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76ca9d88-8bf6-446b-9c5a-0fb87ec29220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_646ac5ca-815a-4e05-a50c-529e251a7e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_646ac5ca-815a-4e05-a50c-529e251a7e70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_316a6b58-7a6c-4ed8-aba3-aee571b53eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_316a6b58-7a6c-4ed8-aba3-aee571b53eb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_d126a44d-402b-45ab-8578-14ed2ce4dc68" xlink:href="clbs-20220630.xsd#clbs_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_TermOfAgreement_d126a44d-402b-45ab-8578-14ed2ce4dc68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_bf37ad62-c216-44fe-8fa4-c25e33ed0ed3" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_bf37ad62-c216-44fe-8fa4-c25e33ed0ed3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_3c245f28-41eb-469e-a391-e0e6b970ed35" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_3c245f28-41eb-469e-a391-e0e6b970ed35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_ec30fcd0-0c12-49ec-8fbb-e5950a041dc7" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_ec30fcd0-0c12-49ec-8fbb-e5950a041dc7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_ae14ad4a-1a3b-40d9-8f0a-549d6c88ef00" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_ae14ad4a-1a3b-40d9-8f0a-549d6c88ef00" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_9ae996b4-9952-4413-a8e8-588ee59b5ece" xlink:href="clbs-20220630.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_9ae996b4-9952-4413-a8e8-588ee59b5ece" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2e5661-124e-4c0d-98be-0ab78da56483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2e5661-124e-4c0d-98be-0ab78da56483" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fd73c03-9832-48c5-b7f1-eb253cf8625f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fd73c03-9832-48c5-b7f1-eb253cf8625f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_faf3c7fb-33e9-4d6a-afd7-09cf44dd2e36" xlink:href="clbs-20220630.xsd#clbs_LincolnParkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:to="loc_clbs_LincolnParkAgreementMember_faf3c7fb-33e9-4d6a-afd7-09cf44dd2e36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_cd8e2f76-eb94-4e2a-b59a-548966be481d" xlink:href="clbs-20220630.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_cd8e2f76-eb94-4e2a-b59a-548966be481d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="ica443ad95fea48c4ac5bffddc6e06c44_StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_fe2fd9e4-85b3-4259-b452-0bf1315e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_fe2fd9e4-85b3-4259-b452-0bf1315e4162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38d7d347-0197-4c76-8efa-851331cc9983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38d7d347-0197-4c76-8efa-851331cc9983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8894ef-d671-403f-8fb3-f3302a7aa464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8894ef-d671-403f-8fb3-f3302a7aa464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a5dfa22-b776-4b89-ad81-0ff3f1fd12fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a5dfa22-b776-4b89-ad81-0ff3f1fd12fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:to="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a46bd1e-e335-459a-a751-35b1dcd1fad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a46bd1e-e335-459a-a751-35b1dcd1fad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6d267302-af2e-4311-b5bf-716c71bfa9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:to="loc_us-gaap_RestrictedStockMember_6d267302-af2e-4311-b5bf-716c71bfa9d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_684af915-664b-4dd4-a985-64998e7b253b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_684af915-664b-4dd4-a985-64998e7b253b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:to="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43d9f196-97cc-4f42-8e96-8a0766c734c8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:to="loc_srt_RangeMember_43d9f196-97cc-4f42-8e96-8a0766c734c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:to="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8edd6c69-d137-4e2f-86ae-7babbc1c22d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:to="loc_srt_MinimumMember_8edd6c69-d137-4e2f-86ae-7babbc1c22d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4ff2268-0f9b-49e9-b736-98d5fce97709" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:to="loc_srt_MaximumMember_f4ff2268-0f9b-49e9-b736-98d5fce97709" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="ic659913f11704a58ae32c205d0a7aa97_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39b42dc7-5b85-4fe6-9b4e-90bbfc648d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39b42dc7-5b85-4fe6-9b4e-90bbfc648d23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30071671-ea9d-427b-b8e7-248ea1e1200c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30071671-ea9d-427b-b8e7-248ea1e1200c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6f7c5725-e8a7-474c-84b7-afa77f9b96df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6f7c5725-e8a7-474c-84b7-afa77f9b96df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea0bc9bd-0f92-4ac3-ba6e-c2180d1d775e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea0bc9bd-0f92-4ac3-ba6e-c2180d1d775e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended" id="i918a29525a634d62a57de6cf57c501f2_ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f584c7e0-feb8-468d-99c0-61d8dafce02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f584c7e0-feb8-468d-99c0-61d8dafce02b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5209730e-36d0-4bc1-a6c2-f2b18a14f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5209730e-36d0-4bc1-a6c2-f2b18a14f4b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:to="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38e194fc-724c-4d73-9017-43b1ed25a8cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38e194fc-724c-4d73-9017-43b1ed25a8cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1eb80525-c597-4d6b-b9e0-541d058861ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1eb80525-c597-4d6b-b9e0-541d058861ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6ca75a74-b61d-46b6-b77a-197d81497f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6ca75a74-b61d-46b6-b77a-197d81497f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e8b546b8-cbb1-4161-9bcf-d5de7a60b559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_RestrictedStockMember_e8b546b8-cbb1-4161-9bcf-d5de7a60b559" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended" id="i2adec4db09054f819d315f516e00954e_ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_62e23e60-ee66-4242-b7d6-d40f4390662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_62e23e60-ee66-4242-b7d6-d40f4390662a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0315cee7-fe5d-4497-b856-3aad33fd1786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0315cee7-fe5d-4497-b856-3aad33fd1786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:to="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20138fd8-04a2-4e2b-bcbb-85e6edb29471_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20138fd8-04a2-4e2b-bcbb-85e6edb29471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8eebc2fa-c4c0-4309-b50e-cf45b9a4f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8eebc2fa-c4c0-4309-b50e-cf45b9a4f91d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended" id="i76249270c0544caa833470faee870750_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_389bf5ff-04b4-4659-923d-6679804387b6" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_389bf5ff-04b4-4659-923d-6679804387b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_590c3243-444a-4552-8747-c75d2a3953c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_us-gaap_OperatingLossCarryforwards_590c3243-444a-4552-8747-c75d2a3953c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_f7dc357c-40a6-4221-a812-0916e4bdb5eb" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_f7dc357c-40a6-4221-a812-0916e4bdb5eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_e78106eb-9787-4a98-9c00-3c372993a42c" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_e78106eb-9787-4a98-9c00-3c372993a42c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_a12ae1d5-6abc-4c0c-a734-fda02b11f3c5" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_a12ae1d5-6abc-4c0c-a734-fda02b11f3c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_78d408e2-8f2a-474e-a2bb-5cf1ca1b9593" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_78d408e2-8f2a-474e-a2bb-5cf1ca1b9593" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_655215f4-6927-41ad-9bb6-84bffc155f5d" xlink:href="clbs-20220630.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_655215f4-6927-41ad-9bb6-84bffc155f5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b925d469-9e27-4ff1-9ece-4f18323ff9b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b925d469-9e27-4ff1-9ece-4f18323ff9b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_354bc2ed-8408-4371-9cc2-4cadef86bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:to="loc_us-gaap_DomesticCountryMember_354bc2ed-8408-4371-9cc2-4cadef86bc74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_be9396e4-aacb-452c-b086-29f806daf03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_be9396e4-aacb-452c-b086-29f806daf03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5edbb2ad-404a-4d15-b19b-0e1d9097082e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5edbb2ad-404a-4d15-b19b-0e1d9097082e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1fa9a044-5827-4f48-ba62-b2d953a045f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1fa9a044-5827-4f48-ba62-b2d953a045f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2dfdf711-6875-443f-97da-7ea3c289c252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2dfdf711-6875-443f-97da-7ea3c289c252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_fa1efd48-79ce-4579-a995-6bfa5a376550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_fa1efd48-79ce-4579-a995-6bfa5a376550" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>clbs-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_ba2f5887-083f-44a5-a715-69e26992adf2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_dff0b815-3b9c-4659-9422-42fdffc8e5b5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_20309f93-604a-4028-87c8-1de5a050ea20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bdf17a70-e359-435b-8839-ab0c5055195a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_6e590698-c8a4-455c-9b7e-e100b8e959d5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_80fdc14c-4af8-4a89-993e-011f660216ef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d9265904-5219-4f37-b3f3-3dd720b6ab65_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f1ac425-4bd9-4181-a0b2-b80b485ec8e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5d270899-8ea3-4130-9b8b-73f8b0cefe62_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2a1b3589-db2b-4b60-9cac-9895cf63c657_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_7a9de198-36ae-4a58-a810-bccf9f1e0797_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of NOLs, gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6dd4593e-da04-4730-ab51-14dffbf4f647_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_bd6d1bde-e62a-43d9-b916-be75e2b0b2f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1f7fd31c-ca6e-4311-9331-b9a34b10a52e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c882b396-348f-4890-a92b-94d9d89a6ed7_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_68e08e76-3495-4240-919e-68a092cdf8a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cf7a16e6-5d53-4da4-8501-f7c40553e129_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_e92299cc-0a9b-44e0-be30-ebf5d8d37480_terseLabel_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest" xlink:href="clbs-20220630.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_Sharesvestedandexpectedtovest" xlink:to="lab_clbs_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_949f2af2-c36e-4b13-9a71-d524c9cae58d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58a26592-4226-4749-a348-060b21e8d04a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_a9884cb8-84f9-4556-876c-8b44ba357a0b_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of NOLs</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_6b5d7245-f187-4fa2-992f-66ef8c757a42_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6d5e97c2-118b-4aee-a592-3e0ce2af750d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_35fc1fa9-c2e3-47be-8161-3bc10dfb2272_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a6fdbc9a-9c51-4260-a6d8-3792c5573bb5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1697eb9a-b970-4ca6-a3b3-2c88980c788a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_767fc7f3-f782-4753-acb3-32ad6c07842c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5ed7c891-3054-4d42-9838-082a5fe909b3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d170370c-a9db-4439-b826-7cd0035790a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_259dba9b-f001-41b5-b979-a626a706f4bc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c8223200-251a-4fa1-ae1b-44e5d24a6439_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_20f871e3-6666-4986-a1ba-50d660dc5de5_terseLabel_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="clbs-20220630.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a37095b2-9709-4e9e-a4fe-9e6596803300_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExpired_264d2c60-c492-4dcc-ab91-317b1b18d966_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExpired_label_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_clbs_WarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired" xlink:href="clbs-20220630.xsd#clbs_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExpired" xlink:to="lab_clbs_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_64add457-9a51-42bf-ad20-918eefa6961d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3ad16510-2d8a-438e-9639-1f399d44873f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExercised_506f3298-ec50-4cac-87f4-8dc8d484f75b_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExercised_label_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_clbs_WarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised" xlink:href="clbs-20220630.xsd#clbs_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExercised" xlink:to="lab_clbs_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5762d2c4-f619-4766-a6ff-98101748347f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_880852a2-21fa-490a-beb5-5f7131140c6e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ff2a16ee-8c59-4e82-a5bd-d1510e480833_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_acf06bbd-b44e-419a-a778-637d6e526c25_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c926314c-2432-4479-8259-b14c9688a338_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9747fb35-6873-4b6e-a76d-39b301e23444_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_986245d1-830b-4d78-aebf-b70f9d685c59_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0fd8a773-1de2-46ba-8aad-d6639a64e39c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6fd0597e-923a-461f-9f51-09e8f02b6e39_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_338ea3b4-2dd9-4041-8e90-5a5a72e9456b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0dd5dcb7-617c-41bf-afd5-dfacb88f7ec9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_10c323d6-abf8-4de5-a1bf-0e8c4486f0c1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2997caeb-70d4-4829-8ed0-a4acf76720c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ff380791-a612-4631-94c6-6809a55c4255_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_af77dc0e-29e3-4f92-a1a0-e70b3159a6e2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ad904f3f-7bc0-4424-99ce-e78495194e8f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_81316a2b-61f1-4f9a-bfe1-4e3e8583635c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e945f53a-c9e3-46cc-bc55-5b7376d74891_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_0445c059-c49f-4045-b237-d08caec70830_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeePayable_a86aada0-58a4-4d5d-9202-4e25775e7523_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential termination fee payable</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeePayable_label_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Termination Fee Payable</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeePayable_documentation_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Termination Fee Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:to="lab_clbs_MergerAgreementPotentialTerminationFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8061d332-cf8f-48e5-b087-21a24d4913a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_10701842-80ee-49ac-8c2b-0ff786182823_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfd514b7-36cc-46ea-adb7-23b24fec1381_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a78aa542-ce14-42e1-8279-9202e08feb94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0827a269-1ccb-4318-8af4-bbbf436248d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_563ff451-7a5f-46da-be0b-7d2b53287d29_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_08a91455-65f5-4c5b-90f8-1126f4357d98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2aa77d94-d1e7-48c4-aee5-65d2ff6653fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5b51289b-1ac4-480c-8b5f-41f45330ae30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_321436c8-54ac-498f-9ffa-4e863e4ef397_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bf9031b3-2d45-45de-99f9-6ba4b025aa65_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_ccf78c9d-8b04-4fbd-8d8a-607754da329d_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares allowable to direct for Regular Purchase (in shares)</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsVested_f58de87f-f784-4e9c-83d5-91453141a6ac_terseLabel_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsVested_label_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_clbs_WarrantsVested_documentation_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested" xlink:href="clbs-20220630.xsd#clbs_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsVested" xlink:to="lab_clbs_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_00987681-b340-426c-b1d6-36538be97571_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember_12cc9d16-2109-4235-a2fa-7fa39eee4e9f_terseLabel_en-US" xlink:label="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement</link:label>
    <link:label id="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember_label_en-US" xlink:label="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement And Plan Of Merger And Reorganization [Member]</link:label>
    <link:label id="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember_documentation_en-US" xlink:label="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement And Plan Of Merger And Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:href="clbs-20220630.xsd#clbs_AgreementAndPlanOfMergerAndReorganizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:to="lab_clbs_AgreementAndPlanOfMergerAndReorganizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PurchaseOfPreferredStockPricePerShare_8368bc60-c65f-4714-8393-203b643d191e_terseLabel_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D original issue price (in usd per share)</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockPricePerShare_label_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Price Per Share</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockPricePerShare_documentation_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockPricePerShare" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PurchaseOfPreferredStockPricePerShare" xlink:to="lab_clbs_PurchaseOfPreferredStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_89fdd242-fd53-4590-828e-da30dfe05593_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0c8a44a-2591-43e9-800a-57f77ae7bbfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SeriesDPreferredStockCendMember_bd79c77c-0745-48b7-88d8-6c93eefc3d74_terseLabel_en-US" xlink:label="lab_clbs_SeriesDPreferredStockCendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Series D preferred stock</link:label>
    <link:label id="lab_clbs_SeriesDPreferredStockCendMember_label_en-US" xlink:label="lab_clbs_SeriesDPreferredStockCendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Preferred Stock, Cend [Member]</link:label>
    <link:label id="lab_clbs_SeriesDPreferredStockCendMember_documentation_en-US" xlink:label="lab_clbs_SeriesDPreferredStockCendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Preferred Stock, Cend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SeriesDPreferredStockCendMember" xlink:href="clbs-20220630.xsd#clbs_SeriesDPreferredStockCendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SeriesDPreferredStockCendMember" xlink:to="lab_clbs_SeriesDPreferredStockCendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a6cf2917-7f18-440f-8ec8-f4ce32f54f8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78cc72e8-fda0-4294-827c-6caece0c3357_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_cc2e2cd8-01e5-4df7-b030-d18078568cdc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15eba964-6ca4-4def-b752-db64b05b53e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ba15401f-17f0-438b-bd48-0287e0034741_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_BusinessTextBlock_ae766f91-1c54-4099-bdc4-289d12a1a42a_terseLabel_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_label_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_documentation_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock" xlink:href="clbs-20220630.xsd#clbs_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_BusinessTextBlock" xlink:to="lab_clbs_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3ded37b9-c534-40b1-b47b-981847d04f5d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_68dd7861-c489-48ba-a1f5-f7db0cf3b35e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58fc47ac-b8b0-499f-8dc6-d6c45f0b7206_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_737a74a8-705c-49b9-b4d4-83a83aee400e_terseLabel_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum beneficial ownership allowable per agreement (percent)</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_label_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_documentation_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:href="clbs-20220630.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:to="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_28afed3c-5aa6-417b-afa8-e919ef82ea55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_faeeb97c-8725-4abe-87b4-bc2220d28742_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b924ddcc-f3e9-43e3-a5b4-153e36cb753d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1c7aae1c-e015-460b-8007-57ac8ee1ca6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_687ea057-6b6b-4f20-9f40-0d9a6fe222f7_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation per directed purchase transaction for Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_18a56f3e-0972-4960-a44f-46cfa54b254c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_cd0c6b21-311a-42e4-80b0-cc0ae04babcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f9000ff3-603a-45f1-8234-b86e9a122c19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_9260a686-a10f-411a-83f4-94ec428762b3_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b0e9102a-14cb-48e6-ae6e-92bb86a13148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_15ba8da7-9b79-4184-a687-862066eda222_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_0733d050-3a18-4586-afa9-c3f0adcb0f2c_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_875e92f8-6631-4a3c-8edd-09342976a510_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_f8185dcc-f4c8-4339-bfbb-ee4302d2a691_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3e5a36c3-227f-4b4a-9496-404dbf15b4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ec47a6c5-d47c-4845-854e-4b2017c9b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_37a7ea17-3089-4ed1-bfae-5737a58ad4b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_a3b6bbae-929f-4c56-8a7f-955e437b369e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_36a250a2-e45f-4a3d-bbf5-570be2b40ce6_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_d02b4446-0446-404b-914a-e3a852332665_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9cd2e673-21a8-4105-9e72-820a72937ab9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d492be4-96e5-4387-b57a-2f7b0f9da4af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cbf49260-3259-46d5-aabf-becb6bb9e99c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e579526b-6b7c-4c32-be15-9c8252228b6b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f01a2516-07da-49c5-b8fa-489c16546d9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_200a083d-faa4-4b88-b7fd-5273eb0206e3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f396cbc5-0cc0-4850-b9e2-8a1fd5fc65fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_ea3430e5-ba04-4c4c-8de5-4995aa01c7db_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_58805369-45cc-4e7b-93e9-1edc92b30988_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_71f80497-e9a4-421d-b73f-68a2ed86727b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8f1406cf-6d3b-4a13-b887-f9c4a357ab05_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b66262c1-ff08-464a-9211-805cc671138b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f32bcf0a-3204-471c-aa72-b165c7e333bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborationAgreementMember_bee7168b-0925-4178-b8b9-fab6b6191239_terseLabel_en-US" xlink:label="lab_clbs_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_clbs_CollaborationAgreementMember_label_en-US" xlink:label="lab_clbs_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_clbs_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_clbs_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborationAgreementMember" xlink:href="clbs-20220630.xsd#clbs_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborationAgreementMember" xlink:to="lab_clbs_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4b8102aa-40f4-4ffd-8b96-be458bce54d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_07bb9b6c-ceeb-437f-b809-892279b01fbd_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7495e3cd-d110-4d02-b479-595a68eb431e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4dc57d6b-d314-49f1-9ca8-73c8c519e85a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_67c780ff-f31f-4089-a962-cf1d1873dd20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_bd76c670-e4ad-4426-b34a-effd71bc6ae9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5037af20-edce-4249-a9b3-4bfbc744d05d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b93296a2-5dbb-4e0b-8ef9-52ec29ad886d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d259693b-0c75-423e-b5dc-3365e40dde72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9c877e0f-783b-46a1-bb06-befeca71458e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d850dbd4-08b1-4caa-84b5-4b038e8ef453_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9e5e0bb1-474c-4a39-a4e0-f78a250c2b67_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0b60ef23-0742-460d-9121-636631160846_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9748d85c-4deb-49b8-9533-97a4bcf69de5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4b2ef15f-08fd-4910-b509-edfdf9d0f312_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_cb43d20a-f91a-4385-a428-b9c36f658b43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_486d9dd7-18f6-4d97-aea3-34e48e0f6c81_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c9a0c027-ebf6-414d-875d-7c478d9e9b00_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_24c2ee0e-2929-422a-bc7f-a898545c0513_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_9d059359-4a56-466e-9d6f-2ea68011f8b4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_TermOfAgreement_8fde773c-ae17-40c3-aae5-b20ab3f31960_terseLabel_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in months)</link:label>
    <link:label id="lab_clbs_TermOfAgreement_label_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_clbs_TermOfAgreement_documentation_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement" xlink:href="clbs-20220630.xsd#clbs_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_TermOfAgreement" xlink:to="lab_clbs_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable_0d1660d9-6bdc-4e38-8479-0964911a21fd_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential termination fee receivable</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable_label_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Termination Fee Receivable</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable_documentation_en-US" xlink:label="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Termination Fee Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:to="lab_clbs_MergerAgreementPotentialTerminationFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CendTherapeuticsIncMember_82f65676-6e14-4c51-ae76-53b55283d5e3_terseLabel_en-US" xlink:label="lab_clbs_CendTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend</link:label>
    <link:label id="lab_clbs_CendTherapeuticsIncMember_label_en-US" xlink:label="lab_clbs_CendTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_clbs_CendTherapeuticsIncMember_documentation_en-US" xlink:label="lab_clbs_CendTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendTherapeuticsIncMember" xlink:href="clbs-20220630.xsd#clbs_CendTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CendTherapeuticsIncMember" xlink:to="lab_clbs_CendTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06372620-5d71-4403-b28d-1ba94d4dd90e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6535f514-9235-4d83-ba98-157c009cc523_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsCanceled_077cf424-067e-4e8a-ac47-d13949bee48c_negatedLabel_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_label_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled" xlink:href="clbs-20220630.xsd#clbs_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsCanceled" xlink:to="lab_clbs_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_671d44e6-3127-4e35-8c68-fb2f552bbac4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_107367bd-e4ad-43c9-9dd7-8fe02b774c15_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0af8b40e-19c4-4ec5-98fd-0fe4490bf0fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b5e8abfd-a3c1-461b-9ff5-1f2546608a23_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ac9b7a35-fdae-4db4-bb23-9f66d043e20f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_89390932-470a-42ef-897c-628775a7f3a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1eb223fe-3332-49ec-8d8d-ed344cab2fd5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1b595771-9ccd-45af-a5fc-c9170e2bcd6c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9c841d52-433e-44c7-b4eb-2c0c69395ef8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_72f075c6-b4d6-4e62-a3b2-6133c138ed73_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_2efed217-5995-47dd-aeea-0fcfadc1b0eb_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction expenses threshold for allocation</link:label>
    <link:label id="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_label_en-US" xlink:label="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Transaction Expenses Threshold For Ratio Allocation</link:label>
    <link:label id="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_documentation_en-US" xlink:label="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Transaction Expenses Threshold For Ratio Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:to="lab_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_8ec68d4e-b8d7-4d4e-afd0-9b125f847490_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_51703d79-bb0d-47ff-9ddb-04ee97504923_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_107fc2cf-b72d-4812-89d8-350cd3b5d487_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_72d42325-0339-4e92-b105-2860d8054cfa_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1d1dd0f8-e7dd-495c-b27d-df6cc8d08707_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_962a3b8b-efcc-4668-96d7-79b38d7e839e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_247de034-74e9-4171-8e58-d7d370ed6466_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_55146cd4-c1d9-4546-b5e4-7d69bd01fd82_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_345c7706-125e-4511-942e-529f4317de94_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ee2c6e24-6f74-4af1-bb44-9cda92a7f088_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14c81615-dbdb-4556-8369-5c017d5476a9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f1e7f301-7bcc-48e8-bd69-25dd3b5bf970_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5205c21e-25f2-4f58-817f-b8dde845c14e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting terms (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_349654c0-7f4f-4275-89c9-bb2331c38eab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a31c0675-888d-41a4-97f6-9ca15db4616c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_88df46f7-ad59-4d59-9559-a6dceffc306e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_de32c4e3-4b5d-4e52-8d41-e32827c17da2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_17accb8e-343b-46c9-b4f5-9473b10eb339_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3689141a-404b-4a5e-a8c4-e11cfec9aadb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7572c361-ddef-4d05-abe8-6d09a01784cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_fd25d675-6ee0-4f49-bd2e-30a2f33ac75e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_bbd6d8e0-79aa-4372-8627-e0d23a6fcb9e_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_bcca2087-3b2e-4c88-b618-01366396cdbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d4e00f9f-3950-4ff9-a783-f8ff93edd936_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_87eb867f-e2a2-4fa7-ba0a-7563eccad858_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_840751ed-2e18-4074-a9a9-ea7e7ec0360b_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ae0a92cb-c9c3-43bc-8de8-4959c06084a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_33704ca7-b2a1-483e-bcce-8216fa77ad12_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsGranted_6b9dc9d4-df69-4fac-a83a-fe7fd00cd63f_terseLabel_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsGranted_label_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_clbs_WarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted" xlink:href="clbs-20220630.xsd#clbs_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsGranted" xlink:to="lab_clbs_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_150d4a9b-fa97-40e6-91e4-5b74899c08c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_dbb5fdb4-782b-43f1-9e23-4f87ae61d654_terseLabel_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="clbs-20220630.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PurchaseOfPreferredStockAggregatePrice_fdfeebcb-f0c2-45c5-989e-b3b34bfa3531_terseLabel_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate price</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockAggregatePrice_label_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Aggregate Price</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockAggregatePrice_documentation_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Aggregate Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockAggregatePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:to="lab_clbs_PurchaseOfPreferredStockAggregatePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5c65c1dd-6b4f-45e4-a9e6-f49eb7f65b3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e43a90d3-c7ee-45e6-85a5-f116f7f19a51_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_19aae752-c1fa-4c06-8f93-0307afb1808c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_617ca084-a707-4dc4-970d-3313f7a44433_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7b4ec6e-f50e-4d2e-a3c7-e52343c95861_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_3eeabf77-5037-487c-b84e-f7524a7ee3d2_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write down of NOLs set to expire unutilized</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:to="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_692c74df-7446-451f-8004-5e03a90d4e7c_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0549b481-a2c8-410a-830c-466b5673b951_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8fd0be94-7bd6-41c2-b6ce-921312adaa4d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_c498f89f-4633-45b7-887a-0bd8cb4913b9_periodStartLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_bd8d0030-30de-461a-9c99-9dff9fc7703f_periodEndLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7a5e31a9-2485-49a4-8855-c3ad96dffeb5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_034e662b-bb54-4514-976a-506bf3b6fd0f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_db3ab944-c0d0-4a50-9bab-f780b478fc84_terseLabel_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="clbs-20220630.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_88eecb02-f820-4f16-ab12-0ef9aec99fa5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b931a8c3-06dd-4ff2-84ad-80cba887951a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_710a588a-9a53-4af1-9aad-52b1b7a6bf06_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e0332257-6de3-4582-8799-f072676a4843_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_283e4d38-2621-454e-8197-dca7f0f1d125_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d40c95c-c046-40d5-870f-538697e01ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_6db79cde-f032-428f-b5fa-cf43437fd908_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:to="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_73587eda-9e35-46b6-bc56-d0aaa91f0d62_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_09a9932e-6b06-4028-96f0-6b5f10aaa91d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_f5d3d733-bf3d-431a-b047-44c011e9bf57_terseLabel_en-US" xlink:label="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Purchase Agreement</link:label>
    <link:label id="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Series D Preferred Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cend Series D Preferred Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:href="clbs-20220630.xsd#clbs_CendSeriesDPreferredStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:to="lab_clbs_CendSeriesDPreferredStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f38a165a-27e9-49de-8cce-efeeb1a2d56a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_677776cc-d633-4f79-b8c9-5c76a271ab46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_36fa6ca0-7831-45e5-a8f9-56073884fdc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dccbdf57-0e69-40af-b5da-79e449ff665e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_38519737-a307-4c48-aaf8-157dee7394d4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9684509e-866f-4c74-97b7-277c328e1bbd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_50458952-a205-4878-a139-3e7f69b867c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_95261bf9-131b-490e-a79f-ee6920aef351_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b5d6ec8b-b5b1-4739-8b80-afa560bdf8a2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_1b95f3c1-04f0-453c-a283-8b034a831352_terseLabel_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of Use Assets:</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:href="clbs-20220630.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_2f42d952-41c7-4418-97dc-705865f5ac1c_terseLabel_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment of CMD</link:label>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_label_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment Of CMD [Member]</link:label>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_documentation_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment Of CMD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember" xlink:href="clbs-20220630.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CLBS16TreatmentOfCMDMember" xlink:to="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_aa945b24-ba87-458c-b777-738baa0b206a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_735f2ffc-6963-4a33-b85a-48190a1a20bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementPotentialExpenseReimbursement_bed0dc7d-6344-44b6-ab6f-595f5b31d07e_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential expense reimbursement per agreement</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialExpenseReimbursement_label_en-US" xlink:label="lab_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Expense Reimbursement</link:label>
    <link:label id="lab_clbs_MergerAgreementPotentialExpenseReimbursement_documentation_en-US" xlink:label="lab_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Potential Expense Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialExpenseReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:to="lab_clbs_MergerAgreementPotentialExpenseReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_3b49eac4-3576-4fd2-9872-686fc70c5833_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_eff87b2d-74ca-4c31-bff8-d52fc90fe22f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b51681c0-6acc-4cd7-a66b-3cb0dbf219ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_446b1187-acd0-4496-9853-fcf04068b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_b074a821-16ba-4ec3-b786-53e9f5c7ffc3_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_11745a42-f70d-4b09-ae45-e8c4bc48e8af_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LincolnParkAgreementMember_57431fd3-5759-4105-998b-14db3fb9a3ff_terseLabel_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_label_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_documentation_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember" xlink:href="clbs-20220630.xsd#clbs_LincolnParkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LincolnParkAgreementMember" xlink:to="lab_clbs_LincolnParkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7baadb46-12db-4a51-a7a8-804e39c4b607_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ea39d645-b829-420b-8d5a-4f5b556f10db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_05665619-9f8f-41a5-829a-3672fd4525bf_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected post-merger ownership in Company by Company stockholders (percent)</link:label>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_label_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Expected Ownership In Company, Company Stockholders, Percentage</link:label>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_documentation_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Expected Ownership In Company, Company Stockholders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:to="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_22e06f36-6148-4b19-ad02-835d793f553e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cb0b5060-22c2-4f3a-90e4-991bb8db00a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_af1a4095-c87a-4981-9757-af65a8673e97_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_5df72da0-f78e-4bb3-96a3-4c0b3b4e3462_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7d09e95b-0530-41ac-9d5a-a2d9c65b7c65_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_964bc5e6-b102-4f79-a984-4f47bec5e7a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_df366f92-c4ae-434b-a953-2ef3af367910_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_5725db6e-c55e-463b-80cc-a46d7075f0d3_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9193b189-b730-4a50-aeae-7b8faa37bc11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_c5aea840-b9f1-4013-9c6a-2677a319bfa5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_639b27b7-5e97-4541-ac7a-d6e1e638fe24_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_ef7f9f79-152e-4987-9029-d98a77cb5d7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 11,080 shares at June 30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_71cfefca-2734-4d44-a7d8-251dfab781ef_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_95f46999-d00d-4e70-b51a-0c0a75d6adbc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dc4475a9-b4cf-48b3-857e-611068a33f9a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_GrossProceedsOnTransaction_abed4293-3a9b-4002-8972-88a70246479b_terseLabel_en-US" xlink:label="lab_clbs_GrossProceedsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential gross proceeds</link:label>
    <link:label id="lab_clbs_GrossProceedsOnTransaction_label_en-US" xlink:label="lab_clbs_GrossProceedsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds On Transaction</link:label>
    <link:label id="lab_clbs_GrossProceedsOnTransaction_documentation_en-US" xlink:label="lab_clbs_GrossProceedsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds On Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_GrossProceedsOnTransaction" xlink:href="clbs-20220630.xsd#clbs_GrossProceedsOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_GrossProceedsOnTransaction" xlink:to="lab_clbs_GrossProceedsOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3307fa53-4c7c-4818-816b-0d90c34acb33_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d6e06d6a-778f-4102-982f-f9380a8828d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_d18166b1-cc25-4ab7-8daa-db091d479845_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_56e277cd-212a-4405-88cb-36c1cf2fe463_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,594,329 and 59,800,792 shares at June 30, 2022 and December 31, 2021, respectively; and outstanding, 60,583,249 and 59,789,712 shares at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_68dbe918-3f5e-4487-a074-98ff936da74f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d89390b2-d250-44ef-814b-799c3b759fc8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c9b214f-8d0c-44b1-828d-6a6e3e097f19_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_854e26ed-916a-48b9-8d76-bbe8885cf746_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ab401bdd-a7b7-4f48-bdb1-45eb3429c590_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7696fd4c-e0b8-42b7-a170-e533b4867b72_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_16471d58-3c31-4f55-9783-42398811fa0c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a8cb18a0-f05d-47f5-b015-94a405c60c64_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c89928b5-d119-4543-9890-9a5b590c9c30_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_5e2a7d3a-c4ea-498f-9902-7702389a0aed_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_08460444-6c94-4d29-a5d7-a72fc727cef4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_3ca8f0cd-5ed7-4477-bed4-de089ae32ec8_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_2af2cb79-9eee-4382-93a9-70c12e57616c_terseLabel_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment shares issued as consideration per agreement (in shares)</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_label_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_documentation_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:href="clbs-20220630.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:to="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ce5c0563-4382-44d7-8d8a-e5f25b2d91e5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_15483c7f-cca4-4cfe-89f1-aec5f3c686b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_314e5014-4a61-4e47-a599-cf9ef529c341_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_629d8b76-32e3-4885-83c0-77eeee11071b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3ae4e545-d479-4d13-ad01-9f1cde77ea9a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dc219689-d9cb-4b2c-8a63-a27be01d6113_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_07af7030-9ed6-4f15-974c-b82f96582930_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a56dc9a0-3144-4e7b-9069-6b8a1e96e78f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9161261d-851f-4c59-a350-652c1e6d8756_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c4184a24-a62d-4568-9778-64dc735d84c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e168611d-97bc-4e2e-bb6b-39e835e61194_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a3480051-9e56-42ce-beee-21449d43da79_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ba2339b3-10af-42f1-b290-8b8cf8419916_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9b56103-352f-4b01-b038-0afb7cc6c267_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b04984e-f09f-4b83-a0e5-fcd17b9ae19e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_020cd6e1-ba15-40fb-8158-ffd7ac42f262_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_92fcab30-0818-4e22-8725-33886177a5b4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_51e83f8c-8777-43e7-a140-1ef0ca9e2427_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_1cfe8ab6-26d8-426f-9e8e-6e86ecfaaf7d_terseLabel_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:href="clbs-20220630.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:to="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_0c64f2cf-044b-4418-8fb0-bfd88bb5262c_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected post-merger ownership in Company by Cend stockholders (percent)</link:label>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_label_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Expected Ownership In Company, Counterparty Stockholders, Percentage</link:label>
    <link:label id="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_documentation_en-US" xlink:label="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Expected Ownership In Company, Counterparty Stockholders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:to="lab_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_168fcde1-a9af-4b63-97a9-6a535b939154_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e6775f8c-f65a-4740-873c-a4b94545dc05_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_cba2e2a4-4e95-43fc-9323-45d6f8b05652_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d3cdba3b-6ab3-4084-b354-9e8c5452f153_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a25c7f68-c172-4706-ab4d-3450cd59b327_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_e01a6306-abdc-4a4c-8def-a1d776bbd41a_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_496e967d-5ffd-416f-810b-ba9cd014de02_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8263276b-b895-43ea-9871-5e298301e9eb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross price for stock transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CommonStockWarrantsShares_4241acfb-786f-454b-b07c-90ec12b8a4f3_periodStartLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_941d43dd-0f12-49c4-bb70-55f8aeec09ba_periodEndLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_label_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares" xlink:href="clbs-20220630.xsd#clbs_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CommonStockWarrantsShares" xlink:to="lab_clbs_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d3df442c-2956-4a51-b20a-7814248f52cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MergerAgreementMinimumNetCashThreshold_5518a45f-8d0b-464a-a628-0ba7f2ee0fe4_terseLabel_en-US" xlink:label="lab_clbs_MergerAgreementMinimumNetCashThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum net cash threshold at closing per agreement</link:label>
    <link:label id="lab_clbs_MergerAgreementMinimumNetCashThreshold_label_en-US" xlink:label="lab_clbs_MergerAgreementMinimumNetCashThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Minimum Net Cash Threshold</link:label>
    <link:label id="lab_clbs_MergerAgreementMinimumNetCashThreshold_documentation_en-US" xlink:label="lab_clbs_MergerAgreementMinimumNetCashThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Agreement, Minimum Net Cash Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementMinimumNetCashThreshold" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementMinimumNetCashThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MergerAgreementMinimumNetCashThreshold" xlink:to="lab_clbs_MergerAgreementMinimumNetCashThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b65ef66c-ef90-4249-a647-5663665a23fc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75856f3f-f8bb-4d3d-9574-06ff99659f8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a3001859-b068-4268-b5fa-d8e43621c29d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd674a24-40f9-4a7f-9eef-3db14cae9b5e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a4021bdf-d99a-4720-87aa-07e9d06227b7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_062d10c2-270a-4f60-8e2d-b0f85e02299f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_18a0f35b-0459-409a-927b-9295f0015591_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_517156af-5fb4-4baa-acf4-e9dfd88cf11e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_db0984e0-391a-49db-97ea-017855bd3cb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d433717-dcf4-4a7f-8906-05e16e206142_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_04730753-0d39-410b-b969-081dd6143d72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f18d49ec-a131-408f-a9e4-75577961da47_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_019211b9-92ec-4c93-b6a1-fdb1e341732b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6baf279d-338f-4d67-8120-b2d0e5ae99de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_60da55a3-1f29-4277-92d5-ba09f080d0ac_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2d1c1d6f-0d38-4557-a336-2308a6e48da5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2d4a3e36-ff27-4c3c-af65-5966184c019b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4a225df-23ec-4109-ab5e-1a75f7655ec9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b9981025-2fef-43ff-a5cd-dc905ff42ef3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc5cb11a-47ce-4b91-b0b3-4ab7e31bbfc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6689ea68-9dd0-4639-812e-f3c1875889cc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5686242c-f75f-4abc-b141-9006aff31c2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f8cb1806-8c92-4aae-904d-f46405b73385_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_554e9ea4-1c94-4eef-b07a-ba1a15166c5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3ad5ebd0-20ff-400b-bc17-fd84ee46e31d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b4ee54c6-0d81-4956-942c-00c673f9d2ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_eae24191-85c3-4959-8a3e-6a49cd8d4bee_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_e4fccadb-0336-4e67-9876-ea9c2aca83ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b8deb18d-9e73-4d85-9682-82475bb28042_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f2581f30-689f-4e16-a5c2-5fe64bf71a04_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5025604e-e481-4aea-8368-df313bf1be95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_95e20c64-bee9-460c-9a50-5221d16196dd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a15b83-dd0b-47f0-9f26-8be588379ae9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_71a830ea-f540-449e-8537-447384030ebc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_5c81425e-ff1a-4d8f-829b-ba5c3ae24fb8_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_label_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_documentation_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:href="clbs-20220630.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:to="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_42084043-867a-4532-92ae-e1f453571f68_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7182cda8-068d-42a8-8b07-3baae16982cb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_4168946d-d986-4fae-a80d-80b4b2cbb871_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_08ba6fc7-c99d-4062-9358-49e06597a237_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a3c3b152-9d47-4acd-abfa-5bacf79db4df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_13915a8c-b8ac-42e3-a460-ab51ba4797c1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_173d56ec-ef49-49ec-9e61-502bb65e9999_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec7758bc-a9f7-4aef-aae2-b8c42488b022_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_6211b0c5-f865-4458-ba95-7d8fa2a9fb0f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6af6a6e6-2c79-4330-aa94-88cc366bb865_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_80a25858-b9f1-4a1b-b45a-f055edde86b8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7711ddd7-cbed-4ab5-9b67-d8498fef0d27_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4a9b8685-2e63-4009-a118-2a98c765e2e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3a20037a-0337-4c94-841c-baf11014525a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_43bb8d1a-1a7e-4643-81c5-ef56a9aa46dd_terseLabel_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:href="clbs-20220630.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:to="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4a9eaecc-d2a2-41fb-ad24-02155cbb0a8b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_59b6fe12-2aa3-40ea-8c28-5c7035611003_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3f981c91-cb22-4499-9886-3cf6a7a55584_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b41a919c-81d2-45e8-8701-b50b13c0b04e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_07cb3f22-7d5c-4edf-b573-d6c401bd9072_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_8ea60e60-d094-4f5a-af76-d82d39902ba1_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1b3ddcb-5d41-4011-b151-30df75ff1776_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_08585eaa-c434-4aec-a792-f2e04dc22c2e_terseLabel_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offices under operating leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_label_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_documentation_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:href="clbs-20220630.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:to="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1fc3a57c-0b00-4548-b295-f685bfed03e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_d1aa5920-37ce-4c75-8f31-1a1023a3aa74_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_5ac0abf0-9d59-4093-a3be-2e0116ef861f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_45c2cadc-53b9-4cdd-bc48-08eae4235360_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2e7dd17a-375d-45ad-950a-014186c2c588_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreEquityOfferingValueAfterConversion_6ea3d698-93d1-40c3-b664-31cec75b902f_terseLabel_en-US" xlink:label="lab_clbs_PreEquityOfferingValueAfterConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Equity Offering Value After Conversion</link:label>
    <link:label id="lab_clbs_PreEquityOfferingValueAfterConversion_label_en-US" xlink:label="lab_clbs_PreEquityOfferingValueAfterConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Equity Offering Value After Conversion</link:label>
    <link:label id="lab_clbs_PreEquityOfferingValueAfterConversion_documentation_en-US" xlink:label="lab_clbs_PreEquityOfferingValueAfterConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Equity Offering Value After Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreEquityOfferingValueAfterConversion" xlink:href="clbs-20220630.xsd#clbs_PreEquityOfferingValueAfterConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreEquityOfferingValueAfterConversion" xlink:to="lab_clbs_PreEquityOfferingValueAfterConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_280bd400-e8a3-47a7-896c-d1f0cd604636_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Cend Therapeutics</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bb5aa7f4-9d57-47de-b46c-2c068fbdabd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_dd62ca7f-9103-4757-97db-cac031dad01a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_132b974b-76f6-4a75-908d-d55198ca5131_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_label_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_documentation_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated" xlink:href="clbs-20220630.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockSharesDesignated" xlink:to="lab_clbs_PreferredStockSharesDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c8b3ae44-2c49-4233-99f4-515d668d3aff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6e23f24b-054a-4682-a073-fd18f5b788d7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc9da42d-f2af-47fc-ba73-640b9ac1b8f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_26ef7ff5-5d74-421e-b2b4-1e5502cc94ed_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7b7189cf-2c27-4cd4-baab-789a5bce52ca_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_30e98418-26e2-4649-9ae9-b9b5b972c459_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants awarded</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_859bc5bf-ade1-45e3-9f43-6850fb0a26df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6dd538af-1677-42f8-8c3f-7000a53109d2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_cc1b5c7e-81c3-4a95-9cc3-c64984fcc719_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_138cd651-4b16-4ff6-b418-de648cdce722_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bb95236c-fe01-4062-921d-e70b0c168c63_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0797bbb1-1c03-445a-9980-98b8d6eb52e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d437fa4e-2d61-4226-845c-0c8a8a5a8e2e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_46b1c428-4ca8-4d74-883d-add720c6445f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_52e9a2c2-4236-4be2-962a-a46469898943_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_75483980-fa3e-49ca-84fb-ab003af928fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PurchaseOfPreferredStockShares_9f777120-a0e6-48b1-9b4f-30ef34193881_terseLabel_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockShares_label_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Shares</link:label>
    <link:label id="lab_clbs_PurchaseOfPreferredStockShares_documentation_en-US" xlink:label="lab_clbs_PurchaseOfPreferredStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Of Preferred Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockShares" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PurchaseOfPreferredStockShares" xlink:to="lab_clbs_PurchaseOfPreferredStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_3903846d-c9be-413e-96b0-e8109a2685fb_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_20545c99-015f-48d7-8a84-a13d56ee8eea_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_43c46afe-84ea-4ba1-ab21-677392254b48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b47acf9d-64fc-4cf8-9f6f-fcf78d8e11bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_ebc21581-ce63-401d-bf54-071fa2823a41_terseLabel_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="clbs-20220630.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6afc4327-4287-4257-acf5-f9ab75bfb330_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c62ac9ab-9c63-490e-857c-1e9a498e9309_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31a7581c-3ff1-4516-aa36-ee2d723ae93c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_2fc032e0-9312-4afa-b0f3-3f46834557bd_terseLabel_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of NOLs</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_label_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_documentation_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:href="clbs-20220630.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:to="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_656bf768-a153-4dca-b451-9f5faf530439_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2919e307-7d34-41e9-b72c-ae887a9d8945_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c020ce71-a88e-4ee1-a73e-c2a686f48246_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>clbs-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e883f380-b3de-4712-8994-e42f75844bef,g:ae21c298-d562-467d-888d-968a0f9ca1ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_83d991e6-8b6e-4efd-aea6-4e1aff2caa03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentType_83d991e6-8b6e-4efd-aea6-4e1aff2caa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d8613447-b322-46bc-b93b-3ded8bc7c8df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentQuarterlyReport_d8613447-b322-46bc-b93b-3ded8bc7c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8bedb080-5df6-4f23-9259-940493ed84ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentPeriodEndDate_8bedb080-5df6-4f23-9259-940493ed84ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c98eaae1-688b-424e-8c53-385b5ebb3093" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentTransitionReport_c98eaae1-688b-424e-8c53-385b5ebb3093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_18087930-6451-46d3-b143-b413d226b9f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityFileNumber_18087930-6451-46d3-b143-b413d226b9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2b71cb80-0677-4161-a284-0ff1de13c512" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityRegistrantName_2b71cb80-0677-4161-a284-0ff1de13c512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d0272c75-7b6c-48ce-9f8c-98741d2cfe63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d0272c75-7b6c-48ce-9f8c-98741d2cfe63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1790b759-a910-42b6-a092-2423297914f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityTaxIdentificationNumber_1790b759-a910-42b6-a092-2423297914f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f53eba6a-8578-46f3-9102-584090b912ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityAddressAddressLine1_f53eba6a-8578-46f3-9102-584090b912ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ba9e3d3b-16db-4fba-950c-ee4983695806" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityAddressCityOrTown_ba9e3d3b-16db-4fba-950c-ee4983695806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d8352637-f510-4e5f-837e-2284f3fe8ce2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityAddressStateOrProvince_d8352637-f510-4e5f-837e-2284f3fe8ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4174b9cf-70f0-4df4-bf6f-3a347860f55e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityAddressPostalZipCode_4174b9cf-70f0-4df4-bf6f-3a347860f55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f635a2b0-f8b8-4661-9267-cd0b2b2a1e03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_CityAreaCode_f635a2b0-f8b8-4661-9267-cd0b2b2a1e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6800daa4-430c-4d40-9235-36e26db8ff69" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_LocalPhoneNumber_6800daa4-430c-4d40-9235-36e26db8ff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2acde0ad-918f-45e4-9b94-fa9894bbd9df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_Security12bTitle_2acde0ad-918f-45e4-9b94-fa9894bbd9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_84379191-601d-493e-bd5e-ac9b3e7b3d9c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_TradingSymbol_84379191-601d-493e-bd5e-ac9b3e7b3d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2b97afad-2d2a-4ab5-b6fd-cd8222d69ce0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_SecurityExchangeName_2b97afad-2d2a-4ab5-b6fd-cd8222d69ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_10027ff0-13ce-4d83-a1d4-0d46895562af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityCurrentReportingStatus_10027ff0-13ce-4d83-a1d4-0d46895562af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_07aade82-8dfd-40a9-a206-5552874f5096" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityInteractiveDataCurrent_07aade82-8dfd-40a9-a206-5552874f5096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_64c67abd-af6d-4986-9f1d-45310b0cc2f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityFilerCategory_64c67abd-af6d-4986-9f1d-45310b0cc2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f89034dc-3965-4abf-88e5-5dcf1d331f7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntitySmallBusiness_f89034dc-3965-4abf-88e5-5dcf1d331f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3b11c861-77f1-4d0e-80ce-32e22ffb523e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityEmergingGrowthCompany_3b11c861-77f1-4d0e-80ce-32e22ffb523e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b3492990-6c1c-4481-bcfc-76d06246897a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityShellCompany_b3492990-6c1c-4481-bcfc-76d06246897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0bb15930-d0be-4a07-b102-76cbcef93123" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityCentralIndexKey_0bb15930-d0be-4a07-b102-76cbcef93123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e31b4e25-8f6d-4408-884e-5a34b2d5eced" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_CurrentFiscalYearEndDate_e31b4e25-8f6d-4408-884e-5a34b2d5eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bb797c80-b450-423d-8f14-c90261c92503" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentFiscalYearFocus_bb797c80-b450-423d-8f14-c90261c92503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1908b074-5701-4d53-8106-cfdae4826dad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1908b074-5701-4d53-8106-cfdae4826dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fcd2ad11-fa0a-4b48-87a0-ffbead8775b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_AmendmentFlag_fcd2ad11-fa0a-4b48-87a0-ffbead8775b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d7acfa32-36c7-4a15-a60b-18f96d591e83" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6421645d-0f45-4b94-9786-c89c8d7ec1cd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d7acfa32-36c7-4a15-a60b-18f96d591e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cf313708-2939-4e4b-8eb7-7c74fb375cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf313708-2939-4e4b-8eb7-7c74fb375cb4" xlink:to="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5276334d-192f-4180-a37b-3fc617e484f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5276334d-192f-4180-a37b-3fc617e484f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_5fabe792-a7b6-4cff-97de-98f3f2df629e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_MarketableSecurities_5fabe792-a7b6-4cff-97de-98f3f2df629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_97837241-6847-4c1b-89c5-6421be487125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_97837241-6847-4c1b-89c5-6421be487125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3dc5b173-88e6-4a44-8c0b-7bdcdbe38f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_AssetsCurrent_3dc5b173-88e6-4a44-8c0b-7bdcdbe38f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a948a09-ff1c-4beb-b571-7332e9c0eed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a948a09-ff1c-4beb-b571-7332e9c0eed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_9015f7d9-304f-4fff-9457-4914c265b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_OtherInvestments_9015f7d9-304f-4fff-9457-4914c265b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9bcfdeec-20ea-489b-b829-b7b632aa621d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9bcfdeec-20ea-489b-b829-b7b632aa621d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99b10909-7953-494b-837c-ebcd83361e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1502ebb-fe09-419b-93d4-6d8fa7ac10b2" xlink:to="loc_us-gaap_Assets_99b10909-7953-494b-837c-ebcd83361e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf313708-2939-4e4b-8eb7-7c74fb375cb4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:to="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f402ade3-65c6-46e5-8f9d-a1ffeaa5968c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:to="loc_us-gaap_AccountsPayableCurrent_f402ade3-65c6-46e5-8f9d-a1ffeaa5968c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d8162e9b-2e97-49bc-9e6b-a2c23bacae43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d8162e9b-2e97-49bc-9e6b-a2c23bacae43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9b42d6c3-c9c9-4603-9429-4b41049c39f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:to="loc_us-gaap_LiabilitiesCurrent_9b42d6c3-c9c9-4603-9429-4b41049c39f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7f521998-8e85-452e-bf69-de012525e846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7f521998-8e85-452e-bf69-de012525e846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e9e519a7-0996-4fa7-a527-8a91033c4815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_546b0f36-eaf6-485c-9ba7-4ca6e24efebe" xlink:to="loc_us-gaap_Liabilities_e9e519a7-0996-4fa7-a527-8a91033c4815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_df2b20b0-2df1-4fa3-badb-75687a75625c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:to="loc_us-gaap_CommitmentsAndContingencies_df2b20b0-2df1-4fa3-badb-75687a75625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:to="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6de250b2-02b2-4573-af0b-e323b23daada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_PreferredStockValue_6de250b2-02b2-4573-af0b-e323b23daada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b77a6fa-1372-47e1-8e98-8db19d36926b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_CommonStockValue_0b77a6fa-1372-47e1-8e98-8db19d36926b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c1685879-a0da-4ba3-ab88-c0b4d2475209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c1685879-a0da-4ba3-ab88-c0b4d2475209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_39de7c98-8cef-48a4-ac7b-34aaedf691b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_39de7c98-8cef-48a4-ac7b-34aaedf691b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_963e24a9-caf9-4216-80ee-920ebc048be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_963e24a9-caf9-4216-80ee-920ebc048be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_185f9538-26e9-425e-943f-c63b9f93bd95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_185f9538-26e9-425e-943f-c63b9f93bd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_916276d2-65f2-4dc2-aaaa-079c41a7fb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_StockholdersEquity_916276d2-65f2-4dc2-aaaa-079c41a7fb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e510d615-7133-4b31-9350-99a5638bb76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_MinorityInterest_e510d615-7133-4b31-9350-99a5638bb76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_875eb240-3083-40f3-9f31-3c8ab1f28a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_be9c083c-d5d2-47c4-ae1c-393ff6c1f6f1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_875eb240-3083-40f3-9f31-3c8ab1f28a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85e9c399-9a63-4a45-b400-721270c6974c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_08a31a24-b9a4-456f-8ed2-b06b5215c905" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_85e9c399-9a63-4a45-b400-721270c6974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_68ea8c90-3653-48b2-958d-6c442899bcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_68ea8c90-3653-48b2-958d-6c442899bcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare_0d1fcab1-e613-4c45-bbd4-f16ad355a75f" xlink:href="clbs-20220630.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_clbs_PreferredStockLiquidationPreferenceShare_0d1fcab1-e613-4c45-bbd4-f16ad355a75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2e8fa07d-dc70-4200-bffe-946cf8af301f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2e8fa07d-dc70-4200-bffe-946cf8af301f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated_80ee8a6b-3b3f-4d53-8654-33d217a32fd4" xlink:href="clbs-20220630.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_clbs_PreferredStockSharesDesignated_80ee8a6b-3b3f-4d53-8654-33d217a32fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d56c911c-e52e-4a04-80e9-cc184acf924d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d56c911c-e52e-4a04-80e9-cc184acf924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6e2767ac-8986-4c38-ab5e-afcde7b607ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6e2767ac-8986-4c38-ab5e-afcde7b607ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e31937bc-f1e8-4aeb-bf52-422db502a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e31937bc-f1e8-4aeb-bf52-422db502a8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8221d8d0-3856-4b40-931e-a64fcfbcbf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8221d8d0-3856-4b40-931e-a64fcfbcbf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4658c915-3ee8-43ac-b476-3adb8fe0b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_CommonStockSharesIssued_4658c915-3ee8-43ac-b476-3adb8fe0b31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_46e0fe3d-5846-4122-8426-c49bcd282a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_46e0fe3d-5846-4122-8426-c49bcd282a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b72bf066-40ba-499e-b95c-affaf331deb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6e2d9831-44ef-4f32-a95b-67eebb3bbc99" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b72bf066-40ba-499e-b95c-affaf331deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bade82d3-529f-448a-b30a-3744e8327b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bade82d3-529f-448a-b30a-3744e8327b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5377be8d-3618-4870-92f6-7e448f1145e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bade82d3-529f-448a-b30a-3744e8327b7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5377be8d-3618-4870-92f6-7e448f1145e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9b4c7ed3-fb00-4d4f-a053-c4a660c5fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bade82d3-529f-448a-b30a-3744e8327b7b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9b4c7ed3-fb00-4d4f-a053-c4a660c5fe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_250e2cff-b816-4369-ab01-2ddce7b6f322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bade82d3-529f-448a-b30a-3744e8327b7b" xlink:to="loc_us-gaap_OperatingExpenses_250e2cff-b816-4369-ab01-2ddce7b6f322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f26349b3-6920-49ad-a8ea-8d55d4fec41c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_OperatingIncomeLoss_f26349b3-6920-49ad-a8ea-8d55d4fec41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bcfe6170-ee03-466b-99e5-ea0d1a0545f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bcfe6170-ee03-466b-99e5-ea0d1a0545f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_4222a9a7-13c9-43d3-b2ca-1cc4e668d193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bcfe6170-ee03-466b-99e5-ea0d1a0545f3" xlink:to="loc_us-gaap_InvestmentIncomeNet_4222a9a7-13c9-43d3-b2ca-1cc4e668d193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a4551feb-68b1-47a7-b68c-a7dd1cd9951a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bcfe6170-ee03-466b-99e5-ea0d1a0545f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a4551feb-68b1-47a7-b68c-a7dd1cd9951a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_33f0d07f-7644-4309-bc86-47234904066e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_bcfe6170-ee03-466b-99e5-ea0d1a0545f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_33f0d07f-7644-4309-bc86-47234904066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4880643-c259-4022-a37f-772f98fa3de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4880643-c259-4022-a37f-772f98fa3de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eef63061-c8f7-44e4-bfff-065025b908f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eef63061-c8f7-44e4-bfff-065025b908f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0548500a-e007-4387-9780-c7b65c816a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_NetIncomeLoss_0548500a-e007-4387-9780-c7b65c816a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_40107761-f970-4801-9b8f-f6a5f40872ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_40107761-f970-4801-9b8f-f6a5f40872ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab5585b1-7656-4581-a4b8-8e2b67944fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_40107761-f970-4801-9b8f-f6a5f40872ca" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab5585b1-7656-4581-a4b8-8e2b67944fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_339958a5-82a1-4a17-a40b-890f2a18bcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_40107761-f970-4801-9b8f-f6a5f40872ca" xlink:to="loc_us-gaap_EarningsPerShareDiluted_339958a5-82a1-4a17-a40b-890f2a18bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39328d14-05ea-458c-af85-dd777d204394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d9e2d87f-6c91-4ae5-b10a-2b4e839e776f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39328d14-05ea-458c-af85-dd777d204394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3227bc38-c452-4aac-8280-deb05478e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39328d14-05ea-458c-af85-dd777d204394" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3227bc38-c452-4aac-8280-deb05478e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dcf90e2d-e36c-49b5-9cd6-f026aef57416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_39328d14-05ea-458c-af85-dd777d204394" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dcf90e2d-e36c-49b5-9cd6-f026aef57416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e2541ee-8a4a-4b8c-8ac7-0ac23c1ab06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_54d79df1-fb81-4dc3-936e-633f983f27d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e2541ee-8a4a-4b8c-8ac7-0ac23c1ab06b" xlink:to="loc_us-gaap_ProfitLoss_54d79df1-fb81-4dc3-936e-633f983f27d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0478d851-565e-46ba-a427-4b8dfe51dc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e2541ee-8a4a-4b8c-8ac7-0ac23c1ab06b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0478d851-565e-46ba-a427-4b8dfe51dc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef8e9f5d-ac83-46c1-b1b4-099154bbe510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e2541ee-8a4a-4b8c-8ac7-0ac23c1ab06b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef8e9f5d-ac83-46c1-b1b4-099154bbe510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9abd62a5-53ca-46fa-b3ff-36567afbe5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3e2541ee-8a4a-4b8c-8ac7-0ac23c1ab06b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9abd62a5-53ca-46fa-b3ff-36567afbe5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2f1d971-e70e-4d87-ac40-6dd1fdb8559a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a2f1d971-e70e-4d87-ac40-6dd1fdb8559a" xlink:to="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a807979f-c665-4d8b-b7b4-8e645454eb7f" xlink:to="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:to="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_068bc310-41cc-4190-b98f-f925be98d097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_PreferredStockMember_068bc310-41cc-4190-b98f-f925be98d097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_86b31684-75e4-4216-8edc-f0baac07e6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_CommonStockMember_86b31684-75e4-4216-8edc-f0baac07e6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53f96426-c3ca-4087-bdd2-b8fd14032ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53f96426-c3ca-4087-bdd2-b8fd14032ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09cda4f7-ba65-4282-9859-36c22a1589c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09cda4f7-ba65-4282-9859-36c22a1589c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8cd77b2f-829e-40ee-a542-ac8f9683d914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_RetainedEarningsMember_8cd77b2f-829e-40ee-a542-ac8f9683d914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_840832b5-b4fa-40d5-a48b-54bb257e5d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_0e56997a-a9c6-4b28-a867-bc3e379c1a78" xlink:to="loc_us-gaap_TreasuryStockCommonMember_840832b5-b4fa-40d5-a48b-54bb257e5d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_95337893-4478-488f-b537-d12bf98e21d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c1a82079-cc66-4376-b898-7bd94a29ec8d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_95337893-4478-488f-b537-d12bf98e21d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cf05ff29-5c4e-4782-b378-b41db079d3d6" xlink:to="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ea7a41bf-ffcc-4fc1-9029-e47becbdcb53" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_830cfda3-cd48-4ea9-8da3-8d82d0f1decf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_830cfda3-cd48-4ea9-8da3-8d82d0f1decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26652d97-c22a-46dc-a846-aa9077c60972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26652d97-c22a-46dc-a846-aa9077c60972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09fbf933-d30f-42a5-9e38-c737cbd23701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09fbf933-d30f-42a5-9e38-c737cbd23701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0f4ec236-8f59-4857-98ee-494274047a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_ProfitLoss_0f4ec236-8f59-4857-98ee-494274047a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7dc8cc60-15f7-4696-87a4-15145bcb91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7dc8cc60-15f7-4696-87a4-15145bcb91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88333777-dea8-43c9-b815-42ac8cd18c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88333777-dea8-43c9-b815-42ac8cd18c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4d848374-6de1-470f-a4c6-2e641fe11002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4d848374-6de1-470f-a4c6-2e641fe11002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dff12b13-1f79-41a5-a95d-eed5fb3652fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dff12b13-1f79-41a5-a95d-eed5fb3652fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa7b7108-e219-4a89-9c42-28fb564449ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fa7b7108-e219-4a89-9c42-28fb564449ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acca60b7-1428-4b5b-989c-b504d717d255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_acca60b7-1428-4b5b-989c-b504d717d255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d2f620b-f823-4952-8760-d6b48d721f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d2f620b-f823-4952-8760-d6b48d721f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0308265b-c6d3-46f7-a1b8-df16c4d25f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0308265b-c6d3-46f7-a1b8-df16c4d25f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b545749d-1049-41df-9267-5661bb2417ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b545749d-1049-41df-9267-5661bb2417ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02bce24d-0ba0-4c32-8cad-208ad377b13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_107ec889-1c48-4251-ae7b-e4842c9002e5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02bce24d-0ba0-4c32-8cad-208ad377b13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20220630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3ecc39b9-2459-46fe-a953-711a0c44ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:to="loc_us-gaap_ProfitLoss_3ecc39b9-2459-46fe-a953-711a0c44ee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b30ef7bc-903a-4131-a82a-86ef99f7db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b30ef7bc-903a-4131-a82a-86ef99f7db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_33831512-c3dd-448d-b52c-4171879c8166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b30ef7bc-903a-4131-a82a-86ef99f7db2b" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_33831512-c3dd-448d-b52c-4171879c8166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cbc5ce0e-a913-4f84-bb7b-e398116c828e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b30ef7bc-903a-4131-a82a-86ef99f7db2b" xlink:to="loc_us-gaap_DepreciationAndAmortization_cbc5ce0e-a913-4f84-bb7b-e398116c828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_da5d6fba-ac49-421e-9202-a02e2634c762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b30ef7bc-903a-4131-a82a-86ef99f7db2b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_da5d6fba-ac49-421e-9202-a02e2634c762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad760ae6-6307-41d9-ba4a-78b20f914ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad760ae6-6307-41d9-ba4a-78b20f914ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bfed6b75-f4d0-4947-8c40-65bab24c17b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad760ae6-6307-41d9-ba4a-78b20f914ef9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bfed6b75-f4d0-4947-8c40-65bab24c17b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_be1e9cbf-c944-4e41-a796-c1ff76870443" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad760ae6-6307-41d9-ba4a-78b20f914ef9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_be1e9cbf-c944-4e41-a796-c1ff76870443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_a72e03cf-eb86-4e81-a4d2-b6bbe056f7c9" xlink:href="clbs-20220630.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad760ae6-6307-41d9-ba4a-78b20f914ef9" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_a72e03cf-eb86-4e81-a4d2-b6bbe056f7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1772fc6-2efa-47ea-92d9-f029567b831c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28a71864-d23b-42e9-bd4f-20444c9c7545" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1772fc6-2efa-47ea-92d9-f029567b831c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7dc30353-6f41-4f41-ac5e-9cf0ecb75baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7dc30353-6f41-4f41-ac5e-9cf0ecb75baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_feb981d0-861f-4f41-9810-3de0df81db8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_feb981d0-861f-4f41-9810-3de0df81db8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dce34f4b-776a-4cdf-bb9d-ed39a8f7288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dce34f4b-776a-4cdf-bb9d-ed39a8f7288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_30eed0c0-9915-4c8f-ac9c-51bc3d04bb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_30eed0c0-9915-4c8f-ac9c-51bc3d04bb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5f128bd-7edb-434c-a4f4-94157b6fbed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a221e595-840b-456c-8308-51afcb134e8e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5f128bd-7edb-434c-a4f4-94157b6fbed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_64cedc5f-c1b6-4b55-80ba-6861e14dea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_64cedc5f-c1b6-4b55-80ba-6861e14dea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3110a4dc-3779-46d3-a553-ff36d0bb544f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3110a4dc-3779-46d3-a553-ff36d0bb544f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc6a99d2-82f0-46d6-8972-bd229c1b27fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc6a99d2-82f0-46d6-8972-bd229c1b27fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf2e85db-2eb1-476e-b86d-88653229c8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4a867093-f9e9-4a7f-bbe6-8a6e1322c4ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf2e85db-2eb1-476e-b86d-88653229c8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4689625f-81df-41a4-931b-c40e2196d508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4689625f-81df-41a4-931b-c40e2196d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc7fb807-1233-4de2-9d63-15aaeb1ca72a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc7fb807-1233-4de2-9d63-15aaeb1ca72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dac5bee-792e-48cd-be63-51272985af6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0555ce8e-c886-4449-9b12-56303d89a89b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0dac5bee-792e-48cd-be63-51272985af6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20220630.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d583a82a-1ce2-4191-8720-d48104f3aa64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock_6b837fbf-2254-495f-a870-6e630e176882" xlink:href="clbs-20220630.xsd#clbs_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d583a82a-1ce2-4191-8720-d48104f3aa64" xlink:to="loc_clbs_BusinessTextBlock_6b837fbf-2254-495f-a870-6e630e176882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#TheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43aa1314-c0a7-4489-8c52-913810a8cdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43aa1314-c0a7-4489-8c52-913810a8cdc8" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_6a370e37-5626-4caa-89fa-77cf82556f6d" xlink:to="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember_006ad411-581e-4100-b9a7-97da2eebb0f5" xlink:href="clbs-20220630.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_1b484215-8ad1-44ca-a5ea-7272dc93c023" xlink:to="loc_clbs_CLBS16TreatmentOfCMDMember_006ad411-581e-4100-b9a7-97da2eebb0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9adbaaa2-e4bd-47c9-81e7-e6109bd9b104" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember_a87f6ad9-2227-411c-ba15-cdaff0f423c9" xlink:href="clbs-20220630.xsd#clbs_AgreementAndPlanOfMergerAndReorganizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_874b6f1e-f9d3-44f4-9491-0ab57265c1d2" xlink:to="loc_clbs_AgreementAndPlanOfMergerAndReorganizationMember_a87f6ad9-2227-411c-ba15-cdaff0f423c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b038c408-5cf8-493f-b1bc-234eb8e2bd22" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendTherapeuticsIncMember_1cab5f0d-d924-4fba-9049-9263a647d096" xlink:href="clbs-20220630.xsd#clbs_CendTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ffaa1a6-f52b-4030-8b43-536024797b95" xlink:to="loc_clbs_CendTherapeuticsIncMember_1cab5f0d-d924-4fba-9049-9263a647d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cdf4a4e1-381a-42a3-bcae-bb1177f86d27" xlink:to="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SeriesDPreferredStockCendMember_15a36716-9c69-4a0c-b216-02193f918c2a" xlink:href="clbs-20220630.xsd#clbs_SeriesDPreferredStockCendMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd859c94-6f70-4948-be62-b9908ee3a784" xlink:to="loc_clbs_SeriesDPreferredStockCendMember_15a36716-9c69-4a0c-b216-02193f918c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7ff7d884-77c1-4901-84a5-4bc1deb7fbb0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_3df04576-4a53-41cb-9618-e46630ae2a64" xlink:href="clbs-20220630.xsd#clbs_CendSeriesDPreferredStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94139158-5dc6-45e9-92c0-b720419ea077" xlink:to="loc_clbs_CendSeriesDPreferredStockPurchaseAgreementMember_3df04576-4a53-41cb-9618-e46630ae2a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_54306c44-03c0-4952-825b-f574e9de5498" xlink:to="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CendTherapeuticsIncMember_5070be41-4742-48a5-b7e0-5922c9bdb2bd" xlink:href="clbs-20220630.xsd#clbs_CendTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_62952a87-f83a-4d0b-bb86-559cf69a2eec" xlink:to="loc_clbs_CendTherapeuticsIncMember_5070be41-4742-48a5-b7e0-5922c9bdb2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e22a025b-0b7b-426e-8ced-b54a0e74be1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborationAgreementMember_298d8f98-38e9-41ee-8729-1b80a405967d" xlink:href="clbs-20220630.xsd#clbs_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_49bc6e59-f7c3-4a8a-a30c-0b132d512ac2" xlink:to="loc_clbs_CollaborationAgreementMember_298d8f98-38e9-41ee-8729-1b80a405967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_e7723331-98f5-4327-8bf1-75493f63a69c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_b99e6373-e121-4771-89ee-3c1ff74e5b11" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage_b99e6373-e121-4771-89ee-3c1ff74e5b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_26561b2d-8ba3-4691-8318-26d0abca89bf" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage_26561b2d-8ba3-4691-8318-26d0abca89bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_d5e200f4-edc8-4799-9585-99bef8406449" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation_d5e200f4-edc8-4799-9585-99bef8406449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_092c9611-87c3-4ca9-a784-0120d4154049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_GrantsReceivable_092c9611-87c3-4ca9-a784-0120d4154049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementMinimumNetCashThreshold_796fb500-efdd-48db-9624-b41bb21aa943" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementMinimumNetCashThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementMinimumNetCashThreshold_796fb500-efdd-48db-9624-b41bb21aa943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeePayable_61550e71-c33b-4ca5-9e47-c172f05a54cf" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeePayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialTerminationFeePayable_61550e71-c33b-4ca5-9e47-c172f05a54cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable_ffba5bd3-aed3-4e38-875d-669000274972" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialTerminationFeeReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialTerminationFeeReceivable_ffba5bd3-aed3-4e38-875d-669000274972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MergerAgreementPotentialExpenseReimbursement_1625e306-a020-44e0-8d8b-8d09d40e2139" xlink:href="clbs-20220630.xsd#clbs_MergerAgreementPotentialExpenseReimbursement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_MergerAgreementPotentialExpenseReimbursement_1625e306-a020-44e0-8d8b-8d09d40e2139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockShares_bd00715d-2022-45f9-b34e-c0abf44aba60" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockShares_bd00715d-2022-45f9-b34e-c0abf44aba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0dbe4c71-6e45-44ad-9c53-5f501e79cb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0dbe4c71-6e45-44ad-9c53-5f501e79cb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockPricePerShare_6022d1a0-9eb1-4dd6-8bd8-2719e2b60f16" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockPricePerShare_6022d1a0-9eb1-4dd6-8bd8-2719e2b60f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseOfPreferredStockAggregatePrice_1af2e1dc-664e-4093-92e5-d8871062df5f" xlink:href="clbs-20220630.xsd#clbs_PurchaseOfPreferredStockAggregatePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PurchaseOfPreferredStockAggregatePrice_1af2e1dc-664e-4093-92e5-d8871062df5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreEquityOfferingValueAfterConversion_f63685a3-8323-4ea6-a25b-77f76bad879d" xlink:href="clbs-20220630.xsd#clbs_PreEquityOfferingValueAfterConversion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_PreEquityOfferingValueAfterConversion_f63685a3-8323-4ea6-a25b-77f76bad879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_GrossProceedsOnTransaction_436185c4-2833-4519-a54c-e3ccf809bc9a" xlink:href="clbs-20220630.xsd#clbs_GrossProceedsOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_clbs_GrossProceedsOnTransaction_436185c4-2833-4519-a54c-e3ccf809bc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_375806e2-95c2-4c27-b815-eac09c510d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9a73b8bc-7b80-4e74-a8a3-c19423a66eea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_375806e2-95c2-4c27-b815-eac09c510d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f431aa2-5cc4-440f-9399-8ad117d21c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8d181e1c-df7d-4be2-a7d5-cdb0240a338b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f431aa2-5cc4-440f-9399-8ad117d21c69" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8d181e1c-df7d-4be2-a7d5-cdb0240a338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_043f6571-f158-4b17-8fc2-3ba46e1a6332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_043f6571-f158-4b17-8fc2-3ba46e1a6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5dca7fc6-f682-439e-b282-53421b81ac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:to="loc_us-gaap_UseOfEstimates_5dca7fc6-f682-439e-b282-53421b81ac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1c2938b4-db91-470e-8fe9-e1eec0273802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1c2938b4-db91-470e-8fe9-e1eec0273802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f78472b8-cdaa-4ec6-8c40-b86219ed25f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f78472b8-cdaa-4ec6-8c40-b86219ed25f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b22d9360-d0de-4566-9d91-8662e05e3f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e71d8863-7b0b-4d44-8772-c5d32a4b00a5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b22d9360-d0de-4566-9d91-8662e05e3f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6b91cb89-cf33-49dc-b71a-d0072d968c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_fd74f3d8-c956-4cf3-8cf5-3438499aaab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6b91cb89-cf33-49dc-b71a-d0072d968c4d" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_fd74f3d8-c956-4cf3-8cf5-3438499aaab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1ae356bd-74de-4a00-a677-9b2cad944126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b62924e5-ade0-48ac-b2a3-24f3563c61cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1ae356bd-74de-4a00-a677-9b2cad944126" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b62924e5-ade0-48ac-b2a3-24f3563c61cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_39131647-93ab-40d5-97da-4b8e84720f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1ae356bd-74de-4a00-a677-9b2cad944126" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_39131647-93ab-40d5-97da-4b8e84720f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1bc274ee-b1b6-4fd6-bc4c-ae240b8405ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1ae356bd-74de-4a00-a677-9b2cad944126" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1bc274ee-b1b6-4fd6-bc4c-ae240b8405ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5e63732a-58ac-4e5b-8b60-ea2f31e25741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_5e63732a-58ac-4e5b-8b60-ea2f31e25741" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac019230-3364-4493-9476-2cda72c7c835" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_27e3b89a-6f3c-4698-83cf-0192d5f9a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_27e3b89a-6f3c-4698-83cf-0192d5f9a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aa3de1c8-669c-421b-ba1a-a35676c319a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_CommercialPaperMember_aa3de1c8-669c-421b-ba1a-a35676c319a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_22d30343-8faa-41d2-9920-3b408c9d66a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_22d30343-8faa-41d2-9920-3b408c9d66a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_afb4fd23-2f4f-4268-98ed-e7386e4b3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da4b3bc5-ef25-4727-aa81-d41e17fccca9" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_afb4fd23-2f4f-4268-98ed-e7386e4b3ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1efbec74-6faa-4e25-a063-d7072cf85da2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49eb0cf1-9434-4e2f-bb99-300cd5ae2aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_49eb0cf1-9434-4e2f-bb99-300cd5ae2aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc70a987-1587-49fb-a602-206f4ca27d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc70a987-1587-49fb-a602-206f4ca27d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ea76f1d-29ca-4eed-87fe-a81f08ffcac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ea76f1d-29ca-4eed-87fe-a81f08ffcac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb2295ca-8c8c-45a8-b217-ff72522b3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_846283d7-e9aa-4a61-b419-6f4869b02dd0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bb2295ca-8c8c-45a8-b217-ff72522b3c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c916e724-2175-4de8-8f39-2b7738bebdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_9da0ba18-b3c7-4216-9586-271b75e1af61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c916e724-2175-4de8-8f39-2b7738bebdbb" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_9da0ba18-b3c7-4216-9586-271b75e1af61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_0ea97982-ac94-42eb-b2c5-a280cd7f26f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c916e724-2175-4de8-8f39-2b7738bebdbb" xlink:to="loc_us-gaap_MarketableSecurities_0ea97982-ac94-42eb-b2c5-a280cd7f26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b701c6d3-f14b-41a9-99a3-1aaf9f79ae69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c916e724-2175-4de8-8f39-2b7738bebdbb" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b701c6d3-f14b-41a9-99a3-1aaf9f79ae69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9266f560-8958-41f4-849b-94dd308db0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_48c306b0-f76d-46be-be62-474cf74d5bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9266f560-8958-41f4-849b-94dd308db0d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_48c306b0-f76d-46be-be62-474cf74d5bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_fbe14006-1fdf-4f53-961c-e39dcbac7694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_48c306b0-f76d-46be-be62-474cf74d5bbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_fbe14006-1fdf-4f53-961c-e39dcbac7694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_55f8b32a-349e-473b-80d0-19abd13011f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_48c306b0-f76d-46be-be62-474cf74d5bbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_55f8b32a-349e-473b-80d0-19abd13011f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29672113-f6c6-40b7-9c15-dfb36357c4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_48c306b0-f76d-46be-be62-474cf74d5bbe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_29672113-f6c6-40b7-9c15-dfb36357c4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6f884d17-a491-4e6d-9427-88a984e9ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9266f560-8958-41f4-849b-94dd308db0d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6f884d17-a491-4e6d-9427-88a984e9ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_f2b896fa-e7da-49b8-822b-5ab99050eb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6f884d17-a491-4e6d-9427-88a984e9ae6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_f2b896fa-e7da-49b8-822b-5ab99050eb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a500a187-8b52-4f00-b7f7-7778831a9fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6f884d17-a491-4e6d-9427-88a984e9ae6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_a500a187-8b52-4f00-b7f7-7778831a9fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62f3eb4b-d896-4366-ac0c-4e8ebf0772ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_6f884d17-a491-4e6d-9427-88a984e9ae6b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62f3eb4b-d896-4366-ac0c-4e8ebf0772ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_43cd0e36-35b6-4279-a724-67d15179d03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3ab17620-90a0-4358-823c-52fa53bf7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43cd0e36-35b6-4279-a724-67d15179d03d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3ab17620-90a0-4358-823c-52fa53bf7f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_848f5088-100f-49e8-b219-4414cbd209f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d0d01d0-71e6-417e-af69-36d9400bf486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_848f5088-100f-49e8-b219-4414cbd209f6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d0d01d0-71e6-417e-af69-36d9400bf486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ca14aed6-8c5e-4d4c-b7e8-d25bc9c45d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ca14aed6-8c5e-4d4c-b7e8-d25bc9c45d75" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a098dfa-6b69-43c9-8613-de97b7e6f6e5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_df989564-76c0-4fb7-86e7-afe40a189992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_EmployeeStockOptionMember_df989564-76c0-4fb7-86e7-afe40a189992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ebeb9181-6d80-44ec-a035-93029ad0532d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_WarrantMember_ebeb9181-6d80-44ec-a035-93029ad0532d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0c104a8b-5427-4168-bc3f-6aa924ae70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_310bc750-4441-4350-a109-7af950702d54" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0c104a8b-5427-4168-bc3f-6aa924ae70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0c5bbade-b7f4-4d94-a851-1517f1b1b5ed" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92f57a1f-7004-4a0f-8084-57b9f20b3e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ab3aeaf-f311-4850-a7ee-493847432bb2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92f57a1f-7004-4a0f-8084-57b9f20b3e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71d3748f-7b56-4170-9b04-c05f2440efe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3d312091-c2dd-49fd-93bf-59328b8ea25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71d3748f-7b56-4170-9b04-c05f2440efe8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3d312091-c2dd-49fd-93bf-59328b8ea25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa65e0ca-1c74-49e3-9cf4-0b26f358e05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4d84b954-0092-4237-a1fa-4a425556e7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa65e0ca-1c74-49e3-9cf4-0b26f358e05e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4d84b954-0092-4237-a1fa-4a425556e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77c2afff-2bdc-4288-92f2-f0f6cd2aa3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77c2afff-2bdc-4288-92f2-f0f6cd2aa3f3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fb4e2f3-4162-44ba-8bd3-a011efc67aa4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fae4e065-b83c-4112-9f29-2d1fe225ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fae4e065-b83c-4112-9f29-2d1fe225ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_08ab1f2a-28b7-44a3-a118-6afe52288ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_08ab1f2a-28b7-44a3-a118-6afe52288ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e87e4d74-7afc-4509-ba33-c377b1cd7f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04568f72-9e28-420d-be05-de049a4ffbdb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e87e4d74-7afc-4509-ba33-c377b1cd7f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f68ce61b-751a-44ba-8d3e-ed4f837f7ac0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_361f208a-8ecb-476b-8e05-faab304d8865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f7fc1f3d-c789-4395-9242-8a3dd9bc8577" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_361f208a-8ecb-476b-8e05-faab304d8865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4e9b2458-1e0a-410d-898a-e8b7725b53a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4b5408d2-324f-41ba-9aa1-9898908a38a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4b5408d2-324f-41ba-9aa1-9898908a38a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4c7bb5bc-5ba3-4fec-9a19-ff3649876876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4c7bb5bc-5ba3-4fec-9a19-ff3649876876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6308d963-9cee-4d61-b984-55cf67978163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1157b727-cea1-4f5e-b9d4-b77e7bd483da" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6308d963-9cee-4d61-b984-55cf67978163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20220630.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_4234158a-79fd-47d5-9e04-80c877983d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6e353063-4701-420d-ba03-1c87222f5128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_4234158a-79fd-47d5-9e04-80c877983d1e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6e353063-4701-420d-ba03-1c87222f5128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_5c649505-bf45-4f44-823e-2008ae2dc5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1f204991-c3fd-4966-a84d-2d9c81303ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_5c649505-bf45-4f44-823e-2008ae2dc5c6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1f204991-c3fd-4966-a84d-2d9c81303ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_21369e0b-d20f-4963-839f-ccff91081d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_41aef8c6-3716-47f3-8d99-41c4b1993c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_21369e0b-d20f-4963-839f-ccff91081d25" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_41aef8c6-3716-47f3-8d99-41c4b1993c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_376944cf-7ce8-48a1-b9bf-11250225005f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_21369e0b-d20f-4963-839f-ccff91081d25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_376944cf-7ce8-48a1-b9bf-11250225005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73d4e5a4-c9ea-449e-82a3-8d2df18aa3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_21369e0b-d20f-4963-839f-ccff91081d25" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_73d4e5a4-c9ea-449e-82a3-8d2df18aa3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eb8232ee-8324-42d3-897a-7aba21c82e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_21369e0b-d20f-4963-839f-ccff91081d25" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eb8232ee-8324-42d3-897a-7aba21c82e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_824a890a-09e7-418c-96e4-8c0b7ebbc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5ee2fa64-3695-4948-8b1e-e3b9872badc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_824a890a-09e7-418c-96e4-8c0b7ebbc2cb" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5ee2fa64-3695-4948-8b1e-e3b9872badc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_22b6f113-e81a-4a23-864d-a34fbdca464e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_5ca5ce00-91a5-4463-98a4-8dad13ba826a" xlink:href="clbs-20220630.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22b6f113-e81a-4a23-864d-a34fbdca464e" xlink:to="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_5ca5ce00-91a5-4463-98a4-8dad13ba826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d00e6f6d-6378-4795-986c-c625d87d7258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22b6f113-e81a-4a23-864d-a34fbdca464e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d00e6f6d-6378-4795-986c-c625d87d7258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_853ed468-c34e-49b3-93f7-06cd2b69733c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases_8f1813b0-4647-40e8-937b-651e46ccbd80" xlink:href="clbs-20220630.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_853ed468-c34e-49b3-93f7-06cd2b69733c" xlink:to="loc_clbs_NumberOfOfficesUnderOperatingLeases_8f1813b0-4647-40e8-937b-651e46ccbd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c3468675-e008-4897-ad4f-75b147979f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_853ed468-c34e-49b3-93f7-06cd2b69733c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c3468675-e008-4897-ad4f-75b147979f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_85203102-d291-47c1-87ba-882566e0d1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_853ed468-c34e-49b3-93f7-06cd2b69733c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_85203102-d291-47c1-87ba-882566e0d1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ca4c3018-86a9-4cf5-8371-e74b91fd7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_69fd800a-7c14-4772-bb37-76177ed8f12d" xlink:href="clbs-20220630.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca4c3018-86a9-4cf5-8371-e74b91fd7d84" xlink:to="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_69fd800a-7c14-4772-bb37-76177ed8f12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_285258b8-0c51-4557-8c37-d7bb60911691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_69fd800a-7c14-4772-bb37-76177ed8f12d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_285258b8-0c51-4557-8c37-d7bb60911691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e53c783e-9196-41ad-82ca-2e29a283d88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_69fd800a-7c14-4772-bb37-76177ed8f12d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e53c783e-9196-41ad-82ca-2e29a283d88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca4c3018-86a9-4cf5-8371-e74b91fd7d84" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_df6ca661-398c-4141-a2f6-bd97610b8080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_df6ca661-398c-4141-a2f6-bd97610b8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6bd3bd6a-4648-43bd-8bb5-23ea6804e793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6bd3bd6a-4648-43bd-8bb5-23ea6804e793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c0c4835a-4587-48d5-be05-f61c3c0756fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:to="loc_us-gaap_OperatingLeaseLiability_c0c4835a-4587-48d5-be05-f61c3c0756fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1156f0d1-79e8-4b64-bf22-63916f0a46c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1156f0d1-79e8-4b64-bf22-63916f0a46c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6a9d6a8c-95c7-417c-a966-a29fc06d6965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_c4a3807d-1862-4155-ad68-9c9f9eb57bca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6a9d6a8c-95c7-417c-a966-a29fc06d6965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f7972522-5aee-41b8-bafc-6a945bcd48d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f7972522-5aee-41b8-bafc-6a945bcd48d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0f13ecdb-ace8-4213-b612-27d6ba6ffd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0f13ecdb-ace8-4213-b612-27d6ba6ffd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ed5fb6f8-0766-4972-9283-6d9c1cf80fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ed5fb6f8-0766-4972-9283-6d9c1cf80fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e70decd-9c14-46ee-9677-e3f16ead82af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6e70decd-9c14-46ee-9677-e3f16ead82af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_06a9e6f2-e3bb-4608-b21a-8d1dd3289b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_06a9e6f2-e3bb-4608-b21a-8d1dd3289b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e414265-4f77-45af-a4ba-34e1c3675986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e414265-4f77-45af-a4ba-34e1c3675986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_191c61e4-3449-45b1-a8e8-3a1260413733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_191c61e4-3449-45b1-a8e8-3a1260413733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_008a027d-7d56-45a3-9963-81c58c58d88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f3f91696-daca-4171-a3b9-80e49cfa57d7" xlink:to="loc_us-gaap_OperatingLeaseLiability_008a027d-7d56-45a3-9963-81c58c58d88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20220630.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_00b7b9cc-f87e-4c0a-a1ff-4fb8c8ae3bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a01aafb1-bc0b-4fc8-80a7-c878e523947f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00b7b9cc-f87e-4c0a-a1ff-4fb8c8ae3bc8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a01aafb1-bc0b-4fc8-80a7-c878e523947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_00484a04-2a11-4de8-8406-1ab5fa346dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ed1ea43-b7a0-401a-8b84-b13d605c93fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00484a04-2a11-4de8-8406-1ab5fa346dc1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ed1ea43-b7a0-401a-8b84-b13d605c93fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_820b5c99-4806-4716-b7fd-1cbf4fc21285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00484a04-2a11-4de8-8406-1ab5fa346dc1" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_820b5c99-4806-4716-b7fd-1cbf4fc21285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_c717043a-429e-4dd4-a91f-ec44cf0635ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00484a04-2a11-4de8-8406-1ab5fa346dc1" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_c717043a-429e-4dd4-a91f-ec44cf0635ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c5fdd2e-1870-4105-afe8-f24175ff4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c5fdd2e-1870-4105-afe8-f24175ff4c7c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fd73c03-9832-48c5-b7f1-eb253cf8625f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_faf3c7fb-33e9-4d6a-afd7-09cf44dd2e36" xlink:href="clbs-20220630.xsd#clbs_LincolnParkAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:to="loc_clbs_LincolnParkAgreementMember_faf3c7fb-33e9-4d6a-afd7-09cf44dd2e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_cd8e2f76-eb94-4e2a-b59a-548966be481d" xlink:href="clbs-20220630.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47888be9-3b81-4444-80fe-c75ade195083" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_cd8e2f76-eb94-4e2a-b59a-548966be481d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_34279e25-55b2-4542-ade0-5c1245e39a6f" xlink:to="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_3b8b8d5c-d2ed-497f-8917-bd477129214c" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_3b8b8d5c-d2ed-497f-8917-bd477129214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_1b6d58ba-2d8b-431d-b1e2-1a5c5a91e10f" xlink:href="clbs-20220630.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_1b6d58ba-2d8b-431d-b1e2-1a5c5a91e10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76ca9d88-8bf6-446b-9c5a-0fb87ec29220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_76ca9d88-8bf6-446b-9c5a-0fb87ec29220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_646ac5ca-815a-4e05-a50c-529e251a7e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_646ac5ca-815a-4e05-a50c-529e251a7e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_316a6b58-7a6c-4ed8-aba3-aee571b53eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_316a6b58-7a6c-4ed8-aba3-aee571b53eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_d126a44d-402b-45ab-8578-14ed2ce4dc68" xlink:href="clbs-20220630.xsd#clbs_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_TermOfAgreement_d126a44d-402b-45ab-8578-14ed2ce4dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_bf37ad62-c216-44fe-8fa4-c25e33ed0ed3" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_bf37ad62-c216-44fe-8fa4-c25e33ed0ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_3c245f28-41eb-469e-a391-e0e6b970ed35" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_3c245f28-41eb-469e-a391-e0e6b970ed35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_ec30fcd0-0c12-49ec-8fbb-e5950a041dc7" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_ec30fcd0-0c12-49ec-8fbb-e5950a041dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_ae14ad4a-1a3b-40d9-8f0a-549d6c88ef00" xlink:href="clbs-20220630.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_ae14ad4a-1a3b-40d9-8f0a-549d6c88ef00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_9ae996b4-9952-4413-a8e8-588ee59b5ece" xlink:href="clbs-20220630.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_9ae996b4-9952-4413-a8e8-588ee59b5ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2e5661-124e-4c0d-98be-0ab78da56483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0500371-d44d-4c40-81bf-798af0288ccd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c2e5661-124e-4c0d-98be-0ab78da56483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d12bc894-0674-4201-85a9-2b1e3f8762cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d12bc894-0674-4201-85a9-2b1e3f8762cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80826458-bdcf-4e70-a57f-62422c629e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80826458-bdcf-4e70-a57f-62422c629e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bb761e04-a430-4ff8-8fc7-36cd9864b391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_bb761e04-a430-4ff8-8fc7-36cd9864b391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe5c0a32-7109-4215-8fc3-191de4b60130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fe5c0a32-7109-4215-8fc3-191de4b60130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_07a4f7e4-2736-4123-a910-094fdb96722c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_07a4f7e4-2736-4123-a910-094fdb96722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3d8df4e8-6491-41cb-83f0-2594f8e0c86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3d8df4e8-6491-41cb-83f0-2594f8e0c86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5540b81e-853a-49ff-a6ef-0bb3bd86e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_832c64b8-d2ae-4307-85b9-9f9a0387d033" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5540b81e-853a-49ff-a6ef-0bb3bd86e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a0f47f7f-0919-4163-9585-7b258cb9a03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a0f47f7f-0919-4163-9585-7b258cb9a03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_459e9736-4d64-4fd2-b0c7-746601b1dd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_459e9736-4d64-4fd2-b0c7-746601b1dd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60466713-3473-4980-aadf-40de8f1253f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60466713-3473-4980-aadf-40de8f1253f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8e80b2-0bbb-4095-91f8-bd5a28c42beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8e80b2-0bbb-4095-91f8-bd5a28c42beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a950f633-5cb9-4bac-8427-e5e72120b4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a950f633-5cb9-4bac-8427-e5e72120b4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18165bbc-7ad1-4428-8fa6-8acb7869bd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18165bbc-7ad1-4428-8fa6-8acb7869bd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b5d0c3c6-4885-46a0-952c-d8c7b98f2484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b5d0c3c6-4885-46a0-952c-d8c7b98f2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e870bdc-0080-420d-b188-ef12d1edd96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1cf3e4fe-4b6d-45ca-acee-585f075a45ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e870bdc-0080-420d-b188-ef12d1edd96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d9002c04-df88-42aa-8bb1-2178f0cdf9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d9002c04-df88-42aa-8bb1-2178f0cdf9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b8acfad3-1d72-493c-be0b-42d1f0ec5272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b8acfad3-1d72-493c-be0b-42d1f0ec5272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_2b25658a-299f-48ee-8fb0-9f4b2277f530" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_020792b3-e3bb-4eb0-879a-835b264b681a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_020792b3-e3bb-4eb0-879a-835b264b681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd0bbcdc-3926-4219-8f96-a2f667d35533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dd0bbcdc-3926-4219-8f96-a2f667d35533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_ff773b4b-e68e-445e-ac9d-97a0e91933a8" xlink:href="clbs-20220630.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_ff773b4b-e68e-445e-ac9d-97a0e91933a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c52a745-ced4-40df-b561-8148926bb063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2c52a745-ced4-40df-b561-8148926bb063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_88a6aa8a-f871-430e-a778-649519f8eebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_88a6aa8a-f871-430e-a778-649519f8eebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8f6a7b9a-dd6a-4688-83fc-00a04585da70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0e2e5437-3c19-4a63-aade-abf807873d27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8f6a7b9a-dd6a-4688-83fc-00a04585da70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d12bc894-0674-4201-85a9-2b1e3f8762cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_7de65ba8-c883-470b-b5f2-e4a1a2aae769" xlink:href="clbs-20220630.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_CommonStockWarrantsShares_7de65ba8-c883-470b-b5f2-e4a1a2aae769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_7842d011-b04d-4dff-ae0e-610c56624a56" xlink:href="clbs-20220630.xsd#clbs_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_WarrantsGranted_7842d011-b04d-4dff-ae0e-610c56624a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_e27eabf1-a2ab-47bc-b343-e089be4fd997" xlink:href="clbs-20220630.xsd#clbs_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_WarrantsExercised_e27eabf1-a2ab-47bc-b343-e089be4fd997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_9cd7521f-23ec-49b1-bb6c-133459117db0" xlink:href="clbs-20220630.xsd#clbs_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_WarrantsCanceled_9cd7521f-23ec-49b1-bb6c-133459117db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_00f87101-61e4-4145-bb63-30a95b0e4586" xlink:href="clbs-20220630.xsd#clbs_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_WarrantsExpired_00f87101-61e4-4145-bb63-30a95b0e4586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_d4683e85-ca94-47c3-8847-f93a90df0fbf" xlink:href="clbs-20220630.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c80df53-adb7-4bc6-b358-8dfe8bcff0f3" xlink:to="loc_clbs_CommonStockWarrantsShares_d4683e85-ca94-47c3-8847-f93a90df0fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_3b1edc5a-8ab6-4a08-b3d5-e648820b467e" xlink:href="clbs-20220630.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_3b1edc5a-8ab6-4a08-b3d5-e648820b467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_eb69643f-32d2-4cef-8963-6f2d5762ad60" xlink:href="clbs-20220630.xsd#clbs_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_WarrantsVested_eb69643f-32d2-4cef-8963-6f2d5762ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:href="clbs-20220630.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e41a75eb-0d73-48b7-8643-a9bc2d47624c" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_e41a75eb-0d73-48b7-8643-a9bc2d47624c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_b30ace3c-e8a1-41c0-9c46-bbff4c654a5c" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_b30ace3c-e8a1-41c0-9c46-bbff4c654a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_49921e0e-07d5-4093-9593-1439c7fdd8f0" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_49921e0e-07d5-4093-9593-1439c7fdd8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_e4cf0af1-760e-4636-a67c-03cf161e393b" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_e4cf0af1-760e-4636-a67c-03cf161e393b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_42d1eecc-186e-409f-982d-f9cbf3bf0745" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_42d1eecc-186e-409f-982d-f9cbf3bf0745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_76253cc1-d7f6-4b5d-b419-cfc1158a51ec" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_d2780114-bc4c-4df4-ae4e-df9c6905373a" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_76253cc1-d7f6-4b5d-b419-cfc1158a51ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_14858946-a4dd-4fd5-a047-622457903c99" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_14858946-a4dd-4fd5-a047-622457903c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_c5ee428c-e1af-4401-9a9d-3f1debf781d7" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_c5ee428c-e1af-4401-9a9d-3f1debf781d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:href="clbs-20220630.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_b8652709-4128-4407-9d58-e49a97b47e3f" xlink:to="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_9e92254d-c283-4a3a-9f28-f3e735098951" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_9e92254d-c283-4a3a-9f28-f3e735098951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_4e5efd2f-1663-4688-a268-a43aea66cd92" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_4e5efd2f-1663-4688-a268-a43aea66cd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_0156f1c6-6b48-4f94-b759-f499de626dca" xlink:href="clbs-20220630.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_0156f1c6-6b48-4f94-b759-f499de626dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_90634369-5cb1-4206-bb04-c38a7a74eca3" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_90634369-5cb1-4206-bb04-c38a7a74eca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_35333d85-0983-4c67-a08e-bd73cf3e6594" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_35333d85-0983-4c67-a08e-bd73cf3e6594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_6eb1398f-f324-4134-9faa-201979d2e2ba" xlink:href="clbs-20220630.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_a5daa9fe-4275-4ae9-898b-0901e9f9f9b4" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_6eb1398f-f324-4134-9faa-201979d2e2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4b7388c0-a2a0-4752-9faa-c008d3bf3815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4b7388c0-a2a0-4752-9faa-c008d3bf3815" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:to="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9a46bd1e-e335-459a-a751-35b1dcd1fad9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_6d267302-af2e-4311-b5bf-716c71bfa9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:to="loc_us-gaap_RestrictedStockMember_6d267302-af2e-4311-b5bf-716c71bfa9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_684af915-664b-4dd4-a985-64998e7b253b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fed8ee7-9ca7-423c-ab98-effa1792ca42" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_684af915-664b-4dd4-a985-64998e7b253b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:to="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_43d9f196-97cc-4f42-8e96-8a0766c734c8" xlink:to="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8edd6c69-d137-4e2f-86ae-7babbc1c22d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:to="loc_srt_MinimumMember_8edd6c69-d137-4e2f-86ae-7babbc1c22d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4ff2268-0f9b-49e9-b736-98d5fce97709" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2616b7a-2879-4fbd-98cf-5ad6b0249d15" xlink:to="loc_srt_MaximumMember_f4ff2268-0f9b-49e9-b736-98d5fce97709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8b60284d-f93f-4f84-83a1-69428d8923a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_fe2fd9e4-85b3-4259-b452-0bf1315e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_fe2fd9e4-85b3-4259-b452-0bf1315e4162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38d7d347-0197-4c76-8efa-851331cc9983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38d7d347-0197-4c76-8efa-851331cc9983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8894ef-d671-403f-8fb3-f3302a7aa464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8894ef-d671-403f-8fb3-f3302a7aa464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a5dfa22-b776-4b89-ad81-0ff3f1fd12fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fad7b064-0253-46c1-9e3e-1ce432c83187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a5dfa22-b776-4b89-ad81-0ff3f1fd12fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_677e6031-3048-436c-9fc1-b6f72fc98867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637d7efc-752d-4034-a59a-c1e755968ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_677e6031-3048-436c-9fc1-b6f72fc98867" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637d7efc-752d-4034-a59a-c1e755968ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_e031a417-7bf1-42b9-9ed3-e574f3e4e503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4044f944-eb92-4a18-a7ca-2161eac6be06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e031a417-7bf1-42b9-9ed3-e574f3e4e503" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4044f944-eb92-4a18-a7ca-2161eac6be06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_60825c48-050c-44ac-ac21-5f73c25bdb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e031a417-7bf1-42b9-9ed3-e574f3e4e503" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_60825c48-050c-44ac-ac21-5f73c25bdb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d88e714-c0a8-4cff-8e4a-f87abe15a142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e031a417-7bf1-42b9-9ed3-e574f3e4e503" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4d88e714-c0a8-4cff-8e4a-f87abe15a142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_ca2cc58e-decf-463d-a19d-3d32fb8e1ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_ca2cc58e-decf-463d-a19d-3d32fb8e1ded" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cb0dcbc-f4cc-4278-ae35-f4582cd6dc17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30071671-ea9d-427b-b8e7-248ea1e1200c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30071671-ea9d-427b-b8e7-248ea1e1200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6f7c5725-e8a7-474c-84b7-afa77f9b96df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6f7c5725-e8a7-474c-84b7-afa77f9b96df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea0bc9bd-0f92-4ac3-ba6e-c2180d1d775e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_536ed474-a946-4f05-8153-0b4686695c54" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea0bc9bd-0f92-4ac3-ba6e-c2180d1d775e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2914ac23-b3cf-4c1d-91be-9070d94f2f17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39b42dc7-5b85-4fe6-9b4e-90bbfc648d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_badffcd7-2f24-40bd-b061-f2310ea78938" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39b42dc7-5b85-4fe6-9b4e-90bbfc648d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0fa4c3f5-5bf2-4326-892d-b36abf98fd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0fa4c3f5-5bf2-4326-892d-b36abf98fd88" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:to="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_38e194fc-724c-4d73-9017-43b1ed25a8cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1eb80525-c597-4d6b-b9e0-541d058861ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1eb80525-c597-4d6b-b9e0-541d058861ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6ca75a74-b61d-46b6-b77a-197d81497f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6ca75a74-b61d-46b6-b77a-197d81497f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e8b546b8-cbb1-4161-9bcf-d5de7a60b559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4658e224-27ec-4f5c-8c53-fa03e607b06a" xlink:to="loc_us-gaap_RestrictedStockMember_e8b546b8-cbb1-4161-9bcf-d5de7a60b559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_810cce5e-1dfa-467c-a768-59a46d569dc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f584c7e0-feb8-468d-99c0-61d8dafce02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f584c7e0-feb8-468d-99c0-61d8dafce02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5209730e-36d0-4bc1-a6c2-f2b18a14f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d737fdda-74fe-4209-8845-153d7b339778" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5209730e-36d0-4bc1-a6c2-f2b18a14f4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d5f7b57-2241-48fc-87cb-324e75a706ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d5f7b57-2241-48fc-87cb-324e75a706ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:to="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_20138fd8-04a2-4e2b-bcbb-85e6edb29471" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8eebc2fa-c4c0-4309-b50e-cf45b9a4f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a81b32b-fd58-4546-9c91-7fc7152950d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8eebc2fa-c4c0-4309-b50e-cf45b9a4f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d6fe137-9720-4108-961c-1008912ae9cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_62e23e60-ee66-4242-b7d6-d40f4390662a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_62e23e60-ee66-4242-b7d6-d40f4390662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0315cee7-fe5d-4497-b856-3aad33fd1786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7503d0cf-0be2-4bc2-b16d-0219934863c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0315cee7-fe5d-4497-b856-3aad33fd1786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16df1bd1-977a-4533-af3e-cb8ae89c4f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9f9fcd8e-34ce-4cab-877c-315f36af015f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16df1bd1-977a-4533-af3e-cb8ae89c4f1f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9f9fcd8e-34ce-4cab-877c-315f36af015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_01e5acf7-c4f7-4248-b292-abd196b99eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01e5acf7-c4f7-4248-b292-abd196b99eaa" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b925d469-9e27-4ff1-9ece-4f18323ff9b8" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_354bc2ed-8408-4371-9cc2-4cadef86bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:to="loc_us-gaap_DomesticCountryMember_354bc2ed-8408-4371-9cc2-4cadef86bc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_be9396e4-aacb-452c-b086-29f806daf03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e3791b0f-2c0f-444f-814e-f6bcb1553da6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_be9396e4-aacb-452c-b086-29f806daf03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5edbb2ad-404a-4d15-b19b-0e1d9097082e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1fa9a044-5827-4f48-ba62-b2d953a045f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_1fa9a044-5827-4f48-ba62-b2d953a045f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2dfdf711-6875-443f-97da-7ea3c289c252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_2dfdf711-6875-443f-97da-7ea3c289c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_fa1efd48-79ce-4579-a995-6bfa5a376550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_ce38ab5e-7aa2-45f2-a5d1-13d29560762a" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_fa1efd48-79ce-4579-a995-6bfa5a376550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_893336ea-0c37-4cb4-aeea-9fbcde147d5f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_389bf5ff-04b4-4659-923d-6679804387b6" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_389bf5ff-04b4-4659-923d-6679804387b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_590c3243-444a-4552-8747-c75d2a3953c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_us-gaap_OperatingLossCarryforwards_590c3243-444a-4552-8747-c75d2a3953c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_f7dc357c-40a6-4221-a812-0916e4bdb5eb" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_f7dc357c-40a6-4221-a812-0916e4bdb5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_e78106eb-9787-4a98-9c00-3c372993a42c" xlink:href="clbs-20220630.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_e78106eb-9787-4a98-9c00-3c372993a42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_a12ae1d5-6abc-4c0c-a734-fda02b11f3c5" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_a12ae1d5-6abc-4c0c-a734-fda02b11f3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_78d408e2-8f2a-474e-a2bb-5cf1ca1b9593" xlink:href="clbs-20220630.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_78d408e2-8f2a-474e-a2bb-5cf1ca1b9593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_655215f4-6927-41ad-9bb6-84bffc155f5d" xlink:href="clbs-20220630.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2b971191-0fba-4e4b-9a43-4cb55826d197" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_655215f4-6927-41ad-9bb6-84bffc155f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20220630.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cfddfe9b-f407-41e7-af06-d95ee4a18799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1b645c24-fa6a-46b3-beee-3690661296d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cfddfe9b-f407-41e7-af06-d95ee4a18799" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1b645c24-fa6a-46b3-beee-3690661296d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307747962800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CALADRIUS BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,583,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748093504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,348<span></span>
</td>
<td class="nump">$ 24,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">39,643<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">74,947<span></span>
</td>
<td class="nump">96,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other Investments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">85,877<span></span>
</td>
<td class="nump">97,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,594,329 and 59,800,792 shares at June 30, 2022 and December 31, 2021, respectively; and outstanding, 60,583,249 and 59,789,712 shares at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">546,976<span></span>
</td>
<td class="nump">545,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 11,080 shares at June 30, 2022 and December 31, 2021</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(463,868)<span></span>
</td>
<td class="num">(453,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Caladrius Biosciences, Inc. stockholders' equity</a></td>
<td class="nump">82,391<span></span>
</td>
<td class="nump">92,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">82,137<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 85,877<span></span>
</td>
<td class="nump">$ 97,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f,g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307744204848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockLiquidationPreferenceShare', window );">Preferred stock, liquidation value</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">60,594,329<span></span>
</td>
<td class="nump">59,800,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">60,583,249<span></span>
</td>
<td class="nump">59,789,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (shares)</a></td>
<td class="nump">11,080<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockLiquidationPreferenceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockLiquidationPreferenceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748439216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,239<span></span>
</td>
<td class="nump">$ 4,329<span></span>
</td>
<td class="nump">$ 6,517<span></span>
</td>
<td class="nump">$ 9,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
<td class="nump">6,823<span></span>
</td>
<td class="nump">5,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">7,147<span></span>
</td>
<td class="nump">13,340<span></span>
</td>
<td class="nump">15,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,720)<span></span>
</td>
<td class="num">(7,147)<span></span>
</td>
<td class="num">(13,340)<span></span>
</td>
<td class="num">(15,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(6,626)<span></span>
</td>
<td class="num">(7,190)<span></span>
</td>
<td class="num">(13,331)<span></span>
</td>
<td class="num">(15,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Caladrius Biosciences, Inc. common stockholders</a></td>
<td class="num">$ (6,626)<span></span>
</td>
<td class="num">$ (5,682)<span></span>
</td>
<td class="num">$ (10,852)<span></span>
</td>
<td class="num">$ (13,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">60,533<span></span>
</td>
<td class="nump">59,510<span></span>
</td>
<td class="nump">60,546<span></span>
</td>
<td class="nump">50,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">60,533<span></span>
</td>
<td class="nump">59,510<span></span>
</td>
<td class="nump">60,546<span></span>
</td>
<td class="nump">50,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307747883120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (6,626)<span></span>
</td>
<td class="num">$ (5,682)<span></span>
</td>
<td class="num">$ (10,852)<span></span>
</td>
<td class="num">$ (13,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized gain (loss)</a></td>
<td class="nump">126<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">126<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</a></td>
<td class="num">$ (6,500)<span></span>
</td>
<td class="num">$ (5,686)<span></span>
</td>
<td class="num">$ (10,852)<span></span>
</td>
<td class="num">$ (13,749)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743879408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Caladrius Biosciences, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 32,242<span></span>
</td>
<td class="nump">$ 32,496<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 458,748<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (425,550)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(13,745)<span></span>
</td>
<td class="num">(13,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">85,479<span></span>
</td>
<td class="nump">85,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">85,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">104,679<span></span>
</td>
<td class="nump">104,933<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">544,893<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(439,295)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">110,014<span></span>
</td>
<td class="nump">110,268<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">544,601<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(433,613)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(5,682)<span></span>
</td>
<td class="num">(5,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 104,679<span></span>
</td>
<td class="nump">104,933<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">544,893<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(439,295)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">59,789,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">92,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">545,988<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(453,016)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(10,852)<span></span>
</td>
<td class="num">(10,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">60,583,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 82,137<span></span>
</td>
<td class="nump">82,391<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">546,976<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(463,868)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">88,241<span></span>
</td>
<td class="nump">88,495<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">546,580<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(457,242)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,626)<span></span>
</td>
<td class="num">(6,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">60,583,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 82,137<span></span>
</td>
<td class="nump">$ 82,391<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 546,976<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (463,868)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748030640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (10,852)<span></span>
</td>
<td class="num">$ (13,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion on marketable securities</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(744)<span></span>
</td>
<td class="num">(1,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(1,268)<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,704)<span></span>
</td>
<td class="num">(12,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(30,291)<span></span>
</td>
<td class="num">(105,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">60,070<span></span>
</td>
<td class="nump">29,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Investment in Cend Therapeutics</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">19,544<span></span>
</td>
<td class="num">(76,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(168)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">85,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(139)<span></span>
</td>
<td class="nump">85,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">8,701<span></span>
</td>
<td class="num">(3,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,647<span></span>
</td>
<td class="nump">16,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 33,348<span></span>
</td>
<td class="nump">$ 12,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307751569888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 26, 2022, the Company and Cend Therapeutics, Inc., a Delaware corporation (&#8220;Cend&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;), subject to the terms of the Merger Agreement and stockholder approval of the transaction. Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock and the Company&#8217;s stockholders as of immediately prior to the Merger are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock.  The actual allocation will be subject to adjustment based on our net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $250&#160;thousand at the time of closing. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including but not limited to Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept, open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease and was expected to complete enrollment in approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">as well as with a contrast agent typically used in many catheter laboratories. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intends to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The interim analysis is expected to be completed in the third quarter of 2022, and the next steps in development of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> will subsequently be determined after appropriate regulatory and business review, expected to be announced prior to year-end 2022.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment in the fourth quarter of 2021. Following study suspension, the Company completed all protocol-defined patient observations and is preparing the clinical study report. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is now in the pre-consultation phase of the registration process with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan.  Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan has been compiled and is expected to be reviewed by PMDA during the third quarter of 2022 after which the PMDA is expected to provide important perspective to be considered in preparation for the formal consultation meetings which precede the Japanese new drug application. The Company is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan. This may include the completion of enrollment of the four-remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's PMDA under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt of orphan designation from FDA in March 2021 in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue U.S. development in Buerger's disease at this time.<br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol includes six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study then permitted the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. The Company treated the first patient in the CLBS201 proof-of-concept study in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">end Merger Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, the Company and Cend entered into the Merger Agreement. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Cend and the Company&#8217;s satisfaction of a minimum net cash threshold at closing, expected to be approximately $64.9&#160;million assuming a closing at the end of the third quarter of 2022, and as described further in the Merger Agreement. The Merger Agreement contains certain termination rights for both the Company and Cend, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Cend a termination fee of $1.0&#160;million, Cend may be required to pay the Company a termination fee of $4.0&#160;million, or in some circumstances reimburse the other party&#8217;s expenses up to a maximum of $1.0&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the effective time of the Merger, the Company&#8217;s Board of Directors is expected to consist of nine members, four of whom will be designated by the Company, four of whom will be designated by Cend and one member who will be mutually agreed between the Company and Cend.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide Cend with capital for its development programs prior to the closing of the Merger, the Company and Cend entered into a Series D Preferred Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company purchased from Cend 1,135,628 shares of Series D Preferred Stock, $0.00001 par value per share (the &#8220;Series D Preferred Stock&#8221;), of Cend at a purchase price per share equal to $8.8057 per share (the &#8220;Series D Original Issue Price&#8221;), or approximately $10&#160;million in the aggregate. The Series D Preferred Stock ranks senior to Cend&#8217;s common stock and the other series of preferred stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of Cend. The Series D Preferred Stock has a liquidation preference equal to the Series D Original Issue Price plus an amount equal to any accrued and unpaid dividends to the date of payment and will participate with Cend&#8217;s common stockholders and other preferred stockholders thereafter on an as-converted basis. The Series D Preferred Stock shall vote with the common stock on an as-converted basis on any matters presented to the stockholders of Cend.  Each share of Series D Preferred Stock is convertible, at the option of the holder thereof, into such number of shares of Cend common stock as is determined by dividing the Original Issue Price by the conversion price in effect at the time of conversion, which conversion price shall be the Original Issue Price as appropriately adjusted for stock splits, stock dividends, combinations, and subdivisions of Cend common stock, and as adjusted pursuant to a weighted-average antidilution adjustment. The Series D Preferred Stock will automatically convert into shares of Cend common stock upon the closing of a firm-commitment underwritten initial public offering implying a pre-equity offering value of at least $250&#160;million, resulting in at least $50&#160;million of gross proceeds to Cend. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with such Purchase Agreement, Cend entered into a Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;), pursuant to which the Company agreed to collaborate with Cend on certain developmental and clinical activities prior to the closing of the Merger. Pursuant to the Collaboration Agreement, the Company and Cend have formed a joint steering committee (the &#8220;Committee&#8221;) comprised of individuals from both entities. The Committee meets regularly and is responsible for monitoring ongoing studies and making recommendations for development activity and trial planning. Cend has agreed to pay each member of the Committee from the Company an hourly consulting fee for such service.  As of June 30, 2022 the cumulative services provided under the agreement totaled $0.2&#160;million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as well as with a contrast </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in subjects with CMD and corroborate the ESCaPE-CMD study results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.<br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750422352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2021 Form 10-K. There were no changes to these policies during the three and six months ended June&#160;30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Cend Therapeutics</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in which the Company has no significant influence (generally less than a 20% ownership interest) or does not have the ability to exercise significant influence are accounted for under the measurement alternative method pursuant to ASC 321, Investments&#8201;&#8212;&#8201;Equity Securities (&#8220;ASC 321&#8221;) as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as investments on the consolidated balance sheets and any impairment recognized related to these investments are presented in other income (expense), on the consolidated statements of operations (see Note 5, &#8220;Fair Value Measurements&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307842664000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307842664000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per ShareFor the six months ended June&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At June&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750254144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Cend Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750344784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750399888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating LeasesThe Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the weighted average remaining lease term for our operating leases was 2.0 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307752987472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with HCW, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million.  During the six months ended June&#160;30, 2022 and since inception the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#8217;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the six months ended June&#160;30, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,131,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,612,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,574,724&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,388,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3Mw_d6c91bb1-b895-4964-8aed-4a7cfaa67b1d">one</span> to four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,379,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted average estimated fair value of restricted stock issued for services in the six months ended June&#160;30, 2022 and 2021 was $0.92 and $1.59 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750312320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750340304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#8220;NOLs&#8221;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had approximately $281&#160;million and $264&#160;million, respectively of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020 the Company had state NOLs available in New Jersey of $97&#160;million and $99&#160;million, respectively, California of $70&#160;million and $70&#160;million, respectively, and New York City of $13&#160;million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $2.5&#160;million of its NJ NOLs related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3&#160;million. The gross proceeds of $2.5&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750316048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">ContingenciesContingenciesFrom time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307747812688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Cend Therapeutics</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in which the Company has no significant influence (generally less than a 20% ownership interest) or does not have the ability to exercise significant influence are accounted for under the measurement alternative method pursuant to ASC 321, Investments&#8201;&#8212;&#8201;Equity Securities (&#8220;ASC 321&#8221;) as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as investments on the consolidated balance sheets and any impairment recognized related to these investments are presented in other income (expense), on the consolidated statements of operations (see Note 5, &#8220;Fair Value Measurements&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307747911424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750312320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At June&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750312320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Cend Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750321904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of June&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307750232912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text">Future minimum lease payments under the lease agreements as of June&#160;30, 2022 were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748422448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the six months ended June&#160;30, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,131,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,612,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,574,724&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,388,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,061,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,379,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748423712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743998704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=clbs_CollaborationAgreementMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_CendSeriesDPreferredStockPurchaseAgreementMember', window );">Cend Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PurchaseOfPreferredStockPricePerShare', window );">Series D original issue price (in usd per share)</a></td>
<td class="nump">$ 8.8057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PurchaseOfPreferredStockAggregatePrice', window );">Aggregate price</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreEquityOfferingValueAfterConversion', window );">Pre-Equity Offering Value After Conversion</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_CendSeriesDPreferredStockPurchaseAgreementMember', window );">Cend Purchase Agreement | Cend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_GrossProceedsOnTransaction', window );">Potential gross proceeds</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=clbs_SeriesDPreferredStockCendMember', window );">Cend Series D preferred stock | Cend Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PurchaseOfPreferredStockShares', window );">Number of shares purchased</a></td>
<td class="nump">1,135,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=clbs_AgreementAndPlanOfMergerAndReorganizationMember', window );">Merger Agreement | Cend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage', window );">Expected post-merger ownership in Company by Cend stockholders (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage', window );">Expected post-merger ownership in Company by Company stockholders (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation', window );">Transaction expenses threshold for allocation</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementMinimumNetCashThreshold', window );">Minimum net cash threshold at closing per agreement</a></td>
<td class="nump">64,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementPotentialTerminationFeePayable', window );">Potential termination fee payable</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementPotentialTerminationFeeReceivable', window );">Potential termination fee receivable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MergerAgreementPotentialExpenseReimbursement', window );">Potential expense reimbursement per agreement</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember', window );">CLBS16 Treatment of CMD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_GrossProceedsOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds On Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_GrossProceedsOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Expected Ownership In Company, Company Stockholders, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Expected Ownership In Company, Counterparty Stockholders, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementMinimumNetCashThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Minimum Net Cash Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementMinimumNetCashThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementPotentialExpenseReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Potential Expense Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementPotentialExpenseReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementPotentialTerminationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Potential Termination Fee Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementPotentialTerminationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementPotentialTerminationFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Potential Termination Fee Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementPotentialTerminationFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement, Transaction Expenses Threshold For Ratio Allocation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreEquityOfferingValueAfterConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-Equity Offering Value After Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreEquityOfferingValueAfterConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PurchaseOfPreferredStockAggregatePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Preferred Stock, Aggregate Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PurchaseOfPreferredStockAggregatePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PurchaseOfPreferredStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Preferred Stock, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PurchaseOfPreferredStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PurchaseOfPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Preferred Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PurchaseOfPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=clbs_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=clbs_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_CendSeriesDPreferredStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_CendSeriesDPreferredStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=clbs_CendTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=clbs_CendTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=clbs_SeriesDPreferredStockCendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=clbs_SeriesDPreferredStockCendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=clbs_AgreementAndPlanOfMergerAndReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=clbs_AgreementAndPlanOfMergerAndReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_CendTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_CendTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748478560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 69,757<span></span>
</td>
<td class="nump">$ 91,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">69,688<span></span>
</td>
<td class="nump">91,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">26,966<span></span>
</td>
<td class="nump">53,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,900<span></span>
</td>
<td class="nump">53,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">22,727<span></span>
</td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">22,727<span></span>
</td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">17,086<span></span>
</td>
<td class="nump">20,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 17,083<span></span>
</td>
<td class="nump">$ 20,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748260800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 30,045<span></span>
</td>
<td class="nump">$ 21,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">39,643<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 69,688<span></span>
</td>
<td class="nump">$ 91,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748097040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 69,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">69,757<span></span>
</td>
<td class="nump">$ 91,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">69,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total estimated fair value</a></td>
<td class="nump">$ 69,688<span></span>
</td>
<td class="nump">$ 91,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748239616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,612<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="nump">21,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748154848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">$ 39,643<span></span>
</td>
<td class="nump">$ 70,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">49,643<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">39,643<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">39,643<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Securities, FV-NI, Current</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743793600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">$ 2,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 2,260<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307747813200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>office</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NumberOfOfficesUnderOperatingLeases', window );">Number of offices under operating leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberOfOfficesUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Offices Under Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberOfOfficesUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748240208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 561<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748013648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 561<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743741568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember', window );">Lincoln Park Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration', window );">Commitment shares issued as consideration per agreement (in shares)</a></td>
<td class="nump">181,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross price for stock transaction</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_TermOfAgreement', window );">Term of agreement (in months)</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase', window );">Number of shares allowable to direct for Regular Purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase', window );">Maximum obligation per directed purchase transaction for Regular Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase', window );">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod', window );">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty', window );">Maximum beneficial ownership allowable per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307745220144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">2,131,849<span></span>
</td>
<td class="nump">2,131,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,612,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748227952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">1,061,175<span></span>
</td>
<td class="nump">300,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">1,379,860<span></span>
</td>
<td class="nump">458,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307748230080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">$ 1,128<span></span>
</td>
<td class="nump">$ 867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307752827472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 6 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 14 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743869296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140307743718592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain', window );">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross', window );">Proceeds from sale of NOLs, gross</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram', window );">Net proceeds from sale of NOLs</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_LossOnSaleOfNetOperatingLosses', window );">Loss on sale of NOLs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown', window );">Write down of NOLs set to expire unutilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LossOnSaleOfNetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale Of Net Operating Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LossOnSaleOfNetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Set To Expire, Written Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsSetToExpireWrittenDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>clbs-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clbs="http://www.caladrius.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clbs-20220630.xsd" xlink:type="simple"/>
    <context id="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d3a997d407f4fc9ab8117094e2692af_I20220804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="i36939ec815f849cd909b1f34151f6a3b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6a4a7a34fc2249628d10e950713caaf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i826be2afc3e749308a9751d74830964a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i144cc71857f7429bb51d544f0b8f9310_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7256a903af4b431abebe6883b6c15999_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5008ebb64ec147a187a521f9673cad8e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if7b06dfb1afa472fb9d01295762e7c9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i939cc2c2c6074c0c982765101de3e1fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i210747314c0e49419773d046301904e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i89ed3ac0e8cc48fd808c48dea00e34fe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31306c1aab0247159feb2af89726ee3f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0a0e8a04a5dd47a2955a1779dfb31298_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1123d58c65b6489e899c1698307885f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3acaa30e875044229e6d0b25653dfa68_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2302b303b3d24af1bcafe4350909d9ee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i09a24b47dd254dc19e95b10e49ccbed7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6bed893df04e44c1ad362c17a93cfdaf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i18265c74af504470b75337fdb7546118_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3285245ca04f458aa72087031b59e41b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie84bb799d59f441f8d0036b10575869f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c77282d142f4fb59c41c5f204dbfe92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b047433f88e46ecbc8f6948247e2441_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c105eba1be9452dbca6993cb4fae77b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa027f593cfd45789ab829afc443cd85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7b9cf1c6314423d88f7c7d52b11e494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifade1f65a2fc44a9a294052965852540_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1246f6d72c59416bb70643adff3c35cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia3384336a7944494b8cb1446514d3f7e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibd00509623ed44ddb8f0004f1abf6120_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88c32da30d114addbead3f239466b8e9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78c2932e69ef4d54ac788754fdca2d18_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6af4cb66e154f95939adbff59e13392_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9599115241c54766a1a636684b8b060e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ad465c32b5844118f00a809aaff3997_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b43e8ae838c493d815ea92bdae4b1fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i603559893c614cd2912e389072705619_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i65449c0457314898a5bd53ecab85713e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7a4c8cad9db9466db265fc7fc23b3c86_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b57810d948345c6bc01749f37102642_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icff1dcadd5124a7ba11055ac74a67ee4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i840c3e9cbefb43e9b146dfd41f33662f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id525428cb5044f9dad07f0198a966b18_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id4aa152b86594c1daab508f7a3371e7e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ief022a2aaa62471fba1ace6d10742f26_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i11509a49300e4d2cad12d712bd9a7433_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7c51dda04204b5ea7441d1f68c81706_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92a95e7cdc8d4bc1ad9b84ffd5e3f68b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6aedcf6bdef487f875f1aafded60667_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1573c590f9ad4ed5bbed7597658b47ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8a41562d90542fdbfbc872ae7d68b02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib04d15ea5e1d45368d6e6e3fe784f7e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1920cbc31b314e8681271adf19a0cce4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i052a9e1cdcbe4746bce1dc6273233d80_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:CendTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:AgreementAndPlanOfMergerAndReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="i7de6a11cd3474c6287cb381192ae5762_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:CLBS16TreatmentOfCMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0492a0dc655845a9b2daa971f3aa0ee6_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clbs:SeriesDPreferredStockCendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="ib7d7e60b43454d24bd9f8aab2bdd049a_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">clbs:SeriesDPreferredStockCendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="i1b3345a69c3d4ae293e0976208942eda_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="i2adcb8be9d2546328e9ae61565dec3b3_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:CendSeriesDPreferredStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">clbs:CendTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="i4bfdf542e13048bbbd63568d248c0ea6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">clbs:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i760113b860d24918972b88966a39461f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29d7da78337e4f97b4635d629086a480_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17f028c9834d4aa8851347d4e1ac46ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie67a57e844cf4196b7d6aaece131e76a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i472af80a2f724a30858b9461b417ed5e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i31c748eba28b4b64a8ec1143527c0ae4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie46e3b754c67413c88f24c3ddff1552f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c93d7a7931742669a283947008740ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d5ab7d1d8304b70a0409715de916340_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5311053f8ab4baab4847164c5f36d3a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94f725c87ad542dcb3ff3f4d00fc0e9d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f6233584e5a4a50b728139e0d6c6159_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i461576cc6a4e4084a8c496c3c34ed239_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib070372249f24e5daa9dce2156efdc26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c4f1d501291470683152d8d06246393_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i169c2b19485743c494294b605e1c9637_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a0af1b219794ef094dabc670988af20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i881d1b5361494535a4dff620655e80cc_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib0d46abc623a4ea5a97d1bf45a62c876_I20210604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="i14632cb149ee4f8e824d0bc59caba108_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12ea05efc6ab4cc59782212d5667a800_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68930bc1046341ffaf2ee9a38956674a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49d7272724ce4f578cc742d1dc931327_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie15f75b9306d45999b283daf73a43b48_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i61b5af72af5c4772bf134572a931b93d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66c459ae881647fd8f328d90c28330bf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f0d245d793c45a1ba1cb80e8b960908_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i823661ad4a944545a75121b92daaf1a9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62c6b1a91ccc4441ba38426fe098aeb0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ief352e26ae67416cafff90b9793d7ccd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a169106c4a54b75a790607dc184b040_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1213c6cc96c2467caca65a5f1102dc7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie96074b249ba4cb3811d86696759685a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id96396af1f5f4e578519538caff67b2c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i069758af4d36436e817e90b87a8a130d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia572f9b4029b4d02bd17de8d331b2d60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ce48fc27b9345c79034d9b1582abdf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc8328428e264834bf3b4a202bab364f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib17745a6d80b45f587961fd01e5ac1bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a9b55d334b140a0a9c8cf4c0b5ced19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i148b071e62cb48e389a032a63261b95b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e7dbcff99b643cba5824b529d4831aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-02-22</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="office">
        <measure>clbs:office</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV8zLTEtMS0xLTIwMzYw_7b1d448e-6651-4b43-9e7e-595745c12935">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV80LTEtMS0xLTIwMzYw_a874b216-2224-49bf-934c-e29e49690e19">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV81LTEtMS0xLTIwMzYw_641607ea-32b6-4378-b25e-377247df660d">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV82LTEtMS0xLTIwMzYw_d4d29c33-0693-490d-a022-5fd6bf92723b">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80L2ZyYWc6OTlhOTNjZGM0ODM3NDQxZDgyYjQ0OWY1OGJlYzYwYmUvdGFibGU6NjE1ZGJlNmMwZmRhNDEyZDkzMjY2YTQ4ZThmZTk1NDEvdGFibGVyYW5nZTo2MTVkYmU2YzBmZGE0MTJkOTMyNjZhNDhlOGZlOTU0MV83LTEtMS0xLTIwMzYw_5633f277-0eda-4678-91af-819832e6e536">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i12ea05efc6ab4cc59782212d5667a800_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3Mw_d6c91bb1-b895-4964-8aed-4a7cfaa67b1d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI4_f70b5934-1300-4580-a695-0487f0aa8684">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6ODRiNjM1MzUyMmEzNGU5YmJmNzBiYmU0YzhiZTJhMTEvdGFibGVyYW5nZTo4NGI2MzUzNTIyYTM0ZTliYmY3MGJiZTRjOGJlMmExMV8wLTAtMS0xLTIwMzYw_0670e054-2f58-48a0-8401-d3bb0ab84728">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8xMjY_af4bcc92-0210-4376-8948-903660d98d80">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6NGIxYjcxMDA2M2EwNDQ5Y2EzY2NkNWFiZjQ1MmMyYjMvdGFibGVyYW5nZTo0YjFiNzEwMDYzYTA0NDljYTNjY2Q1YWJmNDUyYzJiM18wLTAtMS0xLTIwMzYw_c4ccb3fd-2a18-41fb-90c7-4f3558c7c995">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI5_759e4136-b32e-4b6d-baeb-a12d7531daef">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDMw_807f02c7-93d7-4892-8abe-d9c805bb76d0">CALADRIUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8wLTAtMS0xLTIwMzYw_2b583f67-b5fd-4c58-b980-76a6e1800f47">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8wLTEtMS0xLTIwMzYw_453fba70-432b-440c-8757-9b73dac1ceaf">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfNA_7baf7899-ebad-4996-b490-d41e6e1d9600">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfOA_f1a52abc-f405-4a50-9d76-ea2b3b961676">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTAtMS0xLTIwMzYwL3RleHRyZWdpb246NGVkNGJhYzU5ZjJjNGE4ZDgyMTBjZDUzMWI1NmJlZWVfMTI_a3781d64-4ae7-49de-b8b5-22f5ea6cf504">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6N2FhNmRjYTNlODc4NGQ5OWI4Mjg5OTkzYTY4YzYzMGIvdGFibGVyYW5nZTo3YWE2ZGNhM2U4Nzg0ZDk5YjgyODk5OTNhNjhjNjMwYl8zLTEtMS0xLTIwMzYw_d8534c45-3e74-458f-89d3-81ec7d2c9989">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDMz_fa869d76-7486-45c9-9905-ef2dcfe3e77d">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDM0_f10bd18a-eecb-4b7d-86a0-2c49e08c068b">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTAtMS0xLTIwMzYw_d1f2f95a-2948-43e0-8217-4a01820fc06e">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTEtMS0xLTIwMzYw_b64e81c9-fda5-483f-9d6e-1a2087b0dd8c">CLBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6OTk1ZDU3YTE5OWIwNGNjNDg4MDMzZGY2OWFlNGZiN2MvdGFibGVyYW5nZTo5OTVkNTdhMTk5YjA0Y2M0ODgwMzNkZjY5YWU0ZmI3Y18yLTItMS0xLTIwMzYwL3RleHRyZWdpb246MDBmNjE5YWFhMWRmNGEwYTk2ZWRiMDMxZTQzMzIxZDRfOA_9350cacc-baae-442d-a8c5-f67d7c815020">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI0_3d686061-207e-4677-a953-546835f488ba">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI2_f3add66f-fd31-4567-b4fc-2bc0e8574c46">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8xLTAtMS0xLTIwMzYw_30c76bdf-e80b-421a-bcf4-fa8e4264f2ce">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8xLTQtMS0xLTIwMzYw_e75f95e1-98a4-4159-8da3-b817358815b4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6MmZlZGFiMzdmZmYwNGZmOWIxZWY0Yzk3OTNkOTE3ODYvdGFibGVyYW5nZToyZmVkYWIzN2ZmZjA0ZmY5YjFlZjRjOTc5M2Q5MTc4Nl8yLTQtMS0xLTIwMzYw_d7b7607c-99db-4515-9614-be5b8cd46cd4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGV4dHJlZ2lvbjozMGQ2ZjVjZWNhN2E0MGE3YmQwODdmYWIzNTIwOTNkYl8yMDI3_64727023-e2f5-4143-ac57-25537dccf861">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8d3a997d407f4fc9ab8117094e2692af_I20220804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xL2ZyYWc6MzBkNmY1Y2VjYTdhNDBhN2JkMDg3ZmFiMzUyMDkzZGIvdGFibGU6NjY4N2E4MmM1YmEwNGYyZmI3YTNhOGNhOGE2MDhiOGIvdGFibGVyYW5nZTo2Njg3YTgyYzViYTA0ZjJmYjdhM2E4Y2E4YTYwOGI4Yl8xLTEtMS0xLTIwMzYw_da2c2fdd-3dc0-4ceb-ab03-c5874eb22607"
      unitRef="shares">60583249</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMi0xLTEtMS0yMDM2MA_4f8ffaf4-63c8-480f-83e9-912d55954a02"
      unitRef="usd">33348000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMi0zLTEtMS0yMDM2MA_e6c34f06-7fe8-4cc1-a132-f035b60b87d2"
      unitRef="usd">24647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMy0xLTEtMS0yMDM2MA_8800017c-4e85-4188-bba6-33a0b27a4109"
      unitRef="usd">39643000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMy0zLTEtMS0yMDM2MA_7b82aa10-2e3d-4fb5-852d-174c690a4d4c"
      unitRef="usd">70323000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNC0xLTEtMS0yMDM2MA_0f6828c3-28e2-4b7d-9935-7b64c7680234"
      unitRef="usd">1956000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNC0zLTEtMS0yMDM2MA_e370a2e0-964d-4652-a40b-63542407f1e6"
      unitRef="usd">1212000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNS0xLTEtMS0yMDM2MA_6decff44-26b7-4b6f-937d-d72fb0e8232f"
      unitRef="usd">74947000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNS0zLTEtMS0yMDM2MA_b2083575-b2f2-480d-9de6-3a001261fa9a"
      unitRef="usd">96182000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNi0xLTEtMS0yMDM2MA_4bfac620-2e2b-4952-9fb3-20b99f835d0e"
      unitRef="usd">282000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNi0zLTEtMS0yMDM2MA_2f18792a-6e8f-46a8-bd8d-49320dda9dde"
      unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherInvestments
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0xLTEtMS0yMTU2Ng_71646e90-f826-4b64-a887-cebacaeea4ae"
      unitRef="usd">10000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0zLTEtMS0yMTU2Ng_b4160191-372d-4a36-980f-716245a09a6a"
      unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0xLTEtMS0yMDM2MA_66bcaed6-6dd0-45f7-be53-64389eff4242"
      unitRef="usd">648000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfNy0zLTEtMS0yMDM2MA_7f74760c-11e2-418a-8e0e-34085e41215f"
      unitRef="usd">764000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfOC0xLTEtMS0yMDM2MA_602e7ec7-b8f8-48ab-81ff-8a798f55f6c4"
      unitRef="usd">85877000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfOC0zLTEtMS0yMDM2MA_a9c9222a-2a72-49d0-8739-49d7b271ff97"
      unitRef="usd">97008000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTItMS0xLTEtMjAzNjA_8d0e34ea-ca2d-4563-8798-897e496a1859"
      unitRef="usd">1097000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTItMy0xLTEtMjAzNjA_e4fab26a-3816-4935-b00e-077641897924"
      unitRef="usd">1934000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTMtMS0xLTEtMjAzNjA_d0437f3b-17e1-4683-b4eb-dd3cf9ca52a0"
      unitRef="usd">2260000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTMtMy0xLTEtMjAzNjA_a59522c2-3ce1-4c09-a868-2488a41c90f4"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTQtMS0xLTEtMjAzNjA_c794ccec-e768-4b80-bd04-f86619046d2b"
      unitRef="usd">3357000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTQtMy0xLTEtMjAzNjA_b2327a68-7ddc-40e7-b38c-af615bc45574"
      unitRef="usd">4523000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTUtMS0xLTEtMjAzNjA_75e631b2-c17b-4412-be79-73e34a5b1be6"
      unitRef="usd">383000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTUtMy0xLTEtMjAzNjA_7079a0f2-1377-4702-bbe8-7db119a43fa7"
      unitRef="usd">485000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTYtMS0xLTEtMjAzNjA_595c5e38-d7f8-423a-a39a-f818b224ea79"
      unitRef="usd">3740000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTYtMy0xLTEtMjAzNjA_84e74549-722d-46b3-96ce-d975b157a965"
      unitRef="usd">5008000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTctMS0xLTEtMjAzNjA_65ff7bab-cfb7-46a2-8bcc-d0f1c49b3282"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMTctMy0xLTEtMjAzNjA_aa3f500f-5812-48c8-bf13-a9dd36634718"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8zNA_56986b53-2c9b-4fe8-b78a-bc575387b9ff"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8zNA_f3595206-15ac-41ee-90db-31603c09fcd0"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMTE_54e439d3-652d-42d8-9554-f6242060e168"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMTE_735a50b8-7418-4bb8-ad99-c70e23a7ba25"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMzc_010a9481-ff8f-44b3-8981-60dda3a2bc39"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xMzc_d521978d-445e-4255-af66-0e7fa871156d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <clbs:PreferredStockSharesDesignated
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xNTE_470dbfa8-1703-43ab-96df-463cba5ffe51"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <clbs:PreferredStockSharesDesignated
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xNTE_dff22cb9-0d46-4bf3-afea-a88086766bc1"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_163f451f-6ee6-4786-b029-9958c5cfca0c"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_855fc3a1-7ef7-41ed-a7a2-61fdee7298c0"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_dfb1cdcf-f2be-4a1e-aa90-d780205c7974"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjoxMzU5NGFiMjIxMDM0N2Y0OGEyOGYxMjZhZjQ2YTlmYl8xOTc_f8e3fd0d-d6ed-4022-92df-e0add07e5eff"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMS0xLTEtMjAzNjA_e04d0d3d-836b-4e8d-8823-7f7c2c5e1b87"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjAtMy0xLTEtMjAzNjA_4f804783-4e3f-4025-8b15-78be2fa658a4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xOA_c240b118-6268-4e8a-8b81-7c6ef6d97644"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xOA_c6f3d7cc-ce9b-46b9-b2fc-cd920b45fe07"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV80Mw_161df537-c134-4629-84de-525c855bc156"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV80Mw_3ec9394d-3dfc-4ac7-ba5e-94cc9e9c53ee"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV82MQ_05ac8c12-0f5b-4a4d-96e0-0faaca73fcf3"
      unitRef="shares">60594329</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV82OA_a31286fa-d45f-4207-990f-5f722139b0d8"
      unitRef="shares">59800792</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xNTE_e448d452-2aba-4292-95dd-4d297ec86e01"
      unitRef="shares">60583249</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjpjYTFiMTMzYTAzMGE0MGRhOWMzMWE0ZjNjNjVkYzA4NV8xNTg_eecaac50-f235-49db-956c-2135216bffe2"
      unitRef="shares">59789712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMS0xLTEtMjAzNjA_2c799a8f-34ec-4ea9-beed-8b9adc9c4feb"
      unitRef="usd">61000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjEtMy0xLTEtMjAzNjA_635cec90-56eb-4d0b-a44c-2ca7c9883282"
      unitRef="usd">60000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjItMS0xLTEtMjAzNjA_1c755929-d414-49de-8bc2-a9cfb176ebd1"
      unitRef="usd">546976000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjItMy0xLTEtMjAzNjA_d943878a-81fc-4082-9cd1-582e2d163009"
      unitRef="usd">545988000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjo4ZjNhMTk1NTMzNTI0NDg3YjRkYzg1MjFjZjQ1MjMwMV8yOQ_760eb86a-c56d-4985-9075-433cff4d84f6"
      unitRef="shares">11080</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMC0xLTEtMjAzNjAvdGV4dHJlZ2lvbjo4ZjNhMTk1NTMzNTI0NDg3YjRkYzg1MjFjZjQ1MjMwMV8yOQ_ff21d8af-a2b3-40ce-b557-f3df797de1b9"
      unitRef="shares">11080</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMS0xLTEtMjAzNjA_2c600767-e764-40cf-965f-8889f982085d"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjMtMy0xLTEtMjAzNjA_6dba7feb-a81d-46f9-aacd-d4a007cfdc33"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjQtMS0xLTEtMjAzNjA_2f0917c0-356b-46c0-ab55-5247c6684e4d"
      unitRef="usd">-463868000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjQtMy0xLTEtMjAzNjA_d57cb2d3-89fc-4519-95b4-28b1389ac6ed"
      unitRef="usd">-453016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjUtMS0xLTEtMjAzNjA_5002b8cb-fbad-46f6-871e-0a17b7b8c87a"
      unitRef="usd">-70000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjUtMy0xLTEtMjAzNjA_ffd6359a-7f02-4fce-b07d-38dddf74622b"
      unitRef="usd">-70000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjYtMS0xLTEtMjAzNjA_bf6b785a-e34c-47cd-b314-01aa73e1788e"
      unitRef="usd">82391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjYtMy0xLTEtMjAzNjA_be4bd98a-08d4-423a-9fdd-39292d1ac254"
      unitRef="usd">92254000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjctMS0xLTEtMjAzNjA_db0cf75d-c77a-43bf-95ce-cf1f169e7750"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjctMy0xLTEtMjAzNjA_810d0bbb-6048-4678-b18a-a76055526b26"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjgtMS0xLTEtMjAzNjA_b06ff435-82ec-4525-8be7-ea74d110cc6b"
      unitRef="usd">82137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjgtMy0xLTEtMjAzNjA_2f1f7f8c-4163-4a6a-b5b5-316a20896a9e"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjktMS0xLTEtMjAzNjA_e1a70ba7-eab9-406b-bd4b-63c6715cce86"
      unitRef="usd">85877000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xNi9mcmFnOjZkMjcxYWNmOTlkMTQzNjI4MDg0MzU4YzZmN2QxMjRhL3RhYmxlOjUzMDkxMDAzMDU5YTRhZGE4ZTljMjQwYTQ5Njg5NzY4L3RhYmxlcmFuZ2U6NTMwOTEwMDMwNTlhNGFkYThlOWMyNDBhNDk2ODk3NjhfMjktMy0xLTEtMjAzNjA_163e7789-4d40-4751-a7c4-50d58d2f5369"
      unitRef="usd">97008000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy0xLTEtMS0yMDM2MA_02cc104e-672e-4f19-b521-00fae57ef0a4"
      unitRef="usd">3239000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy0zLTEtMS0yMDM2MA_e6cb550e-1179-42f3-91a7-bc9573e93a19"
      unitRef="usd">4329000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy01LTEtMS0yMDM2MA_b200d892-a2ec-4b0e-8987-da65160f9492"
      unitRef="usd">6517000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMy03LTEtMS0yMDM2MA_ba1b9c21-44ce-413d-80d9-89babfe44311"
      unitRef="usd">9405000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC0xLTEtMS0yMDM2MA_657ac2f8-eab6-4a84-a92d-d3a9cc2b691b"
      unitRef="usd">3481000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC0zLTEtMS0yMDM2MA_3f2ed090-da4d-4aa3-b1cf-dbdd33183004"
      unitRef="usd">2818000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC01LTEtMS0yMDM2MA_6ca1f979-837f-452e-9eeb-44475fe6ba50"
      unitRef="usd">6823000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNC03LTEtMS0yMDM2MA_509b4e17-f479-4bfb-9f08-a82f054e6fa0"
      unitRef="usd">5828000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS0xLTEtMS0yMDM2MA_1f9bfc1c-a421-426f-a294-a15ea3d14f06"
      unitRef="usd">6720000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS0zLTEtMS0yMDM2MA_4b0099ca-7b60-49cd-94bb-faa5f68c4021"
      unitRef="usd">7147000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS01LTEtMS0yMDM2MA_d490444c-b320-488f-bc49-d5f9636e96bb"
      unitRef="usd">13340000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNS03LTEtMS0yMDM2MA_bf162895-ac81-4e95-8bb9-3cfac9f3f55f"
      unitRef="usd">15233000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy0xLTEtMS0yMDM2MA_1f12bd8d-a66d-4e54-b0ac-27019cc071c3"
      unitRef="usd">-6720000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy0zLTEtMS0yMDM2MA_e90952bd-cd04-46ac-8b0d-1e9d173828e0"
      unitRef="usd">-7147000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy01LTEtMS0yMDM2MA_c5fa1b80-2e1e-47bb-8da5-f44c2ddd8151"
      unitRef="usd">-13340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfNy03LTEtMS0yMDM2MA_0ae0128c-1c8a-4ad5-9d96-52efab2053eb"
      unitRef="usd">-15233000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtMS0xLTEtMjAzNjA_e7f6cc33-ff16-4873-a35c-95241af04af8"
      unitRef="usd">94000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtMy0xLTEtMjAzNjA_42fcfa86-3152-400d-92a3-afb6cb2e022d"
      unitRef="usd">47000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtNS0xLTEtMjAzNjA_e0e98cfd-444d-49aa-bfd1-43ea9e622bab"
      unitRef="usd">158000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTAtNy0xLTEtMjAzNjA_aba121a1-5802-409f-8726-8287433cf6c2"
      unitRef="usd">70000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtMS0xLTEtMjAzNjA_24677c41-63a1-4301-8528-7359bcc20639"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtMy0xLTEtMjAzNjA_af06b5b3-1dce-475a-a560-2bbc37ce2eb4"
      unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtNS0xLTEtMjAzNjA_443c45af-f498-40b0-bdb7-43320898239e"
      unitRef="usd">-149000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTEtNy0xLTEtMjAzNjA_1e2da3e9-55fc-4f1f-a8c1-f4b28374c6f6"
      unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItMS0xLTEtMjAzNjA_50b1a52e-6b34-4dad-b643-b59b8c9b9126"
      unitRef="usd">94000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItMy0xLTEtMjAzNjA_327445df-df04-41da-a4e3-c1d9f752f9d7"
      unitRef="usd">-43000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItNS0xLTEtMjAzNjA_be0a891f-9036-4bbf-ac81-0deeee8ed5d3"
      unitRef="usd">9000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTItNy0xLTEtMjAzNjA_379b8bc3-73bb-4592-8d0b-3b443f2e18c1"
      unitRef="usd">-20000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtMS0xLTEtMjAzNjA_7d67629f-f20c-4fe7-9b25-ec579f2455b3"
      unitRef="usd">-6626000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtMy0xLTEtMjAzNjA_5ce7a17b-b30f-4827-b13e-fcf6fe101e53"
      unitRef="usd">-7190000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtNS0xLTEtMjAzNjA_2657742e-2b98-4a5c-b777-cc56d74469c0"
      unitRef="usd">-13331000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTQtNy0xLTEtMjAzNjA_0f2c75eb-58ee-499a-992b-857f8245675b"
      unitRef="usd">-15253000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtMS0xLTEtMjAzNjA_f2ff4842-328a-4d20-8f24-a5c691eefc7b"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtMy0xLTEtMjAzNjA_d0c8a8ed-dc67-4da7-90dd-fed3fd4704d3"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtNS0xLTEtMjAzNjA_1445bce1-46fa-4185-b6ee-d80df273fb02"
      unitRef="usd">-2479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTUtNy0xLTEtMjAzNjA_ba3f4f4c-9b92-44da-a3d3-e0ca27e9baf0"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtMS0xLTEtMjAzNjA_0c7fe10f-e276-45e5-85ed-f018562dd1bf"
      unitRef="usd">-6626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtMy0xLTEtMjAzNjA_977662a6-25c4-4b2b-9892-6f1c7b83c44b"
      unitRef="usd">-5682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtNS0xLTEtMjAzNjA_cdb6ac01-0dc9-40f2-98cc-a98fb9ef5c63"
      unitRef="usd">-10852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMTgtNy0xLTEtMjAzNjA_aa4f35b5-c80e-4008-b73b-ddf4cea2b90e"
      unitRef="usd">-13745000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMS0xLTEtMjAzNjA_a0526032-8395-41e3-85ed-dc3b7fe0e4ba"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMS0xLTEtMjAzNjA_c7dd9f93-2319-4ef4-9b38-0eff2bac1fb9"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMy0xLTEtMjAzNjA_9c2fd36c-dc16-43d3-9a42-1e964e4e26e7"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItMy0xLTEtMjAzNjA_ffd14dcc-f4b6-44ff-99ea-4f3699a13653"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNS0xLTEtMjAzNjA_7684db9d-aa21-4f31-b5ad-962c966eddfe"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNS0xLTEtMjAzNjA_ac04932f-77b8-4c97-95bc-f8a40d988d48"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNy0xLTEtMjAzNjA_6f6eeecf-700b-4245-b0c4-eb0aa88b9ca0"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjItNy0xLTEtMjAzNjA_725d7ac2-8533-44a0-9617-714f48e18a03"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMS0xLTEtMjAzNjA_69421ae0-18aa-4148-82d4-c784f6e9f7e3"
      unitRef="shares">60533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMS0xLTEtMjAzNjA_bba99ab3-c157-41e8-9837-93afa3e7540f"
      unitRef="shares">60533000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMy0xLTEtMjAzNjA_1a399f05-11a5-4c86-bc80-8e25658eca5d"
      unitRef="shares">59510000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtMy0xLTEtMjAzNjA_447970ac-5fa2-405f-be1a-234b19196f01"
      unitRef="shares">59510000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNS0xLTEtMjAzNjA_a45d68f7-a43a-4167-8465-0b4b6bbeb878"
      unitRef="shares">60546000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNS0xLTEtMjAzNjA_da36d905-c40c-40ba-ba03-3f84e2ed2b06"
      unitRef="shares">60546000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNy0xLTEtMjAzNjA_30ca7c2f-eb96-4b51-9ade-bb59a6bb9e62"
      unitRef="shares">50862000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8xOS9mcmFnOjVjYzMzMjI5ZWYyMTRmNWVhMjVkNDBlMDI5ZTVkNjljL3RhYmxlOmJlMWZmMGViZDhlYTQxM2ZiYTc2NTZmMTZmMmJlNGZiL3RhYmxlcmFuZ2U6YmUxZmYwZWJkOGVhNDEzZmJhNzY1NmYxNmYyYmU0ZmJfMjUtNy0xLTEtMjAzNjA_daf15435-9961-42ab-aaa8-92e5297524a0"
      unitRef="shares">50862000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi0xLTEtMS0yMDM2MA_d3bbf3b3-4ad8-496e-9366-d1027c6c1304"
      unitRef="usd">-6626000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi0zLTEtMS0yMDM2MA_ad3f4e11-7595-4da5-9055-874f4b471c3f"
      unitRef="usd">-5682000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi01LTEtMS0yMDM2MA_dc7e5961-88e1-4c12-a4eb-b6d98e4b8526"
      unitRef="usd">-10852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMi03LTEtMS0yMDM2MA_e08c004f-70d0-4303-9bba-968ba53a3b70"
      unitRef="usd">-13745000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS0xLTEtMS0yMDM2MA_cab84911-c12a-4925-8730-928732fafdf9"
      unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS0zLTEtMS0yMDM2MA_64a66cbd-d3af-4555-9695-a28d66abde93"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS01LTEtMS0yMDM2MA_5a262f60-7fd0-47d6-bb54-56846e921fd9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNS03LTEtMS0yMDM2MA_ce780232-a3b2-496a-9d25-c2aa2e9eccdf"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi0xLTEtMS0yMDM2MA_b66bd60e-2bc8-4eaf-8d42-46c387ea05ad"
      unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi0zLTEtMS0yMDM2MA_32a2158d-8d47-4200-8e91-ae9893fc0dc4"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi01LTEtMS0yMDM2MA_c4c9b122-e48b-4d57-b564-ce418062b365"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfNi03LTEtMS0yMDM2MA_ec6d7342-8606-4e0b-909d-902439c64411"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItMS0xLTEtMjAzNjA_c8f823a3-31a1-4ef1-9c90-d64384c1a188"
      unitRef="usd">-6500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItMy0xLTEtMjAzNjA_7e47396f-bf4a-45b6-8a15-066d79c90f8e"
      unitRef="usd">-5686000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItNS0xLTEtMjAzNjA_dc2ea0f7-896b-4374-b668-c997533dd1f7"
      unitRef="usd">-10852000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yMi9mcmFnOmE1NWM5MmMxMDkyYzQwMmVhOTFhMzk0N2ZhZjVhZTRlL3RhYmxlOmFhNjkyNmFjMDQ3MTQ1OWZiNjdjMDhjZWU0NmZhODhjL3RhYmxlcmFuZ2U6YWE2OTI2YWMwNDcxNDU5ZmI2N2MwOGNlZTQ2ZmE4OGNfMTItNy0xLTEtMjAzNjA_7f52c839-ef76-4163-abc9-6ec86582deb1"
      unitRef="usd">-13749000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i826be2afc3e749308a9751d74830964a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_1638f7bf-46d4-4adb-bf11-412392e12518"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i826be2afc3e749308a9751d74830964a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_ee6f9f92-711f-4634-82f4-142fbb104c88"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i826be2afc3e749308a9751d74830964a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xLTEtMS0yMDM2MA_f85e2175-6756-4d58-b01e-f51a56beb57c"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i826be2afc3e749308a9751d74830964a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0zLTEtMS0yMDM2MA_1c1b4a12-4baa-4e2d-8a64-b4cdd634f9aa"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i144cc71857f7429bb51d544f0b8f9310_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi01LTEtMS0yMDM2MA_ab2b967a-9347-4491-8c5c-fa43da6ede5b"
      unitRef="shares">60544000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i144cc71857f7429bb51d544f0b8f9310_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi03LTEtMS0yMDM2MA_46515b87-42d3-4fbc-bc44-b902e6f39b3f"
      unitRef="usd">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7256a903af4b431abebe6883b6c15999_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi05LTEtMS0yMDM2MA_6a0dfa4d-cccb-4234-aa3a-7d585f2ccd87"
      unitRef="usd">546580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5008ebb64ec147a187a521f9673cad8e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xMS0xLTEtMjAzNjA_06789f19-8e68-4a82-8d20-0a4eeaf7a55a"
      unitRef="usd">-196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7b06dfb1afa472fb9d01295762e7c9e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xMy0xLTEtMjAzNjA_11901f33-987d-4893-a464-4f58b5a0e668"
      unitRef="usd">-457242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i939cc2c2c6074c0c982765101de3e1fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xNS0xLTEtMjAzNjA_30a7980a-782d-456b-ad4f-403222754118"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i210747314c0e49419773d046301904e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xNy0xLTEtMjAzNjA_b5052771-5fea-417d-97e6-a938eeb7c7bc"
      unitRef="usd">88495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89ed3ac0e8cc48fd808c48dea00e34fe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0xOS0xLTEtMjAzNjA_78b786e3-61b4-4b91-ac95-e26d5d534bb1"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31306c1aab0247159feb2af89726ee3f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMi0yMS0xLTEtMjAzNjA_3cc6231e-f18b-41e1-98f9-90d43cea1594"
      unitRef="usd">88241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0a0e8a04a5dd47a2955a1779dfb31298_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0xMy0xLTEtMjAzNjA_edf167e7-283b-4c3e-8eeb-552195f9cf86"
      unitRef="usd">-6626000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0xNy0xLTEtMjAzNjA_f341a27a-68f6-4804-a359-872bd17aa3ad"
      unitRef="usd">-6626000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMy0yMS0xLTEtMjAzNjA_db5573e8-f179-4022-b727-a9a0bc4ffd0f"
      unitRef="usd">-6626000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1123d58c65b6489e899c1698307885f5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0xMS0xLTEtMjAzNjA_81e22ae7-cf7a-4b32-93ad-823c5f679dd0"
      unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0xNy0xLTEtMjAzNjA_444aed04-5289-45d7-b3c9-7e0dec7cba74"
      unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNC0yMS0xLTEtMjAzNjA_3813266a-791a-4a62-aa8e-b3dfc0398a35"
      unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS01LTEtMS0yMDM2MA_a938f9d6-9549-4491-871e-761a868ac1b9"
      unitRef="shares">-15000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS05LTEtMS0yMDM2MA_eb79f6a1-c10d-447d-9302-5c2403b14923"
      unitRef="usd">367000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS0xNy0xLTEtMjAzNjA_33e1723c-f517-4702-8dca-29694939296a"
      unitRef="usd">367000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNS0yMS0xLTEtMjAzNjA_2109c702-d09e-4423-8ab5-c2bf8722efae"
      unitRef="usd">367000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c0c0a35c5a3420ab434d6f775303b5e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi01LTEtMS0yMDM2MA_6595dd45-c87d-4e34-a686-2b758ede1c68"
      unitRef="shares">65000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i250ae58aa61b4f95bc1b4fd0dc4abfb0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi05LTEtMS0yMDM2MA_410ff332-45a4-44cc-bcff-277a48018ccc"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i925b8acdcb664e7a8129e830adf35df2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi0xNy0xLTEtMjAzNjA_1a4bb583-0701-4e90-ba8e-549a67a92e18"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfNi0yMS0xLTEtMjAzNjA_95831b43-2adf-42a0-af7b-6e41631e646f"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xLTEtMS0yMDM2MA_667ea17f-6ae7-40c9-9b79-931c34752add"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0zLTEtMS0yMDM2MA_85597fe9-6a06-4945-a082-fc1f5dfaeaf0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS01LTEtMS0yMDM2MA_965cdc6a-4ea5-459b-9077-9bf8a213c294"
      unitRef="shares">60594000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS03LTEtMS0yMDM2MA_06942d96-9dcf-491f-8c99-3cf2ebf03f57"
      unitRef="usd">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a24b47dd254dc19e95b10e49ccbed7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS05LTEtMS0yMDM2MA_d6e5d19b-757d-4324-9de3-77fba0e276be"
      unitRef="usd">546976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bed893df04e44c1ad362c17a93cfdaf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xMS0xLTEtMjAzNjA_ef8d7109-16a8-42ca-abbf-d0306078654d"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18265c74af504470b75337fdb7546118_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xMy0xLTEtMjAzNjA_359644ff-1af8-4089-b1de-de3578999098"
      unitRef="usd">-463868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3285245ca04f458aa72087031b59e41b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xNS0xLTEtMjAzNjA_6807c491-4e35-45c0-a10d-5dc452101853"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xNy0xLTEtMjAzNjA_13da9c32-e7cd-4473-8bc8-3642df3178d9"
      unitRef="usd">82391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie84bb799d59f441f8d0036b10575869f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0xOS0xLTEtMjAzNjA_92dc2b90-97b2-4ef8-857f-0e65210a234c"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfOS0yMS0xLTEtMjAzNjA_e8a99f19-040e-43f1-9315-7f88efd9609d"
      unitRef="usd">82137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMS0xLTEtMjAzNjA_fdfa2ca1-ecd1-4156-b288-f685b41d3db7"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2ffc81d02dc4ce7bd0e9d5671125019_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMy0xLTEtMjAzNjA_c707f6eb-78a8-4bfc-b8df-99dee0c1f0c0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtNS0xLTEtMjAzNjA_305dea48-9e66-49cd-8241-a81871c4bc54"
      unitRef="shares">59801000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbdafdaa62d24f59a6a5ce4ee6b7c994_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtNy0xLTEtMjAzNjA_f67639ec-0e35-4811-a581-f9418853733c"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c77282d142f4fb59c41c5f204dbfe92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtOS0xLTEtMjAzNjA_a508ec91-e8a4-4590-9ad0-cbcda1e03ad0"
      unitRef="usd">545988000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b047433f88e46ecbc8f6948247e2441_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTEtMS0xLTIwMzYw_0ee3606a-7c64-4939-a5ea-9b946d0d7386"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c105eba1be9452dbca6993cb4fae77b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTMtMS0xLTIwMzYw_76dc3113-0450-4ff8-855e-92aa6c9bac71"
      unitRef="usd">-453016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa027f593cfd45789ab829afc443cd85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTUtMS0xLTIwMzYw_9efaa2f0-ab17-41d7-8250-9013e9ac6e84"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7b9cf1c6314423d88f7c7d52b11e494_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTctMS0xLTIwMzYw_f8852cd4-2f93-4c2f-8dac-4b1da1b20893"
      unitRef="usd">92254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifade1f65a2fc44a9a294052965852540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMTktMS0xLTIwMzYw_b93e0ed2-8e01-45ef-9781-92cce8af4a27"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTMtMjEtMS0xLTIwMzYw_7fda6695-5925-4852-bfe6-ff5827050999"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1246f6d72c59416bb70643adff3c35cb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMTMtMS0xLTIwMzYw_b347b50c-f843-4f2a-9dc8-27826e40b664"
      unitRef="usd">-10852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMTctMS0xLTIwMzYw_cd18c3fe-158d-435d-a5d4-2cfaa053e7b8"
      unitRef="usd">-10852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTUtMjEtMS0xLTIwMzYw_10c4dcdd-a0fc-4a33-bb24-db24d24834b4"
      unitRef="usd">-10852000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctNS0xLTEtMjAzNjA_6584c6f2-8bd4-4213-a162-d26d1909d032"
      unitRef="shares">728000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctNy0xLTEtMjAzNjA_56ee592d-25fd-4a1a-af01-87e3a7f89d35"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctOS0xLTEtMjAzNjA_738e4919-ea8c-47f9-9261-fb66ea586e6f"
      unitRef="usd">959000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctMTctMS0xLTIwMzYw_014688ae-2d8b-4631-968e-9a368e03bf51"
      unitRef="usd">960000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTctMjEtMS0xLTIwMzYw_99b0053b-dc81-4c4a-83cf-9b5d8e2e745b"
      unitRef="usd">960000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtNS0xLTEtMjAzNjA_a432c79f-24fd-4d19-8baa-7c66defa4fb0"
      unitRef="shares">65000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic4dfa2a63f0d40718b6e42289b43ca37_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtNy0xLTEtMjAzNjA_ce060ff3-acae-4d0b-bafc-0f20f76b2b4a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i04ebc715c6244e168a87ffcfa86716b1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtOS0xLTEtMjAzNjA_c59f59c9-7d29-4cc7-807d-26a2205b0fac"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic975a5b926d647608f98ce85f0102f2e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtMTctMS0xLTIwMzYw_73de6f1a-9025-40f0-a5f8-230acf35f99f"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMTgtMjEtMS0xLTIwMzYw_6e2ac21e-b1c1-461f-af89-87b19e0108ad"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMS0xLTEtMjAzNjA_9c011e9f-ffd7-4d56-adb0-3ed663203037"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3acaa30e875044229e6d0b25653dfa68_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMy0xLTEtMjAzNjA_e0fc36b1-e321-490b-9d5d-bd46df74031e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtNS0xLTEtMjAzNjA_48e66ded-127d-4ac8-9270-f7b03ae731d9"
      unitRef="shares">60594000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2302b303b3d24af1bcafe4350909d9ee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtNy0xLTEtMjAzNjA_1e62d892-f136-4b01-a01c-30bd606583fc"
      unitRef="usd">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a24b47dd254dc19e95b10e49ccbed7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtOS0xLTEtMjAzNjA_62b480e9-4f10-42c2-a03d-8014d99284fa"
      unitRef="usd">546976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6bed893df04e44c1ad362c17a93cfdaf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTEtMS0xLTIwMzYw_7a31190a-15a8-4829-8348-6123f7b42a28"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18265c74af504470b75337fdb7546118_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTMtMS0xLTIwMzYw_582dc3f9-7e34-4005-a1ed-f2036fb53e7c"
      unitRef="usd">-463868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3285245ca04f458aa72087031b59e41b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTUtMS0xLTIwMzYw_46077275-6191-4ad4-b845-c3afefb29b03"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i807ec609e7de4274a4da5a0dd02a1a4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTctMS0xLTIwMzYw_f60e5d1c-e6bc-48f1-acca-a49bd619cfd4"
      unitRef="usd">82391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie84bb799d59f441f8d0036b10575869f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMTktMS0xLTIwMzYw_3712f806-a538-4c96-9fe3-ccdaca24ddc4"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjFlNTBjYzQwNjA3ZTRlYmE4OGFjOTk2NWZkYzQzOTVhL3RhYmxlcmFuZ2U6MWU1MGNjNDA2MDdlNGViYTg4YWM5OTY1ZmRjNDM5NWFfMjEtMjEtMS0xLTIwMzYw_130cb90c-d8fb-40c1-8b22-48aa5f89cf79"
      unitRef="usd">82137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia3384336a7944494b8cb1446514d3f7e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xLTEtMS0yMDM2MA_f3af4651-b986-4d08-af54-4a9d045e8b02"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3384336a7944494b8cb1446514d3f7e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0zLTEtMS0yMDM2MA_17ec84bc-aab2-424b-80a7-5f6fdda3395b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi01LTEtMS0yMDM2MA_e9be90a6-9d7e-47dd-aad5-1191a2cfd247"
      unitRef="shares">59510000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iceb0ebb2d4d940c381c7a3fc25607d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi03LTEtMS0yMDM2MA_3c6d00ba-162b-4f66-ab22-ac75bdb18085"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd00509623ed44ddb8f0004f1abf6120_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi05LTEtMS0yMDM2MA_44f28e41-2eef-4064-b61f-f8638d5260bb"
      unitRef="usd">544601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88c32da30d114addbead3f239466b8e9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xMS0xLTEtMjAzNjA_cd2d6592-d52f-4b68-8ee8-af766533a4a6"
      unitRef="usd">-72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78c2932e69ef4d54ac788754fdca2d18_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xMy0xLTEtMjAzNjA_f074ffd3-7c53-4487-9c84-8c6dec5eea89"
      unitRef="usd">-433613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6af4cb66e154f95939adbff59e13392_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xNS0xLTEtMjAzNjA_c4ed690c-b841-43ad-8f36-d8589a7f3890"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9599115241c54766a1a636684b8b060e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xNy0xLTEtMjAzNjA_64e147d9-99b9-44ce-8159-9069c6bb5bdf"
      unitRef="usd">110268000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ad465c32b5844118f00a809aaff3997_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0xOS0xLTEtMjAzNjA_e5f992a2-4c7f-476a-9e94-6144eceacf5e"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b43e8ae838c493d815ea92bdae4b1fc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMi0yMS0xLTEtMjAzNjA_715d4f47-f56e-4238-a685-0fd1c3914be1"
      unitRef="usd">110014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i603559893c614cd2912e389072705619_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0xMy0xLTEtMjAzNjA_6e4014d9-855a-4c20-a655-6ff79d0b7a16"
      unitRef="usd">-5682000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0xNy0xLTEtMjAzNjA_d9915101-f81d-4be8-8d70-0f73a7b4bc68"
      unitRef="usd">-5682000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMy0yMS0xLTEtMjAzNjA_1b28a9c6-4c44-4627-b6c4-141ec5ff0192"
      unitRef="usd">-5682000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7a4c8cad9db9466db265fc7fc23b3c86_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0xMS0xLTEtMjAzNjA_a1353bc7-90c7-44c0-bec6-697c3e91981d"
      unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0xNy0xLTEtMjAzNjA_7de8edb3-0870-47ef-a932-3de26eea5569"
      unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNC0yMS0xLTEtMjAzNjA_b2074ec5-cb14-412a-9ef7-d07f6c34e2eb"
      unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4b57810d948345c6bc01749f37102642_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS05LTEtMS0yMDM2MA_801f875e-04c1-46bc-b414-9439aadaa4ba"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS0xNy0xLTEtMjAzNjA_a438e982-7829-458c-bdfa-ae41abd2abe0"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNS0yMS0xLTEtMjAzNjA_68527e79-f524-4bc3-8257-da1037089b01"
      unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi01LTEtMS0yMDM2MA_c4fa84a5-ee1e-48f6-aea7-671a7cbfcdd5"
      unitRef="shares">19000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i464a5faae5704d479b2a1bf1da0c8816_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi03LTEtMS0yMDM2MA_c247b5b0-3ae6-4977-ad43-d5bf7ecd53e4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b57810d948345c6bc01749f37102642_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi05LTEtMS0yMDM2MA_fccf4540-83e5-4f75-8ed6-6548182dbec6"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i65449c0457314898a5bd53ecab85713e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi0xNy0xLTEtMjAzNjA_0deb88fc-40b0-4000-8868-26f7bc14ed5a"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfNi0yMS0xLTEtMjAzNjA_b16883f4-cea3-412e-b7d6-8f2c4615e19e"
      unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xLTEtMS0yMDM2MA_f747dc02-1dfb-462c-aed2-a27f47d2d495"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0zLTEtMS0yMDM2MA_499ec592-fed6-4d2f-b072-5147f6752051"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS01LTEtMS0yMDM2MA_5e9251e2-592c-4d1f-83f6-8748567898cd"
      unitRef="shares">59529000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS03LTEtMS0yMDM2MA_7df58f32-561c-4d20-8695-d11eb1ecc663"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id525428cb5044f9dad07f0198a966b18_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS05LTEtMS0yMDM2MA_ef0d1e0c-b809-4681-aa84-19654b126267"
      unitRef="usd">544893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xMS0xLTEtMjAzNjA_31e6dc75-0c28-4a7e-abc1-7f9f21950a09"
      unitRef="usd">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xMy0xLTEtMjAzNjA_fc2be709-8296-4817-b82a-9df24e62e8a6"
      unitRef="usd">-439295000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNS0xLTEtMjAzNjA_128cb016-3c1d-499b-9a4c-4aabb9a54403"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNS0xLTEtMjAzNjA_821dc3db-2050-445b-af2c-1f89e54deb51"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xNy0xLTEtMjAzNjA_b9350a0e-58d5-4ac9-8796-0d262ea47875"
      unitRef="usd">104933000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4aa152b86594c1daab508f7a3371e7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0xOS0xLTEtMjAzNjA_24ad045c-fb6f-4cf0-b0f6-1233a3a4f57e"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfOS0yMS0xLTEtMjAzNjA_9af7c39c-0a5c-43f3-b819-9a7a79a19f7d"
      unitRef="usd">104679000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i11509a49300e4d2cad12d712bd9a7433_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMS0xLTEtMjAzNjA_e4106993-e811-47a1-8d9d-1f63cbb958be"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11509a49300e4d2cad12d712bd9a7433_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMy0xLTEtMjAzNjA_323dea8c-de26-4661-bca2-b959a1c3ae5d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtNS0xLTEtMjAzNjA_bb55cec7-27e8-4d3e-b995-df6468966612"
      unitRef="shares">19389000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if71bffe6bcc145dcaee16b5a8e96b4af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtNy0xLTEtMjAzNjA_4ef518c2-b122-4a93-a6ec-ba1040e759fd"
      unitRef="usd">19000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7c51dda04204b5ea7441d1f68c81706_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtOS0xLTEtMjAzNjA_8c93266e-a287-478b-9e0f-3751e639aa76"
      unitRef="usd">458748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92a95e7cdc8d4bc1ad9b84ffd5e3f68b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTEtMS0xLTIwMzYw_874bc0bf-6e6a-4e33-9429-81ba092b6e4b"
      unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6aedcf6bdef487f875f1aafded60667_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTMtMS0xLTIwMzYw_508e87f3-7216-4b99-9584-d4379810c10d"
      unitRef="usd">-425550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1573c590f9ad4ed5bbed7597658b47ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTUtMS0xLTIwMzYw_4bf0b7cd-687e-4c5f-91dd-b05494c4eb3b"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8a41562d90542fdbfbc872ae7d68b02_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTctMS0xLTIwMzYw_446f3176-16b0-4ea3-9cf7-09a060281976"
      unitRef="usd">32496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib04d15ea5e1d45368d6e6e3fe784f7e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMTktMS0xLTIwMzYw_070e771f-089a-400d-8bfb-89f876954574"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTMtMjEtMS0xLTIwMzYw_6233b26a-2b62-4de8-9ecb-f45ee169c852"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1920cbc31b314e8681271adf19a0cce4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMTMtMS0xLTIwMzYw_784a98d7-a064-400c-8ce9-824d4b920571"
      unitRef="usd">-13745000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMTctMS0xLTIwMzYw_9893c7d1-def3-4129-bd57-3aaf8b9b9832"
      unitRef="usd">-13745000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTUtMjEtMS0xLTIwMzYw_dbb98d6e-969b-4b71-8158-f0a14a25b1a6"
      unitRef="usd">-13745000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i052a9e1cdcbe4746bce1dc6273233d80_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMTEtMS0xLTIwMzYw_61ccffca-550e-475a-afb6-4b4f939e7714"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMTctMS0xLTIwMzYw_a5e8aa26-53f8-435f-85cf-c0366099fe06"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTYtMjEtMS0xLTIwMzYw_905e36de-f2f1-4d27-895f-556ecdd841d1"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctNS0xLTEtMjAzNjA_6ac46fc1-7a59-45b8-83ee-33db3daac138"
      unitRef="shares">273000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctOS0xLTEtMjAzNjA_948ebc70-0d69-4298-8b87-12eb9eda8581"
      unitRef="usd">683000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctMTctMS0xLTIwMzYw_f76069e0-67a7-4c0e-8f56-a744674186c1"
      unitRef="usd">683000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTctMjEtMS0xLTIwMzYw_efb284a9-021c-4ef6-8fa7-1ebaf740b949"
      unitRef="usd">683000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtNS0xLTEtMjAzNjA_7005bfd5-bfc4-4d0d-b320-a30a2e2b57c7"
      unitRef="shares">39860000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtNy0xLTEtMjAzNjA_9fdbfba4-834d-471d-86e1-414937fea460"
      unitRef="usd">41000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtOS0xLTEtMjAzNjA_a3a54fdd-9bd9-422b-b3a2-335c6175f81c"
      unitRef="usd">85438000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtMTctMS0xLTIwMzYw_9983ef26-b8e1-42ba-864a-33f4300c2142"
      unitRef="usd">85479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTgtMjEtMS0xLTIwMzYw_dbccf54d-d1f6-45fd-91d0-c50950b1eef1"
      unitRef="usd">85479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6338cfcfd39e40b1ba56500c3796883a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktNS0xLTEtMjAzNjA_71ccf796-3605-4c7d-b56b-354aa9c75e2d"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i94f466cdac444ce8af71425f2d1af6e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktOS0xLTEtMjAzNjA_e5ab5b5e-7575-4646-aa60-78e8e910085f"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5795d8b08e2d46bab20523feb0c9dcf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktMTctMS0xLTIwMzYw_a7d33ca4-cad4-42a9-bc6d-0fd5d24c483b"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMTktMjEtMS0xLTIwMzYw_9e1af3e9-63ed-4ef2-b50f-47930694f7d0"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMS0xLTEtMjAzNjA_ebbcd55a-00ad-402d-b71b-5a435f02a337"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icff1dcadd5124a7ba11055ac74a67ee4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMy0xLTEtMjAzNjA_83c5d3db-e0f5-4ec3-9d94-4ab5f110e1e9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtNS0xLTEtMjAzNjA_9497b17e-a406-4466-92d9-1893a00dc2fe"
      unitRef="shares">59529000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i840c3e9cbefb43e9b146dfd41f33662f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtNy0xLTEtMjAzNjA_bfc7dd68-ab5b-4690-a467-e6d3c0a24534"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id525428cb5044f9dad07f0198a966b18_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtOS0xLTEtMjAzNjA_2615bef3-d8eb-4b2e-84da-d1bc7c907edc"
      unitRef="usd">544893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b4e5ebdb4f84ab4bd17a6ae816b4213_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTEtMS0xLTIwMzYw_4a3beff4-bf46-469d-86e0-0eb56e31c7f0"
      unitRef="usd">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9534f6dbe4c24639b520c6dcb4e375bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTMtMS0xLTIwMzYw_0c24463e-f5a7-46d3-bfaa-de26afdf29e3"
      unitRef="usd">-439295000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc9dad9b784949389c4d72d8f2d7f7fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTUtMS0xLTIwMzYw_d254625e-4df7-45c6-8f14-8c30e4ce0766"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcb6afa9a16c479c9619b35b9ea16a19_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTctMS0xLTIwMzYw_db8ebe49-d2b3-4f65-bc26-650bdee87f95"
      unitRef="usd">104933000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4aa152b86594c1daab508f7a3371e7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMTktMS0xLTIwMzYw_fffb59e1-6f88-4613-b2e4-baa6bdf395e8"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yNS9mcmFnOjkzMWQ3ZGRlYTNmZTRkNWE4OTRlM2IxY2IxMzYzYWQ3L3RhYmxlOjI5NTAwOGE3NGZmMDRiNDc4Y2QzOTA1ODgyZTBjZDMzL3RhYmxlcmFuZ2U6Mjk1MDA4YTc0ZmYwNGI0NzhjZDM5MDU4ODJlMGNkMzNfMjEtMjEtMS0xLTIwMzYw_fd10a50d-0491-49e8-b3c5-226d2351e759"
      unitRef="usd">104679000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMy0xLTEtMS0yMDM2MA_0d52e56e-dda2-423d-ab75-63ae34433aa9"
      unitRef="usd">-10852000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMy0zLTEtMS0yMDM2MA_b8946df4-6ebf-42ae-9b4f-02e086703cae"
      unitRef="usd">-13745000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNS0xLTEtMS0yMDM2MA_53a2daa5-d7ab-4939-8d4f-b2d4c5022d8f"
      unitRef="usd">1128000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNS0zLTEtMS0yMDM2MA_af6c5881-6f76-41d2-a73f-743307321d21"
      unitRef="usd">867000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNi0xLTEtMS0yMDM2MA_93899255-4291-4d58-8d54-24656bd709f5"
      unitRef="usd">14000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfNi0zLTEtMS0yMDM2MA_b0bf4537-4753-48e6-b17d-0222e8fbc155"
      unitRef="usd">33000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfOS0xLTEtMS0yMDM2MA_e2246424-52c3-4565-9539-a482d2a4de7e"
      unitRef="usd">-900000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfOS0zLTEtMS0yMDM2MA_c4f2aa91-824d-4c57-88b3-096cecfaaaf8"
      unitRef="usd">-1133000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTEtMS0xLTEtMjAzNjA_de5f9b81-7511-4c29-90a9-a31f1b4afd3d"
      unitRef="usd">744000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTEtMy0xLTEtMjAzNjA_3ee88200-0684-4de9-ac3f-833ac0137f35"
      unitRef="usd">1232000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTItMS0xLTEtMjAzNjA_1f9cc056-39b7-4c6e-a49a-49a3eda6c248"
      unitRef="usd">-118000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTItMy0xLTEtMjAzNjA_692f20e0-66c3-4350-b34e-31ed09736f6c"
      unitRef="usd">-166000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTMtMS0xLTEtMjAzNjA_f55857f9-f5b0-4c3c-9046-03e39cb15f25"
      unitRef="usd">-1268000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTMtMy0xLTEtMjAzNjA_017c0ee6-d473-4553-b382-b066fdb03f07"
      unitRef="usd">176000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTQtMS0xLTEtMjAzNjA_b08d7043-7382-4c7a-a325-9c46805e466c"
      unitRef="usd">-10704000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTQtMy0xLTEtMjAzNjA_4d96deb6-032b-4a17-91fc-9f7498bfc173"
      unitRef="usd">-12602000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTYtMS0xLTEtMjAzNjA_e5674435-8626-49f4-8c53-969921b30120"
      unitRef="usd">30291000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTYtMy0xLTEtMjAzNjA_82eeec67-da61-45a1-ba42-fa902dcfdbd8"
      unitRef="usd">105792000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTctMS0xLTEtMjAzNjA_8759fcc4-7314-4c05-bb8e-41acdeb2a3d3"
      unitRef="usd">60070000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTctMy0xLTEtMjAzNjA_75282651-a163-4459-b76a-3f2bdfa8a57f"
      unitRef="usd">29558000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTgtMS0xLTEtMjAzNjA_e5ab22d8-64bc-40cf-99d2-6ac2eb3dcc9e"
      unitRef="usd">235000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTgtMy0xLTEtMjAzNjA_1fcb8772-62b2-4d88-ae44-37d37534350f"
      unitRef="usd">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMS0xLTEtMjE1NDQ_59ae514d-ed03-4031-b4f8-98afb4aa50d5"
      unitRef="usd">10000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMy0xLTEtMjE1NTE_5ccb8733-b27d-466b-ae4a-dc3feaf74873"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMS0xLTEtMjAzNjA_00d87df8-00a6-4b73-bb43-f5ca07e4fcca"
      unitRef="usd">19544000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMTktMy0xLTEtMjAzNjA_efd01db6-55ea-4700-9fe7-b17ab86cb542"
      unitRef="usd">-76294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjEtMS0xLTEtMjAzNjA_3f1b0e67-9412-4fc8-9244-3488bdc1b21f"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjEtMy0xLTEtMjAzNjA_959019cd-ceef-4ea9-8331-81433da208b3"
      unitRef="usd">24000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjItMS0xLTEtMjAzNjA_699e2f88-430e-4995-9f1c-9ff6c4e9bd26"
      unitRef="usd">168000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjItMy0xLTEtMjAzNjA_a205fab6-9125-4314-b781-8f66fc0f182a"
      unitRef="usd">184000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjMtMS0xLTEtMjAzNjA_1e35468d-6d17-48fd-b1fb-8387dac0bfab"
      unitRef="usd">29000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjMtMy0xLTEtMjAzNjA_4d43769a-eba0-4882-8e71-76e91eec3479"
      unitRef="usd">85479000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjUtMS0xLTEtMjAzNjA_9ed4a323-0bb0-4666-9f8f-4fb3c90c4163"
      unitRef="usd">-139000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjUtMy0xLTEtMjAzNjA_77a4b12e-cad6-4176-a865-35baa60901be"
      unitRef="usd">85319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjYtMS0xLTEtMjAzNjA_4a32edc4-0c65-44ae-9cb1-e173f9a48896"
      unitRef="usd">8701000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjYtMy0xLTEtMjAzNjA_f2949196-8790-480a-a566-686281005409"
      unitRef="usd">-3577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjctMS0xLTEtMjAzNjA_526dea1e-88d6-4584-82e1-6083fec9a1aa"
      unitRef="usd">24647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic7d258e44d2949bf8e8213c5ccc971d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjctMy0xLTEtMjAzNjA_e92f504f-22f4-4b44-aaba-12bebc68eafa"
      unitRef="usd">16512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjgtMS0xLTEtMjAzNjA_6777f4a5-79de-4d09-9e3f-601e78386b2a"
      unitRef="usd">33348000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ief022a2aaa62471fba1ace6d10742f26_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8yOC9mcmFnOjliZmUwYmVmYWMyNTRmYWFiNDlkYzMyNDI0MGJkODU0L3RhYmxlOjM1OThmNWI2YWE4ZTQ0ZDI4ODY5NWY0N2E3NTBkYTk5L3RhYmxlcmFuZ2U6MzU5OGY1YjZhYThlNDRkMjg4Njk1ZjQ3YTc1MGRhOTlfMjgtMy0xLTEtMjAzNjA_a41ff09e-80b5-42a5-8181-f016d86df5aa"
      unitRef="usd">12935000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <clbs:BusinessTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ3OTg_b551a274-0a3b-4b31-a571-ff72e197a0e5">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius Biosciences, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;Caladrius&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical product development experience in a variety of therapeutic categories. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#x2019;s current product candidates include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#x201c;CMD&#x201d;); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#x201c;CLI&#x201d;) and Buerger&#x2019;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for Buerger's disease; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;CLBS201, the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#x201c;DKD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;On April 26, 2022, the Company and Cend Therapeutics, Inc., a Delaware corporation (&#x201c;Cend&#x201d;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, a wholly-owned subsidiary of Caladrius will merge with and into Cend, with Cend surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;), subject to the terms of the Merger Agreement and stockholder approval of the transaction. Under the exchange ratio formula, as of immediately after the Merger, the former Cend stockholders are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock and the Company&#x2019;s stockholders as of immediately prior to the Merger are expected to own approximately 50% of the outstanding shares of Caladrius Common Stock.  The actual allocation will be subject to adjustment based on our net cash balance at the time of closing and the amount of any transaction expenses of Cend in excess of $250&#160;thousand at the time of closing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ischemic Repair (CD34+ Cell Technology)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's proprietary cell technology using autologous (a patient&#x2019;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including but not limited to Buerger's disease, CLI, CMD, and DKD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of Coronary Microvascular Dysfunction&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept, open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease and was expected to complete enrollment in approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;as well as with a contrast agent typically used in many catheter laboratories. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intends to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; in subjects with CMD and corroborate the ESCaPE-CMD study results.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The interim analysis is expected to be completed in the third quarter of 2022, and the next steps in development of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:107%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; will subsequently be determined after appropriate regulatory and business review, expected to be announced prior to year-end 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of Critical Limb Ischemia&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's randomized, open-label, registration-eligible study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius suspended further enrollment in the fourth quarter of 2021. Following study suspension, the Company completed all protocol-defined patient observations and is preparing the clinical study report. HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; is now in the pre-consultation phase of the registration process with the Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;) in Japan.  Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan has been compiled and is expected to be reviewed by PMDA during the third quarter of 2022 after which the PMDA is expected to provide important perspective to be considered in preparation for the formal consultation meetings which precede the Japanese new drug application. The Company is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in Japan. This may include the completion of enrollment of the four-remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's PMDA under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt of orphan designation from FDA in March 2021 in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue U.S. development in Buerger's disease at this time.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CLBS201 for Treatment of Diabetic Kidney Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol includes six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#x201c;DSMB&#x201d;) overseeing the study then permitted the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. The Company treated the first patient in the CLBS201 proof-of-concept study in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects by the first quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Out-licensing Opportunities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;end Merger Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2022, the Company and Cend entered into the Merger Agreement. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Cend and the Company&#x2019;s satisfaction of a minimum net cash threshold at closing, expected to be approximately $64.9&#160;million assuming a closing at the end of the third quarter of 2022, and as described further in the Merger Agreement. The Merger Agreement contains certain termination rights for both the Company and Cend, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Cend a termination fee of $1.0&#160;million, Cend may be required to pay the Company a termination fee of $4.0&#160;million, or in some circumstances reimburse the other party&#x2019;s expenses up to a maximum of $1.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the effective time of the Merger, the Company&#x2019;s Board of Directors is expected to consist of nine members, four of whom will be designated by the Company, four of whom will be designated by Cend and one member who will be mutually agreed between the Company and Cend.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to provide Cend with capital for its development programs prior to the closing of the Merger, the Company and Cend entered into a Series D Preferred Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;), pursuant to which the Company purchased from Cend 1,135,628 shares of Series D Preferred Stock, $0.00001 par value per share (the &#x201c;Series D Preferred Stock&#x201d;), of Cend at a purchase price per share equal to $8.8057 per share (the &#x201c;Series D Original Issue Price&#x201d;), or approximately $10&#160;million in the aggregate. The Series D Preferred Stock ranks senior to Cend&#x2019;s common stock and the other series of preferred stock with respect to rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of Cend. The Series D Preferred Stock has a liquidation preference equal to the Series D Original Issue Price plus an amount equal to any accrued and unpaid dividends to the date of payment and will participate with Cend&#x2019;s common stockholders and other preferred stockholders thereafter on an as-converted basis. The Series D Preferred Stock shall vote with the common stock on an as-converted basis on any matters presented to the stockholders of Cend.  Each share of Series D Preferred Stock is convertible, at the option of the holder thereof, into such number of shares of Cend common stock as is determined by dividing the Original Issue Price by the conversion price in effect at the time of conversion, which conversion price shall be the Original Issue Price as appropriately adjusted for stock splits, stock dividends, combinations, and subdivisions of Cend common stock, and as adjusted pursuant to a weighted-average antidilution adjustment. The Series D Preferred Stock will automatically convert into shares of Cend common stock upon the closing of a firm-commitment underwritten initial public offering implying a pre-equity offering value of at least $250&#160;million, resulting in at least $50&#160;million of gross proceeds to Cend. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with such Purchase Agreement, Cend entered into a Collaboration Agreement (the &#x201c;Collaboration Agreement&#x201d;), pursuant to which the Company agreed to collaborate with Cend on certain developmental and clinical activities prior to the closing of the Merger. Pursuant to the Collaboration Agreement, the Company and Cend have formed a joint steering committee (the &#x201c;Committee&#x201d;) comprised of individuals from both entities. The Committee meets regularly and is responsible for monitoring ongoing studies and making recommendations for development activity and trial planning. Cend has agreed to pay each member of the Committee from the Company an hourly consulting fee for such service.  As of June 30, 2022 the cumulative services provided under the agreement totaled $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; as well as with a contrast &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; in subjects with CMD and corroborate the ESCaPE-CMD study results.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</clbs:BusinessTextBlock>
    <clbs:MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjQ5MA_9c40cddc-44de-46e2-b939-bbc317934c2a"
      unitRef="number">0.50</clbs:MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage>
    <clbs:MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjY0OA_72bd1fdb-04fe-43f3-a44c-e8d49f9a49d8"
      unitRef="number">0.50</clbs:MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage>
    <clbs:MergerAgreementTransactionExpensesThresholdForRatioAllocation
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMjg3NA_22dbf7d4-ed3a-4c7e-a9d6-556bec2fb96c"
      unitRef="usd">250000</clbs:MergerAgreementTransactionExpensesThresholdForRatioAllocation>
    <us-gaap:GrantsReceivable
      contextRef="i7de6a11cd3474c6287cb381192ae5762_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfNDM5Nw_19c088d9-c3fc-4640-839d-8378885416f3"
      unitRef="usd">1900000</us-gaap:GrantsReceivable>
    <clbs:MergerAgreementMinimumNetCashThreshold
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTAyNA_43407bfc-1a29-47d0-bd96-65023c98da08"
      unitRef="usd">64900000</clbs:MergerAgreementMinimumNetCashThreshold>
    <clbs:MergerAgreementPotentialTerminationFeePayable
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTAzOQ_f05dcf7f-a6b4-4c0c-b1aa-96fbbc218e6a"
      unitRef="usd">1000000</clbs:MergerAgreementPotentialTerminationFeePayable>
    <clbs:MergerAgreementPotentialTerminationFeeReceivable
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA1Mw_d61324ab-67fc-4cd9-939c-131b2e1fea75"
      unitRef="usd">4000000</clbs:MergerAgreementPotentialTerminationFeeReceivable>
    <clbs:MergerAgreementPotentialExpenseReimbursement
      contextRef="ib9a1123bfe2a4a8fa6a8c5a440b2cac1_I20220426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA2Nw_12927c8a-7b9c-4aee-9603-fa24c01fd9d4"
      unitRef="usd">1000000</clbs:MergerAgreementPotentialExpenseReimbursement>
    <clbs:PurchaseOfPreferredStockShares
      contextRef="i0492a0dc655845a9b2daa971f3aa0ee6_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA5MQ_8dcfa27a-c899-42a5-a6e7-6ac104c7d353"
      unitRef="shares">1135628</clbs:PurchaseOfPreferredStockShares>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib7d7e60b43454d24bd9f8aab2bdd049a_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTA4MQ_2e52e780-90ed-4606-8a35-38eaa8ecb819"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <clbs:PurchaseOfPreferredStockPricePerShare
      contextRef="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTE0Mg_f991113e-356f-4513-9f34-95fb83034635"
      unitRef="usdPerShare">8.8057</clbs:PurchaseOfPreferredStockPricePerShare>
    <clbs:PurchaseOfPreferredStockAggregatePrice
      contextRef="i72d3ff2f24b345b5ac90bbf39855e291_D20220426-20220426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTEwMg_9b8aa6f3-427c-4aab-b91d-ee61dcb5fef3"
      unitRef="usd">10000000</clbs:PurchaseOfPreferredStockAggregatePrice>
    <clbs:PreEquityOfferingValueAfterConversion
      contextRef="i1b3345a69c3d4ae293e0976208942eda_I20220426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTExNQ_8e0b51b6-b7cb-4057-afdb-d1e28e23776c"
      unitRef="usd">250000000</clbs:PreEquityOfferingValueAfterConversion>
    <clbs:GrossProceedsOnTransaction
      contextRef="i2adcb8be9d2546328e9ae61565dec3b3_D20220426-20220426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTEyOQ_b4d1f75f-41a4-496c-a59d-ca9830b3c3b7"
      unitRef="usd">50000000</clbs:GrossProceedsOnTransaction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bfdf542e13048bbbd63568d248c0ea6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMzg0ODI5MDc2NTE1MQ_4fc8d1c1-c74a-49c9-bdd1-8aa207091841"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ4MDk_ba206e7b-debb-4d3a-ad56-3e07fe6b1450">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ3OTM_145d6f5f-7d74-4b85-b0e4-436ea404802b">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNC9mcmFnOjUzMmI3N2U1ZDFiYjRlOTU4ZjBjM2FiM2Q0YzM1ZmFhL3RleHRyZWdpb246NTMyYjc3ZTVkMWJiNGU5NThmMGMzYWIzZDRjMzVmYWFfMTQ4MDU_10e7d46f-3f1f-4886-9f54-ac5bcbb5b8aa">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE1MA_30c08881-5dca-468e-a70f-3030ab9f8f20">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the policies below, the Company's significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in its 2021 Form 10-K. There were no changes to these policies during the three and six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in Cend Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in which the Company has no significant influence (generally less than a 20% ownership interest) or does not have the ability to exercise significant influence are accounted for under the measurement alternative method pursuant to ASC 321, Investments&#x2009;&#x2014;&#x2009;Equity Securities (&#x201c;ASC 321&#x201d;) as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as investments on the consolidated balance sheets and any impairment recognized related to these investments are presented in other income (expense), on the consolidated statements of operations (see Note 5, &#x201c;Fair Value Measurements&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE2NQ_1d071ebc-eccb-44b9-a61b-8343dcae0c34">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV8zNy9mcmFnOjVlYTQ5ZTVmM2MwMDRlNzA4ZjA1M2ZmMDc2NGMxNDlhL3RleHRyZWdpb246NWVhNDllNWYzYzAwNGU3MDhmMDUzZmYwNzY0YzE0OWFfMjE1Mw_eb02d4c5-dc5f-4980-8267-9bf906fd7914">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in Cend Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in which the Company has no significant influence (generally less than a 20% ownership interest) or does not have the ability to exercise significant influence are accounted for under the measurement alternative method pursuant to ASC 321, Investments&#x2009;&#x2014;&#x2009;Equity Securities (&#x201c;ASC 321&#x201d;) as these investments do not have readily determinable fair values. Under the measurement alternative method, the Company records the investment at cost less impairment losses, if any, unless it identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, in which case the Company will measure its investments at fair value as of the date that the observable transaction occurred. Such investments are presented as investments on the consolidated balance sheets and any impairment recognized related to these investments are presented in other income (expense), on the consolidated statements of operations (see Note 5, &#x201c;Fair Value Measurements&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjI1_48f4a56d-20cc-4494-8e45-d1b2e7e92eb9">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjMy_2b003a50-ba34-4b9b-a721-d6c18ba5b6d3">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xLTEtMS0yMDM2MA_87a6c368-4e87-4edc-880f-5bc580b233aa"
      unitRef="usd">26966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0zLTEtMS0yMDM2MA_a2a83651-1b1d-4699-a4b2-11186fdebc1e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy01LTEtMS0yMDM2MA_6f13a452-a08b-44ec-bc15-6c99d664913d"
      unitRef="usd">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93c8b0efeb1d4fc492e16c4348f8bb2a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy03LTEtMS0yMDM2MA_879ff263-28ba-49e0-9b8d-b904a8a94059"
      unitRef="usd">26900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i760113b860d24918972b88966a39461f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy05LTEtMS0yMDM2MA_cb551253-bdd5-4706-9387-1a36226f074a"
      unitRef="usd">53135000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i760113b860d24918972b88966a39461f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xMS0xLTEtMjAzNjA_e26b78c9-69f9-4325-b029-8c7d2cd16008"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i760113b860d24918972b88966a39461f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xMy0xLTEtMjAzNjA_75f3c899-8948-4938-b677-9cf9bb3237ee"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i760113b860d24918972b88966a39461f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfMy0xNS0xLTEtMjAzNjA_f3b964d3-b90b-42b1-ab7a-4c8379069632"
      unitRef="usd">53070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i29d7da78337e4f97b4635d629086a480_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xLTEtMS0yMTYwMw_65edb7d1-875f-4257-acf5-a04c7384483a"
      unitRef="usd">2978000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i29d7da78337e4f97b4635d629086a480_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0zLTEtMS0yMTYwMw_a5249772-451a-4e58-8bfc-ce643b35482b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i29d7da78337e4f97b4635d629086a480_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC01LTEtMS0yMTYwMw_ae0ca589-e7dc-46e4-8411-cad45f9a712b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i29d7da78337e4f97b4635d629086a480_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC03LTEtMS0yMTYwMw_9beb4dc4-978c-4ff1-8366-c9a15167081c"
      unitRef="usd">2978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC05LTEtMS0yMTYxMg_c5608a0d-182b-42dc-b6aa-804a5412fcba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMS0xLTEtMjE2MTI_9769d7eb-075b-409d-b954-869066ab9e95"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMy0xLTEtMjE2MTI_64606d78-72e7-4f56-8b47-b697ee007924"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1cc88d68cd648bda1adfaa5e1fdf7e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xNS0xLTEtMjE2MTI_6094f52b-fc00-4156-98f3-10cfce1acbdd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xLTEtMS0yMDM2MA_e7c6c9ce-38ec-4e67-9c9a-8783ec696e2e"
      unitRef="usd">22727000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0zLTEtMS0yMDM2MA_9ffb08cf-b230-4d86-ae4f-000ddc243576"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC01LTEtMS0yMDM2MA_a772f4d5-9e7f-4c54-8f31-9990a711e117"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17f028c9834d4aa8851347d4e1ac46ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC03LTEtMS0yMDM2MA_49d82579-ab7d-4001-ac2c-08a03f9cc74d"
      unitRef="usd">22727000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC05LTEtMS0yMDM2MA_73db7af9-68dc-444d-8d76-039e2b935933"
      unitRef="usd">18124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMS0xLTEtMjAzNjA_2c0debed-b097-49c9-8add-2f5037e49dbb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xMy0xLTEtMjAzNjA_c74541cc-cd02-461c-b0b9-4997022a681a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie67a57e844cf4196b7d6aaece131e76a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNC0xNS0xLTEtMjAzNjA_5903f9ab-0b89-401d-9e04-abbf12a25fb7"
      unitRef="usd">18124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xLTEtMS0yMDM2MA_8c5aaa19-5a09-4fce-9d8e-125d1463f2d2"
      unitRef="usd">17086000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0zLTEtMS0yMDM2MA_088a8480-0757-46c5-abb4-08433e65b7cb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS01LTEtMS0yMDM2MA_94ca56db-4939-4ecd-b971-6935e3b78326"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i472af80a2f724a30858b9461b417ed5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS03LTEtMS0yMDM2MA_5a8e4c37-53ee-42a8-bfa3-d3cd1869bd29"
      unitRef="usd">17083000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS05LTEtMS0yMDM2MA_b11cb87a-65d2-494c-87a9-af10686acfef"
      unitRef="usd">20263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xMS0xLTEtMjAzNjA_42c1c03e-e4e7-423e-9eb2-e6df7c733daa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xMy0xLTEtMjAzNjA_de075489-fdc7-4ada-8d89-fcf5aef28193"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31c748eba28b4b64a8ec1143527c0ae4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNS0xNS0xLTEtMjAzNjA_86b2da08-1f5c-42e9-ad0d-7c9367f1ec39"
      unitRef="usd">20258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xLTEtMS0yMDM2MA_0ef32d82-a840-4838-afe4-02de7eee7603"
      unitRef="usd">69757000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0zLTEtMS0yMDM2MA_bb0babeb-24eb-449b-b02d-ff6e1da65265"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy01LTEtMS0yMDM2MA_5bbfa505-aef5-47cf-8da1-7083073ac5b3"
      unitRef="usd">69000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy03LTEtMS0yMDM2MA_4f554193-84c6-4710-827a-d9b9f396645a"
      unitRef="usd">69688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy05LTEtMS0yMDM2MA_8a043697-4c9c-4234-b5eb-deed64e4bf01"
      unitRef="usd">91522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xMS0xLTEtMjAzNjA_4fb2293b-a06c-4e50-807f-92288c276f03"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xMy0xLTEtMjAzNjA_6240405b-5a9f-44b6-ac39-c8cb2a184324"
      unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOmRlZThjOTNiOGRiNjRkYWFhY2Y3MGFiNzMyMjk3MTdkL3RhYmxlcmFuZ2U6ZGVlOGM5M2I4ZGI2NGRhYWFjZjcwYWI3MzIyOTcxN2RfNy0xNS0xLTEtMjAzNjA_4078118e-1173-43e8-a1b5-c952c95add07"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjM2_84de7add-e433-4853-a448-9ce0bb23f188">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMS0xLTEtMS0yMDM2MA_ba466893-1194-430d-a85f-72d606e418f5"
      unitRef="usd">30045000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMS0zLTEtMS0yMDM2MA_f0a71969-a319-4ffe-a7f5-a3785a3c8dce"
      unitRef="usd">21129000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMi0xLTEtMS0yMDM2MA_ee31ff35-cfbf-460d-8364-44e40eeae84a"
      unitRef="usd">39643000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMi0zLTEtMS0yMDM2MA_46bac5fd-7fc8-4385-897a-b1034eb3e82a"
      unitRef="usd">70323000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMy0xLTEtMS0yMDM2MA_edaf0f87-0c15-45af-b45c-c160024eed09"
      unitRef="usd">69688000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjEyMWIwZGYwYzI4YjRmZGE4YWUwYzE4M2MwNjQ0YWM1L3RhYmxlcmFuZ2U6MTIxYjBkZjBjMjhiNGZkYThhZTBjMTgzYzA2NDRhYzVfMy0zLTEtMS0yMDM2MA_7d4b6f46-700c-470f-8762-dae11deb5567"
      unitRef="usd">91452000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RleHRyZWdpb246MGE2NThiZDk3MTVlNDA1ZThhNzUxMzQ3ZjhiZjA0Y2JfNjE5_ac11ad65-564b-4956-8f12-1a3a81e2bd98">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMi0xLTEtMS0yMDM2MA_e96dc9d1-9e4c-40a5-a024-7accffdc7919"
      unitRef="usd">69757000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMi0zLTEtMS0yMDM2MA_e845e779-c265-45e2-b419-1430432818c4"
      unitRef="usd">69688000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMy0xLTEtMS0yMDM2MA_4922db38-246e-4df3-8969-ca5ff24845e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfMy0zLTEtMS0yMDM2MA_3238389f-5de7-496a-b13a-ee9978acbfd6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfNC0xLTEtMS0yMDM2MA_da2ad5bf-b7ab-49ff-904a-e361fed33661"
      unitRef="usd">69757000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80MC9mcmFnOjBhNjU4YmQ5NzE1ZTQwNWU4YTc1MTM0N2Y4YmYwNGNiL3RhYmxlOjJjZjY0NTllNWYzMjRhZTBhMzM5NzdlYzEyMGViZDY0L3RhYmxlcmFuZ2U6MmNmNjQ1OWU1ZjMyNGFlMGEzMzk3N2VjMTIwZWJkNjRfNC0zLTEtMS0yMDM2MA_e42658d8-9e18-4b1e-966a-e86a00425b41"
      unitRef="usd">69688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RleHRyZWdpb246YTMzZGE4MDg3OGY2NDI5Nzg3OThjMWI3MDk3ZWExZDJfMzIx_eb3a4bef-ab82-47e5-ad67-8ffabaa4660e">Income (Loss) Per ShareFor the six months ended June&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At June&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RleHRyZWdpb246YTMzZGE4MDg3OGY2NDI5Nzg3OThjMWI3MDk3ZWExZDJfMzMw_93fe93e8-e106-42be-90a4-e6608edbf746">At June&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMi0xLTEtMS0yMDM2MA_60119a0d-d1a2-4b90-a50f-753db078be31"
      unitRef="shares">2612000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie46e3b754c67413c88f24c3ddff1552f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMi0zLTEtMS0yMDM2MA_f6d4b0f1-1ed5-4533-96f1-4516b0166336"
      unitRef="shares">1005000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1c93d7a7931742669a283947008740ed_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMy0xLTEtMS0yMDM2MA_2286d22d-0d04-4aa5-bd4c-5765f9f51094"
      unitRef="shares">21357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d5ab7d1d8304b70a0409715de916340_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfMy0zLTEtMS0yMDM2MA_faa7b193-b935-4af6-8715-6957e1fc1484"
      unitRef="shares">21357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic5311053f8ab4baab4847164c5f36d3a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfNS0xLTEtMS0yMDM2MA_1edbcfe7-5501-4997-8bd9-c8032597b7ab"
      unitRef="shares">1454000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i94f725c87ad542dcb3ff3f4d00fc0e9d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80Ni9mcmFnOmEzM2RhODA4NzhmNjQyOTc4Nzk4YzFiNzA5N2VhMWQyL3RhYmxlOmNlYmM2NDBlMmY5ODQ3MjlhZWQzMDg3ZTUxODYxZGI3L3RhYmxlcmFuZ2U6Y2ViYzY0MGUyZjk4NDcyOWFlZDMwODdlNTE4NjFkYjdfNS0zLTEtMS0yMDM2MA_539c3d59-602c-40ba-bfbc-139210cf98a7"
      unitRef="shares">798000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RleHRyZWdpb246OWMxNmVhMTI1YjQ5NDI5YWFkNTMyMWI5YTIxMTA3ODBfMTQ2Ng_9022c1c4-69d6-4fed-8abe-c1ad4cd1a403">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Cend Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RleHRyZWdpb246OWMxNmVhMTI1YjQ5NDI5YWFkNTMyMWI5YTIxMTA3ODBfMTQ3Mw_3ec1aa52-8c3f-4edd-b65f-0548261e762b">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Cend Therapeutics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7f6233584e5a4a50b728139e0d6c6159_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0yLTEtMS0yMDM2MA_99d52455-5aa4-4c94-a575-6d34f80a2ed0"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i461576cc6a4e4084a8c496c3c34ed239_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy00LTEtMS0yMDM2MA_45243f7b-0dbf-447b-a705-de0f26bd39a8"
      unitRef="usd">39643000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy02LTEtMS0yMDM2MA_23e496ac-25bc-40ec-90e8-f7ccbda60518"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy04LTEtMS0yMDM2MA_ca790a49-3aae-40ea-bd7f-c1ea764bdd71"
      unitRef="usd">39643000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xMC0xLTEtMjAzNjA_21290d85-cd84-4911-8f62-007427a9658b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6c4f1d501291470683152d8d06246393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xMi0xLTEtMjAzNjA_081cc60a-4bd5-40bb-b14c-0104eda0d8dc"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i169c2b19485743c494294b605e1c9637_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xNC0xLTEtMjAzNjA_8f037b27-bd6e-4fbc-ab9d-80533856259c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2a0af1b219794ef094dabc670988af20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfMy0xNi0xLTEtMjAzNjA_5457aed6-a27b-41e9-a081-8074834258da"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC02LTEtMS0yMjM1OA_6d69934b-22a9-48bf-83cf-4a0fc34189be"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC04LTEtMS0yMjM1OA_aafb351d-e201-4d2d-a679-efae6599cbc6"
      unitRef="usd">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7f6233584e5a4a50b728139e0d6c6159_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0yLTEtMS0yMDM2MA_e09c9ad2-aed0-440c-97f1-f3101de0cc18"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i461576cc6a4e4084a8c496c3c34ed239_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC00LTEtMS0yMDM2MA_39939a70-8776-4a04-baca-1cf37b67a838"
      unitRef="usd">39643000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib070372249f24e5daa9dce2156efdc26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC02LTEtMS0yMDM2MA_09c90a15-4cc1-4dcf-9951-43f907c8d141"
      unitRef="usd">10000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72a20efaf2c54cf49ab436cebbcce5d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC04LTEtMS0yMDM2MA_7ed1a111-08ad-49a4-b66f-58ce7d45cac8"
      unitRef="usd">49643000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9776ef21619e4f4a8b10dc94da1c1fa0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xMC0xLTEtMjAzNjA_fe108514-d8fb-474c-86ff-09cf8cd2349b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c4f1d501291470683152d8d06246393_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xMi0xLTEtMjAzNjA_3b4d7bed-cc7a-45fd-b2b5-ad1ab2d6789b"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i169c2b19485743c494294b605e1c9637_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xNC0xLTEtMjAzNjA_15308ece-77fb-4a16-acf7-2e1890657da4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a0af1b219794ef094dabc670988af20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV80OS9mcmFnOjljMTZlYTEyNWI0OTQyOWFhZDUzMjFiOWEyMTEwNzgwL3RhYmxlOmRkNzdmOThhODI0NjRjZTI4ZjJhZDVhMDNjMjU1ZDdmL3RhYmxlcmFuZ2U6ZGQ3N2Y5OGE4MjQ2NGNlMjhmMmFkNWEwM2MyNTVkN2ZfNC0xNi0xLTEtMjAzNjA_05ef0f97-a6f7-4b09-9ad1-881135df1693"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RleHRyZWdpb246MDFiZmZkMDk5MjMyNDg1OWJmMTFmYjQ3OTBhYzkyMDRfMTEx_bf9edcfe-6baf-49b7-91ac-317995802644">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of June&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RleHRyZWdpb246MDFiZmZkMDk5MjMyNDg1OWJmMTFmYjQ3OTBhYzkyMDRfMTA1_b7fe9dc6-55c1-431a-ab53-a764eb1db588">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of June&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMS0xLTEtMS0yMDM2MA_219319ea-1bfc-4dd3-a003-a286dfc8a721"
      unitRef="usd">1397000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMS0zLTEtMS0yMDM2MA_f6def31c-5b03-45ce-8401-d354ad9473c3"
      unitRef="usd">2034000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMi0xLTEtMS0yMDM2MA_bcb5b5a4-c853-4c60-9b65-9f442595d710"
      unitRef="usd">178000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfMi0zLTEtMS0yMDM2MA_5323a087-f664-46a3-ba66-efa363e4108f"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNC0xLTEtMS0yMDM2MA_f6f42f50-553a-4a96-bafc-efbc3631a5f5"
      unitRef="usd">685000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNC0zLTEtMS0yMDM2MA_a2391194-62ff-468a-ac2b-1775ddc62e26"
      unitRef="usd">326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNS0xLTEtMS0yMDM2MA_1f14510d-7591-411a-a913-9855d466d392"
      unitRef="usd">2260000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81Mi9mcmFnOjAxYmZmZDA5OTIzMjQ4NTliZjExZmI0NzkwYWM5MjA0L3RhYmxlOjM2ZTVjNjBiMWZjNTQ3ZjBiMTM2MTc5OGJlZmNiNjgxL3RhYmxlcmFuZ2U6MzZlNWM2MGIxZmM1NDdmMGIxMzYxNzk4YmVmY2I2ODFfNS0zLTEtMS0yMDM2MA_321c3301-b869-4407-bb35-3486364abfa3"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE3Mg_f4a48ce6-74d2-4bf1-998f-17ab07fae016">Operating LeasesThe Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the weighted average remaining lease term for our operating leases was 2.0 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <clbs:NumberOfOfficesUnderOperatingLeases
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfNjg_d445bfaf-25b2-4d4c-aeb7-04c70b8a7e61"
      unitRef="office">2</clbs:NumberOfOfficesUnderOperatingLeases>
    <clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE2Nw_d2728b85-7632-4afe-af64-8917c8c7d585">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_2e0664b3-2dfc-41a8-8c93-a523bd871dde"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0wLTEtMS0yMDM2MA_f3896e04-bf88-4863-abf7-2713ff97b4d5"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_a0a15554-b97b-4270-8680-65d9c16ae59d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0wLTEtMS0yMDM2MA_d23f17f2-822c-4b4d-95fe-682a913ffaba"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_993ecc13-7d70-4eb4-979f-168a62bcc507"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0wLTEtMS0yMDM2MA_f84d1ed6-87af-4057-a1b4-ada594e9a7a7"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0xLTEtMS0yMDM2MA_992f2392-43e0-4a9b-9f95-49c076077f95"
      unitRef="usd">608000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMi0zLTEtMS0yMDM2MA_9c5922ae-316f-4bc5-a971-7facf44c1f8a"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMy0xLTEtMS0yMDM2MA_04b93eee-984a-4379-b03c-518b1998b231"
      unitRef="usd">608000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfMy0zLTEtMS0yMDM2MA_6eb1d5c1-c981-4e05-bda6-1d8491cf5976"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0xLTEtMS0yMDM2MA_5bd24eaa-5457-46c0-9a3b-e41906247f58"
      unitRef="usd">178000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNi0zLTEtMS0yMDM2MA_6a742051-317f-4298-a0e6-ef51b38fe8d0"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0xLTEtMS0yMDM2MA_ffcb3ed0-6753-471c-8012-77d8954c0059"
      unitRef="usd">383000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfNy0zLTEtMS0yMDM2MA_fae04fb0-9807-40ee-8b95-2224459ce8d9"
      unitRef="usd">485000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfOC0xLTEtMS0yMDM2MA_d6d96300-6077-4ba7-b9fd-18666d534a18"
      unitRef="usd">561000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjYyNDI2ODMwZGY1MzQ3MmM4NjU1OTA3M2UzMTg4OWFhL3RhYmxlcmFuZ2U6NjI0MjY4MzBkZjUzNDcyYzg2NTU5MDczZTMxODg5YWFfOC0zLTEtMS0yMDM2MA_d4b22cb7-9b80-4842-a15d-8402e53e311a"
      unitRef="usd">714000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfOTky_5dad1846-b3f4-4604-97b6-5550ce107b12">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTA2NA_99b1f0c2-14ec-443b-9c12-1bdbc26a088d"
      unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RleHRyZWdpb246NzMwMzk5ZTVmMmU0NDE4N2E2ZDA1Y2Y4NzhlMWU4YmZfMTE3NQ_29e29cf2-016f-4245-a87c-34ca36c771f3">Future minimum lease payments under the lease agreements as of June&#160;30, 2022 were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfMy0xLTEtMS0yMDM2MA_07b15fe0-21e8-4702-b9ee-129f8d1235ad"
      unitRef="usd">103000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNC0xLTEtMS0yMDM2MA_b6702b9c-cbe7-47fe-9562-b46544cce97a"
      unitRef="usd">217000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNS0xLTEtMS0yMDM2MA_52134554-e247-4e0a-bad9-34696a660c8c"
      unitRef="usd">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNi0xLTEtMS0yMDM2MA_50419458-fe84-46f0-a05c-e3752d0ddb78"
      unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfNy0xLTEtMS0yMDM2MA_d515bc0b-8a10-460f-a34e-07744450b834"
      unitRef="usd">653000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfOC0xLTEtMS0yMDM2MA_b0e918b9-f35e-4648-8ee9-63d567168bfc"
      unitRef="usd">92000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81NS9mcmFnOjczMDM5OWU1ZjJlNDQxODdhNmQwNWNmODc4ZTFlOGJmL3RhYmxlOjdjMGNkZDI5ZTQwOTRjOGM5ZjhhZjZmMzkyOGE4OGQ1L3RhYmxlcmFuZ2U6N2MwY2RkMjllNDA5NGM4YzlmOGFmNmYzOTI4YTg4ZDVfOS0xLTEtMS0yMDM2MA_7c69977f-187e-4210-ae97-d7a646445064"
      unitRef="usd">561000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ1NA_9078072a-fbcc-4251-944b-67e4075c3fad">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#x201c;Offering&#x201d;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#x201c;Initial Purchase&#x201d;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#x2019;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#x201c;Regular Purchase&#x201d;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#x201c;accelerated purchase&#x201d; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#x2019;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement does not limit the Company&#x2019;s ability to raise capital from other sources at the Company&#x2019;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with HCW, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million.  During the six months ended June&#160;30, 2022 and since inception the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#x2019;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,131,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,612,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at June 30, 2022&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,574,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,388,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3Mw_d6c91bb1-b895-4964-8aed-4a7cfaa67b1d"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,379,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average estimated fair value of restricted stock issued for services in the six months ended June&#160;30, 2022 and 2021 was $0.92 and $1.59 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDI2_4d0555dc-10d6-495b-9d81-efe4bee5a3fe"
      unitRef="usd">26000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration
      contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNjM4_ac5b2834-0e57-4110-a8f5-ebfecbb35fd7"
      unitRef="shares">181510</clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNzQ1_f008399a-4572-4ff7-8e84-bcf6b2908488"
      unitRef="shares">250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNzg2_3fb06001-7c7b-4299-8a33-77268da32e56"
      unitRef="usdPerShare">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfODM2_98214274-0cb5-4dad-9474-2b6980fa645b"
      unitRef="usd">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <clbs:TermOfAgreement
      contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTAxNA_8bd746ea-96d3-4ac8-b349-98feb3694d71">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTE5OQ_2baac941-2ade-4a91-a32f-ab3fe9d87da1"
      unitRef="shares">100000</clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTM5Mw_34176516-b168-4375-a622-3cccd63ffc6b"
      unitRef="usd">2500000</clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMTkzOA_083597c1-81d1-4ad8-802f-3719bb0c4141"
      unitRef="number">3</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMjAyNw_1bcaf354-3a6f-41d9-bfea-08d080686830"
      unitRef="number">0.30</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod>
    <clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty
      contextRef="i881d1b5361494535a4dff620655e80cc_I20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMjkyNw_e301408c-f778-421e-844a-278bfecc3c4e"
      unitRef="number">0.0999</clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty>
    <clbs:TermOfAgreement
      contextRef="i47b0dd35918d4216b73b254deb5366ac_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfMzMzNA_8bd746ea-96d3-4ac8-b349-98feb3694d71">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="ib0d46abc623a4ea5a97d1bf45a62c876_I20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDAwNg_7c18e3b2-8222-45bf-88ce-9cbff69dcebd"
      unitRef="usd">50000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i14632cb149ee4f8e824d0bc59caba108_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDA2NA_5a1d09fc-b0ed-4df4-ae8e-f0a34368b4a5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ0OQ_60462343-52bf-4074-8af8-7feb70bdb42a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,131,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,612,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at June 30, 2022&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,574,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,388,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0yLTEtMS0yMDM2MA_fb8eed84-92e8-4df8-acc1-6ff4e567833d"
      unitRef="shares">2131849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi00LTEtMS0yMDM2MA_49111974-b778-47f6-a291-ef79838baa4e"
      unitRef="usdPerShare">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi02LTEtMS0yMDM2MA_177c83c2-fe01-4d9f-a313-52acc2e20877">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi04LTEtMS0yMDM2MA_9da29be0-522f-43fa-afc3-1e7be20359c6"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xMC0xLTEtMjAzNjA_af2a468e-bddf-4bce-b85b-5462216885c1"
      unitRef="shares">21356600</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xMi0xLTEtMjAzNjA_a0793e1c-2ddf-4f3c-be4c-1d12631b23ee"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i87ae63d1092c44b98bbe9e5e85b500cc_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xNC0xLTEtMjAzNjA_a7b44f37-3f8e-4662-9767-d37ff539f4fd">P4Y4M13D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMi0xNi0xLTEtMjAzNjA_a31c4f9f-684c-4637-89c4-72c5293cc7a2"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0yLTEtMS0yMDM2MA_7ee66662-b97f-4dc9-bbe9-ca6fde8abd80"
      unitRef="shares">547600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS00LTEtMS0yMDM2MA_64801435-a666-413d-89d6-7e3d25f4e001"
      unitRef="usdPerShare">0.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsGranted
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0xMC0xLTEtMjAzNjA_61b73a04-47e7-4bf3-880a-d21ca8ee7a90"
      unitRef="shares">0</clbs:WarrantsGranted>
    <clbs:WeightedAverageExercisePriceWarrantsGranted
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNS0xMi0xLTEtMjAzNjA_d24c4d14-1fbf-4ff3-bf07-b3ad1dc2483d"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0yLTEtMS0yMDM2MA_77a7d8a6-afac-4085-a49b-05a903314b20"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi00LTEtMS0yMDM2MA_74954e2b-e208-412c-9161-41b758337dee"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExercised
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0xMC0xLTEtMjAzNjA_06193ea1-931f-4f2b-a82e-faad5cbe5704"
      unitRef="shares">0</clbs:WarrantsExercised>
    <clbs:WeightedAverageExercisePriceWarrantsExercised
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNi0xMi0xLTEtMjAzNjA_007f9b12-832e-4481-b6c7-37c3adf4a15b"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0yLTEtMS0yMDM2MA_f5c0e9e0-fbc4-4404-8183-5678d9d1b620"
      unitRef="shares">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy00LTEtMS0yMDM2MA_53a3fd51-19c8-48d8-969d-8ab9287f92d5"
      unitRef="usdPerShare">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsCanceled
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0xMC0xLTEtMjAzNjA_d73bbe88-2f55-4165-bb65-e332272f34aa"
      unitRef="shares">0</clbs:WarrantsCanceled>
    <clbs:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfNy0xMi0xLTEtMjAzNjA_036c847b-319a-4ad8-89a6-a6bd5c49268e"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0yLTEtMS0yMDM2MA_c1f1aef4-3a18-4ba4-9121-cbb378eb952f"
      unitRef="shares">49664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC00LTEtMS0yMDM2MA_8275c343-7f4e-461d-8fbb-29d9893896f3"
      unitRef="usdPerShare">27.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExpired
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0xMC0xLTEtMjAzNjA_60350fc5-ee99-4ff9-9810-7c2307f9c633"
      unitRef="shares">0</clbs:WarrantsExpired>
    <clbs:WeightedAverageExercisePriceWarrantsExpired
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOC0xMi0xLTEtMjAzNjA_2fd8ac21-30e5-4bac-ab48-6580e9646686"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0yLTEtMS0yMDM2MA_c2bb9eb8-d209-40ef-97f6-c31ec10f4513"
      unitRef="shares">2612285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS00LTEtMS0yMDM2MA_4d8d6b71-28bd-4f6a-a1b5-1a4a3e666bc4"
      unitRef="usdPerShare">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS02LTEtMS0yMDM2MA_a23f7425-2df2-42ae-a79a-05698bfa794d">P7Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS04LTEtMS0yMDM2MA_6955ea21-1058-4de5-aaa7-912a0778865e"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xMC0xLTEtMjAzNjA_6404a0d3-b210-43d5-8172-ac245759d1c4"
      unitRef="shares">21356600</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xMi0xLTEtMjAzNjA_2e5374f7-b82e-418a-a0c0-e5b18105bbe1"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xNC0xLTEtMjAzNjA_7a0595b9-f98b-4294-a89a-cc8a4ee3da26">P3Y10M17D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfOS0xNi0xLTEtMjAzNjA_a3a70b44-8dee-4282-ba04-976d8008155c"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMi0xLTEtMjAzNjA_7fafb4e0-90e6-42b1-980b-93e6b613c885"
      unitRef="shares">2574724</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtNC0xLTEtMjAzNjA_49837db1-6484-4294-aa48-88a3d5e06a53"
      unitRef="usdPerShare">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtNi0xLTEtMjAzNjA_9019aedc-e80e-4506-ad27-b353ba35c204">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtOC0xLTEtMjAzNjA_ab384704-9ace-48f9-bd1b-b7b57ecd2277"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <clbs:Sharesvestedandexpectedtovest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTAtMS0xLTIwMzYw_035c85ad-5114-4e66-b692-c6ef37ad4da0"
      unitRef="shares">21356600</clbs:Sharesvestedandexpectedtovest>
    <clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTItMS0xLTIwMzYw_85ff6790-e46a-44b5-bc1b-1a9498550063"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTQtMS0xLTIwMzYw_8722b8ce-a670-4dc9-85ab-26b4b17f702b">P3Y10M17D</clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTAtMTYtMS0xLTIwMzYw_a5f16089-e0e7-462c-8421-5ab06d890637"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMi0xLTEtMjAzNjA_2730cb7d-68af-4103-9127-288bb160ae38"
      unitRef="shares">1388935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtNC0xLTEtMjAzNjA_67fa33b1-5b75-4c38-a5ea-5f75610728ed"
      unitRef="usdPerShare">6.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <clbs:OptionsVestedweightedAverageRemainingContractualTerm
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtNi0xLTEtMjAzNjA_4b337edb-980d-4725-9446-7a123bd947ae">P6Y2M26D</clbs:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtOC0xLTEtMjAzNjA_c7cbe95f-6165-44e4-81ec-4f0beb9a27e8"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <clbs:WarrantsVested
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTAtMS0xLTIwMzYw_0ba5cb29-6346-411a-9178-a31ed84ebc81"
      unitRef="shares">21356600</clbs:WarrantsVested>
    <clbs:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTItMS0xLTIwMzYw_e46930b6-b3b3-44d6-b063-1fbce4a46f72"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsExercisable>
    <clbs:WeightedAverageRemainingContractualTermwarrantsvested
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTQtMS0xLTIwMzYw_af16ebc5-487a-454a-811d-5b5388aac219">P3Y10M17D</clbs:WeightedAverageRemainingContractualTermwarrantsvested>
    <clbs:AggregateIntrinsicValueWarrantsvested
      contextRef="i36939ec815f849cd909b1f34151f6a3b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjIyNTZmOWVkMDFlZTQ0MmZhMzdmY2FhOGI1MGIwNTc3L3RhYmxlcmFuZ2U6MjI1NmY5ZWQwMWVlNDQyZmEzN2ZjYWE4YjUwYjA1NzdfMTEtMTYtMS0xLTIwMzYw_d43a7779-323b-4dc3-b2fd-ae459a23d587"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQ1Mw_34be6c0b-6a5e-4459-b90c-5825c2a1ab72">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,061,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMi0yLTEtMS0yMDM2MA_e29bd974-041a-46b1-834c-8553db384e3e"
      unitRef="shares">1061175</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMi00LTEtMS0yMDM2MA_f41dd045-0a6a-4a6c-b495-2fc559eeac38"
      unitRef="shares">300450</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMy0yLTEtMS0yMDM2MA_98347c5a-277d-4e77-9f08-4b53c8171853"
      unitRef="usd">973000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOjA4MzE4Y2QzODk1YTRjZTliYjY3OWNmMzk1ZjNjNWMxL3RhYmxlcmFuZ2U6MDgzMThjZDM4OTVhNGNlOWJiNjc5Y2YzOTVmM2M1YzFfMy00LTEtMS0yMDM2MA_ee67d256-7fc7-43ff-b904-cd8d9443893d"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i68930bc1046341ffaf2ee9a38956674a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNDg3OQ_f88b315d-4c7c-4694-9fcf-9fafc97f71c8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTQzNQ_8002941e-2766-4e37-b8f9-7cce8bd03d14">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,379,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMi0xLTEtMS0yMDM2MA_16432650-559c-48e3-a2a5-deaa707ff245"
      unitRef="shares">1379860</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMi0zLTEtMS0yMDM2MA_414f6fdb-c3cd-4c8a-ad9c-246813fc0972"
      unitRef="shares">458245</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMy0xLTEtMS0yMDM2MA_39ad31f1-f36e-4d65-ae37-b63fc2285a3f"
      unitRef="usd">1265000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8dbac9cb4ed6451b9cd00ab3ab0668d6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RhYmxlOmZhZmUxZWJhZTkzNzQ5OGY4MzZjZjM0ODVmMmY5ODhkL3RhYmxlcmFuZ2U6ZmFmZTFlYmFlOTM3NDk4ZjgzNmNmMzQ4NWYyZjk4OGRfMy0zLTEtMS0yMDM2MA_3f90ab96-b24a-4823-babf-50f26349f248"
      unitRef="usd">729000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTE0Mw_ae9acfcf-ff0d-4196-ba1e-0a5e6b68fb90"
      unitRef="usdPerShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5ee0884354a846919b7b9ba84d0469be_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTE1MA_c8714a2f-6692-4971-b550-50de1734364c"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV81OC9mcmFnOjU3YTA3OWNmZDI1YTRjYjdhNjQwNjMzNTk0NDM2NGFjL3RleHRyZWdpb246NTdhMDc5Y2ZkMjVhNGNiN2E2NDA2MzM1OTQ0MzY0YWNfNTM3MA_9784bf97-f168-406c-bd30-619d6488f1bb">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTEzNw_3bde1e0a-5bcc-4d3f-a7f8-3e82814dfe0a">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June&#160;30, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTExOA_97bc88bf-3174-4664-833a-57b23c69fb14">The following table summarizes the components of share-based compensation expense for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49d7272724ce4f578cc742d1dc931327_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi0xLTEtMS0yMDM2MA_af5e813a-3e0a-4476-8fd5-8d622213ce7e"
      unitRef="usd">141000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie15f75b9306d45999b283daf73a43b48_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi0zLTEtMS0yMDM2MA_5047badb-8e4a-40ec-bcfa-49457460fba3"
      unitRef="usd">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61b5af72af5c4772bf134572a931b93d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi01LTEtMS0yMDM2MA_fd50db6d-9b71-4095-9d8a-b4a727278fe3"
      unitRef="usd">359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66c459ae881647fd8f328d90c28330bf_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMi03LTEtMS0yMDM2MA_990006d2-3ddc-444c-b907-fe1767341801"
      unitRef="usd">120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f0d245d793c45a1ba1cb80e8b960908_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy0xLTEtMS0yMDM2MA_338f7531-6b8d-4269-b0f9-36a845c32a83"
      unitRef="usd">226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i823661ad4a944545a75121b92daaf1a9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy0zLTEtMS0yMDM2MA_f63d8c13-ba1d-42dd-8fe7-a46bd90e94aa"
      unitRef="usd">246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i62c6b1a91ccc4441ba38426fe098aeb0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy01LTEtMS0yMDM2MA_056986e4-a6c4-4d2b-ac03-840e7e949ef4"
      unitRef="usd">769000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief352e26ae67416cafff90b9793d7ccd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfMy03LTEtMS0yMDM2MA_bc6870da-2f5b-497b-b9ae-bc0dc6524b71"
      unitRef="usd">747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC0xLTEtMS0yMDM2MA_92de5f52-b7e1-485c-883a-72e656743fee"
      unitRef="usd">367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i609f59ce3edf4c2ca5ba1c79e739fdc3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC0zLTEtMS0yMDM2MA_f3a4f4ba-4a47-4fe3-9f45-a42e01c15c25"
      unitRef="usd">270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC01LTEtMS0yMDM2MA_c353e828-5a12-43f1-aa34-a2ed9317355b"
      unitRef="usd">1128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0cdf3e79acf74a1184709ce178c18914_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjI0MjZmYTkyZjAzOTRjNTI4MDVkMDcxMjhiNjRiYzdjL3RhYmxlcmFuZ2U6MjQyNmZhOTJmMDM5NGM1MjgwNWQwNzEyOGI2NGJjN2NfNC03LTEtMS0yMDM2MA_b8d44c72-70c0-4a03-bf20-e8a752c6581f"
      unitRef="usd">867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTExOQ_aa89684d-7f44-4c37-9135-ae9cd51872b8">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1a169106c4a54b75a790607dc184b040_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS0xLTEtMS0yMDM2MA_18a7b5ea-5100-4fd7-a810-cbed24c024a3"
      unitRef="usd">685000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1213c6cc96c2467caca65a5f1102dc7b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS0zLTEtMS0yMDM2MA_f7e218b5-3599-4e69-bf65-d0d669d2071f"
      unitRef="usd">319000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie96074b249ba4cb3811d86696759685a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMS01LTEtMS0yMDM2MA_b4fbfc86-bcd1-4cf7-aad4-456f107900b6"
      unitRef="usd">869000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi0xLTEtMS0yMDM2MA_0f04182a-26e7-4394-ad81-b7f62573f474">P1Y6M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i11dd6010467f46508798e81ea93f7f60_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi0zLTEtMS0yMDM2MA_3db41851-da1b-4bd2-93c0-3205645fb903">P0Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjNiNjg4MjhjODdkZjQ0YmI4NWY5NDk4OGJiZDJlMGRmL3RhYmxlcmFuZ2U6M2I2ODgyOGM4N2RmNDRiYjg1Zjk0OTg4YmJkMmUwZGZfMi01LTEtMS0yMDM2MA_caa4b558-7ed3-46aa-8a1d-ab6403874a3c">P2Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RleHRyZWdpb246MGFjYjZiZTgzZDk3NGMzZjhmZDU1MTE2MTU3ZWUyOThfMTEyNA_5be9b866-345e-4cb3-9162-d025be09be11">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June&#160;30, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfMy0xLTEtMS0yMDM2MA_e5274880-3bb2-4205-864c-14b8f3ed8cc9"
      unitRef="usd">385000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfMy0zLTEtMS0yMDM2MA_98ce1e6e-4460-4db2-9798-cf00d5b58ec9"
      unitRef="usd">407000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id96396af1f5f4e578519538caff67b2c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfNC0xLTEtMS0yMDM2MA_58f17911-b21d-4da5-ab82-ecc8b4a209fc"
      unitRef="usdPerShare">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d4a78cd850d4330b31c697104c2879e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82NC9mcmFnOjBhY2I2YmU4M2Q5NzRjM2Y4ZmQ1NTExNjE1N2VlMjk4L3RhYmxlOjgwODBkMGU1YzQ1ODRiZmJiYTU5NDA3Mjg4MDRkMjJjL3RhYmxlcmFuZ2U6ODA4MGQwZTVjNDU4NGJmYmJhNTk0MDcyODgwNGQyMmNfNC0zLTEtMS0yMDM2MA_a4434cf4-6d0b-49cc-8dbd-c4f92822e529"
      unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDI2Nw_d10c359f-b215-400a-ad1e-4e86ede6e107">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#x201c;NOLs&#x201d;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had approximately $281&#160;million and $264&#160;million, respectively of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020 the Company had state NOLs available in New Jersey of $97&#160;million and $99&#160;million, respectively, California of $70&#160;million and $70&#160;million, respectively, and New York City of $13&#160;million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from date of filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#x201c;NJEDA&#x201d;) to participate in the Technology Business Tax Certificate Transfer Program (the &#x201c;Program&#x201d;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $2.5&#160;million of its NJ NOLs related tax benefits (&#x201c;NJ NOL Tax Benefits&#x201d;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3&#160;million. The gross proceeds of $2.5&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="i069758af4d36436e817e90b87a8a130d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNTQw_29d5a3c2-26d2-4dd0-99fa-8ed7f6280db4"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia572f9b4029b4d02bd17de8d331b2d60_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNTQ3_1b73cdf1-aad8-4e3c-81db-647c7382dd82"
      unitRef="usd">264000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsSetToExpireWrittenDown
      contextRef="i069758af4d36436e817e90b87a8a130d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfODIy_edc18b95-2881-41a6-bcb3-35b0d99b09cd"
      unitRef="usd">169000000</clbs:OperatingLossCarryforwardsSetToExpireWrittenDown>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="i069758af4d36436e817e90b87a8a130d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfODMy_ccd701c7-f0ec-44b3-b65e-6312aad97f2d"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i069758af4d36436e817e90b87a8a130d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTAwMA_5cd9e9ef-3a0e-4043-b9d9-d10678344db3"
      unitRef="usd">112000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain
      contextRef="i6a4a7a34fc2249628d10e950713caaf8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTQ4NA_4bf52eea-1b77-4a99-8ffc-a4145ba0cd2f"
      unitRef="usd">1100000</clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2ce48fc27b9345c79034d9b1582abdf0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTY5NQ_1c029349-9ffa-4bd4-bc18-ca86c8656264"
      unitRef="usd">97000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibc8328428e264834bf3b4a202bab364f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTcwMg_6e03f66c-e469-4c03-b4a8-ae6cef60226a"
      unitRef="usd">99000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib17745a6d80b45f587961fd01e5ac1bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTczNA_03f34e69-d93c-4fe6-87a1-285af0838716"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9a9b55d334b140a0a9c8cf4c0b5ced19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc0MQ_12aa2b1c-b311-463e-bfb5-13d87b960651"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i148b071e62cb48e389a032a63261b95b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc4MA_d0150d39-517e-4f51-a650-f74ecae7c133"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0e7dbcff99b643cba5824b529d4831aa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMTc4Nw_65c17bac-8830-4b8b-b983-0ccc45d8359b"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
      contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfMzg5OQ_913afdf3-e8f3-4900-920d-ef257082d3b6"
      unitRef="usd">2500000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
      contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDA3MA_d2363882-46cd-4a7a-8ea5-c56aa0701cf0"
      unitRef="usd">2300000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
      contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDA5Ng_1ee36a08-6883-4a1e-b01e-026eac210668"
      unitRef="usd">2500000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <clbs:LossOnSaleOfNetOperatingLosses
      contextRef="ia3825a772d3e4acdbc5336cf8b0080b1_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV82Ny9mcmFnOmQ4MzE5NmQxNDJmYzQwZjU4Yjg1M2YyMWJiZDhhZDUxL3RleHRyZWdpb246ZDgzMTk2ZDE0MmZjNDBmNThiODUzZjIxYmJkOGFkNTFfNDE4NA_1ec64946-ea26-4591-b153-e79e04b8af35"
      unitRef="usd">100000</clbs:LossOnSaleOfNetOperatingLosses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMyODZmOWZjYjYyMzRhNmRhYzJlYmM1M2Y5YTk3YTZlL3NlYzozMjg2ZjlmY2I2MjM0YTZkYWMyZWJjNTNmOWE5N2E2ZV83MC9mcmFnOjFhNmUyOGZkYWU1NTRkMmU4NmU2NmEzMzNkNDUwNGE2L3RleHRyZWdpb246MWE2ZTI4ZmRhZTU1NGQyZTg2ZTY2YTMzM2Q0NTA0YTZfNDMz_ed8005ad-9524-4584-9fb5-09ef42cc900f">ContingenciesContingenciesFrom time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIJ>0.DJ4'UK1M*6"<*A"X:Y$X?$:U:2$7)2;,\UD<1*K77K\^+B8.H2".!Q
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MR[*)'I@^,#+]Q=DF56A3B/S9!8H^Z6Z]W$"YT'>X*D26E?4VY8KI9:7@;IT
M5=<GOND> !;@?E8 ,%UW'6QZ"<)YQ!LHO+CK7_%H4[9<#3D&U.Z\O!;Z$#U1
MVVPC(!AQ@UYRO,1VKKKK%?%XL]BF!U6J2!\.BCYD6K= -S2C29$>)%JE0L8I
MXS'3A[A//+Y$VC>Y/K[K8V?\?2>RA!6PD_KM'I@@ ,S3O93I* "&[= CIJ<@
MG!.X VTF[OI,[(WNS2LJT[ANJM/L4)Z$*\?IYJ0^[X(N&.U=?W27GI1M/2E;
M-!7;>7"ZGAB/-\4_F*[HHGQPI,/Y-N7H(),NBO V4 \>GN:4?8G-<\, S$QD
M&&5N]#",! -IW#73>+R;_G%//:?[*WT5O,Y7,,ST%8SJ^0J$#?JJZ\;Q>#O^
MK7J"J*73HSZ";%GKH/KYEC@HJ71!T%LEZ(E)6_1)V=:3LD53L9V'J6O3\7B?
M7E?F.BA@(/I-LV][CF.F9!_FS3W<ZU1 -M<W<Q)@LT.?P#E)NF:=C#?KZV8U
M#LLE_=89D@O (+DP6T\NQ ;(M4X>0N>LV%9/_Z5>5P>NZH>-[=WV#<.'ZKFZ
M<7^%KVXP<'^-KZ+Z_4%'7[_.^$R+;<HERMA&#V5?!GJN1?V&H+Y08E\] G\0
M2HF\^KEC5!?!$J#_WPBAGB_* =KW-,M_ 5!+ P04    " ",A015K VHJ5X#
M   #"P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U6VV[;.!#]%4(M
MBA9H(EFVY&QJ"X@O1;-HBZ!IMP^+?:"EL46$(EV2LMO]^@XE1;5E1AML\R*1
MU)PS/$>\S&0OU9W. 0SY7G"AIUYNS/;2]W6:0T'UN=R"P"]KJ0IJL*LVOMXJ
MH%D%*K@?!D'L%Y0)+YE48S<JF<C2<";@1A%=%@55/V; Y7[J#;S[@4]LDQL[
MX">3+=W +9@OVQN%/;]ER5@!0C,IB(+UU+L:7"['-KX*^(O!7A^TB56RDO+.
M=JZSJ1?8"0&'U%@&BJ\=S(%S2X33^-9P>FU*"SQLW[._K;2CEA75,)?\*\M,
M/O4N/)+!FI;<?)+[=]#HB2Q?*KFNGF3?Q 8>24MM9-& <08%$_6;?F]\.  @
MCQL0-H"P"Q@] !@V@.%C,XP:P.BQ&:(&4$GW:^V5<0MJ:#)1<D^4C48VVZC<
MK]#H%Q-VG=P:A5\9XDPRET)+SC)J(".W!E^X"(PF<DWFLL"EE]LUL0/R7FI-
MSLB7VP5Y^?P5>4Z8()]S66HJ,CWQ#<[%,OIIDW=6YPT?R#LD'Z0PN29+D4'F
MP"_Z\7$/WD</6B/">R-F82_AGZ4X)\/@-0F#,'3,9_YX^, EY_>R+_]W]B,S
MANVJ&%9\PP?XVH5PN@ZN12H+(']?K;11N,W_<?W[FGWD9K='WZ7>TA2F'A)K
M4#OPDA?/!G'PQF7\4Y(MGI)L^41D1[]HU/ZB41][\A'O$(Y[TF5_C8PKI+TH
M=LE9'(?QQ-\=^NJ(BN*+\#AJX8@:!!=1)VSI"AN.1U$;=B0R:D5&O2*O=I1Q
MNN) \$8DFF)#0UHJ9AC8TTB@":7 ^Y&S?_'\VN"]2%Y:5UZY;*ES10=S')R8
M<AIS-NHX<AH2=,SH)3DR(FZ-B'N-^"P-Y42:'!1)C_;C?VB.'Z'Y-.9$\VE(
M5W,OR9'F<:MYW*OY^-RQ"@DU1K%5::HE82294TXSQ4I-9DSJE(%(0;^V9]2Y
MM:G 2@1OT/0NESP#Y=PK8\=>B8*.NKDC"O=*Q\B%(\JU5UQAN%?^Z-CE']SJ
M!:A-54YIU%4*4Q_E[6A;L5U5A4IG?#:XG \<XPNL\.J"[!=]71Y^H&K#A"8<
MUI@J.!_C?U5UR55WC-Q6-<5*&JQ0JF:.52HH&X#?UU*:^XY-T-:]R4]02P,$
M%     @ C(4$57#^^"E@#@  _JP  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6R]G6]SX[81QK\*Q\VTR4Q\%O]*2GV>R8DB 4R3WL1)^Z+3%[0$VYR3
M1(>DSDD_?4%9)QK$"B+MYWPOSI*]^"U([D(@GP5T^5B4GZI[*6OGC_5J4[T_
MNZ_KAQ\N+JK%O5QGU;OB06[47VZ+<IW5ZFUY=U$]E#);[AJM5Q?>:!1=K+-\
M<W9UN?O=Q_+JLMC6JWPC/Y9.M5VOL_+/#W)5/+X_<\^^_.*7_.Z^;GYQ<77Y
MD-W):UG_]O"Q5.\N#I1EOI:;*B\V3BEOWY_]Z/X@HEV#G<6_<OE8/7OM-(=R
M4Q2?FC=\^?YLU/1(KN2B;A"9^O%9SN1JU9!4/W[?0\\./IN&SU]_H2>[@U<'
M<Y-5<E:L_ITOZ_OW9Y,S9REOL^VJ_J5X9')_0&'#6Q2K:O>_\_AD&RGCQ;:J
MB_6^L>K!.M\\_<S^V)^(9PU<_T@#;]_ ZS0(PR,-_'T#O]/ 'Q]I$.P;!'V[
M%.X;A)T&WC$/T;Y!U+=+XWV#<=?#Z$B#R;[!I'L,Q\[2=-]@VFD0'//@CKY<
MN=$N@IXN^2Y>XJS.KB[+XM$I&WO%:U[L@F[77H5)OFGRX[HNU5]SU:Z^FA6;
MJECERZR62^>Z5C]4\->54]PZ\]^W>?VG<^[\=AT[WW[SG?.-DV^<7^^+;95M
MEM7E1:W\-Y2+Q=[7AR=?WA%?OQ9UMB*:S7HT<V;9*EN6^;9R/N1%M<CE9B&K
M[QV^6;Q3_2X6G^Z+U5*6U=_V_2;\Q'8_U[+,I<([ZIQ\EF6=WZRD\U&EJRS+
MW<E13@CJW$Z=%>NU&@>.M4[LK7]<+O-F'%$GX&.6+\_5!9AE#SE]'M,3K,5B
MN]ZN=E?ZG_6]+-6!KM6@>M^,=I^E\X^BHBXJZT^-Y6V^R&L"PD]<8C6T5]OR
MSZ.G2=C;_UQLSIO+5I?%2OWM3H5%+4M9U4W$7F]OJGR9J]%?!U^H5#GDBW?(
M%V_GR3_B2<5;TU?I?!O+IU??[7P0$>C\YQ?5&T<-XX]9N?POE2]/O@+:5_/1
M^$/UD"WD^S-UF2I9?I9G5W_]BQN-_DYE$1(6(V%S)"Q!PE(DC"%A' D3()B6
M,?XA8WP;_:H=0:LF2;YWJOM,>7'49*VJU0>)2E<J-:S0H:F!A,5/L' ':Z:?
MGZ_<D?IW>?'Y><PC729(6(J$,22,(V$"!--B/CC$?&"-^?V'_C[@;^1=OMDT
M'TLW:A*CYBW.M^HCXRD-OG.R6GUNJDF,[W[O>"-O1"6#U=O09$#"8B1L'IB9
M-?4G4R.Y$J37% EC2!A'P@0(IN5#>,B'T)H/'XP,Z!/U3\SH63CXGA=X>BS,
M**M@&NE6L6G5';!-"W?:"3O3) @GXV"BFZ6FV;GKZS:,L F\, P[O>*$W7C4
M<2@((R\,#D;:)8L.ERQZPXENA!S D+ 8"9LC80D2EB)A# GC2)@ P;2,&1\R
M9FP=Y'Z6M;.B[Z$_C(U/-C4DC(.P,Y;U,XNM_1@:LTA8@H2E2!CK=VHYTJ<
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MUNZ28'I;I^"SZTCQZ1>SLM#J^_*OPV=H;>7"U0])<4_26=^TQ477N[HX?R*
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M0IFNJSE*^ \[$BKS3"1%6VVMJ8?M3I49FD [$YYC_\460(3:"OSL@0M% >:
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ML4:"[BKHD5:V./S.#\AUV7SS[N61VE4VAT!AHJ.CVLF-Z*YORL%KWGJ&0Z$
MP%J<:QBG2-B$*9KI6NZJ*ULZ! ,@4U@T&H%ZBGPUVO4007!.CV$,KL%K^_<0
M"UW%%NL/TF*]TL??HH"%U)^DH=W7-2$ U"M13P_!EU+MD@QF&'J7:QL7.4O7
MEZH3\;HLA9R%XD >/YRT&O8:O=(\Y,IDXRO+5>@;NU\@-YR #C:U.=&,L)2
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M2P/J6TJ^Q+&Y#_K>C^XW3^B@%+".*%57[](GBFZRD5Y9GCVZMK-2;R<_%/8
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MAOXSJ3D*M)_F 73X6B(4[F[I[U0!!9=,9IP)8,8@B3"9@^ LY8);3B&T);/
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MMIP&HP!R+%@C[*U:?\1-/0/'EREA_"^LV]B4,F:-L:K:@,FNN&Q/]KCY#CN
M4?0"(-D $J^[3>157C++9A.MUJ!=-+&YBR_5HTD<EZXI=U;3*R><G<VS3#>8
MPQ?.EEQPR]%,0DO$[CG,-B2+EB1Y@60(5TK:TL![F6/^'!^2H$Y5LE6U2 X2
M?F[D":11#Y(H20[PI5V5J>=+7U\E_)POC=7TK_BUK^"6K[^?STW*V-0LPVE
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M&@TNQD%;L=N)TY5_P:RTH_>0'^;T $7# K2_UMIM)WQ _Z1=_@M02P,$%
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M#\_."TBF^^=A)>6%DQ(<D#(5[TQ:;*QXE48JZNX_AT:-6D&MUHO@J,"_ENE
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MZN)I@'[,#SQH*S?5YP[K,;RW#G'LDE.<SVY4> P<L=$JJB,4^#;20QGPFTO
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M"V20<C0 S^DU;WM!"W0?YZY_ U!+ P04    " ",A015\^P2X6,$  #G"P
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M#U04<(4YUADJ2&+OC6&-"EUX*;EM</OS, &FDJVVX?K=]"^.?_%+RJFR*0>
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M=/3\UJ/]F3^=-@BVHV9P['6L\*2@.'EAT_$#XXJC4FYU%D5Q%G4\C5!]C]I
M8+6JIT75TU?7G>F0S1@(K-:,6=&,V?_2G5EKOR&U+?W&KFQ'>2YT/?VNA$YI
MJLY RI,#F:3'&%(G6'%].)3ZY$AU^6GV41O4U<;27Z'1L2Y6H!RFL=A.JY'M
M,,]UNF02ELX'7[*^*"(\H#@$=_A N):B$:+O@1L*K5YPZ:MP_.H"!(W>W;LA
M Z'5&U)Z.32;>9<(P;8MH]FD:8V:J*X]67HW-)MW#P5J.W/KX)A"Z@1+YX9F
MZ^ZC0).7&9I"Z@Q+EX5&W[I<?:87+7([JHMA:7W0['VW+"8_U#3(G]2\OTNZ
M9BHC2.^3-A!:?>(JG14YKS]S&<V[]] U$%J](:63([.3=TD/:CLR0A/4'+PT
M87 *T5B_-5%E-#9;]^7Z@]JNW#S=QI ZP=*TD=FT>^A/CF1D: JI,RQ=%IG'
MUTOU![5G4^U*M\-,*UUZ'S)[WVT2TX >U#\_%\Q@9JS>1V\@M'KEI<<B__6U
MR&CCO1LR$%J](:6GHY?&\0XM:KLSG#C3YA"A"4,.\MV.'5H:.3(;>0\M,IET
M3O)B'T>ECR.SC_?1HO;$.G*;%#4Q';.86QJO:QYI+U6C',9OK'63HR9,K;4W
M;="T*]]LIS\KW&+^J-8.A&2G\IRKB2J2G[^I/]](=LB^[-XP*5F47>X)WA*>
M!JC/=XS)YYOT^_/B]Y+E?U!+ P04    " ",A015CTHDF8<"  "!!@  &0
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M!=),P/&%$/JE8R[XZCT7_@-02P,$%     @ C(4$51[LNR<E P  Z@P  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULS5=M;YLP$/XK%I.F3=K*2T*2
M=@E2DW9:IU:+FG7],.V#"Y=@%6QFFZ3[][,-H2$E;)60VB]@'W?/W?-P1L=X
MP_B]B $D>D@3*B96+&5V8MLBC"'%XHAE0-63)>,IEFK+5[;(..#(!*6)[3G.
MP$XQH58P-K8Y#\8LEPFA,.=(Y&F*^9\I)&PSL5QK:[@FJUAJ@QV,,[R"!<B;
M;,[5SJY0(I("%811Q&$YL4[=DYEK HS'#P(;L;-&FLH=8_=Z<Q%-+$=7! F$
M4D-@=5O##))$(ZDZ?I>@5I53!^ZNM^B?#7E%Y@X+F+'DED0RGE@C"T6PQ'DB
MK]GF"Y2$?(T7LD28*]J4OHZ%PEQ(EI;!JH*4T.*.'THA=@(43G. 5P9X^P']
M P&],J!GB!:5&5IG6.)@S-D&<>VMT/3":&.B%1M"]6M<2*Z>$A4G@PL:LA30
MNTLFQ'LT!XX6,>;*< 82DT39/B*A+6)[(Q1]CUDN,(W$V):J!HUDAV6^:9'/
M.Y!O@*X8E;% YS2"J!YOJ]HK MZ6P-1K!?R:TR/4<SX@S_&\AGIF_Q_NMI33
MJ_3L&;S^ ;R%9.$]^I;I'FV4IS5<']H3D>$0)I8ZE0+X&JS@[1MWX'QJXM81
M6(UIOV+:-^B] TQ/J20127)]#-$"PIP3251_G#^$2:[>+5IREJ(92[-<8G-D
MV1*=8TX)78F=3OMYJ8#1A814_&H2K-^E8!V!U03S*\'\UM:H"28>!8.:8&%=
M,-@*EBG!S ELTJA([)O$^L.]#KR!JT[#>I?[4R?7<?S*J<9I4'$:M'*ZQ9QC
M*AL[O37RN2^N([ :R6%%<O@J.GW8I6 =@=4$&U6"C5ZJTT=/.]WM^<.]5O^7
M5XW5<<7JN)75-0C)22A5_<57_H:2YLYOQ7GNB^P(K$;9=1[' ^=5]'Y91D>:
M=856%VUGIG)?JO_+S+6O>-_O[_5_@]?P>+37_O;.U)@"7YEA6JBR<BJ+^:NR
M5@/[J1E3]^Q3/<B;:?01IO@+N,)\1:A "2P5I',T5!7Q8K N-I)E9C:]8U)-
MNF89JY\1X-I!/5\R)K<;G:#ZO0G^ E!+ P04    " ",A015J11@2)D#  !S
M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6S-6-MNVS@0_15"&RQ:
MP(E$R9<D:PMHG TVB[0(DC9]6.P#+8UM(I3HDI3=_GU)29&L6*%K5 'B!YND
M9@[/''+$H<<;+A[E$D"A[PE+Y<19*K4Z=UT9+2$A\H2O(-5/YEPD1.FN6+AR
M)8#$N5/"7-_SAFY":.J$XWSL5H1CGBE&4[@52&9)0L2/"V!\,W&P\S1P1Q=+
M90;<<+PB"[@']65U*W3/K5!BFD J*4^1@/G$^8#/IWAD''*+!PH;N=5&)I09
MYX^F<QU/',\P @:1,A!$_ZQA"HP9),WC6PGJ5',:Q^WV$_I5'KP.9D8D3#G[
M2F.UG#BG#HIA3C*F[OCF'R@#&AB\B#.9?Z--:>LY*,JDXDGIK!DD-"U^R?=2
MB"T'W'_!P2\=_%]U"$J'( ^T8):'=4D4"<>";Y PUAK--')M<F\=#4W-,MXK
MH9]2[:?"*T(%>B L _01B,P$Z#52$KV[!$4HD^_1,;J#*!."I@O=_G)_B=X=
MO4='B*;H\Y)GDJ2Q'+M*<S&(;E3.>U',Z[\P[[]9>H("KX=\S_=;W*=V]TN(
MM#O.W7'3W=4*5#+XE0Q^CA?LE:&'/D@)6@$=%[JA9$89513DDSPQTINO5L18
M?>*IJ 8NB*02_7>C)T#7"A+Y?YLX!9M^.QN3NN=R12*8.#HW)8@U..&??^"A
M]U>;5!V!-80+*N$"&WKXD8A'O5-F#) T&A1:'2.RUKLG']:O&B0)@S89"NQA
MCFU>..LP.!OV@[&[WHYOUVKD!7YMU2#>KXCWK<2+5>ZAN5GY=9X ,941XV:1
MV[@6<(,M%OT6KKM6%JZ#BNO RO4&UL 0;F-E=3QT(W4$UHAQ6,4X?%,9..Q2
MN([ &L*-*N%&KYB!HYW]ZCW;T3:+!N'3BO!IMYEWNI>CS:+!\:SB>/8+&==V
M,%U8'0_=.!V!-6+$7GWV>V\JYTHZ'6G7%5I3O*W"";]BWI7@@SU'7XN9Y3S!
M=;F#K47!X3E8XNWENVMFXUM7&=A>9A3Y&+0RLWH>O*DZ0FO&61<EN/^V,M):
M)!TL7D=H3?'J*@G;RZ3?S,C!WF/&:M(D79<]V%H<A']_RZCZ@>XKPCUT]7#\
MZ;J'IGHE]5VLE>MPAPCV].<YW]>H2W!=F&![97+X2V:T4^FWAK5K]GP9W*T;
ML?D[0F^-!4TE8C#7/M[)2$LGBAM^T5%\E5^29USI*W?>7 *)01@#_7S.N7KJ
MF'MW]3]+^!-02P,$%     @ C(4$51K=&B:C @  ! <  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&ULK55=3]LP%/TK5D ()$82IPD%VDC0:F+3IB$*
MV\.T!S>];2P<.[/=%O[]KI,2A394F[27QA_WG'N.W7L]6"O]9'( 2YX+(<W0
MRZTM+WW?9#D4S)RI$B3NS)4NF,6I7OBFU,!F%:@0/@V"Q"\8EUXZJ-;N=#I0
M2RNXA#M-S+(HF'ZY :'60R_T7A?N^2*W;L%/!R5;P 3L8WFG<>8W+#->@#1<
M2:)A/O2NP\M1XN*K@.\<UJ8U)L[)5*DG-_DT&WJ!$P0",NL8&'Y6, (A'!'*
M^+WA])J4#M@>O[)_K+RCERDS,%+B!Y_9?.CU/3*#.5L*>Z_6M[#Q$SN^3 E3
M_9)U'1O''LF6QJIB T8%!9?UESUOSJ$%"'OO .@&0/\6$&T 466T5E;9&C/+
MTH%6:Z)=-+*Y074V%1K=<.EN<6(U[G+$V?0ZR_029N0+9U,NN.5@R/$8+./"
MG) /Y'$R)L>')^20<$D><K4T3,[,P+>8VS'XV2;/39V'OI/G\U*>D2@X)32@
MM ,^V@\?0X;PL(*';^$^.FYLT\8VK?BB?[#]\WIJK,;_U:\N>S5?KYO/U=JE
M*5D&0P^+R8!>@9<>'81)<-5E]C^1O;$>-=:C?>SIA FFT>\I@:(4Z@6 3$'"
MG%M#\&ZQ- 6S>#26/4/G1=?T247OFL0J#:.+\X&_:CO<#:)!U&N"WBCO-<I[
M>Y5_*T$SR^6"",#*):)U>4<'?1K2*RP9K4':+MTU>=S6?=[?DKT;0^E%M^JX
M41WO5VUST%UZXIU<23_>TK,;$]&D6T_2Z$GVZGE0E@ELGW4!M,ZP2V.R>XTT
M";9$=@3%_>U3\UL]RKT/7YE><&GP*N<("\[.T:2N>VX]L:JLVM9466R"U3#'
M9PJT"\#]N5+V=>(Z8?/PI7\ 4$L#!!0    ( (R%!%5E1Z(U3P(  ((%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)6446_3,!#'OXH5)#0D:%)W
M[: DD=9-B"$8U2;8 ^+!32Z)M<0.MI-LWYZSDT8%TDJ\)+ZS[W^_LWT..ZD>
M=0%@R%-5"AUYA3'UVO=U4D#%]$S6(' FDZIB!DV5^[I6P%(75)4^#8*57S$N
MO#ATOJV*0]F8D@O8*J*;JF+J>0.E[")O[NT==SPOC'7X<5BS'.[!?*NW"BU_
M5$EY!4)S*8B"+/(NY^O-TJYW"[YSZ/3!F-A*=E(^6N,FC;S  D$)B;$*#'\M
M7$%96B'$^#5H>F-*&W@XWJM_<+5C+3NFX4J6#SPU1>2]]4@*&6M*<R>[CS#4
MXP 366KW)5V_]B+P2-)H(ZLA& DJ+OH_>QKVX2" SH\$T"& .NX^D:.\9H;%
MH9(=478UJMF!*]5%(QP7]E#NC<)9CG$F_EJ#8H:+G'P&+$Z3-^26*>MJ@9Q=
M@V&\U*]"WV N&^$G@^ZFUZ5'=#\U8D86P6M" TJ)S#*>P)\J/I*.N'3$I4YV
M<41V@/QQN=-&X8G^G"+K)<ZG)>PM7^N:)1!Y>(TUJ!:\^.6+^2IX?P)P,0(N
M3JG'MTVU X4%#S5KTHC4.L9]+ET)4]R]\M(IVV9J8QKZ[03,^0AS?A+FP=U)
M2 EK,7L.V$6V3T<*8D!5!#O['SQRQ@5Y!J:FS_YT6MI'GMC-Y5C \O\*2+E.
M9",,05HX0HZ.!(29!._3S1<'>QS,@G<KNOQKI_V#EK*OTQ>F<BXT)LDP,IA=
MH)+J.[XWC*Q=E^VDP9YUPP(?25!V <YG4IJ]81MW?';CWU!+ P04    " ",
MA015)K&W<?T"   C"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RM
M5FMOVC 4_2M65DV=5)H7A)1!I)9JVJ9.167=/IMP :N.G=D.=/]^MI.F/ )=
M6[Y G-QS<L[AVMS^BHL'N0!0Z#&C3 Z<A5)YSW5ENH ,RW.> ]-/9EQD6.FE
MF+LR%X"G%I11-_"\R,TP84[2M_=&(NGS0E'"8"20++(,B[]70/EJX/C.TXT[
M,E\H<\--^CF>PQC4?3X2>N76+%.2 9.$,R1@-G N_=[0]PS 5OPBL))KU\A8
MF7#^8!;?I@/',XJ 0JH,!=9?2Q@"I89)Z_A3D3KU.PUP_?J)_8LUK\U,L(0A
MI[_)5"T&3NR@*<QP0=4=7WV%RE#'\*6<2ON)5E6MYZ"TD(IG%5@KR @KO_%C
M%<0:((CW ((*$/PO(*P H35:*K.VKK'"25_P%1*F6K.9"YN-16LWA)F?<:R$
M?DHT3B6W.0BL")NC&]!I2-1"5YABE@(:VS8:"9# %+:AGUZ#PH3*3[KL?GR-
M3D\^H1-$&/JYX(7$;"K[KM*J#+>;5@JN2@7!'@7?"W:.0N\,!5X0-,"'A^'7
MD&JX;^'^)MS56=2!!'4@@>4+]_#91F[Q&;J7@"ZE!"5[3:9*EG8SB]E\/9GC
M% 9.;@(42W"2CQ_\R/O<9/%(9!N&P]IP>(B]-MPJM&%L#3?Y+4DB2V+.AF42
M>7'?7:[;V*WI!NVZ9D-=NU;7?JVZ,[UORPXM#SH#041!UB3[,/NM6H#8;WKX
M5O2&U4YMM7.P\[:V(KHA>$(H402:.[!SS X\$MF&\:@V'AW.L39.K7'Z;/Q,
MGX%"Z/.G*8!HI]W\[G9+[M8$P45S2W9KN=VWRV6<'5!<$G?6U(1QN*5XMZ8=
M=YH5Q[7B^*V*FU3&.YEU(G]+Y6Y-U]^SU2]JE1?O;H-7[?W#K[M,4U' ](4P
MAN\DV4C"]Y[_E;UC]-BKXGCIE?8THYS-6PI$]E(NQV(K W+7)A@S/O[ 8DZ8
MU.YGFMX[[^K](,J)K%PHGMNA9L*5'I'LY4)/L2!,@7X^XUP]+<R<5,_%R3]0
M2P,$%     @ C(4$5== )7#3 @  IPD  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&ULK99K;]HP&(7_BI554RNMS8V$RR!2"ZJVJ=50+]MG$U[ JF-G
MM@/MOY_MA(A"2">T+R1V?(Z?8^/+<,/%BUP!*/2:429'SDJI?."Z,EU!AN45
MSX'I+PLN,JQT42Q=F0O <RO*J!MX7NQFF# G&=JZJ4B&O%"4,)@*)(LLP^+M
M!BC?C!S?V58\D.5*F0HW&>9X"8^@GO.IT"6W=IF3#)@DG"$!BY%S[0_&?=/>
M-OA%8"-WWI%),N/\Q12^ST>.9X" 0JJ, ]:/-8R!4F.D,?Y4GD[=I1'NOF_=
M;VUVG66&)8PY_4WF:C5R>@Z:PP(75#WPS3>H\D3&+^54VE^TJ=IZ#DH+J7A6
MB35!1ECYQ*_5..P(_,X105 )@G\5A)4@M$%+,AMK@A5.AH)OD#"MM9MYL6-C
MU3H-8686'Y707XG6J>1G#@(KPI;H#O1H2'2);@M5"$#WA)&LR,IZ-,5O>NZ4
M1.<34)A0>:%;/C].T/G9!3I#A*&G%2\D9G,Y=)4&,_9N6D'<E!#!$8@?!;M"
MH?<%!5X0-,C'[?()I%KN6[G_7N[JX:C')*C')+!^X1&_6\(P2X^-0%.\TJ_3
M[&<6XD#F.(61HU>:!+$&)_G\R8^]KTUA_Y/9N^AA'3UL<T^.3,!-J8JMRFP,
MZ\3WPJ&[WN5N=3Z1NU-S=S[B#INX2U6TPQWXW3WN5N<3N:.:._J(N]/$'1UP
M^WUOC[O5^43NN.:./^*.FKCC0^[._O^DU?E$[F[-W6WE?N(*4T3M@LY;%G3W
M($<<[>=H[>G$'+TZ1Z\UQQU(.4#7&2_,GBS =L'L/DZ8 EU23;%Z![$N^\%>
MK-:.3XS5KV/U6V--RQAHC6D!B"^JF:($SP@EBD#C9/4/-J<H]O=2';;I^IVZ
M30GK[ARCY@ISC\62,*DA%EKE777UP(GR6E 6%,_MR3KC2I_3]G6E;U(@3 /]
M?<&YVA;,85W?S9*_4$L#!!0    ( (R%!%7\L0.)3@4  )L?   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;*U9;6_J-AC]*U9VM;7271.'EY8.D"C)
MW3J-";6WVX=I'TQBP&H2<VVG].[7[XD3 J'!+9+[H>3M'#OG^.W$PRT7SW)-
MJ4*O:9+)D;-6:G/KNC):TY3(*[ZA&=Q9<I$2!:=BY<J-H"36H#1Q?<_KNREA
MF3,>ZFMS,1[R7"4LHW.!9)ZF1'R_HPG?CASL["X\L-5:%1?<\7!#5O21JJ?-
M7,"96[/$+*699#Q#@BY'S@3?AGA0 /03?S&ZE0?'J'B5!>?/Q<E]/'*\HD8T
MH9$J* C\O- I39*"">KQK2)UZC(+X.'QCOV+?GEXF061=,J3OUFLUB/GQD$Q
M79(\40]\^QNM7JA7\$4\D?H_VE;/>@Z*<JEX6H&A!BG+RE_R6@EQ  ">=H!?
M ?R/ CH5H',,Z)X ="M ]Z. 7@70K^Z6[ZZ%"X@BXZ'@6R2*IX&M.-#J:S3H
MQ;*BH3PJ 7<9X-3X4?'H><V3F KY$PJ_Y4Q]1S_O#NZES$D648DN JH(2^0E
MW'QZ#-#%ITOT";E(KHF VRQ#3QE3\C-<A.,92Q)H!G+H*JAC49(;5?6Y*^OC
MGZ@/1C.>J;5$81;3N 4_->/[!KP+VM0"^3N![GPCX8R(*]3!GY'OX4%;?<SP
MW_,,X%X!]_T6>/ !N-?5<-P"#S]<^G'E&V)TZM;2T7S=$WQ_L P:7(;F1#RC
MR4I0"F.&:G/9R%.,?K=R0R(Z<F!XDU2\4&?\XP^X[_W2)K%-LL F66B)K&%&
MMS:CJ]D[)\R8)D1*Q)=(]V'T#YA#T;VBJ?RWS9&N34=LD@4VR4)+9 U'>K4C
M/6/WF*R@2ZR(HN#*D@J6K1!)>9XI1'*UYH+]1V.TH0(14]<QEG&N43;) IMD
M84G6UV3%<N9E[/>'[DN+_/U:_KY1_BE/4Z8*6>MI">8OD)Q(%,%LQ&"2(WIY
MTO  7<",50(NV_PH"^T=5!3?X![VZLJ62AOK=J[2-LE"2V0-3ZYK3ZZ-GOR9
MIPL0&T:IRA():XWW%+]^H[C?\^#O2'%CR><J;I,LM$364/RF5OS&J/A<L(BV
M"1[S)"%"ZL:O[[5J;R0_=_2Q21;8) MOWHP^W?;!9U#+/C#*_JO@,!MOM/B0
MWY#4D[(2))-$9Z(VL0=O:H&/VKBQT',5M$D66B)KB(V]?6SQC')_I2(M&GES
M%$_UVK^U7;_#U^E7X-;(8<2>ZX)5MM 66].'@_B(SQO?29+P+5DD%"F.8B9H
MI'1_>*"K'(8?-,]%M(9D_]X<8"[WW('(*EM@E2VLV!H+#*\QW36]\??>^$9O
M9N25I3ETDT7"5ON%3VE*L1+=67$P2K5ZU>J/L>RS_;')%EAE"RLVW#U<CUSU
M3KBSC]+8G*5W[ASV&S %>L4DBFA2+%7AM.XN1$_<43'2[3O;?=;2KZK'VGN5
MU5QNE2VPRA96;-@_<*USPK-]XL;&^&C%,^AL,3P4YSH?R@V-V)*5N9#Q^!W[
MK(9XJVR!5;:P8FO8YUV=,G ?T+$YH>\,7-",+EG$2(+X-J-"KMGF8.HZRH=&
M2ZS&=:ML@56VL&+#O88EWF P..'*/K=C<W"??)V9OR::\6>+;#6J6V4+;;$U
MG=BG=7QM\YLBMIF:IU;9 JMLH2VVIB_[3(_-H=[.ET5S(6?;937=X[>)O'?T
MP2>T56+3A'W"Q^:(7_:)ZIOBA2F[V S:TXJM,>PVA0FL%AC:8BME=@\V)U,J
M5GI7N/@@"ZVWW*>LK]8[SQ.]W^KN'R^WK6=$K%@F44*7 /6NKD$34>X$ER>*
M;_16YX(KQ5-]N*:PW!+% W!_R;G:G10%U/OQX_\!4$L#!!0    ( (R%!%79
M*F^TY0<  "A"   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+6<:W/:
M.!B%_XJ&[>RV,RD@R3;039A)XNQN=Z;33-/+9Q<4\-38K"QR^?<K7["0;60)
MY"\M.-9Y[<="G,.+N7Q.Z*]T30@#+YLH3J\&:\:V'T:C=+$FFR =)EL2\[\\
M)G03,/Z4KD;IEI)@F0_:1",T'GNC31#&@_EEONV>SB^3'8O"F-Q3D.XVFX"^
MWI H>;X:P,%^PY=PM6;9AM'\<ANLR -AW[;WE#\;52K+<$/B-$QB0,GCU> :
M?O!=E W(]_@>DN?TX#'(3N5GDOS*GGQ<7@W&V1&1B"Q8)A'P_Y[(+8FB3(D?
MQW^EZ*"JF0T\?+Q7_RL_>7XR/X.4W";1CW#)UE>#Z0 LR6.PB]B7Y/D?4IZ0
MF^DMDBC-_P7/Y;[C 5CL4I9LRL'\"#9A7/P?O)0@#@8@[\@ 5 Y N@-P.0#7
M!D#GR "G'.#D9(I3R3GX 0OFES1Y!C3;FZME#W*8^6A^^F&<7?<'1OE?0SZ.
MS1]8LOBU3J(EH>D?X.Z_7<A>P7N0;P:?M]FU24$0+\&/@-(@9BEXZQ,6A%'Z
MCN_V[<$';]^\ V_ "*3K@)(4A#'X%H<LO> ;^>.OZV27\O'IY8CQP\V*CA;E
MH=T4AX:.'!H&GY*8K5-P%R_)LF7\K7J\IQ@_XI@J5FC/Z@8I!3\%= @PO !H
MC%#;\:B'_[N+^?#QT>&^>KA/%E5UJ#@;7%UYG.MAU97?7^(+\)!?OK:K5,@X
M[3+9NO0AW08+<C7@"T]*Z!,9S'__#7KC/]L0V13S+8E)^)P*GZ-2GU?@/N]8
MRO@,#^/5!;@AJS".^4.0/()[0L-D"=[RET'QXGC7AK<HX^9ELE7Z:8X@AE-G
M=CEZ.B2GN9^O/.P3H;@5%%</RM_96D$ZSUVI9CJUW 8@UYEXXW&-CZ6:$A^O
MXN/I\;E[(701IMV$E'JFA+P&H3H<2^4D.),*SD0/#G]#?R2AQO11ZIG"F33@
MO(<3MS%]+-64"$TK0E/=Z;,-:3<?I9HIGVF3CS/S/*?&QU)-B<^LXC,[84WF
M;__ZJ[&R@"FR67/)]B!"4[?&S%)1B1D<"P<XUJ/VG:39BRYS>^1ERXTY?\(2
M\,0W=V%3ES#E5JI)X-R),T'UR6:KK$SNP#M#(W)=D)1JQI!@ Q+$T^D,UV>7
MK;(R)"0@(1.?^2-/8AS6]1.A/%E6;X7@GH8+TLH-6>5F4\VWI2;#%1X>*CUN
MZXHW/.I"ETD4!30%6T*+>=H^38N2TT,C-:RO\[=:>_GJPS\5C_#H4-.D'_I1
M30J6?'1)JU"#WJ'W&LY@'5<?YAT*]PXU[;ML3S6!637SL.GFZT[,5D$9EK#R
M4-/+RW95$Y957U^J2;,+#CU4!]:'NX?"WD--?W_H7C5Q677ZI9J$"TV&>%+G
MU8?7A\+L0TVWW^%F-1%:#0.EFH30&2*O3K"/- !%'(":>:#+V6HBM!H.2K4:
M0MQX2^@C'" 1#I!9.-"GI18VI56J'=H-;SBKKW"V:LJP1!Y \"RK>YO$C 8+
MM@LB\)7033XA/_)M89R&"_ ]B':M!AA9#0Y6U7Q;:C)RD2Z0TF ?620;Y+^0
MK >6.>+Z-6CEK:XY :\DF_\0@DW188 SL Q>VSX]O]74FE12DV-2OEKJ5-0B
M:R#-K*%83<]';[7;T'%&#?A'+Z-OZ[AD]B+((,T@4[ _'[/5=--Q\%Z)&>TQ
M(^\XYSX2$!()"&DF(&DYN5ZM*%D%C&@MUE9S4*DFY<;ZFYYJ%YF#"#=(,]PH
M7^MF7*Q&'M3=R[!54$8HX@[2C#O[EZP9+:N)IU13SJ(^P@X280=-E=9I__4"
M52,:68TP5M5\6VHR/I%TD#KI"'SGMJ-12],"8M=K-%)OM??TU0=_(APL,@Q6
M9Q@!1[,MK=8S_LI#LYM1!V2KH Q(Y!:L[F,(0-I]:;6B,:)F+Z.!J(^<@47.
MP&J?+A!I=Z?5BL:(4#>B/O(!/O@^D=I-'\XBK?:T6L\8$.X&U(>)Q\+$8[4/
M/K)(&_6GU26,F;5^J:AM";=55T8G?#E6^W*![HPFM;J&,;MFA^(8NSX:%5AX
M>:SV\@UV79BL&G7<-.K',/7AU['PZWBBZ4!/:%%CJW;=JIIO2TWF*IP]5K<Q
MJB\.:SE3O<^6RY*'GP:CX;3>HM;:RU<?_JEXA'/'NL[=O$>MEC:>=4T_WWB)
M]F'D'6'D'5TC?TJ#6BUN2LOI=O6V"LJTA*MW=%W]*1UJM;@QK6Z#;ZN@3$L8
M?$?7X)NWI]72QJRZG;ZM@C(KX?0=/:=OIS.M+F9,#[<T]YNKOJVB,L&#FP<Z
MHH#:8ER(VVU*SW;-X=[M_>[7)-_<"M-J/G!:OK;4!K./<."(<."8A8-.!V<R
M.:UFAE*MPY'8JBGC%'G!\4XUPJ<VL!VKD<*JFF]+3:8M8H>C;A,<^5#@S/Y>
M1U&G[,@Y5=<9'VU@=TCA?3-\K-'!5FN=REI$$4<OBO3;PE8?A/%D5Y^2&?X^
MHHXCHHZC&W4L=;'5]8Q)JX_>C'0?0<D50<G5"TIGM+'5%8SOS1MW-B"5N\@<
M1 1R=2.0O3ZVNJ0QF.Y@9*N@S% $(U<W&)W4R%:K&^-"W?/(:C8:'=Q:OR%T
ME?]$00H6R2YFQ5WVU=;J9Q"N\YO_1V+WXC<4/@5TQ6&!B#SRH>/AA%]T6OPL
M0?&$)=O\1OV?"6/))G^X)L&2T&P'_O?')&'[)UF!ZL<AYO\#4$L#!!0    (
M (R%!%6$=4\&! 0  ,D2   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;,5876_;-A3]*X16; W06J(L^2.S#21.AW5HAB!9VH=A#XQU;1.11)>D[!C8
MCR])*;)DRX1=",A++%'W'IUSQ4N><+1A_%DL 21Z2>)4C)VEE*M+UQ6S)21$
M=-@*4O5DSGA"I+KE"U>L.)#()"6QZWM>STT(39W)R(S=\<F(93*F*=QQ)+(D
M(7Q[#3';C!WLO [<T\52Z@%W,EJ1!3R ?%S=<77GEB@132 5E*6(PWSL7.'+
M*1[H!!/QE<)&5*Z1EO+$V+.^^1R-'4\S@AAF4D,0];.&*<2Q1E(\OA>@3OE.
MG5B]?D7_PXA78IZ(@"F+O]%(+L?.P$$1S$D6RWNV^1,*0:'&F[%8F+]H4\1Z
M#IIE0K*D2%8,$IKFO^2E*$0E0>$T)_A%@K^?$!Q)Z!8)72,T9V9DW1!))B/.
M-HCK:(6F+TQM3+920U/]&1\D5T^IRI.3!\EFSTL61\#%;^C3]XS*+?J([D%(
M3F<2(F0B$$FCP\''E$J!WM^ )#06%RKO\>$&O7]W@=XA%XDEX2 03?.X#VI0
M7?^S9)E0:&+D2L5?LW!G!=?KG*M_A&L/W;)4+@7ZE$80U?-=I;L4[[^*O_:M
M@']E:0=UO0_(]WR_@<_T]'1LH=,MOT77X 5'\/;KVU0A*X+N^4NQ(C,8.ZJI
M!? U.)-??\$][_<F>2V!U<0&I=C H'>/33P].S[J#HS0E"5J61+$-/85YR1=
M@%HJ)'K:HFK<'=F:X:L-X1'Z]XN"1)\E).*_IE(%;9:J);!:J<*R5*%U7OR=
M)4_ $9N7+25$MM\ N>8<*#1 >@5?3[#7P[@?CMQU5<YA7-?S@M KPVI$>R71
MGI7H5Q)G<!+/'*=7>?^PW]WC>!@3] ?-!/LEP;Z5X#>SJJN91-; U2Z%5,=1
MM1>HD3FA'*VU@":^.>R@PL7K#/T]PH=!N!,.FQD/2L:#L]8$]#^ZI2E-LJ2)
MIA7KW"G?$EA-]K"4/7SCU6'89JE: JN5"GN[+=RSMYV>Q>D"2>")VHZW0+BX
M:-Q>[3@8Z=0F??;$GQ58\2CX["8@+\>:P YV[J=M"ZTNW=])]]^X$0H";96K
M);1ZN78."MLMU.FM8,<)3"LT>=2I/?-G%>YL$[9:C<->,.:Z46*K!J@MM+KL
MG07"X5OW@=6$G5VNEM#JY=H9,6QW8F=8Q@*IYAF[_>&@Y^W9FX; (!SX0=CL
M</#.E&&[*SO=-A9 54^(_=Z^N6V(ZOM'?!C>&3%L=V*G+RUV',LNVZKC<BN'
M @GPA3DK$6C&LE3F_R*7H^5YS)4YA=@;O];G-.:P80>3'_+<$KZ@J4 QS!6D
MU^FKN<'S<Y/\1K*5.7IX8E*RQ%PN@43 =8!Z/F=,OM[H%Y2G5Y,?4$L#!!0
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ME"_(#9,K3ETAP251>JTS2DR67;F<:)';QK80FMJD'<;TD*$T#K2^%$)O)R9
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M>&UL+G)E;'/-V;MNPD 0A>%707X EIE9;A%0I:&-> $+EHL V_)N%'C[6%#
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M&QZWORWOFR^/R@UG!S]^%K]02P,$%     @ C(4$5:C*A]FK 0  01H  !,
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MCD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A <MR Y)B
MY+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M
M(:M (:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(:M$(6N"0M8$A:P)"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+
M 0(4 Q0    ( (R%!%4'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ C(4$5<**C?3N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MC(4$59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " ",A015-DI53]L%  #7'@  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MC(4$52AMA_L5!@  >A@  !@              ("!'@X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (R%!%522!R\4 ,  '<+   8
M          " @6D4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " ",A015Z0*J%'P%  "S&0  &               @('O%P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ C(4$5:P-J*E> P   PL
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M965T.2YX;6Q02P$"% ,4    " ",A015$^EI&PD$  !Y"@  &0
M    @(%%6P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M (R%!%71RB\LWP(  &D&   9              " @85?  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ C(4$51VC:&^K!   "0P  !D
M             ("!FV(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " ",A0157;^NJ8T"  #/!0  &0              @(%]9P  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (R%!%76JEO!F00
M -X*   9              " @4%J  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ C(4$56INS\)9"@  T!T  !D              ("!
M$6\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " ",A015
MB189+HX$  "C"P  &0              @(&A>0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( (R%!%7BI'@?Y@@  "H6   9
M      " @69^  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ C(4$56T%Y*W, @  . 8  !D              ("!@X<  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " ",A015W[=8;&8*  "H&P
M&0              @(&&B@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( (R%!%7S[!+A8P0  .<+   9              " @2.5  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ C(4$5<[<+B>B
M @  Q@4  !D              ("!O9D  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " ",A015?)O;EQ$#  !0!P  &0
M@(&6G   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (R%
M!%4FW96SG0(  - %   9              " @=Z?  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ C(4$5> @3WY> P  4P@  !D
M         ("!LJ(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " ",A015]&!,9D,$   5#   &0              @(%'I@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( (R%!%47OJ[@^P,  ,X*
M   9              " @<&J  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ C(4$55)QLRSB!@  RS(  !D              ("!\ZX
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " ",A015E/=^
M>Z@$   [&0  &0              @($,M@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( (R%!%6/2B29AP(  ($&   9
M  " @>NZ  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MC(4$5=+.8D#9 @  VPD  !D              ("!J;T  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " ",A015'NR[)R4#  #J#   &0
M            @(&YP   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( (R%!%6I%&!(F0,  ',1   9              " @17$  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ C(4$51K=&B:C @
M! <  !D              ("!Y<<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " ",A01594>B-4\"  ""!0  &0              @(&_
MR@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (R%!%4F
ML;=Q_0(  ",+   9              " @47-  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ C(4$5== )7#3 @  IPD  !D
M     ("!>=   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (R%!%7*1AX'-0,  $<,   9              "
M@7;I  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ C(4$
M5=PF+<O= @  )@<  !D              ("!XNP  'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " ",A015]<:YMW0$  "3&@  &0
M        @('V[P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( (R%!%5)E%FY:0,  +T7   -              "  :'T  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ C(4$59>*NQS     $P(   L
M ( !-?@  %]R96QS+RYR96QS4$L! A0#%     @ C(4$51!U;XBE P  WAP
M  \              ( !'OD  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M (R%!%7N2=W_G@$   @:   :              "  ?#\  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (R%!%6HRH?9JP$  $$:   3
M              "  <;^  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S
- #, W T  *(  0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>249</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusinessDetails</Role>
      <ShortName>The Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TheBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="clbs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="clbs-20220630.htm">clbs-20220630.htm</File>
    <File>clbs-20220630.xsd</File>
    <File>clbs-20220630_cal.xml</File>
    <File>clbs-20220630_def.xml</File>
    <File>clbs-20220630_lab.xml</File>
    <File>clbs-20220630_pre.xml</File>
    <File>clbs-ex311_20220630xq2.htm</File>
    <File>clbs-ex32_20220630q2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="537">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "clbs-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 141,
   "dts": {
    "calculationLink": {
     "local": [
      "clbs-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clbs-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "clbs-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clbs-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clbs-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clbs-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 382,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 12
   },
   "keyCustom": 53,
   "keyStandard": 196,
   "memberCustom": 8,
   "memberStandard": 30,
   "nsprefix": "clbs",
   "nsuri": "http://www.caladrius.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.caladrius.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Available-for-Sale-Securities",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "shortName": "Available-for-Sale-Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Income (Loss) Per Share",
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "shortName": "Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Fair Value Measurements",
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Accrued Liabilities",
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Operating Leases",
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Stockholders' Equity",
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Share-Based Compensation",
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Income Taxes",
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Contingencies",
     "role": "http://www.caladrius.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Available-for-Sale-Securities (Tables)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Income (Loss) Per Share (Tables)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "shortName": "Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Business (Details)",
     "role": "http://www.caladrius.com/role/TheBusinessDetails",
     "shortName": "The Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bfdf542e13048bbbd63568d248c0ea6_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Income (Loss) Per Share (Details)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "shortName": "Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "ia0005abe2ec946f7964f5b4030e33a74_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i72a20efaf2c54cf49ab436cebbcce5d7_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i72a20efaf2c54cf49ab436cebbcce5d7_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i36939ec815f849cd909b1f34151f6a3b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i881d1b5361494535a4dff620655e80cc_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i881d1b5361494535a4dff620655e80cc_I20190630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i6a4a7a34fc2249628d10e950713caaf8_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i28e89e3894634aa0a0e433f5c6b1e9ec_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a169106c4a54b75a790607dc184b040_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a169106c4a54b75a790607dc184b040_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "id96396af1f5f4e578519538caff67b2c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "id96396af1f5f4e578519538caff67b2c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i6a4a7a34fc2249628d10e950713caaf8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i6a4a7a34fc2249628d10e950713caaf8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i1a627c8b45ed493b84f0af4a685e567d_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i11509a49300e4d2cad12d712bd9a7433_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i11509a49300e4d2cad12d712bd9a7433_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Business",
     "role": "http://www.caladrius.com/role/TheBusiness",
     "shortName": "The Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220630.htm",
      "contextRef": "i4bc1cdaddb48455fb69a358f3d6b1d86_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "clbs_AggregateIntrinsicValueWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AgreementAndPlanOfMergerAndReorganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement And Plan Of Merger And Reorganization",
        "label": "Agreement And Plan Of Merger And Reorganization [Member]",
        "terseLabel": "Merger Agreement"
       }
      }
     },
     "localname": "AgreementAndPlanOfMergerAndReorganizationMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_BusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Business [Text Block]",
        "label": "The Business [Text Block]",
        "terseLabel": "The Business"
       }
      }
     },
     "localname": "BusinessTextBlock",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_CLBS16TreatmentOfCMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CLBS16 Treatment Of CMD",
        "label": "CLBS16 Treatment Of CMD [Member]",
        "terseLabel": "CLBS16 Treatment of CMD"
       }
      }
     },
     "localname": "CLBS16TreatmentOfCMDMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_CendSeriesDPreferredStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cend Series D Preferred Stock Purchase Agreement",
        "label": "Cend Series D Preferred Stock Purchase Agreement [Member]",
        "terseLabel": "Cend Purchase Agreement"
       }
      }
     },
     "localname": "CendSeriesDPreferredStockPurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_CendTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cend Therapeutics, Inc",
        "label": "Cend Therapeutics, Inc [Member]",
        "terseLabel": "Cend"
       }
      }
     },
     "localname": "CendTherapeuticsIncMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Shares",
        "label": "Common Stock Warrants, Shares",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_GrossProceedsOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds On Transaction",
        "label": "Gross Proceeds On Transaction",
        "terseLabel": "Potential gross proceeds"
       }
      }
     },
     "localname": "GrossProceedsOnTransaction",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_LincolnParkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Agreement [Member]",
        "label": "Lincoln Park Agreement [Member]",
        "terseLabel": "Lincoln Park Agreement"
       }
      }
     },
     "localname": "LincolnParkAgreementMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_LossOnSaleOfNetOperatingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss On Sale Of Net Operating Losses",
        "label": "Loss On Sale Of Net Operating Losses",
        "terseLabel": "Loss on sale of NOLs"
       }
      }
     },
     "localname": "LossOnSaleOfNetOperatingLosses",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Expected Ownership In Company, Company Stockholders, Percentage",
        "label": "Merger Agreement, Expected Ownership In Company, Company Stockholders, Percentage",
        "terseLabel": "Expected post-merger ownership in Company by Company stockholders (percent)"
       }
      }
     },
     "localname": "MergerAgreementExpectedOwnershipInCompanyCompanyStockholdersPercentage",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Expected Ownership In Company, Counterparty Stockholders, Percentage",
        "label": "Merger Agreement, Expected Ownership In Company, Counterparty Stockholders, Percentage",
        "terseLabel": "Expected post-merger ownership in Company by Cend stockholders (percent)"
       }
      }
     },
     "localname": "MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_MergerAgreementMinimumNetCashThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Minimum Net Cash Threshold",
        "label": "Merger Agreement, Minimum Net Cash Threshold",
        "terseLabel": "Minimum net cash threshold at closing per agreement"
       }
      }
     },
     "localname": "MergerAgreementMinimumNetCashThreshold",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MergerAgreementPotentialExpenseReimbursement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Potential Expense Reimbursement",
        "label": "Merger Agreement, Potential Expense Reimbursement",
        "terseLabel": "Potential expense reimbursement per agreement"
       }
      }
     },
     "localname": "MergerAgreementPotentialExpenseReimbursement",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MergerAgreementPotentialTerminationFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Potential Termination Fee Payable",
        "label": "Merger Agreement, Potential Termination Fee Payable",
        "terseLabel": "Potential termination fee payable"
       }
      }
     },
     "localname": "MergerAgreementPotentialTerminationFeePayable",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MergerAgreementPotentialTerminationFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Potential Termination Fee Receivable",
        "label": "Merger Agreement, Potential Termination Fee Receivable",
        "terseLabel": "Potential termination fee receivable"
       }
      }
     },
     "localname": "MergerAgreementPotentialTerminationFeeReceivable",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MergerAgreementTransactionExpensesThresholdForRatioAllocation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement, Transaction Expenses Threshold For Ratio Allocation",
        "label": "Merger Agreement, Transaction Expenses Threshold For Ratio Allocation",
        "terseLabel": "Transaction expenses threshold for allocation"
       }
      }
     },
     "localname": "MergerAgreementTransactionExpensesThresholdForRatioAllocation",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_NumberOfOfficesUnderOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Offices Under Operating Leases",
        "label": "Number Of Offices Under Operating Leases",
        "terseLabel": "Number of offices under operating leases"
       }
      }
     },
     "localname": "NumberOfOfficesUnderOperatingLeases",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "terseLabel": "Right-of Use Assets:"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "label": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "terseLabel": "Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsBeforeWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Before Write Down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "terseLabel": "Net operating loss carryforwards, prior to write down"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsSetToExpireWrittenDown": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "label": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "terseLabel": "Write down of NOLs set to expire unutilized"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSetToExpireWrittenDown",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OptionsVestedweightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_PreEquityOfferingValueAfterConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Equity Offering Value After Conversion",
        "label": "Pre-Equity Offering Value After Conversion",
        "terseLabel": "Pre-Equity Offering Value After Conversion"
       }
      }
     },
     "localname": "PreEquityOfferingValueAfterConversion",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_PreferredStockLiquidationPreferenceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Share",
        "label": "Preferred Stock, Liquidation Preference, Share",
        "terseLabel": "Preferred stock, liquidation value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceShare",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated",
        "label": "Preferred stock, shares designated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "terseLabel": "Net proceeds from sale of NOLs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "terseLabel": "Proceeds from sale of NOLs, gross"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_PurchaseOfPreferredStockAggregatePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Of Preferred Stock, Aggregate Price",
        "label": "Purchase Of Preferred Stock, Aggregate Price",
        "terseLabel": "Aggregate price"
       }
      }
     },
     "localname": "PurchaseOfPreferredStockAggregatePrice",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_PurchaseOfPreferredStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Of Preferred Stock, Price Per Share",
        "label": "Purchase Of Preferred Stock, Price Per Share",
        "terseLabel": "Series D original issue price (in usd per share)"
       }
      }
     },
     "localname": "PurchaseOfPreferredStockPricePerShare",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_PurchaseOfPreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Of Preferred Stock, Shares",
        "label": "Purchase Of Preferred Stock, Shares",
        "terseLabel": "Number of shares purchased"
       }
      }
     },
     "localname": "PurchaseOfPreferredStockShares",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "label": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "terseLabel": "Maximum beneficial ownership allowable per agreement (percent)"
       }
      }
     },
     "localname": "RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "terseLabel": "Aggregate offering amount authorized per agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "label": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "terseLabel": "Number of shares allowable to direct for Regular Purchase (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "label": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "terseLabel": "Maximum obligation per directed purchase transaction for Regular Purchase"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SeriesDPreferredStockCendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Preferred Stock, Cend",
        "label": "Series D Preferred Stock, Cend [Member]",
        "terseLabel": "Cend Series D preferred stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockCendMember",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_Sharesvestedandexpectedtovest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares, vested and expected to vest",
        "label": "shares, vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "Sharesvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued As Consideration",
        "label": "Stock Issued During Period, Shares, Issued As Consideration",
        "terseLabel": "Commitment shares issued as consideration per agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedAsConsideration",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Of Agreement",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement (in months)"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Canceled",
        "label": "Warrants Canceled",
        "negatedLabel": "Warrants, Forfeited (in shares)"
       }
      }
     },
     "localname": "WarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "negatedTerseLabel": "Warrants, Exercised (in shares)"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expired",
        "label": "Warrants Expired",
        "negatedTerseLabel": "Warrants, Expired (in shares)"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted",
        "label": "Warrants Granted",
        "terseLabel": "Warrants, Granted (in shares)"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Other Disclosures",
        "label": "Warrants Other Disclosures [Abstract]",
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "WarrantsOtherDisclosuresAbstract",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WarrantsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Vested",
        "label": "Warrants, Vested",
        "terseLabel": "Warrants, Vested (in shares)"
       }
      }
     },
     "localname": "WarrantsVested",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Canceled",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "terseLabel": "Warrants, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercised",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Warrants, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Expired",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Warrants, Expired (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Granted",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Warrants, Granted (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "terseLabel": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantsvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted Average Remaining Contractual Term, warrants vested",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "nsuri": "http://www.caladrius.com/20220630",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r40",
      "r88",
      "r89",
      "r201",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r200",
      "r211",
      "r248",
      "r250",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r385",
      "r423",
      "r424",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r200",
      "r211",
      "r248",
      "r250",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r385",
      "r423",
      "r424",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r200",
      "r211",
      "r238",
      "r248",
      "r250",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r385",
      "r423",
      "r424",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r200",
      "r211",
      "r238",
      "r248",
      "r250",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r385",
      "r423",
      "r424",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r39",
      "r40",
      "r88",
      "r89",
      "r201",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r44",
      "r45",
      "r46",
      "r410",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r316",
      "r425",
      "r426",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r283",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r280",
      "r281",
      "r282",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r252",
      "r276",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r85",
      "r134",
      "r137",
      "r143",
      "r167",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r317",
      "r335",
      "r352",
      "r354",
      "r393",
      "r409"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r37",
      "r85",
      "r167",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r311",
      "r317",
      "r335",
      "r352",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r174"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "verboseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "verboseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r149",
      "r152",
      "r174",
      "r396"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total estimated fair value",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r254",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r247",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r247",
      "r249",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r22",
      "r79"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Available-for-Sale-Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r336"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r83",
      "r85",
      "r106",
      "r107",
      "r108",
      "r110",
      "r112",
      "r120",
      "r121",
      "r122",
      "r167",
      "r189",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r209",
      "r210",
      "r214",
      "r218",
      "r335",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r186",
      "r397",
      "r415"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r187",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,594,329 and 59,800,792 shares at June 30, 2022 and December 31, 2021, respectively; and outstanding, 60,583,249 and 59,789,712 shares at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r60",
      "r402",
      "r419"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r125",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r239",
      "r246",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r77",
      "r179"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r254",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r104",
      "r106",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r324",
      "r325",
      "r403",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r106",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r324",
      "r325",
      "r403",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Salaries, employee benefits and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r119",
      "r168",
      "r225",
      "r232",
      "r280",
      "r281",
      "r282",
      "r296",
      "r297",
      "r323",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r425",
      "r426",
      "r427",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity Securities, FV-NI, Current"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r327",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r202",
      "r239",
      "r240",
      "r245",
      "r246",
      "r327",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r239",
      "r240",
      "r245",
      "r246",
      "r327",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r327",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Minimum Lease Payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r203",
      "r223",
      "r322",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants awarded"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r392",
      "r399",
      "r404",
      "r421"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r290",
      "r292",
      "r293",
      "r298",
      "r300",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r102",
      "r103",
      "r133",
      "r289",
      "r299",
      "r301",
      "r422"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities - available for sale"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r85",
      "r138",
      "r167",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r312",
      "r317",
      "r318",
      "r335",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r85",
      "r167",
      "r335",
      "r354",
      "r395",
      "r413"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r85",
      "r167",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r312",
      "r317",
      "r318",
      "r335",
      "r352",
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r85",
      "r167",
      "r189",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r335",
      "r394",
      "r412"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r58",
      "r78",
      "r85",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r109",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r167",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r325",
      "r335",
      "r400",
      "r417"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Caladrius Biosciences, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New York.",
        "label": "New York State Division of Taxation and Finance [Member]",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r232",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r136",
      "r139",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Lease Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, current, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Right-of-use assets, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r54",
      "r56",
      "r59",
      "r225",
      "r337",
      "r342",
      "r343",
      "r401",
      "r418"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Available for sale securities - net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInvestments": {
     "auth_ref": [
      "r23",
      "r416"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments classified as other.",
        "label": "Other Investments",
        "terseLabel": "Other Investments"
       }
      }
     },
     "localname": "OtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Caladrius Biosciences, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Investment in Cend Therapeutics"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred stock, ending balance (in shares)",
        "periodStartLabel": "Preferred stock, beginning balance (in shares)",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r279"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r73",
      "r85",
      "r94",
      "r102",
      "r103",
      "r134",
      "r136",
      "r139",
      "r142",
      "r144",
      "r167",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r310",
      "r314",
      "r315",
      "r320",
      "r321",
      "r325",
      "r335",
      "r404"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r180",
      "r354",
      "r407",
      "r414"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r286",
      "r386",
      "r435"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r232",
      "r283",
      "r354",
      "r411",
      "r428",
      "r430"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r168",
      "r280",
      "r281",
      "r282",
      "r296",
      "r297",
      "r323",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r135",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r236",
      "r237",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross price for stock transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r155",
      "r156",
      "r159",
      "r160",
      "r161",
      "r162",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r252",
      "r275",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r254",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r259",
      "r268",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option and Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r83",
      "r120",
      "r121",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r218",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting terms (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Warrants, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r261",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r251",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r254",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r83",
      "r85",
      "r106",
      "r107",
      "r108",
      "r110",
      "r112",
      "r120",
      "r121",
      "r122",
      "r167",
      "r189",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r209",
      "r210",
      "r214",
      "r218",
      "r225",
      "r335",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r53",
      "r54",
      "r55",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r103",
      "r119",
      "r168",
      "r225",
      "r232",
      "r280",
      "r281",
      "r282",
      "r296",
      "r297",
      "r323",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r425",
      "r426",
      "r427",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r119",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (shares)",
        "verboseLabel": "Net proceeds from issuance of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, Exercised (in shares)",
        "terseLabel": "Proceeds from option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuances of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r12",
      "r13",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r232",
      "r253",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r85",
      "r148",
      "r167",
      "r335",
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Caladrius Biosciences, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r85",
      "r91",
      "r92",
      "r93",
      "r95",
      "r101",
      "r167",
      "r168",
      "r232",
      "r280",
      "r281",
      "r282",
      "r296",
      "r297",
      "r308",
      "r309",
      "r319",
      "r323",
      "r335",
      "r337",
      "r338",
      "r343",
      "r426",
      "r427",
      "r449"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r210",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r232",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r164",
      "r165",
      "r166",
      "r203",
      "r223",
      "r322",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r34",
      "r233",
      "r234"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 11,080 shares at June 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r239",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal debt securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r105",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r104",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f,g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r438": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r439": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r440": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r441": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r442": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r443": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r444": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r445": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r446": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r447": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r448": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000320017-22-000057-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-22-000057-xbrl.zip
M4$L#!!0    ( (R%!%5L&M^]-*$! *AP$@ 1    8VQB<RTR,#(R,#8S,"YH
M=&WLO6E7&\G2+OK]_ I=WG//V[T6A7,>W+U]%P;L3;^6L$&VC_CBE2,4:&!K
M,,.OOY%5$HC!&-M"D^5>;4,-69D9TQ.1D9%__W\7K6;E:^CV\D[[7VMX ZU5
M_K]7?_\_6?9_7^^_JVQWW* 5VOW*5C>8?O"5\[Q_7/GL0^^T$KN=5N5SIWN:
M?S595KRSU3F[[.9'Q_T*083<N=E]&92BD2J46>I#QB0FF=*:98&1*+EBS(:X
M?O32!((=T2KS7)",">DSI93/M% &1>T,MF;=OZ1$B:BCLX)09H0WC@3K.(W:
M:&E$2)\][L/H8(3MWLO\HI_U@OO7VG&_?_;RQ8OS\_,-^'WCJ//U1=YNYNV0
M1ORBWS7M7NQT6Z8/,_*"(,PSI#**U\IV;KU_3C<ZW:,76&O]XB)]:_C0RXM>
M_M"#!"'\XO]6WQVXX] R6=[N]4W;A=%;>:_#"):WWKRPW>;H7?IB^,3:S9@>
M?OBQ 1&4(9)A,FIDT,N.C#F[;BB:GBT:&=Y(K^ ,X9LY> F-GS[2RW3;FM[U
MN"[N/7]KXM+=T:,^W$Q<T>B(1'"CZ,A_V.A1U[2WJ>%,T_AN/NAMN$XK/4R0
MH.BZ$]!:_MC4WB7&Q;<>QG1L?L>;]W?Z/FQ;O"AOCA[M=?OW)QLNWIWHETW3
M/OK76FAG'P_6@)>#\:_^;H6^J:27L_"?0?[U7VM;G78?)#2K7YY!WUWYV[_6
M^N&B_Z)@R1>O_M?_^E]_]_-^,[Q*<Y:-9N;O%^7%OU^43=N.OWSUM\^_5GK]
MRV;XUYK/>V=-<_FRW6D'Z$!^\3(]&+KEC[GWH5W\"/=KH":ZN2N_?]'?#_%?
M:SFS#CMOO+=,,<ZC%=I0KB+UPF*OQ)?MHBL8AGQ#K;9II4^'_.5.&_IWN07#
MZ9KF;MN'B_\)EVN5W$/3GGZZM-N=K^_(_M<&K0[\R<[7P[?Z9.^D>KFW?=C:
M^WQXTCAI7%:O]H]KK?WCQM4_S4:KBJNDP1OU4]JH'S;?T5JS<=6YJIX<D<.3
M9JM!=DGUI(K@WFGC<_7R\/,_)[5Z#=K:X36R0PX_*?2.'%XV/CNQ5V\>[]5K
M)X=OJVAONTIKVQ\N#K>/+ALG']#>YP;>>PO?NVJ<-UH?O_JW;W+[]J.HG>S@
M0[A>:U7/#Z%/M>V=R\/M4_A^@S3J']AA_;AU6#_%<'WXSB?X%F\?UCND6O]T
M"FV1QM7KUN';'52M_W.Z5Z]>0@^@G>/FWMO#YE[](ZI^4E?OZCO]Z@&Z>%??
M/:]"'[Y(F&W&5,B$X#ACEM%,!QDRKKEDW&&B*5][A> /31I*_OWB%E&?D\9;
M@VX7"/PF[X'T-H+I[K3]-EB:M4JILN +%_V7'JYD+?CL<>;-B@6^RP+H'@L8
M)9DE6&2$$)8Q;6.F*7-9(#HP+30*6*^]PN0%Q5.D_@A>W)#_#5SIK0C\/0+C
M>P06# LD@\DHL2)C5*K,$AXR*B5ATD<AD%][E8@P,_J^A_8[?D7A)U&8W*.P
M9YYH1VF&A*8@PLAG!N8\XQ&($361A-JU5Q^F2=]-(*XO"-PT1RN:?H^F]!Y-
MN: T$BDS%+Q)KH[*-#8Q4U@K2H((G(JU5]$T>^%'R"H,,])0%AUH>RV(\A@%
MS9'$U!D3U9?=!#4Q24"SI.80Z[_<.PM=<!3:1^\" /C]Y,OMQ8^]L-GKA?Y!
M'^QP(O=>?).W 2SG(-2=7IX<BYT+P)V]W#;#N[S7GRTOX-J!;KG6F_;>B;NJ
M;E?YWN>/^/ $Z N\L+?MX5L?SFN?X9UM![1] S3ZI_6.PO=;%\T]Z$]M>Y<
M[YP?OFW@ZM4'6FU56>WD(]ZK;](J^7A5K1^QO<]OCD?OP+<&AR3QT2X"GF'5
MJ]>GAR<?KVK;[K)Q=41J]8^\NNVN#NM5^/X1;WQ^$ZLY.A_RPR7TD50WOY"
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M/[3;!C[I%4_@2:W9CG6F6B9,IM&\Z8;_#$+;77ZC)V./]O833W:!9Q<DR,"
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M@U"<)/$VM$/7-(',F[X%KC%@+I.2RX>4?NZR_3.QQHI0(;#QS&C&.!!;<DQ
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M?SX4@]NX7^MS]/?CD>%QPA&T@6]H]]"Q40^GJ#T8%5:+%!/N'8=F<\0GE3^
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M-W0Y"IGM!G.:F0C3\=(TS\UE;^W%SQTO_0 ?QO@S?*B>@.U+TH'.'):(?3D
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M8K<0V+WB.>!L,"OIM2(,'@?] 5#FYNMEVT5+Z?NW)J:(E .V.!ON/CKK=OP
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M)&,EZA,5]3L01+$@&6?@&I"42R8LS;1P(?-:@IO I=&"K[WBT]AX,T_QB_F
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ME_^&3IQ8!31LZ-S41;621;6B[+PV@^Y1L4EPTOB_GKY[0X,QC7^\SMJY51+
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MF_CY.;MR9G*^R<RX:TS,A:X52!U>].;[L>@HC9JKRI"P+4/IO1PU&]+_^;Z
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M$D%[ A$J$^P*\#W[&OC <&NEU87Z><$ $[#@0+.H,%,.T@>N&B980:^"WB:
MWA*8Y[BE:+@GFPAD88204"-/B4L4"-_ O$H VX^#<P<)L^&DDXB,3(C%(LZ"
M88S($'Q(!1MC3K"UZ^2V\C4\4O%P8_!P&1)(#D*PWB?M,X#(+G'>)%!Q;;4S
MOKH#.P-^K[\&/V6%S(X;AEHY!M$;YC,I%F/"B!)2B@7\I%Y,@ZDDL()>]T!O
M&</7>.4I.J&S Q^3YSZ(K$!HD0VJ2@*[C(,+/;P5C\'SR)++@0&/@KD@9:&#
MV%25*"30^BD)%,IV@@3.#G!]',5')=!3M+L<++^;%/P%KGX>NRH#3,/SLG2_
M'OPU[E*_L'YA_<+ZA:O\PBGN_3#=2LOOU/]G]]_EQQP,@MRQ!0E_>C,<]QL$
M_W%$ISCI_T,_O>VGR<N/7.&+#UZ ZX_\\T<P%,0^GUS]D2_P.E*SBZ^:\0C^
M/<HCFS&YWJ>=:3H=7_Y\.?HLDA?$PHCP-<-<!OLCGK[%]^.M'[YZIK/^@,W-
MX?SC7_F0.:^%UI5GO-@:"Q<:CJ;--WXLFRV-FJO*D+ M0^F]'#6\\O\T$163
M?8[!2 5HBJ$E*42MLD=OT=#?=FMWOWSLW;]_P-W+9/>=139=_'/Z4Q[^%-^,
MZ<>/?_ST\=1W?S!]ANF'?CK#T8LBXMEJ;\0[1S*FWW?Q]DSRWN^ =HWP9\?%
M9U\\6Q<[TW4QQXDNWI-R![BZ\FV^(ZY\[UNW53O*7/W);]WUV^\I@#6,U7K3
MD;'J'9"N(V/MTKR:H@5=F5>[PSNC6V;'P<W0Y>['"CO.W>RN]S&OPE_];KO&
MJG>4[,Y8G;W>6"^W[96_AFU_KWY)>\T"D)=Y4SX]D[_.,UUPH?MYJLNKS1R7
M3Y6;/>X]&0ZFPRITZ]]A],/NIXHGO>-O-LU:PGKJZ!1=G(=>W3242T?#M_/G
MV3LU)8_*6!LS D\OU@KV$^L/IG\_P3?]27F]3M1THF(\/SLO1CREZ>P<35[2
MZ&*>AF=O1O22!N-BWT]?^74X'M=INW3:]BCW8W]29V<Z.R<CPO'YZ/UT:BHL
M?3$QP\D,D9[@*:91_[SL;/WA./:I:02Y/7UK?Q!W/L_<+ #V/]-7+L)@=3(O
M.FH.!VR&5)^B?K,)O C]]6:(?WP>QOW4QU&=N?EE>,F"ND4 K/LD^5+_N?PJ
MRGA)H+'=TKZHD;.J1UXN]-#QJ7MT-CP?K&I7W[C9J0NK50OK(5WZL,KL'N"H
MI\2TRJY8597='?U-#=K$\G.HE .E#%H/ !Z"BT$ &"T@J6PO2C,)KI2HI79?
M[>O#DT=OCWYYJ@Y_>7YVL/=[_W OPE^RR2-[)([V7KQ_?O+XU?.]@P\+.66O
M7HN#O4?PUTGDS\_^>GOXRSX__/"RN58?[#V#H[W_G![\<OCZX,-A/NC/:HP<
M\_<'>P?RX-'?66%N9,*"=X9!XHYAUL  ?>*@R04NUU1I]SLZT:$4VYMH]T;E
MV7YO KH):XO)MC?#M%IXM]V8^&$.$X6EZ"!$AA@D PF!.8Z6Z6QR2F4->!W6
M67>WW<!8*="U*5"DP"D$F2!YX%$Y$2VJ'*4VW"8)UZ1 #[T"[YT!@9@# O*!
M/$?#?++$FKI[!1*29D)X@3+F(D*[M:O]MJX$J1*D2I!NBGBU'F\[\$_-X9^*
M)G$>D DC X-L#,/FN!%&JT,*PG&GFP+D%?LJ]E7L"T57-/=&*DH *067R] @
M"PS9",GOTSBLQ/!6P*CG@!$@2T<@F"RKG0$WP$+3>38[HUS2TO 0FN*\L&WX
M.JIQ5'1L$T8\7'1<ICB'<U')A(HG(:#ILTV85);*@S'!D;\:'FMQCA9!X;OY
M7GTQR62TEZS@7L'"8!QS1$T8P1JCE4) L[5KY6I+<U0$;!,.5 2\#@):%Z57
MDHRG#$E#,:.<LQIRBBC3K'+O?2!@98HKA,>YEC:96\@Y*6:C5@S 6>:C ^:*
M;4U1$Z'S6[N@U+81JF)DQ<B'C9%D,$,,QI HP.BU5QY3R%E[$DIY65EB-V!P
MOI=A!$JFJ5P47#&;06%B+BO#DM/.H\W*>;Z&,KX5 ML$! \7 I= P()Y7@@M
M040-Q81"@489XR"XP V_UQR32@YOB8ISY-  ";#),^^#+^0P$G-"EW]RXZ,)
M08>4MW:%X-ORDJX.U8]8X7$SX'&IGE^8P.BH9- .0(@FRH*.>\2<E?>V,L1N
M8.%\PT/2V7N)DD&TF96=#YDG#\P( (J$,6M:0XW?"H%M H*'"X'+,,0 BAR2
M4RZ"5ZE0!D(O0T*"('*L#+&SJ/A^/KIBA4Z0P;*L#3&0RC$T3C.>DXC*"P@D
M+A@B%XO(V%J&N/2)LCS]7SM/E%VNT(<TZ9U^JX;'M_*G9X^[<?G3LZ3Y)=?E
M\K.Q[FU[;CG>*$>^RKC*N,JXRKC*N,JXRKC*N,JXROA.'*A<:>V=5]$(B$EZ
M(:D)OUIIN3;"_[TW=1\ %VSZQ_7;I?TV&N;^I"E<6)T"*W,*O%_,*3)4A /)
M,Z<U,HB2,S1:,Y.S]8D'B\)L[>IMXVZ3=5D1H$L(4%%^\V6\%,IK !\Y:*L$
M..]0AZ0510Q.6Z&HHGS;4'X^.2!Y+[0H\LE.) :!''/)<L:S56@#A&A<1?F'
MA0 5Y3=?QLMQ>9^UCZ0HY<(#8T%Y%-%ZLLKG%%5%^9:A_$* 3P3IT$=3:#P
M R,M"R8"$R HZIRY\+)+*+]1M2(O5]!G@Q&547R@U'N!_4&OJ.@9CE[3K*,9
MQ?-1?]+_1JW6:U1.ZAYLW6QKNESZ7:EO5:54I52E5*54I52E5*5T1^F/%B&Z
MB,FGT-2.2$$:G:/-4:J@HC/7L'F^-G6F79B^:L"T/XC#,VJ,GT?_8/^TX74_
M#T?'Q= Y_L3N'J57Y^/)&0TFAS0YRB?XKMI"2]A"AT\62TF@4%J%:)GGY0=
MY"Q0,8V,MU&1%]Z)5&PAO:(\QZK<%8*KE*J4.B6ENPT!U8VR%1OE?&C()G*4
M@F+<6<[ 4F;HE60JD31$J+7Q=:/LGG)7".Z"E.XV/E,AN T0O!"W"9);H*A9
MTP&$@9#-<=5L6>(VFZB )(660? #.'0U[8_  HZI><2S-T5%L)GUVQS"ZAY
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M]^S"G='Z7LP-V!BKL8&.GA=FJOPKT %5@;^");%U68K3*]#>^:^K#RC>V#Z
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M+[Z/W2WLPX4=/_%X:@VCN@"DPK"T.[<%>CO^!#]657VB8PBC=J-LXCO A=D
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MO&KAQM7 \T;[$82B4=4LI;;A@*%D51Q7L8/=_EH<FCR/OC-W: .ET(E85@N
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MD34YW61GBZP0%3_6G]M;80P%=):F:IC9.H^%_@&V@-JD5 ]RJ4SZ_'>U6)W
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MDDK+%Q /V)%3U>UP,H8]%>BT@,T_'*$=ALGZ($">84F:[5Z)@4/3D7-BU6Z
M-,QKF^MB.=_BIU3C<H;SH+N9A+@J,[VLLU3Z1DQA'7MC2S,4H:;E1SY%EJK:
M<BJQ&S@SQX[_F+7+[.?#$X+A,L<BS,FYM4R5,4:9_%YE,V3CNA%M9BJO;*%4
M$\AF/K3^V.03@3PYK2QNU,#YN#)AX)B_J3$F0/5 7OQLN*5,LJ^I#&VT%JTP
M2&7&AV82P4V?&'Q<;?!N-HW^I5QP\V4M(LH)@*9YB.'L?J85@==!>+*KJ]PJ
MLUJRRZK/,*_"IJV0VD*UR@7<T+9%K4T&$,0#Q? 1>M)W4'-04QRU.D"5!(CE
MB<T2QU$V,L8LFF_V<>5$H!6']\D6SVA%-:+UJF9%%85N.%>;QP<\HLHQ+']Q
MY,>E:>$W@*<K@.Y%)IC[;8+Y6BSEGA/,KTP87T@PE\KWM2?])'%=&LLX52P.
MA? 43^(@4OJ*7O;KK"+LKO+%73A5[/'6J8R'?;XAU[TJ+@^Q!Y>"T75;TLUU
ME&OT8)INTQ8FV5<^[)E+H?J5$5_3%CI"%:9+1-T29R9T&Q''^5YR*"=/L)R@
M]@U6ZOA<UZB%CFS3M5_8<FJN"1U6FF):[V RF#7S&=>M;= <K-:[G"TTETW]
M  UZPLL:]'3L.W35&(=B3GOSM 6L*SOQ_#QQ#_<.PLZ>\+O'.^?=G:\TH&[,
MM2 >\U,"0.P2+M.(1"%8>B)-)'.3C>V(7EG-"HK^9&!=N]/F3]:G4 T8OR*%
MT'3Z*$61\48T^8(NB%9;7>HEB,0&G%9.6<ZFR%7V.L* C0Z9;(U5O&-74C^\
MTK6M%KSI3$;Y_!TO:FEHPP,8B:NR[='1-[ EW@N>.AO <K!:*:OZGHS@(\O'
M<P_32CU0/ZQ+V>U=K>H?S];V1JEW[+PM&[\FU_T\?/]5NZ$4.M:$19P2*EQ!
MN,<822/-N? ]5*6PA/RB7E@5TVU:2KF BN8H_ D14]N&X$;TY'7.OLK("WS*
M.(EB;$D@9$K2( 50#SSN*T^C;KVQ3:^FI]Q@;HD1]3G8 N+*!GQ2E#:@:]44
MTV=TJE],&_E-1K:>:<!^&/5BG2BM:N+WH7X;_+*ELFM0F8^-+_S4CT7"2,R!
MMBA3"@#+#4!5]P'"/"U32:^!6O?;K^O1;0QG9UQ7_=2Y.%6GPIFVL+E20[<Q
M)1.[+>#2O%@JRS#Y/*4)J S1738P%;B@5)BH$7QZULL'TQA+G0G02(.T3[S6
M[Z?&1#Y]$/Y\^NO!!'W V&'9EI%Q-3Y3:KA2L;K=D3_""=_0DK;-?M]-"F%B
MJR_$FCYHN.=KQ[2A&MN[G]GZ<=2XT6L[E_!1>__G&AW7=L/%K'*!A<Z<(YSY
M53I[&,W7RF3'7G0F<[W+E[^^I.'[W$I&U955],PLZD(I9UOR+@@ZEZ8^<Z6(
MPC"A(4NY+QE+8T\'C+E*U8,^0="151+OH/MF3N35KW*HIWM@MN"H>O9UA)S[
MLH5<V'G_-0'%G/DQ(R))P2#V60A*NHI)!*J'2T4L@Q"[.VUZ0;@9^<F2J&NT
M7[Z(*#<OUX?>J<*<V:)>%,M812X'BSVDTJ=@INN$,>YS*8&4V&J]J$$E=;.O
M>?)XQXK#PN2ZR[\Q8#-[>DL32!,4:,)7H:_BQ"6IJR2AD1N1A 4A"1+%6*($
M3[QT8]O=0KSUEBD"].0J&#9"QP#N[AP(740G,RBJ>V.;7I U\B!XBN8]%5;X
M(UK]"GG%O@RT]C40%A 8>N]3EW,=I$D8*C_UKD C>BTL>H<K;BELCL+VW<[)
M5YVFGN<%B@1AI D-O8"D.J D#35/ C>@40 &7+*5N&&\@L N)ZO#.DWVP/1,
M-8?0H*WB%B[=6U(-B:Y%-CLG)Y@Z.E9FZ:V]=@VB.@.B2CG(AT@'(,5BM-<8
M)SSU) '=PI."AUJ91H57F&NU$Y;5AV"]KQ=J7 4;?L/LO&&EV=6S>NP$4SN'
MH)P;CF&]":6](4#=:'I'^SNC3F*&<151J5RY>=VVI+1]5.JXALTX09<TJ&G?
M\_YD:'(,C&MC]L]^]I\))@\8MP?<PX33Z_D\F9VD8$M&C %S^3OW3.ITXY;5
M.Y@>3%-8'C=OL8HIG5%_8CM'V7$)TRN-ZBM$,:F2'"?#$<LD+!MU[JKA1=71
MPEB:(W8^K70P]AJZ:JITK]GLGY6G,AU*@I9?Y0>?.X[Z!_B=LLF#9J]AXS&A
M#<L4T!K$6HPK=@T@"Y;V/:_75)4*S CDHOO6AUO-7&KTR:JKZQ8"9?8(G7T<
MJVR!\A+U#(WNZH%8_K-9QS&JFH3*.JGF%9E=R/6F-41*K%&9]6IN3.)0U3#A
M&?&7=E+VM(R?G]OSK!/Y5A)(9<?;Y966T#([ZKA*E%R<CC#]95V&L'2M/0:N
M+GXJ4O>LO0":_&8L2)U]:@]SU,\P8=7^:TJ96'\XX)5S=S8="[^W3<M6;<XT
M(C1]3M,68XZU2D$58]4<;DQFE%G%P+.9)5?0G^$,[%&%45S;=*<Z]^HT+SD^
M&PV:-UH9YDL."/XN&\]"06<%YOP.IQUY1A/>SP1<4.5H8:^=\ZH2JE $O?BF
M**7ZVFJ.>'OL48.=@FXBH#T>@&!F42H"21F(Y$"Y:1SY;I)27\D+K(9%N5RH
M?;.JPVI1QE+80=[?G5)3*Y:O(99_=,'"5"X//1X1'@M.*&ATA.'P'^DI/U%^
M$,>7#T*9.NMMU4"5*/E+U.$ST ,2KE+IAZ!BPN-3!LI!&(5P;@$/;J:^O2WR
MLGQGFZ>5A\/&[)R6-JY!&^>'[[]R*CT=AV ">(P2FD:"L#"51+ 4S  >P*'$
M*R=!S:ML@!8G>!AU*[NR5L1N.25G_3VQNWF_:I&&^_!R'+' UL.JZLCH4D83
M6?9N;J[TGEZP:7/6Y 6_N:Z[=-9K3DQOU%!%355PE;71<!17+1"FR=Y([-]-
M@OTU/,=;^/[3)=G%K'R'"US,IK[+#(K$9(S3'#8+^UO-LK=1K*N%3:H^G18#
M80E'D96V,QZ:%: 73;"\W7B-328*1B;'IIU?E8-=W1C+L,NJD!0[5%;%Y56I
M95:GS ]F14GY\"2O&RIDU1B6 ?N&'Q7*-F6552HZ7CE7$VUWMBHBLKT"^VPX
M-).UJNUH=@S$! .%ZG05&9IEHU6KGQ:"SO85=.9)-5&\%ER8B6!T2"17K,P"
M=1,4]1VC=?U[,E1.8/MH^/:<)W:*TW=5_[BL(P^RRKNQIFI-P::,#+Z[B5"D
M7$L=@G;D!2Y-..<R"L(HD3Y-A*M8[9?W7,\*Q2AP+Y^N\ 'V>3A1;V!'0%W"
MGJGC3T#XNX N6%FT_Z-* MPQ,Y25/&8_6H%Y#8'I==Y_I5HDTA,>$3%E(#!%
M2KB4'DD8\]W83;V$>NB:]>\S)KT^F<>F6>[WK# C'VWO!\OP3[#N=Z')M)=B
MG^-A_MU,*BA04AC[=O;&OQWM?#@BN_G?Q/]]:NTR4^=3=\6Q Q%LZQ<+9 ;E
MRTFAF;"-!79[8*U6'4NKBOFJO?6GO.C+>B#'87."-# F8'15^Y=/QJ:0P1B.
M=3>>*G=VVG]HUC?Q#.^*_8T A/(!PC97)\P,A\/0/]BNZ$0"E*N;]%E#O]$#
MH"ZW;[82&"# COJ-?D#?F< > J:ZUDQQF[Y8@;EC Y,YB4\P4A@E@5%IJGX(
MX]J=)">S1@JSWL/68!]B=:69@%5/:)\U+ZJZ+0EL-H@=A5@)Y\9M,T-LI3Y@
MTS[G=9D^GL&TL4 MPA<;.2V,/VGTK64(\FB<8B%Q7GRS(JF'N4VC'/CIO-FN
M'7V(0].!UY23FVETXZKF:.8*ZYV?P'%4U^-1H>Q2\,S\7*G9#+-J9A^?%J;F
MV ],+=6GS3<D:KN0W%6OMQG?R(5:,&R)99QELQXD<M:4ZX*67Y5G;:Z5W""W
M:3BK&GTY9HPA4LYQ_NT\;] /MK:H2N.;A&UZ%-?EQC/WX936LZ&NBNJWG$_9
M?/+R/^H,H;I?!K!0X\)JR<;5-2NAS&MV'*)''\X8M;(I-2*F3+N0U56+S9XM
MBW-L6K*]#=G.MY?:Q +(1@>'JL5:W8ZAT00/AQ4N-E*QM:)U1SG3&6[J6I_V
M;FJVA[4%JL:BFG5G,2YT[(AC!DLT3MQ6C[,^]A.81B2V9@WA_E$U_'KH\0[/
MG42:#7N,'8;38)LHMXAL>(JST4WS?0)K=&CG'SS)^0>74O+Z3BJQA'S)_(-V
M4-?E==1!6T>]%DNYYSKJF]5%K\/@+</9OS*]Y$&'@DP3Z%_P5)#G+5N>[$P0
MN_P[Z:ID?9S="9BOE8K5<&L+3T@F):<)#4/-HY0%8:(#&7%/)JO=VO..[->8
M?'.H=X3 ]"2@]W?&CV+_/(8GO>[GXMM+<TH?OZ>=O6]?.8,]4S$'J<$YH3)@
MA,DP(H%R8ZU@CVD(&ZI*P49XIF Y/>$6%Z]9A9CO;.J5$6#/IND5&+96$IDD
MP"$#LP.M%/2H ZE+8_.\F7HVC=?(SMXRSF0CBFRO92L#\7:%- T&K=([Y1^,
M8L)-1B!E:O.G?U[-C9P9)O-C@F'3=PQ[LVG[P;<[.^^F$4=3;U/)MH;[=6@#
M2K6O=FK19<-JUE[51.H-_,SQ7/+>_&P'X1YL1,_%YWZ8-K5UCLC_JP7FT?[N
MU0_=<G;,+L!+]^VP8FS::$1LW2D8L]"J6RZN5N?Y&'YJG!15D3,_7[5CJ[?6
M=B:L9@/.EE=.#\[H(C;'#TP]:^0!)8%2,XL/SQ'%U:2PHCU'9EIS\3(#2Q,U
MH&ECX$+-J&QS;C^&MCVW[5B-_<R,/WJ:X%8V.WQ/^Q[;>BS#E]@I%:W[5>6&
MLXVH13Z:957<U4;'ZN#K+%I1=RK%:#;^9]Y-B!^93B(X;'76BMLVVFSD:5I/
M^(RS1',[5QV0@U$*%/"]?-*7MMJ=H49WHHQC=4K./3#4\Z+N;G;%31?.J%XN
M#C]"S0YUQCH 5>V'9WV]M:O7K0_+\"K65)IO:Q[ZWRWGT&Z0B<#;G9L.(@$[
MPK:5Q5:.=B1E]=#E S T@LQ2'S( 7]VOLFH^USP=H_I6;0&F]:/-U\,'X:*F
M\;7JS19G/?TQIU#<MW[Q$5/_]ZM@4/GR](C@\+CS%?0$&>E0$S#^**$\"0EW
M%?P-K#]&79JX/G\V>L1'.QUB>N;/1H5HSEJ %UP)/YE)VT))AQY* V$HR6L9
M5S9$D.GEC(UOZU!I6:5(EY-!W0 2>9[5W7+5+,AMBPG*1FT$7MK/K&NTSA.2
M68E95).B3AL?5_'0BZX9SU4<5%GIEP/NUNR@K0O[BN5.6THT^MO:WQD!7[5O
MGNM<:3I-FG$3TR?!"32D0B.F/HO+-?>Q:GXY&]Y11:I5(\%H14N?AF"T4AW/
MU7PS&TM1Y6*=3N2)I0#&L2FSN2,KBO/Y=._5^VZ/N9(&* 11$K 1*IO#:HIX
M54\#XDBHA<Z>2$.EZ=EL-^-":C)Y>+8VP6:4@6%';,-_ALW$2[O0<D&O8[8Q
M;+T9PDAKF6':>)T1EI>74/$5XN>IPMP]R\V9-@I[V%KCG;V/7SU7Q9)&F@3:
MTX0F2412'5+"1,@%YR&6QBVVI&1<1J[P0E<GFM+ 30+EARZG*A)QP(-H4>J^
MFUD8&#%J'L(2Y3X'N;;:87WEKE5]I*\RF)H#8RHSSN[K=-K8ZRPOA8%NP-R#
MH=B:VAQGO1S-P/QL6/E^!^P4P]KU1TVKRT*.U@"HB$  8/V^M5U%;:O-LHQG
M!CU(!=.CRJKZ8NFPYX)5JR:,K(YHF2V\,I(0Q!O7H9U[IXN5LT@OB=ITL;;/
M-]G1GO>G<\\P>#1+]5EP4<)1K@T@GM> ^'?_\_'[$$!MT/$[9YV]#_WNSQT
MQ!UXQI>!R7%]V_G1W>LO ^*GOWOP>;_[Z?//SS]WS@ 0@\X> .+>QY]?!I_/
MNC\_ YCNNX<(B*?[7F?G:^ *-TD2CX12,$*C1!$6NP"/;N RG@+O^NXB'D:A
ME@$5(;"TI)RI-. A%B=Y;NPG<;ADA1QA/]3"1#$:1^',SL*I#^-R>%P),U<O
M9G[Q/!324YY2V"O#90G75$=QF'!)&0N2\.9&T[K \ &6.-H6LG7BVC0?$937
M_&PNF/:/<G[69,-!5E^$VN2L]R:@6\6VE5K?S:L.Z]?&<',3Q.5%;\BQ238]
M4T9]Q00.,#'JXN6R\1IS\RQNX";9>LAHR"Y.[QA6:2$?LO+;+H[5'./?7A[&
M^-WW7SWIQAX(+J($%C92GA(6>9PD 0T =90K OIL/!=SIV^<XW#NS\=_T9CB
MV.QE;2C<*>!5K3EGQC',#?]@96_3^H#1BP%&HC5TC4Z&,S&,)5VB+[LJ>OIH
MK.K,H,=W9?W:58+V?%8 *F!XJ\H_8']ML:8J'ZIOBL&!>JG&^;J)K0+PRW-T
MKTO8;A!36+(WVFP^=7P^J@9]8?%[@:VOS7P>4Z$TN[OY=MI3SR3EG6#&[[#J
M#(XOGZ'+VC;2-KJHPTU;C%41G2W'XB(\12UDLYMY*>BR,..MJD8033@732HT
MZO+2$5EH;09E,.!3^6/PJ$]RK$>;]X7_8^5I3.>QF"8=66XW%,4'*ZMTA_)5
M<QJ5<?C7X[;L16@Q51$-:;+SS:O4/\!E;U:--*JTO=DZ[& 3E!"50TS5C<LQ
MW%"[S09V<);1\N>&1)E\*#)F/\SL)O,T!42Q6/OSL"YOTPG)3';#G5?#TFS%
MH?&&[ SE@3E>6/V[/C"T->U?GG#!%K>*N[X$_8](@>71:>*2Q(]BDG*=NI&6
M<>K1I1D3'E,T2;72GJ8*?D)53(-4TU@RSJ+@V0@C0T7$#@ALTM$CY>.8-5G-
MS/[Y[,3BU#-MIJ:9W;?.T6GG'>LDQ:2ONCP(VPQ5?5TWFQGZS.#5++WYI&"5
MZZ/J@C.JQ\BRHF!3< -H'0,BC>N^/)MF\&#EBP8D-&4<595LY2N?36S%7YGG
M6 <^1HEGGF?C@3'KK\9<F#76K\1LN9AB&"N0M@AXT2GOU,.S$+I-"?$;3*2V
M-[!3K51A0OR ;]7.53^M!PJRA9F64X^QL7>*G#<RNV$)Z+)OSE)LW']ZQSJ,
MGH/\_*GL^.^:4^H3G5:N&:,$?=75JIMM>'&I\W[U:1\?N[[Y_:P:!U4WFB4*
MONXS\8T<B5YN7(CF5P1[\I@973ADM HEF!)&4RO>"&08"JHFG%7CQJ9YAM5F
M+:REGLZLX,50;1)Y,3)9<>C,AV.;E',A *-4,?M"*)>)1DO,>,K@ 4:(-H:#
M?,\Q,Z1O-(+IAW4;(.?<3&8TE43U=SB5K#ZM>H@9$,GEPKA-"U],"Z=M6OA:
M+.6>T\*OX<Y:G4Y^E0JT1DK/I81>"S^+N\L":S&[:5$\KI29I@V$:<0V)QGK
M=B(5K-HV:1<\9[%A73,H;B3LW;;<>3P=\V!F#V*5/*+Z\6Q.[_/P?!PT;$UX
MR>4V-EA\-\SG3/!LJ($,4<_X;9:0."L;8 [<V82ABK*7C:;R\W<4=C*W(U%M
MG,GH7;.9R.H'C@<MU05/,V:W]>96R5VS_(1*.[.::!\>.+1I8I7H;[;JV3G:
M=0*LV6N\.Q*WZ_UI:-S_L_J7[0#G',W\('7Z:76+:0:JU1E*-6>Z5\F>YD7K
MM(5::[+C7Z<L/74*7?TJ\THBZG9&Z^XUGVV&F6&YMCD4+$O,BH&="XL-5S9Q
MZ*@9BC 9VE_ +B,A8JU@60\,MS-K$0=JKW7M#,'LREFGLUE^G[T':FIF$'F9
M ;VRHKFN"E%*-E!3C].4Z@2K9JW4+V>'7]O=6'"7F6R<!B2R9C&+LBDC1LV:
MO4MCR78.>(%9F4>H\LW=MU"-[IIL_J$U6C;# ISUC<Y=]E2=O5+U9:AW?:J
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MMI=S(*KR2U=W!-BB"C4_:0T/8$?&NWG._#T'\_I1!J^F48;&S(U9+6*K?$@
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M(R5"QA0\E;6NM$B01"<KDK"8NP5Z1(7+&731(X.C1DEY[X*56!!=ZTHU)BW
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MM$P)@;::M ^4<3/WT@HUDM9(6B/ITQ:%J-72YX'3B0Q'YGA0#H23]\HB+E)
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MI""(<!X[I"W!^7 ](<MX1%@ISKG 3C.^LB[%D[N3%@>]EE"!RMSRKMCHY'B
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M.6DN<Z.9"H":DFL^,I<MUTAKRX*(6%K!<E@3>W3?Q66#SON,<:^76@8@6=3
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M!I1.Y85%5*F >%0*F80UXDXPKXDB.M<P-XJ]GE.X&E1K4%U44'VD.E^#ZHN
MZJ2^'J-4@0J)5/(*<992/N;DR <=#.<@,UE86>=*OQY0?7!HP]/'*"S*@?#.
M02P[HI6GPK'?&5QK!=AN>:S;C\5^[,:^;;=/"Q>')S%VBRM3SR&3J/43';0"
MO-V[9>/3AX<3;.ZSQLFW(+TASA'D-%C#W$B.M(V@QECED[52.0)\UNN.V\[E
MGG0WQ8)(G0.N/<%9I24IV41C-!;X54BIN+UKDXZ'9$66__Q5D4>%T;/;;)P
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MY08X29P .*.@$WBN%'6),. 1:D&# ]@+]TZ4J@'N*0".3%:L#P(')P,R3A$
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M+_-TV%..^*XUA$GZFT\PRMB.\VB>XE(XS]W?8Y'+Y!S$20NA/![N5>]8AI$
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MQB"S5]:IOLX3!L38+OD-B.0^!&"%HLDXCBG\$S!U@:@0=6",.!ID5;4(3Q&
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MQ=OJ860QC 0$SII? #+>!]Z(^2[:I3E'<W#EL==I-W]GGUF!WZ! 9CHT66W
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M.ZV]:C9H5RF9#2NP0N1*MW'!ZI>4.*$1QTMQ0KO>/#MLF-2?++[4).>L %O
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MV-<)=^^F%''N=$N/8URESXW-3-FA40)F"C*QD%(J!;$V9H0YY6 9IWH$=^D
MDXRI@C(UQ@,6&7K8;)=]9Q06L?4I?;(31LJGVTTEBMSP&"#%07@9^VEX""V$
M(090"<PJ#><].3K^1REE$SAGZN<ANW"Q=K*T9\D."J-_Y=C0^<"%*<U6Q_0"
M5$)'(1?Z76JZ^2:A6G*VR$RJ*MV<?:&T9",E@=4DK-2T,9_YNL[36'3@2'$$
M#-_K8!HK /%%7*\(?(DR^FDN,B:*J+$ @O:V&=(6:PU9%=1D1S$JBMI7+EM%
MK0I^Q=+\5\KDMUM[ _.G*JIR7Y?*<A&FH^K2Y)DRSHJ2QU*6OM1>2E+\7-:E
MK_*4]6]3@ +4;TI1:'.I&>"B*0PYHM3^^/L4R)$==D1C\*JA5J-L.)5K*+*+
M@@+<3$C&9J/<XVDY1+KE6I!2U0![F5.MOXD_R-90SY9J%Z2]H$K9F-N)QI-&
M?D(5 KSU 9;'":#K_ LW_Z)7YU^LQ59^N/P+FEB.R@10%75$*#7\<K.O*UD9
M0X[,RM H9BQGD4VBA(8W< MH,[D+HQ)NO5+!TYU4QGZ>48ZT&;J5Q8WY*K6&
M=_CQ!/[Y=,26_-'O1ZL(OW)=5FMK:[T5WR>I^EYI3^M<AKHB<$E/OG!K1@]-
MY?6G4N7U45%Y_0*;8("VW6UW=AN%^T*E&&,D79M<2S]W6OOEYK>7Z-%W!C\H
MJ;T] 2TTQ-$=Y+KZE502[]4!=C7R3IEK?-G:^O5CI[>]M[?_FC0,]DV1EL+Z
MG6W__IC4O;6[!' 6$_/6WK-3\XU(K:YY9JYH2S29G0\&<!VXO=68G/VIUVGM
M6 ^>+1"M;%"@1G&DA72BV!8\9SA]BGAT\?J)':6G,BYH90.N:)[ K1 :9-.J
MHLD"D$0\:,)_0=I@WDN#Q[>,%(@EJ8RED^@HP68M0;%EL;0^J6GL'9(W"T_Q
M)0:AE&88BOQT*AZH0"5I\SR,5.A]DKXHAZ3\X0,?X]0[B"[U"#,O#@_P"-C?
M"]1]A5VSKLEE99M#N.:!.,:Y&(]Z9%%O(+(]T$J@^24 '!&(!"CJ[X6.<+A?
M-$W!GS:*G@^D+F/,(;E"6:<B%81 7H?EQC'GL4]-9PYXH4/J7(0G/0=T9& ;
MRP=_!X,=T0+G!BT=;,L$CPC@OZ:Y)QP0HF0CLJBETIB&EHPD*CC(T2XE4&C+
M$@R&"95%B$3P<7YX<((9^FWOW$=$(11@9RE[Y?\1)E22<AA')HP58W'[U.ML
M-?@Q4#*.$GA]""8)F#R_ N8!1A\.#@\;UC<VQ#9,WJ]QRE%K@.HAZ!)AA.9T
MPSL;AC$Y&MRI-VWB1^RZ\[%+&1&400IR)]O#H]2\ ]]9\ZH[\RIB27$.!-;L
MPZ=! ^.X03S&J5@-3M/LQWCY,[G?,QT47(/;I%W9:6&2>,-5\10!8AHF!S'8
MO?9B4>G(E+QE5_@#2K["D^!Z!S#IB>MP3!XPL"XE:1(Q**EQ'RSJ7!*79]<O
M6I/1Y2@G]W"GF1G"FTE^[*(3.AO:)K_< <-Y1$(MXCK&8F<KV:F7F>&/S)Q-
MYXF(1PW9V4]L!=CK=/:/DZ-F9Q^>!85E+'W3*?8MG@X93PL<69(&X<EB4VZ3
M*_%C^$,*.X1IDD]DM!\G2(G_45VI<.2,DW,F-"GXG**O9'*$)ABO+J-8.E$*
M2M!I.>_C>-9>23=>U>?7D6_6*AS)(#*-R "C?NJ22&HZ$?%F4$,ZA<&8)X$@
MRH=NX:R?+(;-<[FU=/QD5Y")6)89[40>X!IM&Q^1T/2'HP/DX D1+T^I-"VM
M\6/JG494.<2FE4!FZ#8)I$X^G6B.&YD:NX)X25"@ #*=$3SLG)V3C' T#W-?
M:2NE;0]5P.6\:9Y.N/"=/6(X=5%+-;RD]Y$[444\)C,<PX]%?U7)LU L9LD6
MYB8@*G*N-PA(JP%9G8A]H_BEG2;Q#TGOQ;QD6M(=L7@#TZSEW-UOST+! 4(B
MB24X.Z,2LQIEFIUSS>X<:<PDB5(9O6E:)@1962%ITZ!HR"2.L2;I-N/OKE%^
M=Y13GD=I+AKEV]K,&XY".1DN$H(&#LDWS[3TQ]ZFH;Z>+YVUG,B&YG%491,9
M"J+XEK:<*_>YO\5EUF[M=M?6948H>:).;2OM:IT5@A7!6^$T,XW6/F*C-1/=
MVIB I&NKH%^B27X)S(VZM$IGT[:L8W:.OK%')</;V>J-KMHU9JOLF;VYM=_A
MQQ.W9U\1',# ;L-$SAOEL'GAOTDHK15>00E#%=W5V/%18_ ^&*2+\)>T9"*B
M*^T*W7(8?V=]N?"1H<688ZK:J*@#G;-*_Y(:N]502+DMOS9^2Z"28^I:%?G3
M@IHDK>.*TN[1!RYIIF-,F6*=B6>P=SBX1 +6.^*^V!2B=WQZJNBSA8:%F7L@
MR75%Y_Q^G@24HDG.TZH4GM0Y:0"(GE)J:SX9N=9-'LD4'\=DEFQ<4WP;EET+
MB6Z*[YU3=/7C$,1R+1F]YZ3&PBRS_J,YBPXKIP#490VZ@\TU394D\W9>2[*>
M744<,YV-_=H,](#T/^.*B?OHT95T0<I 3F@LTT0E10&F>+V,28#%V*V:#=U/
MD&#;K6N#8\R!EHQ)*:4@?Z_<)%>BLY,M39V<WU)K>$:B"24<:4RV3+T#YC>F
M,=GG3T[/U:+]JW=D37PF/&.GHTN2"BK$N)\S\JIUCAEWJ>5VELOB.L16)>EU
MQL1@RX.Y+F[9"W)+E O,2K)J;,$R/S6SL"DP*]K2(\\U9?/&BH6+%$BJM%P'
M*4@5N4^I1R.OA#1,Y:7Q:KR!";:-"]BPIH,C/\4L)>JA"Z;7R$PP,,,?!K'/
M[A)T^8/0A_U1W8=O>S-QQCP<.I+1 68_)A^LP.8YRH[RE[GJECL<8@8CU968
M%02I9CS%3*I5B09K-?*!U$CRJX0I(<:TM)C'A2,3A".@3&@F&I-3*<DT;DJA
M#FJ@UM4#)LM$N@C:T7U2Z5+X,T/,G$..HC"4):YKN"\CI]4FK(CYWN;NZ>\8
M3,0A/N*_H[. "D37C0O(S9^*L2=7FB<_8/6P^!JD3H]NBZ)V]4B,E3VU*6P2
MQ5>\4/6J9OP$:$8:HV^:&S=.2OVKG=;5Q.D^((<H];!>V!!?VF.3GC2),PP@
M$G-SVQI7Y 4Y$RXDJU\73%9>?^9GL00#.W@Z&<RDRL6N(S$\J+FV>R-)XI/^
MB,.6 YY_1,P.2R*D&[>[%+QRWDBA*"G.^,!DZ$?6R59-B=F,>@%IM#WOJS@R
MS:Q_YV;61XR2C7!6T,QY#+(#>4JO[@%84YB>BPGO:1K[G(;#D9TL2\)2CU],
M>:(^#Z-2YPI>"F,YH#NY*FK(M0 S;<&Y)3$E X[C0%.R-=V74@:[HBAFIFV#
M9*P6T%&8#EWV.[<ETV<?7FM3#,U1)4&KY;UW.O2C<N=HWL7]U2.KJ(SC*SL6
MSD2]. ^@TR^[?&8354R'?PZK4(<:(;P@QCU<A8J#T"!#B,MRB!C HZ65RUS$
M -,96589T6$$%LB9\'OQ;>2>,28^S,1^L^O8D4SLE>;)>+PGSN=&(2"VK\)'
M@++T-QL%*B FK6):WN%(@VH6<9DH1:\"32858(O4V7-^]E-1/\7-+HPN?'3^
MZ;W5A6,:XZ6-H#,Y/IK>1R5/P;S7Q\8QJ,>%49(E-ZFD-_/ AM(I'2_/?/X.
MEH=@I+!)P?T!RUOR[%.*OM-H%E P%UW#:E,62NXF<,UO0)<XA@)A&!F9*_Z"
MF1B,(1S3A ./Z-2=.-<'$3:?@<2A1FH/KK[!A<],BRP2W<;$#;&'%;+!WX\*
MV()NTM*MQNQ%*DU2HWBLS *3>@;)\@^\RQ$HN@FE)0W"D=%=$]M6P(P7-MD(
M\WD*LCT#@[EKQO01VA[V[;G6A3]Z*<%674JP%EOYT4H)9#:=>"G**CIRPY+(
MNLVM .PBGC3Q)<R!J4RO&.%*NKSB<"LO*%YB9B;EQ7J;,HGD(+!&VEF> 71\
M=#X"&,^H66,>4;7S1BBP&&WCV828 $%C&7.VH4$KP+34THS"\MP;ZLMB-26P
MRBB?U;8MDEPS*?*.2X ,G:Y(1CY+/:O5=QUI71Z).(JCRR9&^SV6SI=3]BYI
M;B027$DF$LKSS,XT-64QKA)0./I'&>4"@A[V+_&6H5W=S\0+ 2C]IC-,7AR"
MHO5OQZ=,(LC4TY=FJS8\'9+?F_*YN0\-O,XXK1JNPVXNI9LKU$6W2G/3/(+N
MXR@<Z";V (<-\^[$)5I4#LU7&%VS&PXSS9I&V&H9\"H3+HW9#WKK6"M<>9"/
MI%^%43U899;,7:S[=&M')^&$_%#H>)'WI;F/#AA<*)S%346=)X=\PD229YS(
MCXLVN <ZS6#_]QS$L#8,YZ0Z+_2S1. V@M-<+,QXQ<O/!,])[93;@]YKI[L*
M5^+RC8-G8GH6&]WH".?R*KC;DG9U'2<CZ1?IEG,[I<<VD=':W&;LN/%AE>;'
M7J+E%.'WF^A71_4;Y1[N+]+4(4=-FRIK#M'W3%P-[W:BL!+=[2':P+1-'O%M
M$Y"PVT>>Z%)[IM*!Q8:"^TC?>V$#@<T<ZX+%<]<QS+F6KA]+Y44C6Z<,V0GI
M(#$/IC%0=)$UQ, 3MQ&PS;+<MYLW(?<RT6,[,MK]D[R#\JI#0ND5-B^03EH6
M@04W5]+Z,T-;L.A4JOUB-+WB&3UZ/"$)8[HQJW2N9RAH63*VB>@K(_&!TT1&
M1@9QOQ6GJT/A9\$=1))YB+X6'!^!#)Z\[R)#=705)G%DVMU0&;^!352"KK3R
M94'K@AHX<FBF9* CAL)PZ,>51[3/NJ<JM"F@8%@:HW;B)$:-E+J8FN8I1B(F
M*4:!Q0%@$V4I=@2W-YYJN3-$L:%T;W4SE!5.UZ99RR-D"=_XC71')Z#/^%,W
M[QHO:42YUN2PHYX0F4BJXF8.IY<@C^7Y4!SGQ79,3P'IG-&W+@#NCRPZ3#G@
M_.C1ILV><FK#KL6 \&!&:\#,#FJG5@2:@B*W9$'FBCAX2AE1XYA;Q%;EJU"O
M=B+VB_C;-'9H!B,9XG2T 1(>BU4X<XK2;\OYPF@@[DK0Y%!K),JG2*\J!EPY
M7Y>-7L?Y**AB>!'VG 3,EJM:J+5@N12Q)L>[DV,Y*8!8DN/SEH08X\!V<K2H
M'\A,/(SEBDEXHL0E:ZW8B+N;UUR(!2?(QBU.^N.0Z@ !WS]L.I+Q>Y*70XW0
M]6Q[<,[(4;)-3%%B]A3%B)M]+2J#SJ2A87,IEW7/LFLDX:+PN)S#9YA?HSR-
M2O6!%=?%14]37+3Q='O/TJ)5RS[6UXA[KZ<Q1IFS63.A)+2,_V?F.C8DM2;3
M;BM-J[T8YQM.:J.UTQGSSAGU/F.T%1F_UO?%-A]'2G&3@YRZ93G[M'DYG&7D
M#>&<6%P9F;:=A&/D&*3%2PJP">+#BP;8"]>'8U';1^E8%^3E^;UQGE'81PXO
MZJ4V[;S0Y:!H+_@;Z'NVWQ<Q&30(^1F/(G))9,4YIG-++K(%H5A*=AI")$,>
MC8G))J$X6_&(I2?1D^B@UC7RKD!$FH$5OH*/@3;3T@1$M$+)W8?AAZA(D;:V
M72A.0YF/@.G2E^I2.ZGI5%Z:N:* .V07AF,ZS+,@OD:[/+%MK&-T!+O>%*?N
MN3$;S36,NF3:"N^'VV%T+3.E".X.4K)MM#!BTQ9=IC[IV#BT02'#YYYWB:MA
M<\TU%J^8%LWX!-GFRCZ%SE",R"\PNQN5M,WIBA6W 9"08? &F"TW5B4JBO-J
M?[IS/G_.8NCKJK/0% LK<MUS.6"@)&L^EGWT?J<ZU[8U[9<P_>9]4#3"PPSE
M$D<TI99]@!OD==K-WSD25A /-GC,C0+,&:4VPVT6"3=XH.YSCGD9$ ;_]=,2
M$<O]GY82'/(7%*R=&VL%5ZY$K%>N5_Z!DSRVZR2/M=C*$R5Y+'U7'H\0JR.$
M7PJQ<F;%RF,P@:<^V 4@5F,*8S9,O6.TM->F]OHIG5;5+_\MCS0W">RQS[G+
MF7W<J[H&5$U%=Z*BSIH"YV7PL<7I#<YP3V[MAX5M"2S"#HUJ-X:MMB<2YC9D
M'KL<O8K[CS;&/$+?WC</1C9L%#;,8FC2>)-)JM^:']Z!)056\/1M&!$ Z*%W
MY3=4./7HA?RQ*#S[W5:GO8TZ3Y; _P+S8E&'6J0.O<F"^<^V=UK;G?V%'[=;
MG86?W;1LI]MJ[V[=:=F;7]GM[M6;W=U=:MDW1 Q,$$!R2-#_]5/OIT+)IIXX
M;[N3[UZG3,?8)F?.E4P$]]#<8/\V9D"J/%].>R?EX/9,^_9,?>5_NZ3<I:9L
M;4#_>7?#8=D@>IKCSFKM<PR\72U]B45YP)T6PF >KVT\Z$^K?_6'(9OB3,*@
M20IBK48\"@,/M[<N=#-[WFJZ08'V(*==@G0V!V2=A[U3"P'SXF!S.%31I2Y!
MYQ;><!?V^WQ,H_K4X@X I?-8!H"_7>9.+3KY4N2P#%G=!MK[K+&AFUR96GU?
MZW6EUIM$'/_[1<OL-+1IG.C4+/FN<ORV]P* \/.]3NB>C$8GK]/1>HUN;[]:
MCUF1BKT5#[O2%9UYY>PUKRGNY5#<5J/7K2FNIKBG.]JK3J.]WW[]'-2V4?KL
M[1K"+S+^@/-*BI$#5WJABMM=#1B5=VGM**[7V-KKK,CCJC'_J#QN6>5Y(W'4
M;>QU]FH<K36.=G9ZSX>A![+N&-#=5G?[Y?#Q^7\OJ(]2;'T76GP7=^+K JBE
M/5DOA%@;N]WVW13;57QZSZGU_L#8W6UTMG9K[&XH=E]M=7=7-A >':\_F/7P
M,4ZET#R>3YG[(?2=5R1#EB?$6A]]8OR0%*CQLZ[X 2Z^MO:"R<6*8LK4O@&I
M+_F;-1!J(-1 6!8(F^9#$"\!U7N&$0UW>"6>@CFAN8JU\?(DT?[6BP]Q;3:"
M7FWUGB4B5"-G">1T>G=TM=1Z7"V]:R#40*B!4 -A333Z&SP,+T"C?Z\C/<#1
M'>B6%94^4]_O&/A;)=/VY6@KU)"U^^YNGJ>U"0X]H.-PP_#[JM/8;N^M[/6M
M,5MC]GE33]99L+B!OU.-0R+2.9ERYP#L#Y!^N^39U_OZ[31VNCL/%W=?)P=-
M3;L;3KO;C9V];DV[->V^0-K=W]I:,\JM?0LU$&H@U$"H@5 #H09"#80:"#40
M:B#40*B!4 .A!D(-A!H(-1!J(-1 J(%0 ^&!@/"&VF'_[:7,>:ONQ5Y..GK<
M'50W4C^[PI8_(YR+QE%\'!^& \)^WFGM>/#"$8Y:NJ%K^GS3] ;@T4Y-\'[>
M;NW>:9U.:Y5.]0\WP.<)5GIJ,IMO6KH14Q(_K$:5\^U/@#XSA=,_@=@+(BU1
M[VZK<S?JQ3F*,LV.YII[@>8)U#B08.<_6YYW-K\??'42IC0WU1EP\'8F.?$E
M(XUFR>T\(\\S <\F!K/?=K9P,"I-_*GLCEK@AKBBFDR2^+N9G_ESK]5]$!ZY
MU>H] I7]W'&(%U;M;@/970S#M/C6M<*9BR'.S8#SR*AV9Y4P*@"@TC3V0V5'
M<]:SR^\U[);&BB/^KC2.@DRTK^$  >=JTUA$G /2E^%<WL$ED -1) _.1 P/
M\*DD#\M,1,9L EH!YU.@ZI:WD+KAN\ UAAY. HT#'(_BY\A^9#"G"JY4Y&LS
MO1['JH2I/Z09C4!X*DQP3F>&TU1E'.-(\?SU54:DE"[D;O6<F1+[:J[&OPYA
MI7X2+D)99TF^M;_;[JX3W^H2XUIX/1%9]33JNU[0SV8B/8^8?C4WM/RUG<HZ
M'O,X=;EW P \@/_/7"693O#: *-N,TZ*(>0R@=P\Q&^AT<"\TF\J@@5HI'KG
MW2J*\&-?I@=6!M;M4FWM(##BZ#)&GIKH2^F!&D=-(,[+D.<V(;+LQ4.!7<O"
M>\E"/PEI>]XH'/>-B%%62LI5<X23N3XZ2D!*DGQ"A6JD$0*HY B6_I*Z7X$[
M[?6UAB,"$,(!O)%&3?LY#B(?\=3ERH'$?[%SV O!74SMQD?.,[BY-&SL6&:/
M3WDH-,VA!O&: B&Q7I]H(IEQG&:&.[ R1R(4M<.6=\2:&+&&8J\\*CWFX=%!
MT6=+>O860Y+[>0)W&[>8)ZACPKF5#$23H<NI<\H "&::HDJ:3T9&?."K!:3:
MRR,9RVY&?)NQX^$8 0"_ >UI%]2)!OX"2*7]X<QQ'A1/*"31I < !!S/A@97
M1+/;1(7%*>81 &P83G@KBD&.>R:M.9K2)&I,:.19X[++@I$Z&U&HN<.;<6X\
MS3P'JM8REAJ'=]OSI'E_'&:90:C^#@C#7P*5*7ST\Z>C X]&I#+"#WX_^>7@
M]V. 'F*(SKF*A5;SZ0?@TPN5'U: 04,5[5F4UP%@F^D5#G!R>D37ADDFS8#L
MFOFDS-?I%IB1[OQ%>/CPX_OS;KO#WT"9;13D(%1]8$&^]RT,(CW%6>AH1K6\
M U$H.GWR0T1-T.SUJ %[C.-!$_X+=\#7DPR6P_O+_(XY#.PD#;\C>?Y+^QFK
M]^BV:'G$YOB!>2V$M(RR$M)=50DY !MB5 Q"-!<M< Y-P]_A>I6V&.2)N4;9
M,$R"V7T @XXG3<0QWRZP2(&[A7XXH3>3!42+F@6%+U<=JM?R5O7+E6BIM_/L
M5X]6K!K@^:(\*(N[Q]_F0]E^$!]*M[7W,#X4DIO6B=+=,DX3^]=JIXGS&%R=
M@5[(E6(0// 74A,2_N 0]H:W.5$3G<-% &%\$ODM[PQXUN42<!6Q&MDO^W$R
M0<^!;AJ3')27\ H$LDZ!<=13YYW[U-VII\ZOQ5:>:.K\^OK&?X6K'2>H:XRF
M#60J>-O'L  I+SDS)%^E0U*HR;(@@TAY5\"+-.NQ^L\<-5ID%_PC"MIO)-"!
M<>0HM5.C-@/W4*BW@UR/I\"Q&JR+CS*%7R)'(W6#@_-<A3XQKZL0T)6RB24[
M8G/"71X-+38W6)'PAX %BK<0#ZP<S=P0K8>.-6NE6:>F2K/6BPS!$1Q/I*O>
M\6Q7O9=,M3>U#435K@AJ ;[#Z$JGF?B>Z;MH !))X[]$LE=JI W] 2"^:1F7
MK<&:)0G&LI#"U?AX"M]W7,^LR^+?1.L__<T[/?N8KD(W:S#XO)J.SD'/=D?_
MKNEL^>< S;R&6 /'OORP4)5KJ-2WZ0ZWJ;.FP'D9W'R!Z'2S/#P1<^@*36 1
M]I-6ZDK6P$6W2\F\K;"325K.HW.5"&TEP&2[QOZC^G(?8]:35+\U/[PS"7QA
M1,>GA]Z5WU 1H* 7\L=B/^UW6YWV-II0DOXH+Q;KJD76E4DD+'VVO=/:[NPO
M_+C=ZBS\[*9E.]U6>W?K3LO>_,IN=Z_>[.[N4LO>D@_[XCHJ+>S+MV_/=)>Y
M,4\Y/7[6"5 ]1WU6\A*#\H W+3%-?85QX7<9_+TY1%.<:>GV'\]%-;/GK:8:
M5ZF_UVF7F32_,2#K/.R=6J5_WGK#YG"HHLOR<-N-&MI5?>KY;/"WR]RI>[53
M7(:L[MSY\L?=Y _6:7)1&NN]AI\_;Y^S6T,F+W>\^W)'VVEL=YYQ7,0=+\ZJ
M/?=JBEN?H^TWMMK;-<75%/=D1WO5;>SMK="H^NG&X;PL??9V#6%Q$M*FC*)=
M5JKN=7O/-TSSH97GC<31-N!HK\;16N-H?W]53>'I1M)NVOA)EX_/_RM9)G,U
MT_<93/EBYF$L1ZR=7J.WU;Z;9KLVXTX><'+BIJ%WN]'MK2K4:_2^%/2^ZC3V
M]E>?:KI^TVQ>M@7Q$9,*J0*E2+?XL6R'5RQ'5IZK5"NE3X8@D@0U@M850<3)
MU]9N6+^&;G6GO!H(-1">$PB;YDNXJ2:E]A@4[JW:FMQ0S+[JKJ# UVA]*6CM
MKNN-K85L#80:"#40:B#40'@ Z^,&;\@+L#[>ZT@/PHS=R&)^9.K['8.5JXZM
M?QF:S*MN8VMW?V4?YMKHJ _HX-PTS'8:V^T5LMUJS+X4S.[O=N[FU7YN\V/3
M"B%.95C''<U J;ON ;"#.,<J;K/[^Q'LBT\I?D#XK/5%?M5I-_:VNW?U$#T
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M>0<I2>&BMZ/1I4ESCDL *5H+E/ -?P>EG ]RJ4K;( 4,^$%"+P+ W%!326<
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M4SPR3BY5)%V,Q4+#U8D)ENG!Y3:E?3F,95/D3 57MDVD"XRZQC15<UK^C"Y
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M<:$AEZ\G7-0B%N.:/#Y0D*B2"4D@7WG(9.2!H^=3S CU!O(@,"]F:9K*8RB
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M8&5B[QTT0*V2;>"9BY&<=/T(,W"MZ6^%JA)@'>F_241?D)@\8!>3IRUD.(M
M%;5RK3ZJ[\XVA:NH=N3D;3;CVPL7<K5"#:A$JCH)7+QR^(BC 4T2'K%\"%:^
MX1)D$=#?Q%-D"X.SQ>1;N?D8A:_IG\47;=*I'HA:=?W'QO!5F#/23VIVG[B\
M;<*T*,E87B=&V3IQ9+3RO"'X^R<TRQ4L9?<7\[!N%]1>W5T^.B<#\3OF$SGO
M>G5_7;+_3B%1A;1+;Y&M9 [+!*,:TPK+8?0=@?#3DX4F-[!,$>7!QEJ+-BJ
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M,U$!W9J,SA/KG2)9.*Z "LI;W;95 _Z8XN4'P=OME=^,MV>P+PHQ2<SB\.B
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MQ'2ON,M*5/_ON]WZ.B"BWC=@+9"?:R!K8<&=Q0OLO,):PC+H&GMNS%%764L
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M0AP'#"*A-\Q4,@59%B@B4ISPA+@<I@TCUM0.R>[-&*#<ZT4@*^UZ^!(OG[1
M"4PS3?BAD'JWDS(*,:4"BC2-"4V1C F?/=4.F!4M5E.=ND,1?2X8#_FBRF5D
M5/]#A]'I<]Y2)8*$9!*2**9ZWD(%B4HTSQ&)51#IU3LFS;R]7=B6&[O2K+4"
M^G3MB&M/F(,3?]0I&,.I?]!T9?=0M]$*[*H%5DNPKQAH-1O8Q3\8TL.[_"\7
M;?PC@,'@/'HD,-S3W8\(;O6>39A]V[LY?9C%,98T9@A&0A"( J1M'DD"F-"$
M9I$D*$FM&FF_>/+4-D<;X8"1SOY@8!^N\Z<"O4'PS%Z6^CL=!QS5M?=9P/[3
M1CL(.*K$[BG \0LN;"-7?_K&R[)<&+_*[?>\G 5")(*S#*9AQDW9506I$@D4
MBG*&L<HDMZJ\9S7:U#[0C; W;4.SK;S@BY&X;[>XHUC;&C$#(>C[P,\5L?Z=
MX+J0\-,![NB(U^G\UJ7\R8YOG3?U/>._I]_?"_VT7.6\\M(VY]9AP.,H%BFD
M3&&(A$Q,;3\% XDY0CA5 0_=#OQ/C#0U_FC.O(U;;U_<GK$ IP"V#0P8 +9Q
MH@3<$>L1,W &C0L#"$X]?>1H@C-*O@PM.'=#/R/C'<V+O]'Y6K[)2SY?EN8T
M9M/1("(DXU0RF 4"080CH@U^$4"**%=9FD4!=RJ[UC78U"C"R HJ8<&.M+V;
M1G3B;&=?#(6>9Z;H#YRSG6&#R*!F1N> HUH9-JH?&AE6]_2CD5O-2R*?KU?Y
M-[GMD_7VN_%62&'2IHQ)LZ[S9^_46UH85[*)#:^/B)^//Z"ROI6*<9"1$-(T
M-+[Z.(0$\12F." T23B*$JNPQ!%DG1J)[4JZTT"NUQ;)YQ3;$>!$)LZW\Z7?
MG#F3YPAH#LJ]/N4=E;I' /Z0^<<8TGUS^J8IJO!.+T=T7D< O=._*V=499G@
M@801D3%$BD1Z8TH#*+. Q6%":"HCVXWIR5&F1M:MH*"6M$T/K&2UWY">!O7\
M9G00J#S38R^4G#:A9U'HO0$]_>31-I]GE=O=>)Z_N*>U6)6D:[K7SJ@@ 5*Q
M@AGC 40H0I 0+O7'CA%)0H(D5BX!-'M/GV8<3%.*KU>QR'WP+"VGOI#XMG6:
MLI"#-S(^JO"PYLC>".,:$,>4>['D'[VHW_?Z0>J'R?TBV!]RRO)YOGIN(GO+
M-VLYPV$<IC1B, U5:-9M"IF2^B<92YS@.(T3[O(IVPX\S:^\+L7_U(CI]I5;
M0VY' #Z ],P-M<@F-^*@S/Y&[AL3,<,D^$CS 2OEN$(U**M8#SXJX;A"<LA%
MSO?W/#"G515$$S1C6F7=J?N"+DK*S:;FS=(4Z9^9(!65Q!3R:F.1<@X93Q*8
ML"S.4I$A3*Q.O.R'G-HNPTA<%2 U,M]4C=K,7W?D!E]JR5V/T,^C;WF./BBF
MGEEJ#\[SR+D?I5N#,>QY^OEAQSU4MX;AQ<FZ_9U]ZIYV)"P=U":LBA\'""4\
M2(AIYJ%,"%T"611G4 284\FS ,=6)VI]!I\:$VVKI)[LI+>?YGA1 FVOZ>HF
M+-^3X)FZSJ"MI^.@&JF1WR/8+K5<_8$^5J770<%W+ ;;#[WN4K&.SQRQD&P_
M;??+S/9\1H\5Y6=9/,CB]J&053S8Q^7*Q'S4;??R1?56OI-2&\W5-T-Q2JF@
M 4PP11")1$"B)T=ON*,DRQ*9)9%5U2KWH:>VFFRDK7K?->("):L-N"-SN<V!
MQ2+A#5G/2T0M-]@(?@.V,._(#K3PX*-GF!V6!V]PC[0X# F[V]+0"[G.A<'M
MB>,M"[TTW5L4^CW!4SF@,[46_EHM46V9A1D.TE#$<02YPGH;@J7>A@0X@U%(
M(R00"6/J5NQP4/&FMK1LJK-48O;IY>!I&BW]*5>;'-^^%XO*.[:%=VHE=VON
MF++.2[5;D6?$,CN]IF3<(CIN(DZK1$XO>)T+X/0;Y>*V;,;5]>KY]9R69=UQ
M*PRR(,0H@CB0$B)B6O'PB,% J0RG(8ZPW2;!8JRI4?=>RZW*1:OYH!+WXC9H
M+V"V9.-AP/--K?UQNZ3MV"E$?#42>S'>M5J#G5*\H]G7R5MZ-G(M'N@B_\^*
MPUYK=EK.<U$3VD)\U*]6N^NY4^^T<;O@VM#=)*UM,QF8$DF(6 9C<[2&4DDA
M%?JO4<PBI"0/8^QTOC:(5%,CI5VE;L">6E73@%W%*A.D50UL=>N=B#+,/-MQ
MW>BSYYD5QYHX]Q:X0P(];,O<020;M\7ND&"^:,D[Z,.'=";45JD6X[U&:6$"
MO3_JE[_\J"7DSS.:84H3;4-R&2*((AE"'&6D\C;+ "O)B%.9Q!XR3(W&ZVWE
MJQ?;SR%< MV3<<F^?S"(1]S<;S;M._OZ+[7$X%Y^7X%7^OO]QY F:7_H1MB$
M=\LQ@9VV%5!VVVF[1UV8^US'RNI!VJ"T7)8_2VH2),7=XI/)=S$-&?0%ORP7
M1?M7+6M>?L@7\KVFYW(6:#ZD44I@R#F#* XQQ%0AR!A3*$XCA(53FN*@TDV-
M.[=)PC>@UJ\RH'8T!*V*0-M2&R6KJW;5!)6>X(O1%%2J]DW,'N0EL&/FJTVM
M9\Z^RJSVSQH?$GT_:>:#2'B=O/0AP3V9R#[H(#USF;[1?&[\+^^6A8DUW&9'
MOI%L]3-=-7_;RMSNH9,T5@HE(<QHHB!*A>G"&3"8B8@E<83U?YTJ>/669&J+
MP]MRE3^:7NU@2RB..5*])\6.P$>!VC-9&TEW\LLU8[=*0;4L8*G5N@&[C-XD
M7/Z[I 5H5'SVXLVX&-UA$[UZ2S-N4MBEH+U((+OX@1>6/=QQ@7Q<EGFU#V@_
MTP!3$J(D@6FB$HAXPB )%(9A&*7:VDXR0=RZ%5D,.C6:W,B\[VILQ>[M(;::
M $L7Q,"P^O8Y7(YH_UJ)%A#Y*9G8-?!U*B=:0'&R@*+-O5=JR?;V^U->5#?9
MM=Z**,TTD2$H0IE!A#F"5$K#>2)2*DV36,E16[(Y*C UPMP$^U1Z3*4AF^M;
M<8GS=QIS/:+G^.*&;#LP_#$;LO6<QVDU9'-58@(^</]3-'A#MKYR] PXV4L'
M/QC(5"A<KA<KTQ5>2V)<_[.$)6&$"8,AY:8::< A9L9S$BJ4Q'% I5WN9%\!
MIK:<;3B(-APD&IF!5DL"O8D'RTWMA*H610E^>*IU<5SDG.?*,C[$XPSX#@4Y
MK$KQ8D5HY0=&@1O0J#!@S$=/\(8-[W 58MQ(CIX0O0C:Z/N<JQ13O7TTXLSB
M*$1QRC%,$.40$6Q:92D*D<1I+)%4,<E&+)M:2S4U#MTKMEENBVW*1JVZ/R;?
M*F8\ [)1;;MG&+62:C._EI[JL6?-,^^>JH[Z=F_"7N]/6*N5(>':ZK\!M6:3
M*:>Z#_24"J<VDOV12J3N@SEP,=2#A_>C^$^RU"S"O]XNQ!OY3<Z73U7SC[J]
MZ<^R:A[!% GBD,4P$BB!*!$2$J((3!E%+(@22E.G@!*+,:=&SZW(58" V KM
MQK<V8-NQZ< 0>N;*/?1VY-VT,OY2BSR@-]L!H$$YSF;<41G, 8A#?G*YM4>!
MB9V"2#65?=Q)8KZ=SY>_U\T$W^2%Y*O7Y@I9/-%B]7R__*A?S:_:!/XD']9S
M6K1_G7&N,LR)T!OR0&_-%=,_"4QA&F19@@2-(R*LRU!X$'!JO%:W;C&F29U&
M#&BKEBEI*"K%J@U\HP=H%7%//?8VY]V,.869].UG-J7?[C:5]&H-*Q-SIW##
M1DMPOP2UGF!74?/K5K>;%]-]Y2EV*+EQY:D>J3#'-:?<K9"'Q_GH+/?A8]SQ
MBH)X1&VO=(C/<?I4,6Q*6-5U^&8JP4+B3$&]J.O57!(.<2P2:")NXA"%-*7<
MODCAWK.GMA ?UB#LN;X> &BQ-/:'Q?.J=HA(?Q1<ZOGU1F.L<GVVJ#A6XCNJ
M=W>AO?U;1JRC=U36_3)YQR_I&6ZS9F4N<EH\[[)EU?HX(#A+<0A9C *(HI1#
M%HH4QFD28R9)EF1N19Q/C30UMCHH-MRGS_%)4"W#2H: :@R[W!8E]X",<P@,
M&SEQ<K1Q0QS.*?TB%N'L#3W,E*V%M! F"_!.-278%N*37.XD5C<^O3#BG(@P
MA5$8$,T3<0)II"C,%(V)E%);-LK:CG$<?&K4<5A2T&%9=X7=POKQ"*;O\Z=6
M<G!K"C[H?S/[P19=_:M]^<^[6"_'V\'.\HC[2(:8(_X#V6D]<>LTY%R?.9ZE
MUU/;/5.P[S-Z+ OM#OA.?=1XRZ*0HEINJB"U]M1NAN,4,YX&D*<F9BP+D=[4
MDEA/3,Q2%(N0A%;!U/9#3FT)^"P+<U+^1B.;/^0+JF$LR[4$3YO:^NM2]*NK
M;S<%%@O#X,!Z7@XV?GE-0AN)6_=@W;1@$W,P.)X.Q#\XKB/1_2#XNG&]$U2=
M#&_WI/%XW4FS/39WN[/??O_@R;2X*ZJD'E$E%VYYG"@A(A1!)9(8HH0$$$=8
M0D'C0"@9) EQ*F9I-^S4N'S[+93UM_!$"_#-2-R;R!WGP<Y?,#RZO@G]!<EH
M8)=%7<!-U*G00U)./Z &]3%8#CVJP\$-CD/O@^/=(Y=D?_O;.E\]OU^4JZ):
M0LN[U5=9W'^EBZ.%@0_"C:M_?*.5V>1=ST3 ,46(PB@A(42Q)! ' 85)IK*,
MRHRQ@?,$Q])L:JS[(N-";BI5*%,HX9M[I8K)8.V[F/PUWPW?#N?+Z]#7Z( =
M>$"%#UA]-1Z.TU7J7Z2=5)<  Y5-]93Q*M?[FO]I%+T?7+MI93"./:F#E=KW
M)F"?P,O*__)FWSAY+1>BC?<6&>%9QF&0F7AOS#*(L< PY2264O%89%8E5FT&
MF]K*:B0#&P?5T_[NQB4*[@S&%BZH 9'SO>ZT>+W8M%1P]CAZ. >?2T#@<#".
M%=S7">=0<7EVL'3'V)UYQHCQ<G;:[,>^6=[3;U?V:EWF"UF6MUPS?U/^Q80W
MT)2KB(09S%2((4*!@EAR#!7B,HY4@A2V.@L^,\[4>+45$^S(V2MPY!2N=KN&
M =#RS*5]@'(VGL_ ,*@I>VJL40W+,PH?FGGG+I]"[[SS&^D,<YY%4G.+:<R*
M(H),J7RN[3@JN0QX'"=.B=<CRS\U"K-RNNRDTCS43?JNV9COZLZ6_]^ETMG:
M[P_C-/FOX!KY+^T F8B;8U1G1BMM[5LQDBX76I WRT>:+V:<1S+B NM72"80
M"95!%L0!%"$.,IRDF NKY)'.4::V1C7NVXV4X$LMIZ.1?1Q1N[7B8IP\,[H[
M1,XTVPG!H&1X?*11*:M3V4-BZ;ZX;YUFO6]_;R+(Q)NU*:M?LTY%4.5Q)IN%
MB624I,C8PDB3@U2094D$!4L1"Q*6Q-*II$4/&:9&';L6#-^U=/HWF>XQ,9;V
MJ%^XQ[ I2U#+?U.;CN7-<1-RN^3> *KT>[#3!WK(VL^]\1RX%+2['"-7ANX-
MU,M"T?T?U;/0I3ER,L\KY%?]R/R;?+_07[K\=5%(.L__4XI_7<Z%EN2OFI0_
M+,OR;K$M2W1;Y*7^IUU1?Y&K.W5/O\\8#1,4A J&F0H@BC&#3"!M>44XDQIE
ME"&W9JN>!)T:Y6XZ&U0E-DRCB]W2;Q LY JL-SJ#!ZTM^&&N]76MFNEKXNW8
M>@K3Z9G2[UZ_OP%G&IE\KAJ9;)4&C=;@K]6\&L5_O %,ZFLEN!7_L2Y7N[RO
M%1ZP9J?G*1FVMJ<O8<>M >H9\A>U0GV/UR/RH/6KFUZ95:O,&959FBH2PI G
MVA /"-%+!T<PPD2$$0TIBJAUK,&+QT^-\.^_2M *Z7 :_A(VB_"!B\#P3)>[
M.( O-IU3;4!Q" JX")R1P@#<07*+ #B)0>>9_\N[QCOE/RGQWKG^Z:OZF<T?
M]+.DW"^]W+;Y>VXV:N6;M?Q%CW?_NYQ_DS\O%ZNOY2P64L09(Y GL>$V%D*&
M,@8)#C'*1(!48E6,[E)!IL:"^J6*W0S8WE-@9Z". :QG1JU5,(=-!^7@-WK<
MF(I^3(*/-!<W=?.\N\6 /H1+01S49.PMS*@FX:60'9I\%S^O'T'6=J4V#6_7
MJZ]+TXWQ%_VF5E$Y*18BPVD(.<+$A))22$.50)4)%G 5LSAQR@@Y/=342*Z6
MU.S:P$;6&V"D[17VU(&Q'<<-@YQG%NL/FC-=G<=C4$+J&&Y4RCFO]B&I6-PQ
M=AN[ZH][/6I3T\$(U)Q1)EAQE%$.&68!1(0HB 5/H4@Y2E3 ,FW.CM.J[K20
M4Z.J2E)@1.UY7.QE)BU/@JX\/YX)T65J1FSI=AZ[B;1MZQ!T6G$]%T ]7/LU
MB[%Z./T^R8?<]#TU4GPRD4#EIB;/S_1[_KA^?"474N6F4^K=[PM->%_SITWM
MV7?+8K?L["R+,YHABF$6)*:;D-Y>,R1,#1VJ_U]*% 3VY7,&%6UJM-YHH/=\
MK0I@V>JP4^?=E&>@FV)6CGW9/$RPA6OS:M/FF>UW]0*U8KOUO-L)W2H'-MKM
M%/O6^NV5^;[:3#KX8Z\VHR/Y<D>>63='L!?P.YW(PXXXG@/:"U)[SFL_(_3<
MH/&O4JQ-U=3CG6!V3(K7RT75V?Q^^5$6:ED\:DFJ \CRWL@UBS!54L0<FF91
M$(49@U3I15R2D$B%(TD3MWB[P42;VJK=:F8224[V3=H+"VL5-/[=1L4JGJ16
M$GRIU'3=T0TW]9;[N*M,J.?U?/2Y=-\"#@[[L!N_X<0;=[LW.*PO-GG#C^"V
M2 B9SS[H]VO^\>MR(>L^4C.E-V",9!SB+$H@TC?HGQB"C$?:!! 1SE!D0_/'
M'CXUHJ[D Y6 H);0CF*/ M=-DI?"X?OLT1X):X+J4OD(Q922__EA^>TG?5O%
M+K\A\R.L?ZPHY>@#1R&%+E7:S[KSFI[-F\M2:NN1E=7'/V,D0D)P#I4IRX9B
M&4.:Z$\S3/2/*6=9$CL%(^P_?FH?Y^WGSV_O/SMV0]X'S,YNZ0^#;\]Q)1CX
MTHHVH-%P7.=A6P7O#S%NS]^CZKUHWGO\JDMW6IN08;U(FX#A;4CF)VGDS^=Y
MM3>LENYMZ%O(,TIER*$,0KWPI@$SE1<SF&248ZG_@::LW_ZJGT!3XX-=2WP_
M*KN*NM_IW[VO5=]=4\]I=-TK^9^<$7=(+O/2[(3 H%&10^/K:2O44Z@K;8 N
M@_#TMN?"YU[6K[AQQ;ULF:A_OM<;KU(O"7IL+=K+QHFG>IRF.),T2#*8LI1!
MI*( $H4"& A"4R7U!DI956L90=:IL7OK/E^R>?Y0\X,YU:K;%TL!GMKB_:NM
MOD>[&O=K<^OC;; X!9O.'/M>)/:;W;:S?:SI;?6W'8VK(Y-CK6^';G7LXQWH
MU_7XRN_"=1H@7^N=Z-T+V>,LV;9%]B'"53HD>\3R5+-DGT->I[C<K1!5G3LZ
M?Y.7?+XLU_ISW3A#0DR35,42!B2+(")I "E"2N\TN:()8E&"G(KI>)5V:N9)
MW?]S4P;L1=&OUD&_IG.]H2D>JR.B]_IW^:+,^9D:8%=X&2QWJ5.98M_6R8 5
MXK8Z@QVEO3CQ1IF>215^ZY9X6N&@0X _=%$WNT%[EB;9Y"PMR_(U+8IGO3TS
M8Y<?\H5\OY*/Y8R+@*<L,N]%2"&*)((X8 'D/* R0(PR[N3CM!AS:BO)3G:?
MEAGL"0V^&+%!);=CM(<-^G:D/S"FGJG[<CC="V_8 S1L#0V+<<<MAV$/Q(O*
M%@ZW]BTI1U<5)6[??T6"(% JAFD0:_9)5 AQ%"/(<"H)#:.(A\2M8MSA$%,C
MFXV$%S#+$2 MK<>+X/%M\KDATZ,<VRGE!ZZV]F*8D8NIG5+S9:VTDU?V<.0?
MU*/])$V&BZ:3G7V8V89I1JG*V'Z3I;YX1J(TH"E.(0T#O?$U-@B.%8($28XB
MG*41L^KWV5^$J1'$WQOI;L#?*OF.;&TWBKW8Y#JX6?O-EX4'W?LL>.:AW^WA
MO@&M%J!6PSO^#MYK[_,PDE/:RWRXN9@O@K+3<]SOR>,YA"_2?,_/>]F3KN.^
MK1GX=B'>?G^J#CWOE^97=^M5N:(+4^;M0*NWWV7!\U)6G;-G+) D#"(*0\09
M1%CJ94ZF$I*(:0.7AG&(\)C^W<O4F=I"N?'OU6I5_EW9*&8B_<T;5)59%LOY
MG!9E[Y;95WZ+QG$,C_=N_($\QSMOUMN=-\O\6E^UA>:(C=;" RI\IN-A'F:>
M)^6"OE"E/Y2/>ICI&]J)/9!4DUKDMZ>T":-8T P2EA&]1<4(ZAUK!G&J;;E4
M"AI%5NDW(\D[M65Z[YQV$@OOR$>N \[7?XVE<Y(GKY:S]$=8^/Z8IZ^6$S#2
MTC70">ROGRLG:VE*_RSG^2KG=/YYS43^+2_-Z$WCY2"+8Q$D 8RI:5^;&'^H
MH@3R6 54<!:HR"D0R&[8J:T4/Z\7.<^?Z!P(4_-_V[3!;=6PQ-R._(='TC.'
M__H9U!)7U+N1&>P*?=A3X7PO<6<Z=L-M4%:U''I4<G2#XY#C'._N6V_6.$RJ
M2F:OY[0L<Y5+\>IYQSWW,UV9%^;9=!D\2+'"62))I#!,TSB$B,8<8BD$#$B,
M(I*E- D#MXJT_869&JWMZ *VRA@[:M=]W>I3M2EUK6)[P<S9T>!8\^&9''M,
MA=><N"%@';B@[@4"C5QR]W+H7A;E'>"9EQ^=[SE'VN/@$W;J3.$0)U4% L2U
MZ1C'!#+%&)02Q4$D(IH2JRYAEPHR-=8]XY"] :T^[4[U=G>G>E_O5/L?YSK-
MH?NANJ^9\<R_?Z1)Z7_2[FMR1CIO]SM)%QV\]T'6Y?C=Z?E7.X3O@T+747RO
MYUW'5V]YHO!I.9\WT:NS6"8T3GD,HRA3$#%$(4$DA2A @JDP84A898!?3X6I
M+:WG,J\LCSZG\H*,<PK@=]K_0 <#+L?FDSPIZ#^3DSH\Z*'&'^H\H?\T#7W$
M<($D_5;9C_H]DT4A1<745:;K3)H&+BE/H$ 9APBC!.($2;T@1D&8<<(B9=42
MM&.,J:U3&Q%!6=<SH'6OG?\T0=51<!,$U?_JF+ 2?):%\86_ OH%U=.SRHW;
M1]\MY6-=TG__<6">_[;.1<V#WXS^-R#X<Q"$]?-,[26^?'S4_]B,_G_K?PW!
M$RWJJ_\GP%&R.[Z09?ZPH/KM^)\@KSJ85R[\Y2Y?AGL2TQ7XM_5"@C@P^D11
M4P675^Y@$(?5;_6?^EICP^7?Y-RR;GW7FV2W7E[X?GA>T+:O1E/JXF_U!-:=
MXX=;:SI0&'0Q.#;.J&S=H>@AG79=VC>Q3#^HGKK=WLK5HX^3]\ST.Y$TS& <
MF!9Z4H20*2IA8CJA))@*Q-Q"<YU%F!I;[MIN?$=.U]0TYZFPM+^] CR&_5PV
M[+(AFZ/6\F[=\KI%_;MEH62^6A=#1I'V1G/@7#EG,4;.I>L+T\M<N]Y/ZL>)
M;Y;Z=5SEO*J14SPW00\T9BECU*0@$ 413U*(::8@21*)XHS%*7'J''ITE*DQ
MVSMMPQ5T[D9DQ_&SXZJ+4?%,1ZU\^RU!/42!= (Q*),<'VE4LNA4]I /NB_V
MGGZ[LZF8Q2F-DH!&4*)$F=@- 1E3B3:% B8CA@(NK9I[7B;&U$ACFX;;[;"Z
M0B[N[N2Y'QWZF9*Q#PY/P]ZF@.YNG$>9"F^IN3VGY%K'A0--C<\,W2.(#IBE
MN_OTJ6;J'D'@@FS=8T_K9[9^R"G+YU54ZB9-0P1Z%4(HA8'Y P6(01(B"F5,
M<1+%<92F3FW.CHPQM=5G1T0WL_48?G9&ZX6H>%X =J3S<BC4H?V@=NJQ<4:U
M4CL4/;11NRZ]^O%_T^*)<!')-(MA%%(,41@DD,@L@C@*:!:1.*.,S)ZJO?;G
M%2U6HY_QN_>5.I36WT=U_$SVE7S(%]7ZO52@=E-4:?3UH</(N?,O9SP4B$1,
M(DA2F4 4XPRR)*,P4AD+%!$44=7,^-N%^,/,=ROKV+/]UAPQ37&>1P_+F%P'
M.&]1%T.UD_,^"5,-F!BST9UWD#V&.PS3<N]D3QJ3QK;]VXPSA4P].1A'"8$H
M%0FDE"G()#=>;R()X3.]GV%+ZW9\ED.[D,:N /ZXXVVYRA]-+ %X1_.B3[5S
M:]AEDI$D2AE,F8DLX7&D$0^U'<9QE$11A)GIDK9<T?GU0-\.[P_R>S,&D!O@
ME0'^FT?@[59('W#Z/I_83T^].=+$;,"^BX[X#-N1T7;P<7LU.D+RHHNCZ_W]
M%H9/<D7SA11O:6&V*VUBMPI"&B5A"H-,4(@(3R##2O^$"0_31*\+Q*DGZ_%A
MIN8QNN5\_;B>5\SS1JJ<YY:),F?0M".9RS'R3"FM@*"5T,-I9S<(@_+&B:%&
M98EN=0\YX<S5;@Q0%BO]P+8!W:9-T&X_H%_TR_!F:;S6,ZT<#7 LH*(40<0P
MABQ3 B91%DL61$$JK6H,.XTZ-7[8Z\EEQ 1?:D$M:X^[0=[-&MZ ]$PB/3"T
M)I%>F'1QBG[@#I_HOQURB=N(HU!++Q!:INEW<]]B&;R0>I0WLO[O^\7'0C[1
M7+QI8EM-UMQ"2[$0=ZNOLJC[6L]43%+.M$$2<!YH@R0)H-Z61A#34(E$\311
M;+:0#V85OW>IEM%'&JL/B]0?U@N9_'UDC>AU[+N1%FASL3 ^+5J)[5H;H]=$
MV5D]'G$?JQY&+3CXH57A1Y O0#L%C?C55%0*@-ON*>A1 .,2! <N?=%+E)&+
M7EP"U\MR%Q<];6AOWN:\6M(8Q8'4VS8::'N-(PZQ,&<]A"24!B'/A%-+JO-#
M3LU8LW" V)R"]YV 2QU+$XP?& C1 ;U+7L,,+(:=B$?I7!""PYT] ^4W;??N
MU-FCC_+4V<>VH%:"<9#$*8$HX1PBF3%(8DE@* 4G$8L#@ITRBP:6;VI4]YE_
ME6(]K_(E:P_ZWE'GZV6Y I]D[==:+<$OR\6WINI(U9O,,:A_X+FV(\HKSJ!O
M5MUH9J;/YKRZ[#RP]EILS=,T#)O&,+",XR9 ^ 'X1>J$IV%ZYMK7SRSOE[?\
MMW5>R)]I\0^Y,J_QSE%=%BH<())!28P+,@H%9%FL8(II) 5.LRCKL_&W&GRJ
M^_S&46.8XW$C=N^JOW;S8$?8P\$Z4C9[(Z]9(!N)P5;D';-WP,1V%XB&376W
M&GG<Y'<7,%ZDPSO=W(^D-#D^YG5A2[V9-S'\N>;'!3<GLALVW:GFJT(4I%S3
MDX@91#2,(<,X@XIP1.,DHRQP"KAW&WYJ%NJ>O&ZDY(B['3OY0]/[\<E&\,JE
MN"<ZV+$EOWBQ__KA-BAW.8HP*HGU@^>0S7H^I?<IS/)1FG[5[[0Z]6!K/5[3
MRGJY*%])M2QD?=T]_2[+M]]7!=5CY M:/%<];_6.DINDIN5<C_3PWIP5F?*?
M+$VC-.(A5"K $*6F;& 4AE!O[CE/LS",L5-4FT=9IQ8(]XM<@;EI_<XJC?1_
M%E+E*V#>.9!7^H&54;!B@<6>3OK?:Z7<SWF\O0K6AT%3F&#_)T9F^GXP>OY8
MS^A65;#5M9W[YOI*W1NPKQYH]1OT/,GW) Q]Z.1-WK%/IGP#?^3XRON0_=8E
M$W)=15R_7SRM5^4'^4W.HS8Z,8X85P&%<60.M[*00TJS"+(P37@FXSAFRL6V
M[AAK:H9T)1N(W(B]"TL[8AX((<_$N@W3OP&UH#>@ <Q#J*(%)H/R7-=XH_*4
MA>*'/&-S2X^"+:]-5V*VK*EJ$ZW4O-E,RBQ,,8,!B1*(P@SK'3@C4%&6LC0D
M8103ZYHL72--C2/V9 4;81T*>'3BVLT8@Z+E?3-]%*CS7.&(F$-5DZ&0&ZEP
MB>NKYE:0Q :,SIHCG0\8KZR(C1Y[E4.L;NA9/J Y*[Y3M]K8$_E\;6K:;KVD
M;[_S^5I(4=N#CYJM*R'N5!MT_E$6U6E0=<HX0PR'040I1('2IIA2 FJ.32&3
M*,&,RP0)J[AP/^)-C9EW#^IW]=OM(]AJV&X,-SJ:FS:9%UK-^@BX.>YU#& :
M^"VP,R*O-[>>UY%K3*M[@KD7](?-+A]6Q'%3R[W ^R*OW,\H?4OD+_]#\M;(
M"3+&"$LYY%(RB.),:7,[(!"3*,H("T+%G%(&]YX^-2)OA'/,_SD.G.5Y>E\X
M?)^;VR+1H^[[$8T'KOB^.\+(M=Z/*/>RRONQBX:)&=_/(KY]7!8KT]3!Q J^
MHF5>SC)$$AES 448!A")(((,900F)*$IE@S%H;RD),$Y :9V(F,$NRQ*_"SD
M=DS@$TC/9&$10:Y_UVH .B&_.(S<%C>O0>5GA;AJB+DM1.<"SJV?TX_;?BVU
M0=16:REG2/ D$RF#(@[UGI2H$!).,<QBCGD2$HD3IS8]^X^?FBGR:QW^MY'/
MC:,.H+-CH/Z >.:70RQN@.GUSI_!E^:_7H)BCL,Q*&T<##$J*1Q7[_"3/W'5
MI4ZJMX]/\^6SU%N<XEO.3[1YN)U7DU1M=#Y)OGQ8&':IR_$9CBFWX6%IQC,<
M* 55'"J(3.,:2M((<A6*$&>Q$%'0SU\UL*13HYF-C^-DAD*3Z=C7$37T3+OZ
MI*XX?[[=4^=ZY#0S5^>+OZ9/N;:FZPYO>JE>FP,1CRDEWF? DXMJ:&FOY*WR
M!/IIQY6O 7N&F>0+JA'[8'*W=VHUMP'E;]9RD]'+1);R- N@1%1 A*(4LMB4
M4%=*9"'C*956Y\GN0T]M+6@D!S_GB_QQ_0@J%5IJ<31 '2; CM']P.J9HEM$
M*ZEO0"OW\TV+Z@W0@GO)KG;':]BH%OOAQPUR<8;E1<R+^Q,\9J9LOJ(DB#.J
M(DUC@DN((F0L8!9#Q!3C&4(B2)S\]$ZC3XW)[-,I>E:*<)L;.X;SAKAGDAL2
M;#^9*UZ9SDV"Z>6MG..[?@]QHSPA\UGC2'P.(W:?K^9RQD@<D91&,!&,020#
M!K%4!":1Y!&A N/4BM&./7QJA%4)97Q<8?0#^['UI5MVI#Z*7C?G7(J)9TIQ
MA<.:-KKT/L(*I>1_?EA^^TG?5A'";\C\".L?*Q8X^L!1/O(N5=ION/.:"P/X
M=VR?G[4MI$E W"T^F<%,#]?*___K8LE*O1\T7H8J0MCL^31SS/-J#U@'&8DH
M(2F)&0QXEFC#)9:0)8+#.$X3B0(A9!;UBOH?2,"I4<5N-'Q==JQ:=7>[0+7J
M@N4";!2NKOIEN2@VOZ@@Z!=H-OA;8+D)O.+<^MXJ[DSK^;FL-+P!NSK6J1%@
M7\OAX\U\38&?G(JAA+Q.(L; $)_,WAAZG-YQ9UQ*4:6LF7;@9I=]IXSYN5Q4
M/<)GA.,LDX&"&3;%%U(:0L8"$Y6L)*=9B!+LU*+[[(A3XWZ3/OS4"-WD##=B
M&V.)5X*#TDCN'+EV!GH[?AX44,^$^W$/Q_<[.-;R@L^=./:)>[/#9NA8N#.C
MCAT?9P?"D9@YRQM[QM'5Q8T%3@+!!((!9B%$G%*($=-F*0MB+/7V$R6Q4W2<
M<UGC\=KQ]*D9[50#>G(UG8<NT>RQY/(U2BAWET0>I,3QS@=;G1"6M^O5UV5A
M3@%G1"8R8.:SRQ"'B,8$4B0#J#),HR3@$4LS5P_VB;&FMJZ_WEFY;YHNDX!N
MQ'7W39_"V-X3/0!R(_B=VV7ZIHY?*<'M>=!Z^9C/P#&X1_G4>*/[C\\H?LQ;
M?.Z6?M1QF.IBMB5\%K TD"J*89"A2&\) @%)J%%-XS2-PS -,$I=2./H*).C
M"SJGHLC7)7B5+TN>2SV;I:F-P/^\MPGXNIQK?$L  3-J5"ULUZ4 3[*H2<:Q
MD^WQ*;#CE(N!]<PF+W/U;BHO"Q^.1SHA&)1!CH\T*G=T*GO(&MT7]^.+#U(;
M++*I>+-XV#NO?]XYK?]W28M[C;Z<D0QAO0'0MH<PJ6Z$84B2.(8DHXAQE1(A
MG6H[.DLP-9[1;U?BQA#NH-NQAU<H/3-++?L-V$A_)!QHM03,A%KEX@88'4"E
MQ'#4TQN_06G)78I1*:LW2(=TUO]![L?F;YJ*(/?ZUAEBD51AHF" E= ,%@:0
M)0&!4BBAB A4'%J=I1T^>&K$U,H&C'#VA^1[6)T_(.^+@&<^L5/>Z4C\F*:]
MC\/W'C;:4?@Q%7:/P8_^^Z5I+)N6&Y_TGT7.]4_5UN?71;XJ;_DJ_Z8_^.IL
M9)O P!F*1110J$A((8IQ BF*,&2$QZE*$ZS_O5^J2@]IIO9A[Y;<V&I1[_%!
MI0=H%>F;D-)GSNR,E-%FPC/![$["MJG,F>D8*9GD F0])8STD>A*22$7@'<Z
M\>.2A_;CW^.%29NR&PB;)N8B@R%6J=[)D0Q226,8(XFP#%3*<>A"KUV#38T]
MM:RP"K\]K")L.E=^7K,R%SDM')FS$VT[8AP*0\^\=Z($LX<:HS: #$I7G0..
MRD8VJA^2C=4]_;A$DY;>A/&OMPOQQE0O73X9([')G)QQ0@,>1!F4S)!)B 3$
M62)@QE&&!9&$!4YIQ9VC38U-6F&KP$&Q%=>-/KH!MN./P6#S3"![B.U(>C:'
MVIE K! 9E$&Z1QR50JR4/^00NYMZ%"O^N\P?OFJCY_:;+.B#?/M=%CPOY4=M
M"LF_4Y./O2KU,'DAQ2Q"/)(RD# B$8$HBBAD/%.08H(3E/ @":WV?JX#3XU:
M6O&J''4C8'4T)4QYU*)T/IYRGH9NUO$)KF<":J4&C=B@E1M4@M^ 5O06=T\
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M_5@LO^5"BE?/OY92O%]L*H4U3*>MP1E+)*9,DPV->0A1&C)(E$I@J*($I6F
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MK26?1*V -R/\9)=0^G5B C:9C+[0F9A$1H-(JQ"P?)4?=F&K6#G*,&PQ*S^
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M[E3[;/[G[C?"%P/_+/^L?E.:A#<J58J#G.2F+HN)/<:( H@3$M.$IC%CH0J
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M=)-RJTR#;E<" 7B\<0G5K,<6YM-LP9?SQ1>Z^N=Q3094P"Q1(@.H0 3 )$9
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MN>[N8=UWJ'W!@.]ZP[LPX,KD^7HGZ_]^7%2Y*G9)P.K$@%/.8H;B/ 9IRE,
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M[#+GVMWW-^4N)T(]SH-:3;D_M]/PI]FB"6^WO"=V'"&20\:1S %+8G/&6!!
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MAVCP3@B"3O/S/0TZUSN5/9[PW0_[S?HOJZ6:K8U?WC2C4J_;$ &3\!M D62
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MQ  AA:F4/":,VF:^"0U]_REM+@#_ODYFTQ/DW0M&.!![7AG:(8C1'LA:SB!
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M3T+%.14,Q"9('<J\  07.9"4\)1RBC/E5!7J2G]CLU)VXD9&WNA 8+](R&N
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M'ZGY\L\Z3T.DMJ)'="?[?[A6TG,>%[M%IU^T>UX[M/!1!?96?+-._&0TT$O
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M6F1O5.E?:B4.,WRAE^M 4MUG3=<RS^KB?;O3P2G,6<)AB@'D5/_+!(Y@G E
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M:_XVG<T7E_T%<;F:H.8L&Z[!<BG)9Y0<O-0,O _:2!>C-8VN^MRA9-P*MD:
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M"<_=U=<O-B^L_OWR\)R*9[34 :5)=;R5!I^R@<*$"5BT5;Q-)F]'0L?=N'O
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M5.AL3>*XR</A\-5$)1U@[>Z,WDO;F[*U411PY '2BD&$H)6H&79:2DYFS]L
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MS&+42K5U*W>EN,L(O1E2CZ'6CF*B&POSNKSUQ@7524DF>)\%.%%8Y8ODZ*V
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M5A]Q\:CT)E9FA3HH2![KZ;A'<B]"73\B%^[JW84VM05/TS5R+Y@C@FTX]70
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M [@0#:C ' DH:T"CG*LM!HS=;JKJDZ_Y7AWYX7,= ZNL%_]^<P8QP6B\4;*
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MM=13GDNUZ+\8RQPL.X<YN]0Y+UY$%L-0MV!D&@RM_ 2(">'YVWF _ K]*%G
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M:85$ESR62KH%Y?U=P](B\PSTY KKXX;I1LGJ\\IU-:%I::9(;NOKE"311G@
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M#FV3KH8A2#SR^-SQCG='#G^=S,;AN],II#K/X/3\Q:OC,30<SWO;'GO>))S
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M<RTR,#(R,#8S,"YH=&U02P$"% ,4    " ",A015;+(/AG$.  #"E   $0
M            @ %CH0$ 8VQB<RTR,#(R,#8S,"YX<V102P$"% ,4    " ",
MA015!\F(ZF 6   FU   %0              @ $#L $ 8VQB<RTR,#(R,#8S
M,%]C86PN>&UL4$L! A0#%     @ C(4$52-#8PP'*P  _,8! !4
M     ( !EL8! &-L8G,M,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0    ( (R%
M!%6M9Q)@ K,  #*E!P 5              "  =#Q 0!C;&)S+3(P,C(P-C,P
M7VQA8BYX;6Q02P$"% ,4    " ",A0159)6E3^M?   (9@0 %0
M    @ $%I0( 8VQB<RTR,#(R,#8S,%]P<F4N>&UL4$L! A0#%     @ C(4$
M5<,3E4-G!P  M"4  !H              ( !(P4# &-L8G,M97@S,3%?,C R
M,C V,S!X<3(N:'1M4$L! A0#%     @ C(4$566N,-.C!0  UQH  !@
M         ( !P@P# &-L8G,M97@S,E\R,#(R,#8S,'$R+FAT;5!+!08
.."  ( !@"  ";$@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
